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S U M M A RY
This study aimed to establish whether there was evidence of inequity
in the utilisation of healthcare for coronary heart disease in the popu-
lation of Wales during the period 2004 to 2010. Determining whether
or not such inequity exists is important, because equity in healthcare
is an aim of NHS services and, if present, inequity might contribute
to the substantial differences in coronary-heart-disease mortality by
deprivation that are seen in Wales.
I used linked general practice, hospital admission, and mortality
data from routine sources, and developed a distinctive methodology
to evaluate the utilisation, timeliness, and maintenance of appropriate
treatment, making comparisons across deprivation quintiles. My ap-
proach was based on analysing a pathway of care for coronary heart
disease in a comprehensive way. At each stage in this pathway I ex-
amined ‘clinical triggers’ and the extent to which these were matched
by appropriate ‘clinical actions’.
Findings were broadly in accord with those in the published liter-
ature: using multivariate adjustment and taking account of supply-
side-effects using frailty models, I detected no systematic evidence
of inequity in coronary-heart-disease healthcare provision except in
relation to revascularisation. As an illustration of this broad pattern, I
found that the adjusted hazard ratio for times-to-receiving revascular-
isation in the most deprived quintile (compared to the least) was 0.83
(95% confidence interval 0.77; 0.91) in those with myocardial infarction.
Further, I found no evidence that indicated prescriptions were reissued
over a shorter time-period for more deprived individuals.
In discussing this work, I consider possible explanations for my
findings, and address the way that my distinctive methodology, which
enabled measurement of important aspects of coronary-heart-disease
care, might be applied in other areas. This work has important im-
plications in demonstrating in a systematic and comprehensive way
that healthcare inequity for coronary heart disease in the NHS is
confined to specific interventions, and is unlikely to be contributing
substantially to differences in mortality between deprivation groups.
xiii

C O N T E N T S
i introduction 1
1 introduction 3
1.1 Research question 8
1.2 Rationale 8
1.3 Aims and objectives 12
1.4 Overview of thesis 13
2 background 17
2.1 Inequity, deprivation, and needs assessment 17
2.2 Background information on CHD 28
2.3 Background information relating to thesis methods 38
2.4 Summary 44
ii discussion of previous work 47
3 inequity in chd interventions 49
3.1 Aims and objectives of the literature review 49
3.2 Scope of the literature review 50
3.3 Methods of literature review 51
3.4 Filtering of papers 58
3.5 Review of papers 62
3.6 Discussion 86
iii methods 99
4 data permission, specification, extraction and pro-
cessing 101
4.1 Introduction 101
4.2 Permissions for data access 102
4.3 Data specification 103
4.4 Data extraction 111
4.5 Data-processing 111
4.6 Conclusions 122
xv
xvi contents
5 pathway of care for coronary heart disease 123
5.1 Introduction 123
5.2 Methodological concepts 123
5.3 Implementation 133
5.4 Summary 165
6 analytical methods 167
6.1 Introduction 167
6.2 Descriptive data analysis 167
6.3 Main analysis of clinical trigger-actions 172
6.4 Pathway overview analysis 182
6.5 Sensitivity analyses 185
6.6 Software considerations 185
6.7 Summary 186
7 dataset overview and descriptives 187
7.1 Dataset overview 187
7.2 Population characteristics for key variables 192
7.3 Data validation 229
7.4 Mortality 235
7.5 Summary 239
8 selected pathway results 241
8.1 Statin prescription in individuals assessed as being high
risk 242
8.2 PCI in individuals with MI 256
8.3 Summary 272
9 results overview 273
9.1 Main analysis 273
9.2 Drug cessation analysis 284
9.3 Sensitivity analysis 291
9.4 Chapter discussion 304
iv discussion 309
10 discussion 311
10.1 Key Findings 311
10.2 Appraisal of study 320
contents xvii
10.3 Challenges and lessons 329
10.4 Further work 331
10.5 Conclusions 337
references 343
v appendices 369
a the welsh index of multiple deprivation 371
a.1 Indicators used for the income domain 371
a.2 Indicators used for the employment domain 371
b additional background material 375
b.1 Additional background material relating to inequity,
socio-economic deprivation and healthcare needs as-
sessment 375
b.2 Additional background material relating to CHD 375
b.3 Additional background material relating to thesis meth-
ods 401
c literature review tables 405
d additional results 455
d.1 Main analysis 455
d.2 Drug-cessation analysis 546
e clinical codes 589
f calculation of illustrative example in discussion
chapter 665
L I S T O F F I G U R E S
Figure 1.1 Original coronary-heart-disease pathway con-
ception 5
Figure 1.2 Staircase effect 7
Figure 2.1 Need, supply, and demand 25
Figure 3.1 Search terms used to look for papers on equity
in smoking cessation services 54
Figure 3.2 Search terms used to look for papers on equity
in antihypertensive provision 54
Figure 3.3 Search terms used to look for papers on equity
in cholesterol-lowering drug provision 55
Figure 3.4 Search terms used to look for papers on inequity
in antiplatelet drug provision 56
Figure 3.5 Search terms used to look for papers on equity
in diabetes management 56
Figure 3.6 Search terms used to look for papers on equity
in revascularisation 57
Figure 3.7 Filtering of papers for smoking cessation in-
equity of provision related to socio-economic
deprivation 59
Figure 3.8 Filtering of papers for antihypertensives drug
inequity of provision related to socio-economic
deprivation 60
Figure 3.9 Filtering of papers for cholesterol-lowering drug
inequity of provision related to socio-economic
deprivation 60
Figure 3.10 Filtering of papers for antiplatelet drug inequity
of provision related to socio-economic depriva-
tion 61
xviii
LIST OF FIGURES xix
Figure 3.11 Filtering of papers for diabetes management in-
equity related to socio-economic deprivation 61
Figure 3.12 Filtering of papers for inequity of provision of re-
vascularisation related to socio-economic depriva-
tion 62
Figure 3.13 Summary of findings from review of smoking
cessation 77
Figure 3.14 Summary of findings from review of primary
prevention using antihypertensive medications 78
Figure 3.15 Summary of findings from review of primary
prevention using cholesterol-lowering medica-
tions 79
Figure 3.16 Summary of findings from review of primary
prevention using antiplatelet medication 80
Figure 3.17 Summary of findings from review of diabetes
management 81
Figure 3.18 Summary of findings from review of secondary
prevention using antihypertensives 82
Figure 3.19 Summary of findings from review of secondly
prevention using cholesterol-lowering medica-
tions 83
Figure 3.20 Summary of findings from review of secondary
prevention using antiplatelet medications 84
Figure 3.21 Summary of findings from review of provision
of revascularisation 85
Figure 5.1 Pathway concepts 126
Figure 5.4 Derivation of cohort window 151
Figure 5.5 Relations between the cohort window and the
indication period 153
Figure 5.6 Indication period relations with clinical actions 155
Figure 5.7 Derivation of pathway history variables 160
xx LIST OF FIGURES
Figure 5.8 Derivation of variables relating to previous ac-
tions 162
Figure 7.1 Individuals excluded from the dataset 188
Figure 7.2 Population pyramid showing age and sex break-
down for individuals in the 2004 cohort 193
Figure 7.3 Population pyramids showing age and sex break-
down for individuals in the 2004 cohort by quin-
tile 196
Figure 7.4 Distribution of BMI in men aged 60–64, by depriva-
tion quintile, with population mean for quin-
tile 207
Figure 7.5 Distribution of BMI in women aged 60–64, by
deprivation quintile, with population mean for
quintile 208
Figure 7.6 Distribution of systolic blood pressure in un-
treated men aged 60–64, by quintile, with popu-
lation mean for quintile 210
Figure 7.7 Distribution of systolic blood pressure in un-
treated women aged 60–64, by quintile, with
population mean for quintile 212
Figure 7.8 Distribution of systolic blood pressure in treated
men aged 60–64, by quintile, with population
mean for quintile 214
Figure 7.9 Distribution of systolic blood pressure in treated
women aged 60–64, by quintile, with population
mean for quintile 216
Figure 7.10 Distribution of cholesterol:HDL in untreated men
aged 60–64, by quintile, with population mean
for quintile 219
Figure 7.11 Distribution of cholesterol:HDL in untreated wo-
men aged 60–64, by quintile, with population
mean for quintile 221
LIST OF FIGURES xxi
Figure 7.12 Distribution of cardiovascular risk measured us-
ing the Framingham non-laboratory risk assess-
ment tool in men aged 60–64, by quintile, with
population mean for quintile 223
Figure 7.13 Distribution of cardiovascular risk measured us-
ing the Framingham non-laboratory risk assess-
ment tool in women aged 60–64, by quintile,
with population mean for quintile 226
Figure 7.14 Kaplan-Meier plot of death from CHD by quin-
tile 237
Figure 8.1 Descriptive variables for the clinical trigger-action
‘risk assessed high’ and ‘statin’ 244
Figure 8.2 Relations between categorical variables and times
to provision of statin in those with the clinical
trigger ‘risk assessed high’ 246
Figure 8.3 Frequencies of derived variables relating to an
individual’s history within the pathway for the
clinical trigger ‘risk assessed high’ and ’statin’ 247
Figure 8.4 History variables and rates of provision for clin-
ical trigger ‘risk assessed high’ and the clinical
action ‘statin’ 249
Figure 8.5 Kaplan-Meier plot showing the proportion of in-
dividuals who had not received a statin prescrip-
tion by time and by deprivation quintile 250
Figure 8.6 Univariate mixed-effect model for the clinical
trigger ‘risk assessed high’ and the clinical ac-
tion ‘statin’ by deprivation quintiles and null
model 252
Figure 8.7 Multivariate mixed-effect model for the clinical
trigger ‘risk assessed high’ and clinical action
‘statin’ for deprivation quintiles, adjusted for
age and sex 253
xxii LIST OF FIGURES
Figure 8.8 Multivariate mixed-effect model for the clinical
trigger ‘risk assessed high’ and clinical action
‘statin’ for deprivation quintiles, adjusted for
age, sex, and other variables 255
Figure 8.9 Descriptive variables for the clinical trigger-action
‘MI’ and ‘PCI’ 258
Figure 8.10 Relations between categorical variables and times
to provision of percutaneous coronary inter-
vention (PCI) in those with the clinical trigger
‘myocardial infarction (MI)’ 260
Figure 8.11 History variables for clinical trigger ‘MI’ and the
clinical action ‘PCI’ 262
Figure 8.12 History variables and rates of provision for clin-
ical trigger ‘MI’ and the clinical action ‘PCI’ 263
Figure 8.13 Kaplan-Meier plot showing the proportion of
individuals who had not received a PCI by time
and by deprivation quintile 265
Figure 8.14 Univariate mixed-effect model for the clinical
trigger ‘MI’ and the clinical action ‘PCI’ by depriva-
tion quintiles and null model 266
Figure 8.15 Multivariate mixed-effect model for the clinical
trigger ‘MI’ and clinical action ‘PCI’ for depriva-
tion quintiles, adjusted for age and sex 267
Figure 8.16 Multivariate mixed-effect model for the clinical
trigger ‘MI’ and clinical action ‘PCI’ for depriva-
tion quintiles, adjusted for age, sex, and other
variables 270
Figure B.1 Morphological and pathophysiological changes
of atherosclerosis 378
Figure B.2 Schematic representation of the principal coron-
ary arteries; anterior view 380
LIST OF FIGURES xxiii
Figure B.3 Risk models over time. Coloured rectanges indic-
ate the period of recruitment; black lines show
the period to publication; black points show pub-
lication year; rectangles are coloured by location.
Studies are ordered by the start date of data
collection 399
L I S T O F TA B L E S
Table 2.1 Domains and weightings for the 2005 and 2008
Welsh Indices of Multiple Deprivation 24
Table 2.2 Risk factor data from MRFIT study 36
Table 3.1 Summary of papers examining inequity of pro-
vision of smoking cessation referral and stop
smoking advice 64
Table 3.2 Findings for different study types in the liter-
ature review. The percentages indicated show
the percentage of studies in the relevant column
with each result type 89
Table 4.1 LIKE statements used in searching for Read
codes 107
Table 7.1 Numbers of individuals who appear in the data-
set from different starting years 189
Table 7.2 Number of individuals ending their time in the
cohort for different reasons 189
Table 7.3 Numbers of each different kind of clinical trigger
(according to incident and prevalent definitions)
for individuals in the final dataset 191
Table 7.4 Population of the 2004 cohort by age and sex 192
Table 7.5 Mid-year estimates for the population of Wales
for the year 2004, by five-year age band, and
sex 194
Table 7.6 The number of individuals in each of the WIMD
quintiles in the 2004 cohort (quintile 1 is least
deprived) 194
Table 7.7 Number of individuals in the 2004 cohort, by
local authority 197
xxiv
LIST OF TABLES xxv
Table 7.8 Point prevalence of CHD in 2008, by quintile 199
Table 7.9 Point prevalence (%) of CHD in 2008, by age-
group and quintile 199
Table 7.10 Point prevalence of previous acute coronary syn-
drome in 2008, by quintile 200
Table 7.11 Point prevalence (%) of previous acute coron-
ary syndrome in 2008, by age-group and quin-
tile 200
Table 7.12 Point prevalence of previous CVA/TIA in 2008,
by quintile 201
Table 7.13 Point prevalence (%) of CVA in 2008, by age-
group and quintile 201
Table 7.14 Point prevalence of diabetes in 2008, by quin-
tile 202
Table 7.15 Point prevalence (%) of diabetes in 2008, by age-
group and quintile 202
Table 7.16 Point prevalence of ‘other Charlson comorbidit-
ies’ in 2008, by quintile 203
Table 7.17 Point prevalence (%) of other Charlson comor-
bidities in 2008, by age-group and quintile 203
Table 7.18 Percentage of individuals in the final dataset
with a known smoking status and the percentage
of those individuals that smoked by quintile at
the beginning of 2008 204
Table 7.19 Percentage of individuals with a known smoking
status who smoke, by quintile and age-group,
from 2004 to 2010 205
Table 7.20 Mean BMI and the percentage of individuals
on whom a BMI was known by quintile for
2008 205
Table 7.21 Mean BMI in 2008, by age-group and quintile 206
xxvi LIST OF TABLES
Table 7.22 Mean cholesterol:HDL ratio and the percentage
of individuals on whom a cholesterol:HDL ratio
was known by quintile for 2008 217
Table 7.23 Mean cholesterol:HDL ratio in 2008, by age-
group and quintile 217
Table 7.24 Mean cardiovascular risk and the percentage of
individuals on whom a cardiovascular risk was
known by quintile for 2008 222
Table 7.25 Mean cardiovascular risk (%), using Framing-
ham nonlaboratory assessment tool in 2008, by
age-group and quintile 224
Table 7.26 Mean hospital admissions and CVD-related GP
contacts during the study period, by quintile 227
Table 7.27 Mean number of hospital admissions through-
out the study period, by age-group and quin-
tile 228
Table 7.28 Mean numbers of measurements and readings
performed in general practice during the study
period, by quintile 228
Table 7.29 Mean number of contacts with primary care re-
lated to cardiovascular disease throughout the
study period, by age-group and quintile 229
Table 7.30 Prevalences of major diagnoses by data source
and by year 230
Table 7.31 Prevalences of smoking, obesity and overweight/obesity
by data source and by year. The ‘percentage
known’ shows the percentage of individuals
in the SAIL data on whom a reading is avail-
able 232
Table 7.32 Prevalences of hypertension and related meas-
ures by data source and by year. The ‘percentage
known’ shows the percentage of individuals in
the SAIL data on whom a reading/diagnosis is
available 234
LIST OF TABLES xxvii
Table 7.33 Breakdown of the broad categories of cause of
death for the individuals in the 2004 cohort who
died 236
Table 7.34 Number of CHD deaths per 1000 person-years-
at-risk, by quintile 236
Table 7.35 Hazard ratios for coronary heart disease death
by quintile 237
Table 7.36 Hazard ratios for coronary heart disease death
by quintile, adjusted for age and sex 238
Table 9.1 Comparison of findings for clinical trigger-actions
with an apparent social gradient using 5:1 haz-
ard ratio compared to slope index of inequal-
ity 301
Table 10.1 Numbers of procedures that might have been
carried out and numbers of procedures that
might have been prevented or postponed had
quintile 1 rates of utilisation occurred in other
quintiles throughout the study period 336
Table B.1 Summary of risk models. All models have age,
gender (where applicable), smoking and systolic
blood pressure as predictors in addition to those
shown in the table. Data are from Liew 20112;
The risk models are shown in order of the start
of the time period during which they collected
data 395
Table C.1 Summary of papers examining inequity of pro-
vision of antihypertensives for primary preven-
tion 406
Table C.2 Summary of papers examining inequity of pro-
vision of lipid-lowering medications for primary
prevention 413
Table C.3 Summary of papers examining inequity of pro-
vision of anti-platelet medications for primary
prevention 420
xxviii LIST OF TABLES
Table C.4 Summary of papers examining inequity of dia-
betes managment in patients without coronary
heart disease requiring primary prevention 423
Table C.5 Summary of papers examining inequity of pro-
vision of antihypertensives for secondary pre-
vention 430
Table C.6 Summary of papers examining inequity of provi-
sion of lipid-lowering medications for secondary
prevention 438
Table C.7 Summary of papers examining inequity of pro-
vision of anti-platelet medications for secondary
prevention 443
Table C.8 Summary of papers examining inequity of pro-
vision of revascularisation 449
Table E.1 Summary of clinical codes used for defining dif-
ferent conditions in this thesis 590
A C R O N Y M S
ACE Angiotensin-converting enzyme
ACS acute coronary syndrome
AIC Akaike information criterion
ALF-e Encrypted Anonymised Linking Field
APC Admitted Patient Care
ARB angiotensin-II receptor blocker
BMI body mass index
BP blood pressure
CALIBER Cardiovascular Disease Research Using Linked
Bespoke Studies And Electronic Records
CABG coronary artery bypass graft
CCB calcium-channel blocker
CCF congestive cardiac failure
CHD coronary heart disease
CI confidence interval
CKD chronic kidney disease
CRAN Comprehensive R Archive Network
CRS Collaborative Review System
CRP C-reactive protein
CSDH Commission on the Social Determinants of Health
CT computed tomography
CVA cerebro-vascular accident
CVD cardiovascular disease
CVRG-C Cardiovascular Research Group – Cymru
xxix
xxx acronyms
DB2 IBM DB2
DRL Deterministic Record Linkage
ECG electrocardiogram
GP general practitioner
GPRD General Practice Research Database
GTN glyceryl trinitrate
HDL high-density lipoprotein
HIRU Health Information Research Unit
HR hazard ratio
hsCRP high-sensitivity C-reactive protein
HSE Health Survey for England
ICC intraclass correlation coefficient
ICD International Statistical Classification of Diseases
and Related Health Problems
ICD-9 International Statistical Classification of Diseases
and Related Health Problems, 9th Revision
ICD-10 International Statistical Classification of Diseases
and Related Health Problems, 10th Revision
IGRP Information Governments Review Panel
IMD Index of Multiple Deprivation
LA Local Authority
LHCH Liverpool Heart and Chest Hospital
LDL low-density lipoprotein
LISI Low Income Scheme Index
LSOA Lower Super Output Area
LVH left ventricular hypertrophy
MACRAL Matching Algorithm for Consistent Results in
Anonymous Linkage
acronyms xxxi
MCCD medical certificate of the cause of death
MH Morriston Hospital
MI myocardial infarction
MICE multiple imputation using chained equations
MINAP Myocardial Ischaemia National Audit Project
MRFIT Multiple Risk Factor Intervention Trial
NHS National Health Service
NHSAR NHS Administrative Register
NICE National Institute for Clinical Excellence
NSF National Service Framework
NSF-2001 The Wales National Framework for Coronary Heart
Disease
NSF-2009 The Cardiac Disease National Service Framework
for Wales
NSTEMI non-ST-elevation myocardial infarction
NWIS NHS Wales Informatics Service
OA output area
ONS Office for National Statistics
OPCS Office of Population Censuses and Surveys
Classification of Interventions and Procedures
OPCS-4 Office of Population Censuses and Surveys
Classification of Interventions and Procedures,
version 4
OR odds ratio
PACT NHS prescription analysis and cost
PAD peripheral artery disease
PCI percutaneous coronary intervention
PCT Primary Care Trust
xxxii acronyms
PEDW Patient Episode Database for Wales
PHW Public Health Wales NHS Trust
PRL Probabilistic Record Linkage
PSALF Project-specific Anonymised Linking-field
PTCA percutaneous transluminal coronary angioplasty
PVD peripheral vascular disease
PYAR person-years-at-risk
QOF Quality and Outcomes Framework
RGH Royal Gwent Hospital
SAIL Secure Anonymised Information Linkage
SBP systolic blood pressure
SES socio-economic status
SIMD Scottish Index of Multiple Deprivation
SNOMED CT Systematized Nomenclature of Medicine – Clinical
Terms
SQL Structured Query Language
STEMI ST-elevation myocardial infarction
TIA transient ischaemic attack
TRUD Technology Reference Data Update Distribution
UA unitary authority
UHW University Hospital of Wales
UK United Kingdom
WAG Welsh Assembly Government
WDS Welsh Demographic Service
WHO World Health Organisation
WHS Welsh Health Survey
WIMD Welsh Index of Multiple Deprivation
acronyms xxxiii
WIMD 2000 Welsh Index of Multiple Deprivation 2000
WIMD 2005 Welsh Index of Multiple Deprivation 2005
WIMD 2008 Welsh Index of Multiple Deprivation 2008
YGC Ysbyty Glan Clwyd

Part I
I N T R O D U C T I O N

1
I N T R O D U C T I O N
This thesis is concerned with two potentially linked problems of
importance to those involved with healthcare systems, those interested
in public health, and to society more generally. The first of these
is the difference in age-standardised mortality from coronary heart
disease (CHD) between individuals of different socio-economic status
in the United Kingdom (UK). The second is the possible existence of
healthcare inequity for CHD – systematic differences in interaction
with the healthcare system – between individuals of different socio-
economic status.
Figure 1.1 shows a schematic representation of the concept from
which I developed my ideas. I discuss it here to explain the initial ap-
proach to this thesis: its research question, rationale, and methodology.
In referring to figure 1.1, there is the opportunity to introduce some
of the important concepts discussed in detail later in this work.
The five boxes in figure 1.1 represent points at which comparisons
might be made between individuals of different socio-economic status.
The graphics in figure 1.1 are based on real figures from Welsh data
from the time that this project started. I illustrate comparisons based
on socio-economic deprivation, a relative indication of social status, by
comparing the population across five evenly-sized groups (quintiles)
based on deprivation level. In figure 1.1, I designate quintile 1 as the
least-deprived quintile, through to quintile 5 as the most.
The right-hand box, separated from the others by a broken line,
illustrates age-sex standardised mortality from CHD: more deprived
quintiles have higher rates. This box corresponds to the first of the
problems of concern in this thesis – it is a schematic illustration of the
striking differences in CHD outcomes by socio-economic status.
The four boxes to the left of the broken line in figure 1.1, illustrate,
in a greatly simplified way, factors expected to have a bearing on
outcome mortality. First, on the far left, are represented differences in
risk factors between deprivation quintiles, here illustrated by smoking
prevalences by quintile: more deprived quintiles have higher smoking
prevalences, as well as adverse profiles for some other risk factors.
The middle three boxes represent broad components of healthcare for
3
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CHD – the situation in Wales being unclear when I started this work
with respect to ‘Primary Care Identification’ – a process conceived
as including measurement of risk factors for CHD, assessment of
CHD risk, and the identification of the disease itself – and also for
primary care treatment of CHD and its risk factors. The remaining box
illustrates a difference in specialist care for CHD, here represented
by differences by deprivation in adjusted rates of revascularisation in
Wales.
In the construction of figure 1.1, I broadly conceived the four boxes
to the left of the broken line as independent variables, with outcome
mortality a dependent variable – aiming to give figure 1.1, in a loose
terms, the feel of an ’equation’, with differences at successive steps,
from risk factors through the stages of healthcare, summing to determ-
ine the differences in mortality in the right-hand box. I characterise
the middle three boxes in figure 1.1 as a ‘pathway of care’ for CHD.
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Figure 1.1: Original coronary-heart-disease pathway conception
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6 introduction
In a 2006 paper, Tugwell et al3 discuss the staircase effect in which dif-
ferences in the population-level efficacy of an intervention diminish at
each a number of different stages. Describing stages such as awareness,
access, diagnosis, targeting, compliance of providers, and adherence
of consumers, they characterise differences in the supply of healthcare
to different population groups as being the result of more pronounced
staircase effects in those groups with worse outcomes3. This concep-
tual approach provides a framework to allow further consideration of
the findings from and implications of healthcare-needs-assessment-
type investigations. If a particular group is at a systematically lower
rate of some intervention for a given level of need, the next step to
understanding this finding can be to address it in the light of the stair-
case effect: for example, is the finding due to a difference in awareness
about the intervention? Does it relate to differential acceptability of
the intervention? In figure 1.2, I illustrate schematically the staircase
effect this I conceive to be operating at each point in the pathway of
care for CHD.
An account of the way in which I developed these simple ideas
in order to address formal research questions is a major part of this
work. In this chapter, I relate the above outline to the overall structure
of the thesis. In subsequent chapters, I consider in detail how the
content of published literature in this field might modify this simple
starting point, and discuss the data sources available for investigation
of these issues – specifically the Secure Anonymised Information
Linkage (SAIL) databank at Swansea University.
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Figure 1.2: Staircase effect
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1.1 research question
I begin by formally stating my research question:
Is there a systematic difference in the utilisation of health-
care for CHD between different deprivation groups across
the pathway of care for the disease?
In addressing this question, I have sought to lay the foundations for
the consideration in subsequent work of the following question:
To what extent is any difference in utilisation of health-
care for CHD between different deprivation groups across
the pathway of care contributing to differences in CHD
mortality between those groups?
In these definitions, by the term ’utilisation of healthcare’ I mean
the care that was actually received by individuals.
In this thesis, I partially addressed the second research question: if
no evidence of healthcare inequity were identified across the pathway
of care for CHD, one could logically rule out the contribution of
healthcare inequity to differences in CHD mortality. It was clear that,
if inequity were observed in the pathway, further techniques involving
modelling counterfactual situations would probably be needed to
address the second question. I recognized that any contribution from
healthcare inequity to differences in mortality could only provide a
partial explanation. When referring in subsequent parts of this thesis
to my research question I mean the first of the two questions; I have
throughout borne in mind that its answer has implications for the
second.
1.2 rationale
A number of considerations underpinned the decision to address these
questions. They can be summarized as follows:
1. Individuals from more deprived socio-economic groups in the
UK have worse outcomes for CHD than those from less deprived
groups.
2. Many effective interventions and treatments are now available
that have been shown in well-conducted clinical trials to improve
outcomes for CHD.
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3. Many papers in recent decades have identified potential inequit-
ies in the provision of treatment for CHD, but I am not aware of
any previous studies that used my approach to the identification
of potential inequity across the pathway of care that is developed
in this work.
4. There is interest at both an academic and political level in the
existence of such inequities.
5. The SAIL databank, hosted by Swansea University, presented a
privileged opportunity for researchers from Cardiff University
to undertake research using linked routine datasets.
Taking each of these five points in turn, I discuss them briefly in
this chapter before signposting to subsequent parts of this work where
they are dealt with in detail.
A long history of research, going back as far as the 19th century4, has
demonstrated a relationship between an individual’s socio-economic
position and their health. A general pattern of poor health in relation
to lower socio-economic position has been known for 100 years or
more5. Research in this area in the UK has received particular impetus
from the landmark Whitehall studies, which demonstrated a social
gradient in CHD6,7, and from the publication of the Black report8 and
the subsequent consideration given to its implications.9,10
Individuals from more deprived socio-economic circumstances are
more likely to die from CHD at a given age than those who are
less deprived. For example, McCartney et al11, in examining trends
in social inequalities for premature CHD, found that, in those aged
younger than 75 years, men in the most deprived twentieth in England
and Wales in 2004 had three and a half times the rate of CHD mortality
of those in the least deprived twentieth. When making comparisons
across quintiles for Great Britain as a whole, they found that, in men
in 1994, the rate ratio for premature mortality from CHD was 1.52
(95% confidence interval (CI) 1.47; 1.57) in the most deprived quintile,
compared to the least; by 2008, this rate ratio was 1.84 (95% CI 1.76;
1.93). In women, the corresponding rate ratio was 1.77 (95% CI 1.68;
1.86) in 1994, and was 2.32 (95% CI 2.14; 2.52) in 2004.11 In simple
terms, the findings of this study suggest that individuals in the most
deprived quintiles were between one-and-a-half and two-and-a-half
times as likely to die prematurely from CHD.
Similarly, Bajekal et al analysed socio-economic differences in CHD
mortality in England between 1982 and 2006.12 The rate ratio in men
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between the most deprived and least deprived quintile (this time for
all CHD mortality) was 1.52 (95% CI 1.50; 1.54) in 1982, was 1.65 (95%
CI 1.63; 1.68) in 1994, and reached 1.94 (95% CI 1.90; 1.93) by 2006.
In women, the corresponding rate ratio was 1.64 (95% CI 1.62; 1.67)
in 1982, was 1.71 (95% CI 1.68; 1.73) in 1994, and reached 1.90 (95%
CI 1.86; 1.94) by 2006. Overall, the findings reiterate the picture seen
in the McCartney study. I provide a picture of the situation in Wales,
based on the data used in this project, in section 7.2.2.2 on page 204.
I give detailed consideration to some of the important concepts
relevant to comparisons between socio-economic groups and which
need to be borne in mind when assessing the validity of such find-
ings in chapter 2 (background) and in chaper 7 (data overview and
descriptives). Consideration of such detail does not undermine the
broad conclusion from the above studies (as well as from many others)
that those from more deprived parts of society are more likely, after
adjustment for age, to die from CHD. This finding, which has achieved
widespread acceptance, is a starting point for the work presented here.
The second broad assumption that I have made is that effective inter-
ventions that modify the risk of death from CHD exist – having been
developed in recent decades – and, further, that such interventions
have been widely implemented in managing CHD in the UK popu-
lation over a similar period. It seems very likely that such a position
would be accepted as quite reasonable by most observers – much of
the labour of clinical cardiological research worldwide has focused on
the developing and refining of these interventions over recent decades;
the plethora of randomised controlled trials, systematic reviews and
meta-analyses, as well as the guidelines based upon them, attests to
the weight of evidence behind this contention. I provide an overview
of specific UK guidance related to the management of CHD in ap-
pendix B. Further, other epidemiological research, service evaluation,
and clinical audits underpin the suggestion that such treatments are
in widespread use at a population level in the UK.
In a UK context, modelling studies suggest that much of the decline
in CHD that has been observed relates to implementation of CHD
treatments on a population scale, and using similar modelling tech-
niques this finding has been replicated elsewhere.13–22 It is likely that
overall effects on differecnce in outcome at population level relate
in greater proportion to differences in risk factor profiles. But these
studies, suggesting as they do a substantial reduction in mortality
over time, imply that healthcare may by making a considerable con-
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tribution to difference: if healthcare can contribute substantially to
differences over time (as shown in these studies), I contend that it is,
at the very least, plausible that it might also contribute to differences
across deprivation groups.
The third underpinning of the rationale is that although many pa-
pers have looked at the issue of inequity in healthcare in a UK setting
– including in relation to CHD – none has done so in a comprehensive,
systematic way across the pathway of care for the disease with a view
to addressing potential population-level effects. I discuss the approach
to accomplishing this in detail in chapter 5. The meaning of healthcare
inequity and the issue of how to quantify it remain problematic; I
discuss these issues in chapter 2, where I also set out the justification
for using ‘utilisation-adjusted-for-need’ as an indicator of healthcare
equity, and discuss the caveats and limitations inherent in doing so.
The contention that my approach is unique is based upon the work
presented in chapter 3. Here I present a detailed review of papers look-
ing at healthcare inequity for CHD in a UK context. I discuss findings
from these studies in detail there, and consider the methodological
implications for my own work – to be sure that my work is novel and
unique in this field.
The fourth contention – that the existence of healthcare inequity or
otherwise is of interest to a wide variety of stakeholders – is borne
out by two different strands of argument. First, the idea of healthcare
inequity can be seen as part of the larger field of health equity/inequity,
and indeed well accepted definitions of health inequity in the field23
regard healthcare inequity as being a component of health inequity.
The importance of the field of health inequity in principle and policy is
evinced in major publications on the subject, thus linking enquiry into
the field of healthcare inequity with major concerns about patterns of
health in society. Second, healthcare inequity is one of the principal
rationales for the constitution of the National Health Service (NHS) in
the UK; the field itself rests on considerations of distributive justice
and ethics that justify the subject in its own right. I discuss these issues
further in chapter 2.
Lastly, I knew that the SAIL databank would provide a technical
platform, available for use by researchers at Cardiff University, to
allow me to look on a large scale at the issue of healthcare inequity in
relation to CHD. I discuss the use of the SAIL databank in chapter 2,
as well as in the methods section of this work.
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Taking these points together, at the inception of this project, I knew
that there was an ongoing problem of inequality in outcomes from
CHD in the UK (rationale point 1), that because of the effectiveness and
widespread use of CHD healthcare interventions (rationale point 2),
together with possible inequity in their utilisation (rationale point 3),
the differences in outcomes seen might relate in part to such healthcare
inequities. Further, I believed that this work would be of interest to
many stakeholders both inside and outside the health service (rationale
point 4), and that, with the existence of the SAIL databank, I had
access to a technical platform that would allow me to investigate this
possibility and address the research questions (rationale point 5).
1.3 aims and objectives
1.3.1 Aims
The overall aim for this thesis was to address the research question in
a way that was methodologically sound, maximizing the chance that
valid conclusions might be drawn. I wanted to make this work explicit
and thus reproducible, comprehensive in its scope, and unique in its
approach. Further, I wished set my methods, findings and conclusions
in the context of previous work in this field.
1.3.2 Objectives
I identified five broad objectives, which align with the structure of this
thesis, and which represent critical steps in the achievement of my
aims.
1. Literature review My first objective was to determine in
detail the nature of the literature available relating to the
provision of healthcare for CHD by socio-economic status.
This was necessary to ensure that I was not duplicating
research already completed; to ensure that the thesis would
add to the existing work in this field; to allow me to set
the work in the context of previous work; and to inform
the development of my methods.
2. Development of methods In the light of the published liter-
ature, and on the basis of my own perspective, I wished to
develop a set of methods designed to address as exactly as
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possible my overall aim. It was important to develop these
ideas clearly before undertaking the analysis; in particular,
I had to give detailed consideration to the opportunities
and limitations presented by the SAIL databank used for
the project. I also had to consider and develop the concept
of the pathway of care for CHD as a basis for my analyses.
3. Data handling and performance of analyses I recognized
that my analyses would depend on accurate processing of
extremely large volumes of complex data. I had to ensure
that the analyses conformed to intentions and were per-
formed rigorously.
4. Presentation of results It was clear that the intention to
carry out a comprehensive study meant that the analyses
would yield a very high volume of results; a key objective
was therefore to present results in an assimilable way while
retaining the depth of detail necessary to allow assessment
of the study’s validity.
5. Discussion of findings and implications The final object-
ive was to synthesise previous work and my findings to
address the research question posed in this chapter.
1.4 overview of thesis
In this section, I discuss the way my methods addressed the study
objectives, and, in doing so, consider some of the principles governing
this work; I also map out the approach that used to present the work
in this document.
The detail of the methods by which I searched, reviewed and as-
sessed relevant literature according to the requirements of objective
1, (above) is contained in chapter 3. The methods included detailed
tabulation in order to summarize, compare and assess findings from
the relevant studies. The review was carried out before I developed
the remainder of the project in detail. Because this work predated the
final development of my own methods the interventions included in
the literature review chapter do not correspond exactly with those
eventually included in my analysis. Specifically, although I reviewed
the literature comparing the adequacy of glycaemic control in diabet-
ics between socio-economic groups, I did not look at this area in my
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analysis – a deliberate omission prompted by concern that a self-care
component obscured relationships in this area.
Discussion of data considerations in chapter 4 has focused on the
SAIL databank, highlighting its usefulness in providing access to
linked datasets within a rigorous information governance framework.
In addition, the concept of the pathway of care for CHD was of
crucial importance to the development of my methods. When first
considering this project, I produced the schematic simplification of the
pathway of care, illustrated in figure 1.1. I recognized that measures
of the appropriateness or timeliness of medical interventions and
treatments at different stages in the pathway of care could form the
basis of my analyses. I developed the concept of ’clinical triggers’. For
example, blood pressure (BP) readings above a certain level would
be expected to trigger clinical action. The quality of healthcare could
be reflected in the relationship between the trigger and the response
(the clinical action) and could in turn be expressed by ’trigger-action
times’. These ’clinical triggers’ could appear at specified stages in
the pathway, from routine risk assessment for CHD through to more
complex management of established CHD. Further, I recognised that
in taking a pathway approach, I would be able to consider knock-on
effects in the pathway, in a way that has not been previously attempted.
These and other related concepts are discussed in detail in chapter 5.
The linkage of the SAIL data, and the level of detail it provided on
individuals’ risk factors, interventions and treatments, allowed me to
plan realistically to base analyses on such concepts (objective 3, above).
I describe in chapter 6 the statistical methods used to take account
of uncertainty in my estimates, to adjust for potential confounding
variables, to examine for supply-side effects, to take account of miss-
ing data, and to examine the sensitivity of findings to underlying
assumptions.
Presentation of this thesis required striking a balance between the
wish to give a comprehensive picture and the risk of presenting an
unmanageable volume of information. Achieving this balance was
a key objective of this work (objective 4, above). To do so, I have
conventionally separated the content into its narrative component
(chapters 1 through to 10) and a set of supplementary appendices that
include information extraneous to the main arguments, but potentially
of interest for reference purposes. I have not included source code in
these appendices, but I am happy to supply this on request.
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I present results in three chapters: a first chapter detailing the
structure of the dataset; a second chapter presenting detailed results
from selected points in the pathway of care for CHD, with referral to
relevant appendices for further detail; and a third chapter giving an
overview of the results.
I address the final objective – discussion of findings and implications
– in chapter 10, where I summarise the findings, appraise the validity
of the study, address my research question, consider the study’s im-
plications, and outline a potential programme of further work in this
field.
In the next chapter, I discuss important background material relev-
ant to this thesis, which is supplemented by information in appendix
B.

2B A C K G R O U N D
In this chapter, I present background material related to socio-economic
inequity in healthcare (and related concepts) and to CHD; I also in-
clude further material concerning the methods used in this thesis.
A number of subject areas have an important bearing on this thesis.
These will be considered in turn under the following broad headings.
1. Background information on inequity, socio-economic deprivation
and healthcare needs assessment
2. Background information on CHD
3. Background relating to thesis methods
Additionally, background material is included in appendix B, the
structure of which is detailed at the end of this chapter.
2.1 background information on inequity, socio-economic
deprivation and healthcare needs assessment
The main subject of this work is inequity in health care by deprivation –
specifically, whether it exists in a systematic way in the management of
CHD and whether it is important in population terms. In this section
summaries of the received knowledge, concepts, and opinions relating
to this area are presented. I leave any development of these ideas to
chapters 5 and 10.
First, I consider healthcare inequity, as this concept underlies much
of what follows; the comparisons in this work are by socio-economic
deprivation, so I also address this concept, including a discussion of
its measurement; lastly, I present information about healthcare needs
assessment conceptualised in epidemiological terms.
2.1.1 Inequities and inequalities
The discussion of healthcare inequity ultimately devolves down to
issues of distributive justice, ethics, and philosophy. Rather than enga-
ging in detailed discussion of these issues, since this is essentially a
data-analysis project, I take the approach of:
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• Summarising these concepts
• Distilling a working definition for healthcare inequity, in line
with widespread usage in the field
• Highlighting the strengths and limitations of this definition
• Implementing the analysis systematically based on this defini-
tion, while acknowledging its weaknesses
It is necessary to distinguish three related concepts:
1. Health inequality/equality
2. Health inequity/equity
3. Healthcare inequity/equity
The third of these is the subject of this work. While the distinction
between health and health care is straightforward, that between in-
equality and inequity is not. Whitehead points out that, in contrast to
inequality (“measurable differences in health experience and health
outcomes between different population groups – according to so-
cioeconomic status, geographical area, age, disability, gender or ethnic
group”24)
“The term inequity has a moral and ethical dimension. It
refers to differences which are unnecessary and avoidable
but, in addition, are also considered unfair and unjust. So,
in order to describe a certain situation as inequitable, the
cause has to be examined and judged to be unfair in the
context of what is going on in the rest of society”24
Kawachi refers to inequity as “inequalities that are deemed to be unfair
or stemming from some form of injustice”25, adding that “the crux of
the distinction between equality and equity is that the identification
of health inequities entails normative judgement”. When considering
health equity, the World Health Organisation (WHO)’s Commission
on the Social Determinants of Health (CSDH) has defined the term as
“the absence of unfair and avoidable or remediable differ-
ences in health among social groups”26
In a number of papers, Braveman has examined definitions of health
inequity. In her work she looks to generate useful wording for defin-
itions of health inequity.23,27,28 Importantly, her definition of health
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inequity includes ideas about social determinants of health – which
themselves might include healthcare. Her broad conclusion is that
avoidability should not be used as a criterion for inequity; rather in-
equity should be identified by the presence of patterns of health in
which already socially disadvantaged groups are further disadvant-
aged. By implication, differences in healthcare (insofar as healthcare
can be adjudged a determinant of health) can be regarded as a form
of health inequity, though it is by no means clear that this would
constitute healthcare inequity according to this definition.
Such an approach is unsatisfactory – being insufficiently specific to
underpin the approach in this work, and inferring healthcare inequity
from a definition designed to address health inequity. Further, this
approach does not address the difficulties that arise when considering
healthcare inequity itself. The principal problem to address is ‘inequity
in what?’. While inequity in healthcare is agreed to be an inequality
at some level in the health care system, and one that is also some
combination of systematic, unfair, avoidable, and patterned in such
a way that socially disadvantaged groups fare worse, it is not by any
means clear which aspect of health care one should seek to see equal-
ised. There are a number of different options, which would include
equalising the following between groups (adapted from Mooney29).
1. expenditure per capita
2. inputs (resources) per capita
3. input for equal need
4. health
5. quality of care
6. funding burden for individuals
7. (opportunity of) access for equal need
8. utilisation for equal need
In the above list, need is conceptualised as a capacity to benefit from
healthcare, except in the last point, where the definition is as discussed
below (page 26).
Therefore many aspects could be regarded as the target for ex-
amining healthcare inequity; different commentators favour different
components as representing the concept. There is no consensus in the
20 background
literature about which of these approaches is optimal30–36, and indeed
they are very likely to represent contradictory aims.
Using measures of provision of health care without adjusting for
need is problematic, because receipt according to need is regarded as
a key principle underpinning healthcare equity. This affects points 1
and 2 above. Likewise, even when expenditure is adjusted for need
this may be regarded as a poor marker, because costs and efficiencies
may vary, discriminating against those with need in areas where
provision of health care is more expensive (affecting point 3 above).
At the other extreme, judging equity in health care based on outcome
levels of health would seem to place unreasonable expectations on the
capacity of health care to influence population health (point 4 above).
Legitimately, an analysis of healthcare inequity might address issues of
quality of care (where quality of care is examined independently of the
volume of care) – even if groups are receiving care at the same level,
one can address the issue of whether the actual care delivered is of
equal quality (point 5 above). In some contexts, inequity in health care
might be defined on the basis of the funding burden to individuals
receiving that care (point 6 above). The remaining points in the above
list relate broadly to access adjusted for need (point 7) or to utilisation
adjusted for need (point 8 ).
Access can be envisaged either as the barriers (typically cost to the
individual) to healthcare or as the potential level of healthcare that an
individual might utilise, given the opportunity and inclination. Access
is thus, in the latter conception, related purely to supply. In contrast,
utilisation of healthcare adjusted for need is a reflection of supply
modified by demand. In simple terms, an individual might be likely
to benefit from intervention (need), be offered it (supply), but turn it
down (demand). Some commentators would regard such a situation
as equitable, others as inequitable (citing underlying inequities in
the education, personal resources and so on affecting an individual’s
decision-making). Studies looking only at access (pure analysis of
supply) are less equivocally investigating the possibility of an unfair
situation; in practice, studies examining utilisation as a measure of
healthcare inequity are more common, because utilisation is much
easier to measure.
Particularly where there is sub-optimal care, the volume of health
care, as well as its distribution, matters to patients. In such a situation
it is possible that an increased volume of health care might benefit
everyone but actually increase inequality between the most and least
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deprived. (The most deprived benefit but the least deprived benefit
even more).
How would this fit with concepts of healthcare equity? Rawls,
addressing the general (not necessarily health-related) issue of dis-
tributive justice, derived the concept of the ’difference principle’.37
Essentially this argued that inequality in the distribution of goods is
acceptable only if it is to the advantage of those who are worst off.
Daniels argued that health care counts as a ’primary good’ and that
the difference principle can be applied to it.38,39 These concepts would
have relevance in this thesis to the interpretation of evidence from
any studies that show improvements in healthcare in all deprivation
groups but widening inequality.
Consideration of these issues has led to adopting the following
approach in this work40–47:
• I have favoured examination of utilisation of healthcare adjusted
for need, given that such an approach is both intellectually
justifiable and analytically practical
• I have kept in mind that utilisation adjusted for need gives a
picture of the situation in which need, demand, and supply over-
lap, whereas, in an ideal world, provision of healthcare might
be based upon matching of supply to need only, irrespective
of demand. Thus, in interpreting any findings in this work, I
have kept in mind that any conclusions drawn are potentially be-
holden to differences in demand between groups – information
not available in routine data. Were it found that some aspects of
care for CHD were utilised less by more deprived groups, there
would be no way of determining whether this might relate to
more refusals of care in that group. This represents an inevitable
limitation of my approach, acknowledged from the outset.
When considering either utilisation adjusted for need or access ad-
justed for need, commentators have distinguished horizontal equity
(equal healthcare for equal need) and vertical equity (unequal health-
care for unequal need). Such concepts deal with the issue of propor-
tionate access or utilisation for the level of need. The approach in
this work has been to look at horizontal equity (equal utilisation for
equal need) but to do so at many points in a pathway of care for
CHD, so as to build a composite picture of healthcare for CHD from
multiple comparisons of horizontal equity; in so doing the aim is also
to determine whether higher levels of need at a population level result
22 background
in higher levels of utilisation – thus allowing one to address vertical
equity considerations as well.
2.1.2 Socio-economic deprivation
In this thesis, the concept of deprivation plays a key role in the compar-
isons made between groups. Deprivation is a term that is not defined
or used in the same way by all commentators. Townsend offers the
following definition:
“...a state of observable and demonstrable disadvantage
relative to the local community or the wider society or
nation to which an individual, family or group belongs”48
The concept is thus overlapping with, though not synonymous with,
that of poverty48. There is no universally accepted definition of poverty,
and the distinction is often made between absolute and relative
poverty; absolute poverty refers to a lack of the means of physical
subsistence; relative poverty extends the concept to individuals as
social beings who have psychological needs to participate in a society
and share its norms. A common measure of poverty, as used in Child
Poverty Act 2010, is ‘household income below 60 percent of median
income’.49 Similarly, deprivation itself can take a number of different
forms.48 Material deprivation implies a lack of access to goods and
resources; social deprivation involves a paucity in relation to an in-
dividual’s roles and relationships in society48. Multiple deprivation
occurs when an individual is at a disadvantage across a number of
different domains.
A further related concept is the idea of socio-economic position.
Individuals in a society can be classified according to some dimension
of socio-economic status, for example income, education, occupation,
housing tenure and so on50. Again, there is substantial overlap with
the concept of deprivation: higher status within society is correlated
with an increased capacity to access both material and social resource
within that society.5
2.1.2.1 Measures of deprivation
A number of specific measures have been developed and implemented
to characterise levels of deprivation within populations. Particular to
the UK are a number of different deprivation measures.
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While socio-economic position is more meaningfully measured at
an individual level, the concept of deprivation has, in contrast, given
rise to measures based on the characteristics of the area in which an
individual lives – so-called ecological measures. Such measures have
the advantage of being readily ascribed to individuals even in the
absence of individual-level data on socio-economic position, because
they rely only on information about the area in which an individual
lives; the accompanying disadvantage of such an approach is the
ecological fallacy: determining an individual’s level of deprivation
based on the area in which they live may be an invalid inference51. For
this thesis, area-based deprivation measures have been used, simply
because the routine data-sources on which this thesis is based do not
provide individual-level indications of socio-economic position (or
deprivation). While Office for National Statistics (ONS) mortality data
does contain a field for occupation, this is only available for individuals
who have died. In theory, individual-level data from the census on
income, occupation, and other individual-level characteristics such as
ethnicity might be linked to the data employed in this thesis; at the
moment this is not possible in practice.
A number of different indices of deprivation have been used in the
UK. The majority have employed data from census returns, used in
varying combinations, sometimes with a weighting system. Examples
of such scores include the Jarman Underprivileged Area Score52, the
Scotdep Index of Carstairs and Morris53, the Scottish Development
Department Index54, the Matdep and Socdep Indices of Forest and
Gordon54, the Index of Local Conditions54, the Breadline Britain in-
dex50(census data combined with survey data) and the Townsend
index55,56. Census-based indices are in general comprised of variables
that are proxy indicators of deprivation – an approach dictated by the
absence of data on income in census returns. Census data in the UK
are only available at 10-year intervals.
The UK Indices of Multiple Deprivation (Index of Multiple Depriva-
tion (IMD), Scottish Index of Multiple Deprivation (SIMD), and Welsh
Index of Multiple Deprivation (WIMD)) overcome two of the disad-
vantages of census-based indices: they are based on data sets updated
at more frequent intervals than that collected for the census, and they
include data related to income. Constituent nations of the UK use
different versions of the Index of Multiple Deprivation, each differing
in specifics but sharing underlying principles. The index specific to
Wales is the WIMD.
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Table 2.1: Domains and weightings for the 2005 and 2008 Welsh Indices of
Multiple Deprivation
2005 2008
Domain Weighting (%) Domain Weighting (%)
Income 25 Income 23.5
Employment 25 Employment 23.5
Health 15 Health 14
Education 15 Education 14
Housing 5 Housing 5
Access to services 10 Access to services 10
Environment 5 Environment 5
Community safety 5
The WIMD is the official measure of deprivation at Lower Super
Output Area (LSOA)-level in Wales. The original development ofLSOAs are
discussed in
section B.1.1
the deprivation index was carried out in the year 2000 by the Welsh
Office (and subsequently Welsh Assembly Government (WAG)) in
collaboration with the Social Disadvantage Research Group at the
University of Oxford57. Officials required a replacement to the Welsh
Index of Socio-Economic Conditions (the then current index in Wales,
which used a number of ward-level indicators from the 1991 census)
that utilised new methodologies and sources of data57. The Welsh
Index of Multiple Deprivation 2000 (WIMD 2000) has been followed
in the intervening years by further revisions of the index, Welsh Index
of Multiple Deprivation 2005 (WIMD 2005), Welsh Index of Multiple
Deprivation 2008 (WIMD 2008), as well as further versions released
during the writing of this thesis.58,59Information on the
indicators used in
the calculation of
domains for the 2.1
is provided in
appendix A
In common with other indices of multiple deprivation, the WIMDs
have a number of domains. The domains for the WIMD 2005 and
WIMD 2008 are summarised in table 2.1.58,59
The WIMDs contain a health domain. When looking at health out-
comes in relation to deprivation using these indices, the inclusion of
this domain predisposes to the development of circular logic, whereby
an association is sought between deprivation and the particular health
indicator when health has already being included as a component of
deprivation. Despite this theoretical concern, evidence suggests that
the inclusion of a health domain within the index is not important
in generating such circularity. Criticisms of the WIMD include the
fact that it is unvalidated, and that it is based on the use of the data
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Figure 2.1: Need, supply, and demand
Need Demand
Supply
Adapted from Stevens A, Raftery J, Mant J; An Introduction to HCNA
that are available rather than the data that might a priori be sought
in attempting to quantify deprivation (though this limitation applies
to all deprivation measures that rely on routine data). The decisions
about which domains to include, which data to use to derive domain
scores, and the weighting to be given to each domain are all subjective
decisions. Further subjectivity arises from the technical implementa-
tion of the index, with some domains subject to shrinkage techniques,
and with the use of statistical techniques to accomplish the ranking
of LSOAs58. Despite these caveats, the WIMD correlates very closely LSOAs are
discussed further
in section B.1.1
with other deprivation measures.
The use of the WIMD as a deprivation measure for comparisons
is based on my judgement that its disadvantages (ecological nature;
validation issues; statistical underpinnings; subjectivity; presence of
a health domain; and use of available rather than desirable data) are
overall outweighed by its advantages (routine availability; widespread
use; widely accepted; frequently updated; available at LSOA level,
thereby allowing linkage; and correlation with other similar measures).
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2.1.3 Health care needs assessment
Healthcare needs assessment is a systematic process used to ascertain
the extent to which the supply of health services matches the need
for such services. The optimal situation from an efficiency and equity
perspective is to match exactly the level of healthcare supplied to the
need for it. In reality, mismatches exist. The process of healthcare
needs assessment is important in guiding efforts to ameliorate such
mismatches.
Underpinning healthcare needs assessments is the idea of need
as, “The capacity to benefit from an intervention or treatment”. Thus,
individuals can be deemed to need an intervention where the balance
of risks and benefits is favourable.
Supply can be conceptualised as the rate of health care provided; it
is identified by looking at the delivery of interventions and services
across populations.
A further important concept is demand: it can complicate the re-
lationship between need and supply. While someone may be likely
to benefit from an intervention, they may not ask for, be identified
as needing, or consent to it; the converse also applies in that those
wishing to undergo an intervention may be unlikely to benefit from it.
Thus, demand, the expressed intention of an individual to undergo an
intervention, is a distinct concept from need and independent of it.
Indeed, several possible combinations of need, supply, and demand
can occur in any one situation, as illustrated in figure 2.1. The ideal
lies in the middle of the figure, where an individual with capacity to
benefit from an intervention, wishes to and consents to undergo it,
and is supplied with the intervention. Other combinations shown in
figure 2.1 correspond to situations which are undesirable.
Situations in which healthcare inequity occur, can be considered
as systematic mismatches between supply and need between groups
within the population that vary with respect to a particular character-
istic (for example gender or deprivation level).
Three categories of healthcare needs assessment exist: comparative
(comparing need and supply between populations), corporate (asking
key stakeholders), and epidemiological. The last of these is the most
rigorous, but is often not performed in reality due to data limitations.
Broadly, it involves estimating, usually from routine data, the level of
need for an intervention in the population and ascertainment of the
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level of supply of the intervention in the same population. Gaps in
need are identified.
While such assessments can be rudimentary, relying on quite crude
estimates of need (in particular), there is no theoretical reason why
this should be so. In an idealised situation, valid ascertainment of
need would take account of all factors that might affect an individual’s
capacity to benefit from an intervention, for instance the stage or
severity of the disease or risk factor at which the intervention might
be directed, comorbidities, allergies, intolerance to medications, and
other factors. Similarly, identifying demand requires determining if
an individual wants an intervention, independent of whether it is
supplied or needed. Where demand overlaps with supply (an inter-
vention is supplied to a consenting individual) identifying demand
is fairly straightforward: supply, which is usually quite readily as-
certained, accompanies demand. The situation in which there is no
demand, despite clinical need and the potential for supply, is diffi-
cult to identify: offers of interventions which are declined are not
systematically recorded in routine data.
These considerations mean that a number of possible explanations
for findings from need assessments can be differentiated. Specifically
in relation to CHD, where inequity in provision is observed between
deprivation groups (for example), explanations might include the
following.
1. The relationship does not in fact exist as postulated. More socio-
economically deprived groups in fact have just the same chance
of receiving interventions. The relationship that appears to exist
is, in fact, a product of methodological weaknesses and random
effects.
2. Utilised supply of CHD interventions does, in fact, match the
existing need for these procedures, but appears not to. This po-
tential explanation applies particularly to surgical and invasive
radiological procedures. Despite an increased burden of CHD
in those from more deprived socio-economic groups, they may
have a decreased ability to benefit from procedures (need), be-
cause of comorbidities and adverse risk factors. This explanation
would represent a mis-ascertainment of clinical need.
3. Offered supply does match need. Those in more deprived socio-
economic groups may be offered CHD drugs or revascularisation
procedures at a rate appropriate to their level of need, but turn
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them down more frequently. In this explanation, there is need
and supply, but no demand for the intervention from the in-
dividual in question, and insufficient information available to
ascertain this fact
4. Those in more deprived socio-economic groups are systematic-
ally less engaged with the health care system, so that there is
less opportunity for care to be offered by the health care system
to these groups. This explanation would reflect a lack of demand
and supply for the intervention, despite the presence of a clinical
need.
5. The healthcare system systematically offers fewer CHD interven-
tions per level of need to those individuals in more deprived
socio-economic groups. This situation would reflect a lack of
supply, despite the presence of need and demand.
6. Those in more deprived groups are receiving the intervention
exactly according to clinical need; the observed gradient seen
relates to an over-supply of the intervention to less deprived
inderviduals – a situation in which there is supply and demand
for an intervention, but no clinical need.
Such potential explanations are important for this thesis, and high-
light some of the problems with epidemiological healthcare needs
assessment, which relate particularly to unknown information.
The degree of simplification entailed when using definitions based
closely on those postulated by Braveman (see section 2.1.1) becomes
clear when considering these permutations of interpretation that can
occur with healthcare needs assessment approaches: essentially such
definitions simplify the situation to consideration only of need and
supply – differences in demand are by definition ignored. Despite this,
the overriding advantage of the approach is that it makes it possible
to address issues of inequity using routine data.
2.2 background information on chd
The epidemiology of CHD, is relevant to the background of this work.
For the interested reader, I include information on the pathophysiology,
classification, and management of CHD in appendix B – as well as
information on the organisation of cardiac services in Wales. In the
introductory chapter, I discussed patterns of CHD mortality in relation
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to deprivation – introduced earlier because of its importance to this
work – and that discussion is not reprised here; neither do I cover
the detailed epidemiology that underpins the management of CHD
here (in other words the randomised control trials and meta-analysis
on which guidance is based), but limit the discussion to that in sec-
tion B.2.3 of appendix B, where I detail the guidance relevant to the
management of the condition.
2.2.1 Epidemiology
Historically of less importance than infection and trauma, the burden
of CHD achieved prominence in Western countries in the middle of
the twentieth century. Two factors explained this: firstly, the public
health breakthroughs of the preceding decades (including mass im-
munisation, provision of clean water, perinatal care, and improvements
in social conditions) increased survival to older ages and unmasked
CHD; secondly, the 20th century, particularly the latter half, saw two
of the major risk factors that drive CHD, adverse diet and smoking,
become mass phenomena in Western industrialised countries60. Fur-
ther, adverse diet, abetted by sedentary lifestyle, contributed to high
population prevalences of other common traits predisposing to CHD:
above-optimal levels of serum total cholesterol, raised blood pressure,
overweight/obesity, and diabetes mellitus60.
As late as the 1940s, there was very little widespread understanding
of CHD risk factors (a term not coined until 196161) and very few
interventions were available to prevent or treat the disease itself. For ex-
ample, in 1944, a moribund President Roosevelt – smoking, immobile,
cocktail-drinking, blood pressure 260/150, with clinical manifesta-
tions of angina, malignant hypertension and congestive heart failure
– was attended by a personal physician who insisted that his health
was good and who believed that his subsequent death from cerebral
haemorrhage ‘came out of the clear sky’62.
Since that time, there have been important improvements in un-
derstanding of the aetiology of CHD and of effective interventions.
Initially, in the years following the Second World War, long-term pro-
spective within-population studies60, which followed large cohorts
of individuals over time, began to implicate a number of patient
factors in the development of CHD; best known is the Framingham
study62. Evidence from such studies was complemented by findings
from studies which looked at cross-cultural variations in disease oc-
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currence, including in migrant populations62. From the late 1960s
onwards, increasing numbers of interventional studies evaluated the
effects of interventions to treat CHD and its risk factors62. All types
of epidemiological investigation of CHD have continued apace to the
present day, with a resultant continual increase in knowledge about
the condition62.
Increased understanding of risk factors for CHD and other cardi-
ovascular diseases, of effective treatments, and of the public health
principles that underpin prevention strategies, have all contributed
to a continuing decline in CHD in Western countries since the 1970s.
However, in developing areas of the world, economic progress is fre-
quently being accompanied by an increasing burden of CHD63. Even
in developed Western countries, CHD remains a major cause of death,
including of premature death, particularly in economically deprived
populations63.
2.2.1.1 Descriptive epidemiology
In North American64 and Western European populations the burden
of coronary heart disease has declined since the 1970s, but this is by no
means a global phenomenon. Declining trends in mortality mirroring
those seen in Western Europe and North America have also been
observed in Japan, Singapore and Hong Kong since approximately
198065, but the latter third of the 20th century saw a peak in CHD
in Eastern Europe and the countries of the former Soviet Union,
particularly prominent in Russia66. It is predicted that in many of
these countries the proportion of CHD-related deaths as a fraction of
total deaths will rise sharply, and that cardiovascular disease (CVD)
overall will become the leading cause of death, with CHD as a main
contributor67,68.
The situation the UK is broadly typical of the western European pic-
ture69. Routinely collected data on CVD mortality is available for the
whole of the 20th century for the UK, and corresponding population
data is available to allow calculation of mortality rates. Since the 1960s,
a clear picture emerges in which the rates of CVD have declined, with
a significant part of this trend related to a decline in CHD69.
In 1961, CVD accounted for 48% of all deaths in men and 55% of
all deaths in women69; by 2001 this figure was 33% for both sexes69.
In 1981 CHD accounted for 31% deaths in men and 23% of deaths in
women, figures which had fallen to 18% in men and 12% in women by
200969. Further, these deaths tended to occur at older ages, such that
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the age-standardised mortality rates for CHD have fallen substantially.
In men, the age-standardised mortality rate for CHD fell from approx-
imately 500 per 100,000 in 1961 to approximately 120 per 100,000 in
200969. In women, the rate fell from approximately 240 per 100,000 in
1961 to approximately 60 per 100,000 in 200969.
In those under 55 years of age, the age standardised mortality
continued to rise until the early 1970s, but has declined since then. In
men aged less than 55, from a high of approximately 53 per 100,000 in
197269, rates had fallen to approximately 12 per 100,000 by 200969. In
women aged less than 55, there was a drop from approximately 9 per
100,000 in 1979 to approximately 2.5 per 100,000 by 200969. Against
this background decline, there is some suggestion that declines in
CHD may have stopped or be reversing in younger age groups – an
effect presumed to relate to increasing obesity and type 2 diabetes
prevalence70.
The adverse trends in obesity and diabetes are clearly of great im-
portance in relation to prevention of CHD. Of particular relevance to
this thesis is the evidence of unequal socio-economic patterning in
those trends. Hotchkiss et al, in a study of the Scottish population,
1995-2009, considered the relationship between CVD biomarkers and
socio-economic patterns. They found significant evidence of persisting
inequalities, particularly for the anthropometric measures (includ-
ing waist circumference and waist to hip ratio) when stratified by
education.71 Agardh et al, in a systematic review of evidence from
high-, middle- and low-income countries found that the risk of get-
ting type 2 diabetes was associated with low socio-economic position
overall, but that the strength of the associations was more consistent
in high-income countries.72
The burden of coronary heart disease has not been evenly distrib-
uted across the constituent nations of the UK69. In 1961, age standard-
ised CHD mortality rates in Wales were 14% higher than in England
in men and seven percent higher in women. Similarly rates in Scotland
were 30% and 37% higher respectively69. This disparity has persisted;
in 2009 rates in Wales were 13% higher than in England for men and
17% higher than in England for women; with corresponding figures
of 25% and 36% in Scotland69.
The pattern of decline in CHD since the 1960s predominantly re-
flects changes in population risk factors, but also relates to improved
treatments and survival for those with established CHD20–22,73,74.
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The decline in CHD mortality observed in USA during the 1960’s
coincided with a marked reduction in cigarette smoking and consump-
tion of animal fats.75 Dwyer and Hetzel, comparing CHD mortality in
Australia, the USA and in England and Wales, noted the sharp decline
in rates in Australia from 1966, in the USA from 1968, and the later
decline (1972 onwards) in England and Wales. They found correla-
tions with patterns of smoking and diet that correlated with these
changes.75 Capewell, in a study of the Scottish population, estimates
that in 1975, when CHD mortality had begun to fall, the relatively
limited treatments then available were saving approximately 554 CHD
deaths a year, compared with 6203 deaths saved by treatments in 1994.
It is estimated that by 1994 40% of the overall decline in CHD deaths
was due to cardiovascular treatments, the remainder due to reduction
of risk factors.20 Therefore the broad picture of the decline in CHD
mortality since the 1960’s appears to be of an earlier phase due very
largely to risk reduction and a later phase when increasingly effective
treatments contributed substantially.
Unal et al, studying the population aged 25-84 in England and Wales
between 1981 and 2000, reported that CHD mortality was reduced
by 62% in men and 45% in women. They attributed 42% of this
reduction to treatments – 8% to treatment of myocardial infarction,
13% to treatment of heart failure, 3% to treatment of hypertension,
and 11% to secondary prevention. The remaining 58% they attributed
to due reduced risk factors – this despite adverse trends in physical
inactivity, obesity, and diabetes. Hughes et al modelling CHD mortality
in Northern Ireland 1987-2007, estimated that 35% of the reduction was
due to treatment and 60% due to reduction in risk factors. They also
noted the adverse trend in physical inactivity, obesity and diabetes.15
Unal et al, in a study of the population of England and Wales 1981-
2000, estimated that reductions in major risk factors led to four times
as many life-years gained as cardiovascular treatments led to.76
In Oxfordshire, the case-fatality rate for myocardial infarction de-
clined in all age groups between 1968 and 1998 for both sexes69. For
example, the case-fatality rate for men aged 80 to 84 declined from
close to 90% in 1968 to approximately 70% by 199869.
Prevalence data for angina are difficult to compare over time69, but
evidence from both the National Morbidity Survey and the Health Sur-
vey for England (HSE) broadly suggest that the prevalence of angina
increased (rising from 380 per 100,000 to 1300 per 100,000 between 1955
and 1991 in men); a similar, smaller rise occurred in women. Between
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1994 and 2006 prevalence continued to increase – by 46% in men over
75 and by 20% in women over 75.69. The increase in incidence and
prevalence of angina contrasts with declining CHD mortality. Lampe
reports that when the prevalence of angina was assessed according
to symptoms and using a standardized questionnaire, the prevalence
of angina symptoms appeared to fall between 1978-1996 in men in
the UK.77 However her later study of men in the UK aged 40–59 at
entry, over the period 1978–80 to 1998–2000, using NHS central re-
gisters and general practitioner (GP) records, showed an increase in
the incidence of diagnosed angina. It is suggested that this may be a
feature of changes in diagnostic practice rather than a real increase in
disease incidence, and that an increase in ascertainment and diagnosis
of angina may result from general practitioners prioritising the early
identification and treatment of coronary heart disease, as well as from
an increase in availability of diagnostic investigations for chest pain.78
An additional reason for the apparent divergence between increased
incidence of angina and decline in CHD mortality is thought to relate
to more effective treatment and this may apply particularly to treat-
ment of heart failure (CHD being a major cause of heart failure). An
additional effect may be the improved diagnosis of CHD-related heart
failure leading to its specific treatment. Cowie, in a UK study of heart
failure in all age groups,79 reported that when diagnosis was based
on clinical assessment, electrocardiography, chest radiography and
transthoracic echocardiography, the primary aetiologies were CHD
(36%), unknown (34%), hypertension (14%), valve disease (7%), atrial
fibrillation alone (5%), and other (5%). However, in a separate study80
in which diagnosis was assisted by angiography Cowie found that
CHD was the cause of 52% of incident heart failure in the general
population under 75 years, and concluded that clinical assessment
without angiography under-estimates the proportion of patients with
heart failure with coronary artery disease, and fails to identify those
patients who may benefit from revascularization.
There was a less clear-cut picture for MI69; the prevalence of heart
failure substantially increased between the 1950s and 1970s (230 per
100,000 in 1955 rising to 700 per 100,000 in 1974 women), with a more
recent increase likely though difficult to characterise from available
data69.
The incidence of CHD, being largely unaffected by changes in sur-
vival, has decreased for CHD, MI (from a peak in the late 1970s) and
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heart failure, with the steepest declines occurring in younger age
groups69.
Epidemiological studies have been instrumental in identifying a
number of important risk factors for CHD (discussed further in sec-
tion 2.2.1.2) and changes in their prevalence. Smoking prevalence has
declined throughout the UK; it was 46% in 1972; this had declined to
21% by 200869. Consumption patterns of fats has changed: skimmed
milk has displaced whole milk; vegetable fat consumption has risen,
while consumption of animal-derived fats (butter and lard) has de-
clined; consumption of red meats has significantly declined, being
replaced with poultry69. Consumption of oily fish has increased since
the 1990s, with some suggestion that this increase is at the expense of
white fish, rather than other forms of protein69. Availability of fruit
and vegetables has increased since the 1970s. This increase relates
principally to an increase in the availability of fruit69.
Long-term trends in physical activity levels are difficult to assess
accurately in the UK over the long-term. In recent years, compliance
with government recommendations for physical activity has slowly
increased in the UK,69. Proxy measures of physical activity level, such
as television ownership, car ownership, and active travel, provide
indirect evidence of a reduced level of physical and activity at the
population level69.
Heavy drinking prevalence, measured since 1978 in the General
Household Survey, appears not to have substantially increased since
the 1970s69, though difficulties with changing definitions of heavy
drinking make interpretation of such data difficult. WHO data on the
total amount of alcohol consumed corroborate this finding, suggesting
that total intake has not changed greatly since the late 1970s69.
Data on the population prevalence of obesity from the HSE suggest
that, since the 1960s and particularly since the 1990s, the average body
mass index (BMI) for both men and women has increased69.
2.2.1.2 Aetiological epidemiology
A prodigious research output in the years since the Second World War
has produced an enormous amount of epidemiological evidence – as
well as evidence from animal experimentation, pathological investiga-
tion, clinical research, and molecular and cell biology – on risk factors
for the development of CHD60,81. Beyond the major non-modifiable
risk factors (age and sex), six modifiable risk factors are now regarded
as major established risk factors, classified by Stamler as follows60,81:
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1. Serum total cholesterol
2. BP were
3. Overweight and obesity
4. Smoking
5. Diabetes mellitus
6. Adverse diet
The exact relative risks from these risk factors vary according to study.
By way of illustration, the large Multiple Risk Factor Intervention
Trial (MRFIT) study81 – which includes 25 years of follow-up data on
smoking, BP, cholesterol, as well as other risk factors – is sufficiently
large to allow stratification by BP, cholesterol, smoking status, and age.
The hazard ratios for the 39 to 44 age group are presented in table 2.2.
It is clear that for any given level of cholesterol and smoking status,
risk rises as blood pressure rises; similarly risk rises with increased
serum cholesterol for any given blood pressure in smokers or non-
smokers; at a given cholesterol and BP smokers have a higher risk.
Moreover, these major risk factors are multiplicative in their effects81.
Similar patterns and approaches have been used to establish the other
major risk factors as strong, graded, and independent risk factors for
the development of CHD81.
At the height of CHD incidence, when many of the studies looking
at risk factors were performed, only a small proportion of those
individuals included were in low risk categories for all risk factors.
This meant that it was initially difficult to infer the extent to which low-
risk status was beneficial except by means of statistical interpolation.
Pooling of the increasing amount of data from large studies and the
increasing proportion of the population that is in low risk groups
means that such inferences are now possible based on actual data81.
This concrete understanding of the benefits of achieving low risk status
has important indications for prevention of CHD in the population as
a whole, as discussed further in section B.2.5.181.
An extensive list of other factors has been considered as potential
risk factors for CHD and CVD. The extent to which the aetiological
connection has been demonstrated from epidemiological and other
evidence varies; such factors include well known risk factors such
as physical activity level, alcohol consumption, metabolic syndrome,
and psychosocial factors82,83; other putative factors include antioxid-
ants, fish consumption and n-3 fatty acids, oral contraceptives, mental
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Table 2.2: Serum cholesterol (SC), SBP strata, smoking, and hazard ratio for
CHD death, for 149339 MRFIT men aged 39-44 at baseline. All
analyses exclude persons with history of MI at baseline; follow up
25 years; 3345 CHD deaths.Hazard ratio adjusted for age, race, and
diabetes; substratum for non-smokers with total cholesterol <180
mg/dL and SBP 6 120 mmHg set at 1.00
SC (mg/dl) SBP (mmHg)
6120 121-9 130-9 140-59 160+
Non-smokers at baseline
<180 1.00 1.38 2.45 4.09 10.25
180-99 1.78 2.50 2.95 4.79 12.64
200-19 1.96 2.26 3.14 5.63 8.57
220-39 2.68 2.84 5.47 7.61 21.72
240+ 3.66 6.64 8.65 13.18 26.77
Smokers at baseline
<180 3.35 3.10 7.55 10.32 37.61
180-99 5.78 6.86 7.82 12.82 24.74
200-19 5.69 7.28 10.22 18.92 22.25
220-39 7.94 10.74 14.74 23.16 41.23
240+ 14.53 19.09 20.36 34.46 52.26
Figures from Stamler81, page 43
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illness, and air-pollution84–88. A number of candidate factors are bio-
markers thought to relate to the pathogenesis of CHD, for example
C-reactive protein (CRP)89,90, homocysteine91,92, lipoprotein(a)93, and
haemostatic factors (for example plasminogen activator inhibitor 1,
thrombin and platelet-derived factors). The literature in this area is
extremely extensive, and a thorough review of all cardiovascular risk
factors is far beyond the scope of this thesis; it is useful to note that if
consideration is only given to major established risk factors, it is still
possible to explain a large proportion of the observed difference in
cardiovascular risk between individuals.
A further influence on an individual’s cardiovascular risk arises
from their experience at the start of life, including their time in utero.
The hypothesis that maternal nutrition is an important predictor of
chronic disease in later life, including CHD and other CVDs, was
first advanced by David Barker, based on evidence from retrospective
cohort studies, and is known as the Barker hypothesis or thifty pheno-
type94. The initial hypothesis has received further support from the
Dutch famine study (a natural experiment that occured in the Nether-
lands in the Second World War, when a proportion of the population
was exposed to a famine with a fairly discrete onset and cessation);
detailed medical records were kept throughout the period of interest.
A number of investigators have examined the influence of maternal nu-
trition on the subsequent health of the affected offspring95. Evidence
from such studies suggests that children exposed to famine condi-
tions in utero have an altered risk profile as adults, and, specifically
in relation to CHD, have increased risks of developing a number of
adverse risk factors for the disease (atherogenic lipid profile, disturbed
blood coagulation, increased stress responsiveness, and obesity) as
well as having an increased risk of CHD itself95. These studies present
more direct evidence of the effect of maternal nutrition in pregnancy
on chronic disease in offspring – as they look directly at maternal
nutrition rather than using birth weight as a proxy. In support of
the Barker hypothesis, numerous studies have now demonstrated a
link between birth weight (and sometimes maternal nutrition) and a
number of chronic diseases: CHD, diabetes, hypertension and stroke96,
though the potential for important variables (for example maternal
smoking) to confound this relationship must be borne in mind96 .
The mechanism by which a true association is thought to occur is by
foetal programing by nutritional stimuli or excess fetal glucocorticoid
exposure96.
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2.2.1.3 Overview
On consideration of the epidemiology of CHD, a number of clearly-
established points emerged:
• The disease is still of major public health importance in view of
its effect at a population level, including its implication in pre-
mature mortality and its increasing impact in many developing
countries
• There has been a decline in the burden of CHD in Western
countries in recent decades
• Understanding of the aetiology and risk factors has progressed
enormously in recent decades, though some variation remains
unexplained
• For many risk factors, population profiles have improved in West-
ern countries (including the UK), though obesity and diabetes
prevalence are worsening on a population scale
I discussed in the introductory chapter two further points, which
underpin this thesis and are themselves derived from epidemiological
investigation:
• Inequalities in outcome between socio-economic groups in mor-
tality from CHD have been consistently observed in epidemi-
ological studies; over time absolute differences between these
groups have reduced; relative differences have worsened. De-
prived groups consistently have a higher burden of the disease
• Many interventions are now available to manage CHD; the evid-
ence for the effectiveness of these interventions comes from
randomised controlled trials and studies that synthesise their
results
2.3 background information relating to thesis methods
In this section I look at the background relevant to the way in which I
addressed the research questions. Specifically, I describe the opportun-
ity presented by the SAIL databank at Swansea University, including
an overview of its operation and background information about the
relevant datasets held within the SAIL databank. Some additional
information on clinical coding has been included in appendix B.3.1, as
many readers will already be familiar with this material.
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2.3.1 Anonymised data linkage and SAIL
The SAIL system is based in the Health Information Research Unit
(HIRU) at Swansea University. The unit’s aim is to ‘realise the poten-
tial of electronically-held, person-based, routinely-collected data to
conduct and support health-related studies’.97 To achieve this, HIRU
have established the SAIL databank which operates on a DB2 plat-
form (Data Warehouse Edition on AIX), running on an IBM ‘P’ series
supercomputer (Blue-C).97 The system holds over 2 billion records of
health and health-related data, and accumulates additional records
over time.
For the purposes of this thesis, I required that data held within
SAIL be linked to allow primary-care data, hospital-activity data, and
mortality data to be brought together to inform the clinical history
of individuals. In general, data linkage has enormous potential to
improve the usefulness of the increasing number of health and social
service data available for health and social care research, for service
planning, and for service improvement, but the process of data linkage
raises a number of ethical and technical issues.
Ethical considerations arise because much of the data held is sens-
itive in nature, and thus steps must be taken to prevent researchers
identifying individuals; moreover, the process of data-linkage poten-
tially makes identification more likely, as more information can be
retrieved for an individual. The ethical management of large, linked
databanks therefore presents a number of Information Governance
challenges to those administering them.
A number of approaches might be taken to minimising the risk
of any breach of confidentiality associated with the use of linked
databanks. These range from simply anonymizing all potentially iden-
tifiable information in the data bank, through to a multifaceted ap-
proach that includes anonymization but also employs data-aggregation
and data-suppression techniques, user-authentication processes, scru-
tiny of data-use, and disclosure-control at the stages of analysis and
publication97. The HIRU team at Swansea have addressed in detail the
information-governance arrangements required to operate the SAIL
databank, and have presented information on these processes in peer-
reviewed publications.97,98 Specifically, they have developed a number
of processes that address information-governance concerns:97
1. Ensuring data transportation is secure
2. Operating a reliable record-linkage technique
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3. Anonymisation and encryption of data to prevent re-identification
of individuals
4. Applying measures to address disclosure-risk in data-views
created for researchers
5. Ensuring data access is controlled and authorised
6. Establishing methods for scrutinising proposals for data-utilisation
and improving output
7. Gaining external verification of compliance with information
governance
In adopting a pragmatic approach to the ethical issues surrounding the
operation of the SAIL databank, the administrators at SAIL have been
able to address the key challenges in establishing a national databank
of anonymised person-based records for the purposes of research and
evaluation, while at the same time adhering to the requirements of
information governance97.
The formal scrutiny process at HIRU requires applications to be
approved by independent adjudicators in HIRU Collaborative Review
System (CRS), the panel of adjudicators making up the Information
Governments Review Panel (IGRP). Membership of the IGRP is com-
posed of senior representatives from the British Medical Association,
the National Research Ethics Service, Public Health Wales NHS Trust
(PHW), NHS Wales Information Service, and Involving People (an
organisation which aims to encourage public involvement in health
and social care research in Wales).Members of the panel assess the ap-
plication against a number of criteria, including the project’s rationale,
design, protocol and data specifications.
In addition to developing information-governance systems, HIRU
have put in place technical capabilities to deal with very large datasets
and with data-linkage between datasets.
When linking data for an individual, it is common for important
information, such as a correct NHS number, to be missing or incorrect.
This clearly presents issues for the data-linking process. HIRU have
developed algorithms capable of matching records together for an
individual, even in the absence of complete, correct data.
Deterministic Record Linkage (DRL) of an individual to records in
the dataset is very specific (in that those records identified correctly
relate to the individual in question), but is frequently not very sensitive
as any missing or faulty data in the matching fields will mean that
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records are missed. Probabilistic Record Linkage (PRL) can increase
sensitivity, because of its ability to identify records in the absence
of complete and correct matching fields, but at the cost of some
specificity.98 Thus, the nature of the matching algorithms used in
large linked databanks needs to be considered to ensure that the
performance of the algorithms used has been ascertained using a valid
methodology and to ensure that a sensible balance has been struck
between sensitivity and specificity.
The technical solution to record-linkage at SAIL involves the use of
the Matching Algorithm for Consistent Results in Anonymous Linkage
(MACRAL) algorithm. This is an Structured Query Language (SQL)
algorithm that uses DRL and PRL based on a number of matching
fields (NHS number, first name, surname, gender, date of birth, and
postcode of residence)98. On test datasets, this algorithm has been
shown to pick up a very high proportion of records with a low error
rate, both for general practice (>99.9% sensitivity) and hospital activity
data (>99.3% sensitivity)98. It is possible to vary the sensitivity of the
algorithm by varying the probability threshold of PRL; the optimum
threshold for use with MACRAL on the test datasets was 50%98.
2.3.2 Routine data sources
The data in this thesis came from three principal sources. The first
was the mortality data collected by the ONS based on death registra-
tions and on information submitted by medical practitioners on death
certificates. The second source of data related to admissions to NHS
hospitals; this information is contained in the Patient Episode Data-
base for Wales (PEDW), an administrative dataset produced by the
collection of information from clinical coding of hospital admissions.
The third main source of information was primary care data, routinely
collected by general practices in Wales. Each of these datasets is held
within the SAIL databank.
2.3.2.1 Demographic data
Since 2009 the Welsh Demographic Service, part of a set of services to
manage administrative information and demographic data for NHS
patients in Wales, has replaced the NHS Wales Administrative Register.
Amongst its other functions, it enables authorised staff to trace and
verify patients’ basic demographic details and their GP registration.
This dataset is held in SAIL. It contains information on, for example,
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a patient’s date of birth, sex, address (available as LSOA of residence
in SAIL), and GP. Because the latter two pieces of information change
over time, the dataset contains a record of each modification to a
patient’s address and GP at appropriate time-points.
2.3.2.2 Mortality data
Information on deaths in England and Wales comes from the ONS.99
The information used in mortality statistics is based on information
collected when deaths are certified and when they are registered.99 The
information itself may come from three sources: details supplied by
the doctor when certifying the death; details supplied by the informant
to the registrar (the informant is usually a family member or close
friend); the coroner may also supply details. The registration of deaths
(as well as the registration of births, marriages, and civil partnerships)
is carried out by the General Register Office (part of the Identity
and Passport Service).99 Information is submitted to the ONS. The
information includes the usual residence of the deceased, date of birth,
sex, marital status, place of death, occupation and employment status,
date of death, and underlying cause of death.
The underlying cause of death in mortality data generated by the
ONS and used in this thesis is coded using International Statistical
Classification of Diseases and Related Health Problems, 10th Revi-
sion (ICD-10) codes (having switched over from International Stat-
istical Classification of Diseases and Related Health Problems, 9th
Revision (ICD-9) in January 2000).99 The raw information providedICD-10 codes are
further discussed
in section B.3.1
from the sources listed above is in the form of text. The selection of
the underlying cause of death is made on the basis of the condition or
conditions provided by the certifier, using International Classification
of Disease rules.99 The underlying cause of death is generally selected
from the condition entered in the lowest completed line of the medical
certificate of the cause of death (MCCD).99 In cases where death certi-
ficates have been completed ambiguously, the ONS applies ‘selection’
rules to determine which cause of death should be used.99 Even in
situations where the death certificate has been completed properly,
some circumstances or combinations of causes require that ‘modifica-
tion’ rules can be applied.99 The aim of such selection modification
rules is to derive the most useful information from the death certificate
and to ensure that the underlying cause is comparable between places
and times and that each death certificate produces one, and only one,
underlying cause of death.99
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In the deaths processing system within the ONS, there are two
distinct sets of data held. The first, termed the ‘registration database’,
contains mostly textual information derived from the death certificate;
the second, the ‘statistical database’, contains only coded information
on each death. It is this latter database that provided data for this
thesis.99 The statistical database is continually updated and amended
as further information becomes available.99
2.3.2.3 Hospital admissions data
Data on admission to hospital for individuals resident in Wales and
for individuals treated by NHS Wales is contained in PEDW. This data
set contains records for inpatient and day-case activity. The dataset
contains records reaching back to 1991; substantial changes were made
to the format of the data collected in 1997, with the adoption of the
mandated Admitted Patient Care (APC) dataset100.
The data are collected by clinical coders in NHS trusts in Wales (or
where patients resident in Wales are admitted to trusts in England by
their counterparts there), and are collated by their Information Tech-
nology Departments. The data are then submitted from those trusts
to the PEDW Data Acquisition Team responsible for the collection,
processing and monitoring of the dataset100.
APC includes clinical, administrative and demographic information
on each patient. The dataset also includes diagnostic and operative
procedures. Diagnostic information is coded using ICD-10, with up
to 14 codes present (a primary diagnosis field; a subsidiary diagnosis ICD-10 and
OPCS-4 are
discussed further
in section B.3.1
field; 12 secondary diagnosis fields); procedures carried out are coded
using the OPCS-4, with up to 6 codes being present100.
Administrative data in the PEDW dataset include details of the
treating NHS trust, the method of admission (for example emergency
or elective), the discharge destination of the admission, and of episode
(time under the care of one consultant) and spell (time in hospital)
numbers and dates for the admission.
Demographic data include age, sex, and postcode of residence, from
which LSOA- and unitary authority (UA)-codes are derived.
2.3.2.4 Primary care data
Primary-care data relating to patients living in Wales are not contained
in a comprehensive dataset. The SAIL-databank contains records of
primary-care activity for a proportion of general practices in Wales.
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The proportion of practices submitting data to SAIL was approxim-
ately 40% when this work was carried out.
The information in the data imported from general-practice computer-
systems into SAIL contains Read codes for general practice activities,Read codes are
discussed further in
section B.3.1
measurement values relating to these Read codes, individual codes
that allow linking to demographic information, and the date at which
the event occurred.
The SAIL-databank stores GP data primarily in the Read code
version 2 format. It also includes codes from practices that use more
modern versions of the Read code system – Read code version 3.
2.3.2.5 Socio-economic deprivation
The data on socio-economic deprivation were incorporated into the
SAIL databank as part of another project that used SAIL data (the
Wales Electronic Child Cohort). The data contain three deprivation
measures: WIMD 2008, WIMD 2005, and Townsend 2001, all derived
at LSOA-level. I used WIMD 2005 for the analysis. Background inform-
ation relating to these deprivation measures is discussed in section
2.1.2.1.
2.4 summary
Much background material is relevant to the subjects considered
in this thesis. To balance the competing requirements of readability
and comprehensiveness, I have sought to avoid overburdening the
reader by including some background matter in the appendices of this
document. The material there has been structured as follows:
Additional background material relating to inequity, socio-economic
deprivation and healthcare needs assessment: ‘Geographical di-
visions’ in section B.1.1 on page 375
Additional background material relating to CHD: ‘Pathophysiology’
in section B.2.1 on page 375; ‘Clinical classification’ in sec-
tion B.2.2 on page 379; ‘Treatments and management’ in
section B.2.3 on page 381; and ‘Organisation of cardiac
services in Wales’ in section B.2.6 on page 400
Additional background material relating to thesis methods: ‘Clin-
ical coding’ in section B.3.1 on 401
2.4 summary 45
In this chapter, I have discussed important background information
for this thesis. In the next, I move on to review the published literature
relevant to this work, in line with the objectives, as set out in chapter
1.

Part II
D I S C U S S I O N O F P R E V I O U S W O R K

3I N E Q U I T Y I N P R O V I S I O N O F C O R O N A RY H E A RT
D I S E A S E H E A LT H C A R E I N T E RV E N T I O N S
In section 1.3.2 I highlighted a comprehensive literature review as one
of the key subsidiary aims of this thesis. In this chapter, I consider pa-
pers in the medical literature describing studies of healthcare inequity
relating to CHD. I also discuss in the final section of this chapter
papers that enable me to give a brief overview of the National Service
Frameworks (NSFs) and Quality and Outcomes Frameworks (QOFs)
that formed an important part of the background to my work. My
study period coincided with the early years of QOF and therefore
evidence about the overall impact of QOF is clearly relevant to my
findings. To ground this thesis adequately in previous research, I have
necessarily undertaken a review of substantial scope. Many decisions
about which areas to review and which to leave out inevitably arose; I
include a section detailing the scope of the review and justifying many
of the decisions made (section 3.6.2).
3.1 aims and objectives of the literature review
The aim of this literature review is to identify, appraise, and synthesise
the literature on healthcare inequities in the provision of interventions
for CHD. Underpinning this aim are a number of subsidiary objectives.
1. To develop inclusion criteria for studies
2. To determine which components of the pathway of care for CHD
to address, and to justify these decisions
3. To identify papers meeting the inclusion criteria
4. To extract the relevant information from these papers
5. To synthesise the findings from disparate papers so that broad
patterns might emerge (accepting from the outset that any meta-
analysis based on statistical approaches would be impractical in
this case)
6. To consider the findings of studies in the context of common
problems with those studies and their methodological limitations
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3.2 scope of the literature review
The inclusion criteria that I used related to relevance to the main thesis,
comprehensiveness, and practicality. Some element of trade-off proved
inevitable. It was not possible or desirable to review every area that I
might have considered; I justify these decisions below.
I wished to consider publications that met the following criteria:
1. They considered inequity of provision of healthcare interventions
for CHD, as defined by one of the areas discussed below
2. They described studies that examined inequity from the point
of view of socio-economic deprivation or social class at area or
individual level
3. They described studies carried out in the UK
4. They described studies carried out in or after 1995
5. The studies are described in the published literature or in the
grey literature in Wales
After consideration (see section 3.6.2), I decided to include stud-
ies in the review that looked at the following components of the
management of CHD and its risk factors:
• Smoking cessation in primary care by means of smoking cessa-
tion advice or by means of referral to smoking cessation specialist
services
• Primary prevention of CHD by the medical management of risk
factors
• Secondary prevention and medical management of chronic dis-
ease
• Revascularisation
Primary prevention of disease by medical management was defined to
encompass provision of antihypertensive treatments, of lipid-modify-
ing therapies, and of anti-platelet therapies. I also included the medical
management of blood glucose in those with diabetes. Because dis-
tinguishing between primary and secondary prevention was difficult
in the papers relating to diabetes, I combined the review of primary
and secondary prevention. For some of the papers, I found it difficult
to determine whether or not primary or secondary prevention was
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being assessed, and for some it is clear that a mixed group of patients,
some with and some without pre-existing CVD, was included (thus
implying a mixture of primary and secondary prevention). I have
included such studies in the primary care component of the review,
but have endeavoured to make clear when I have done so.
As discussed in appendix B, revascularisation can be accomplished
either by coronary artery bypass graft (CABG) or by PCI. I included
both. Informed readers will be clear that a number of other areas
might have been included in this review; I justify the reasons for
omitting these in section 3.6.2.
3.2.1 Agentic versus structural emphasis in the scope of the review
In a 2010 paper, McLaren et al discuss the potential of prevention
strategies to increase social inequalities in health.101 They draw an
important distinction between ‘agentic’ and ‘structural’ interventions.
They consider that proposed interventions fall on a continuum from
‘agentic’, where interventions pertain to an individual’s capacity to
make the choice to act, to ‘structural’, where interventions pertain to
social institutions and norms that shape the actions of individuals.101
They argue that “population strategies that are more superficial in
nature rely on individual agency and aptitude, and as such are poten-
tially more likely to increase (worsen) social inequalities in health.”101
The focus of this review is interventions whose differential imple-
mentation might be contributing to health inequality from CHD. Thus,
following McLaren et al, I have limited the scope of my review to
interventions towards the ’agentic’ end of the above spectrum.
3.3 methods of literature review
I employed very similar methods for each of the stages of the pathway
of care for CHD examined in this chapter. In overview they comprise:
1. Development of search terms
2. Database searches
3. Selection of papers based on title and abstract
4. Importing records and record storage
5. Review of fulltext papers
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6. Snowballing based on relevant papers
7. Tabulation of important information
8. Summarisation of findings
In developing the search terms used, I wanted to have a sensitive
definition of the areas considered to ensure that relevant papers were
not missed; the subsequent examination of titles and abstracts allowed
elimination of irrelevant papers. I wanted to use the same search terms
to cover deprivation and to cover coronary heart disease for each of the
searches carried out. I wished to employ the thesaurus terms available
within the databases, again to maximise the sensitivity of the searches.
I started by searching for and reading a number of clearly relevant
papers, and then used these as the basis for the systematic searches
which followed.
The search terms used for the main six areas are shown diagram-
matically in the following figures: smoking cessation in figure 3.1
on page 54; antihypertensive medications in figure 3.2 on page 54;
lipid-modifying medications in figure 3.3 on page 55; antiplatelet
medications in figure 3.4 on page 56; diabetes management in figure
3.5 on page 56; revascularisation in figure 3.6 on page 57. The search
strategies for antihypertensives, lipid-lowering medications, and an-
tiplatelet medications include both terms related to socio-economic
factors and to CHD. For smoking cessation, diabetes management,
and revascularisation, search terms for socio-economic factors were
included but not those for CHD. This distinction was necessary be-
cause, without the search terms related to CHD, the searches for
antihypertensives, lipid-lowering medications, and antiplatelet medic-
ations returned an unmanageably large number of references.
The following databases were searched.*
1. EMBASE 1947 to present
2. Ovid MEDLINE(R) 1946 to present
3. HMIC Health Management Information Consortium
4. ICONDA 1976 to December 2011
5. Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations
*Because the searches were carried out before I made the decision to limit the
review to papers published after 1995, I employed databases covering periods prior
to 1995
3.3 methods of literature review 53
6. PsycINFO
The searches were carried out using OvidSP, accessed via the Cardiff
University Portal. They were carried out in November and December
2011, and in January 2012. For all searches, duplicates were removed
using the OvidSP default algorithm for duplicate removal. Search
results were limited to ‘English’ and ‘Humans’. Searches were saved
for future reference using the OvidSP save facility. Although initially
the time-limit of 1995 onwards was not included, I subsequently ad-
ded this to the search criteria (though I did not change the databases
used in the saved searches); I included papers up to the ‘most recent’
available. In carrying out the original search,I identified a conference
abstract that was clearly relevant102. I contacted the authors to de-
termine that a full paper would follow the abstract, and subsequently
added this paper by Hawkins et al103 to the review of secondary
prevention of CHD.
Having performed these searches, I examined the titles and, where
available, abstracts for those papers within the OvidSP environment.
If papers were of possible relevance, I imported them into a file on a
local desktop computer (using the RefMan format); there was one of
these files for each search. I then imported these files into the Zotero
reference management system that I have used for the management of
papers for this thesis. Within Zotero, I obtained and stored relevant
fulltext papers for those studies relevant to the review.
The identification of relevant papers made use of two separate
approaches, firstly, systematic searching of databases of academic
papers (as outlined above), and secondly a snowballing approach, in
which relevant papers meeting inclusion criteria were back searched
(using their reference list) and forward searched (looking at other
papers that cited that paper via Google Scholar). For the second of
these two processes, I used electronic copies of fulltext papers held
within Zotero to identify referenced papers; I copied the paper’s title
into Google Scholar and examined the ‘cited by’ papers returned
from searching. In turn, I imported relevant papers identified by this
process into Zotero.
Having identified relevant papers using the above methods, I ended
up with those papers relevant to more detailed review within Zotero
in electronic fulltext form.
I decided that if a paper addressed more than one of the points on
the pathway of care for CHD
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Figure 3.1: Search terms used to look for papers on equity in smoking cessa-
tion services
Socioeconomic factors OR Social justice OR Income OR 
Poverty areas OR Poverty OR 
Social class OR deprivation 
Smoking cessation 
AND 
Figure 3.2: Search terms used to look for papers on equity in antihypertensive
provision
Socioeconomic factors OR Social justice OR Income OR 
Poverty areas OR Poverty OR 
Social class OR deprivation 
Diuretic OR 
Adrenergic beta-antagonists OR 
Angiotensin-converting enzyme Inhibitors OR  
Antihypertensive agents OR 
Calcium-channel antagonists 
Coronary disease OR Coronary heart disease OR 
Cardiovascular diseases OR Myocardial infarction OR Angina, 
unstable OR Myocardial ischemia OR Atherosclerosis OR 
Angina pectoris 
AND 
AND 
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Figure 3.3: Search terms used to look for papers on equity in cholesterol-
lowering drug provision
Socioeconomic factors OR Social justice OR Income OR 
Poverty areas OR Poverty OR 
Social class OR deprivation 
Anticholesteremic agents OR Hypolipidemic agents OR Lipid-
regulating drugs OR Hydroxymethylglutaryl-CoA reductase 
inhibitors OR atorvastatin OR  fluvastatin OR lovastatin OR 
pitavastatin OR pravastatin OR rosuvastatin OR simvastatin 
Coronary disease OR Coronary heart disease OR 
Cardiovascular diseases OR Myocardial infarction OR Angina, 
unstable OR Myocardial ischemia OR Atherosclerosis OR 
Angina pectoris 
AND 
AND 
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Figure 3.4: Search terms used to look for papers on inequity in antiplatelet
drug provision
Socioeconomic factors OR Social justice OR Income OR 
Poverty areas OR Poverty OR 
Social class OR Deprivation 
Platelet aggregation inhibitors OR Aspirin 
Coronary disease OR Coronary heart disease OR 
Cardiovascular diseases OR Myocardial infarction OR Angina, 
unstable OR Myocardial ischemia OR Atherosclerosis OR 
Angina pectoris 
AND 
AND 
Figure 3.5: Search terms used to look for papers on equity in diabetes man-
agement
Socioeconomic factors OR Social justice OR Income OR 
Poverty areas OR Poverty OR 
Social class OR deprivation 
OR glycaemic control OR glucose 
control 
Diabetes 
AND 
management 
AND 
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Figure 3.6: Search terms used to look for papers on equity in revascularisa-
tion
Socioeconomic factors OR Social justice OR Income OR 
Poverty areas OR Poverty OR 
Social class OR deprivation 
Angiography OR Coronary angiography OR Coronary artery 
bypass OR Angioplasty OR Balloon dilation OR Heart 
catheterization OR Angioplasty, Balloon, Coronary OR 
Myocardial revascularisation OR Angioplasty, Transluminal, 
Percutaneous Coronary 
AND 
I would treat each area addressed as a separate study. This has
the advantage of allowing the evidence for a particular part of the
pathway to be considered as a whole. Therefore some studies appear
in more than one table.
I tabulated important information for each included paper within
an access database. The information collected for each paper was as
follows: sample size, study type, dimension of comparison, publication
date, data collection dates, text summary of study methods, text
summary of study results, and comments.
I collected study size information, but in ecological studies partic-
ularly, it can be problematic to identify the number of people in the
population being studied. Where it was clear that more than 50,000
individuals were included, I collapsed the sample size entry to 50,000
exactly. I did this in order to give as much clarity as possible in the
visual summaries of the results, presented later in this chapter. The
study type was recorded as ecological, individual-level, or prospect-
ive cohort, the distinction between the latter two being made on the
basis of whether or not bespoke data were collected on individuals
at baseline in a cohort followed up through time (as opposed to the
employment of routine or survey data collected on individuals). Tech-
nically, any study employing an ecological measure of deprivation
might be classified as an ecological study but I have not classified such
studies as ecological on this basis alone. The dimension of comparison
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field contained the deprivation or socio-economic position measure
used in this study (sometimes more than one).
The information obtained and stored in this access database was
used to produce figures to summarise the findings from the different
papers. (The summaries are shown figures 3.13 to 3.20). Each figure
is structured along the same lines. The categories along the x-axis
represent the following four categories: ‘Favours less deprived’, ‘No
evidence of difference’, ‘Favours more deprived’, ‘Unclear’. According
to this classification, ‘Favours less deprived’ would be a result suggest-
ing inequity of provision. Further, studies published later are shown
higher up in these figures; thus, the publication date increases at the
y-axis. The sample size for the study is shown beneath the study name
and date on the left of the figure; this study size is illustrated in the
figure, with the size of the marker for each study being proportional
to study size; study sizes over 50,000 were rounded down to 50,000 to
aid presentation. Study design is illustrated by the colour of the study
marker.
3.4 filtering of papers
The results of the processes used to identify papers for inclusion in
the literature review are summarised in figures 3.7 to 3.12. The results
vary considerably according to the area examined. For example, for
smoking cessation 2219 titles were returned by the original search (see
figure 3.7); for the search related to lipid-lowering medications 274
titles were returned (see figure 3.9); other searches returned values
intermediate to these extreme values. For smoking cessation, quite
a large number of papers were retained from the search (261), but,
despite this, following the snowballing process and comparison of
the papers against the inclusion criteria, I included only four papers
in the review (see figure 3.7). I also retained quite a large number of
papers from the original search for diabetes (252 papers), and sub-
sequently included 15 in the review (see figure 3.11). For the other
searches (antihypertensives, cholesterol-lowering therapies, antiplate-
let drug provision, and revascularisation), only a few tens of papers
were retained out of those returned by the database search: anti-
hypertensives (42 with 24 papers eventually included – figure 3.8),
cholesterol-lowering therapies (52 with 24 papers eventually included
– figure 3.9), antiplatelet drug provision (48 with 20 papers eventually
included – figure 3.10), and revascularisation (17 with 15 papers even-
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tually included – figure 3.12). Because the Hawkins et al paper was
identified by a different process (directly contacting the lead author
on the basis of a conference abstract), it does not appear in these
figures. Thus, one additional entry appears in tables for secondary
prevention with antihypertensives, antiplatelet therapies, and statins –
each dealing with findings from the Hawkins paper103.
While the search strategy to identify papers for prevention using
antihypertensive therapies, lipid-lowering therapies, and antiplatelet
therapies did not distinguish between primary and secondary pre-
vention, I make this distinction in subsequent sections of this chapter.
Figure 3.7: Filtering of papers for smoking cessation inequity of provision
related to socio-economic deprivation
Database search 
Selection by title 
Snowballing and  review by abstract 
Papers included in the review 
2219 papers 
261 papers 
4 papers 
60 inequity in chd interventions
Figure 3.8: Filtering of papers for antihypertensives drug inequity of provi-
sion related to socio-economic deprivation
Database search 
Selection by title 
Snowballing and  review by abstract 
Papers included in the review 
775 papers 
42 papers 
24 papers 
Figure 3.9: Filtering of papers for cholesterol-lowering drug inequity of pro-
vision related to socio-economic deprivation
Database search 
Selection by title 
Snowballing and  review by abstract 
Papers included in the review 
274 papers 
52 papers 
24 papers 
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Figure 3.10: Filtering of papers for antiplatelet drug inequity of provision
related to socio-economic deprivation
Database search 
Selection by title 
Snowballing and  review by abstract 
Papers included in the review 
460 papers 
48 papers 
20 papers 
Figure 3.11: Filtering of papers for diabetes management inequity related to
socio-economic deprivation
Database search 
Selection by title 
Snowballing and  review by abstract 
Papers included in the review 
1017 papers 
252 papers 
15 papers 
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Figure 3.12: Filtering of papers for inequity of provision of revascularisation
related to socio-economic deprivation
Database search 
Selection by title 
Snowballing and  review by abstract 
Papers included in the review 
782 papers 
17 papers 
15 papers 
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3.5.1 Smoking cessation
Italicised name and
date references in
section 3.5.1 refer to
papers in table 3.1
on page 64
I identified four papers that looked at smoking cessation provision in
line with the inclusion criteria. These papers are summarised in table
3.1. Two studies looked only at the provision of smoking cessation
advice (Saxena 2007104, Millett, Gray et al105), while two looked at both
smoking cessation advice and referral to smoking cessation services
(Strong 2006106, Simpson 2010107). Because of the small number of
studies in this area, I have combined these two types of study. Two
of the studies were ecological (Saxena 2007104 and Strong 2006106)
and two used individual-level data (Millett, Gray et al105 and Simpson
2010107).
Of the four studies identified, one, Saxena 2007104, found that provi-
sion of smoking cessation advice was increased in areas of decreased
deprivation. However, the overall effect size was not large; there was
a difference of between one and three percent between deprivation
bands in the proportion of smokers offered smoking cessation advice.
For example, in practices of size less than 3000, in the most deprived of
the three bands, 90.3% of smokers with CHD had a record of smoking
cessation advice being offered, compared to 93.3% in the least de-
prived; for practices with greater than 10,000 patients, the equivalent
figure for the most deprived band was 92.7% compared to 94.6% in
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the least deprived group. Other results from this study, for individu-
als with raised blood pressure or with a history of cerebro-vascular
disease are comparable.
The other three studies reviewed found no evidence that there was
an increased provision of smoking cessation advice (Millett, Gray et
al105, Strong 2006106, Simpson 2010107) or of referral to stop smoking
services (Strong 2006106, Simpson 2010107).
Overall, there is little evidence of a differential effect between pop-
ulation groups based on socio-economic position in the extent to
which smoking cessation advice or referral to stop smoking services
is provided. Only one study found evidence of inequity of provision
(Saxena 2007104), and here the effect was relatively small.
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Table 3.1: Summary of papers examining inequity of provision of smoking cessation referral and stop smoking advice
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Strong
2006106;
Rotherham
Primary
Care Trust,
United
Kingdom,
2003 – 2004
data
Mean IMD
(England)
2004;
calculated at
practice level
Practice-level analysis;
mean practice-level
index of multiple
deprivation. Looks at
the Quality and
Outcomes Framework
CHD registered
patients, standardised
indirectly for age and
sex. Spearman’s rank
correlation coefficient
for standardised CHD
against practice
deprivation for
quality-of-care
indicators
The Spearman’s rank correlation
coefficient for the correlation
between the percentage of patients
with CHD who smoke and the
mean deprivation score for
practices was 0.19. This result was
not statistically significant, though
an exact p-value was not specified
The results suggest that the
practice level there is no evidence
of increased provision of smoking
cessation services and advice in
less deprived populations. Indeed,
though the result is not statistically
significant, the positive correlation
coefficient in this case leans
towards greater provision of such
services in more deprived practices
Saxena
2007104;
UK, 2004,
2005
IMD 2004.
Grouped into
three bands
Ecological study using
QOF data. Large
number of GP practices
in the UK. Examination
of practice performance
in relation to a number
of practice
characteristics,
including practice size,
deprivation
Gradient across practices in the
proportion of antihypertensive
patients, patients with CHD, and
patients with cerebro-vascular
accident (CVA) receiving smoking
cessation advice shows higher rates
of smoking cessation advice in the
less deprived. Kruskal Wallis exact
test p-value is <0.0001
Ecological data at practice level on
deprivation; the effect is not large,
with the difference of the order of
1– 3% between deprivation bands
in the proportion of individuals
given smoking cessation advice
Continued on next page
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Table 3.1 – Continued from previous page
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Millett,
Gray et al
2007105;
London,
2003,
2005/6
IMD, derived
from the
postcode of
residence of
the patient;
comparisons
made by
quintile
Population-based
longitudinal study of
patients with diabetes
identified from
diabetes registers in the
Wandsworth area of
South West London.
Comparisons were
made at two time
points, 2003 and
2005/6. The proportion
of patients with
diabetes who smoke
receiving smoking
cessation advice was
compared across
quintiles (as well as
across age, sex and
ethnicity)
In 2003, rates of smoking cessation
advice were highest in quintile 2 at
52.5% , and lowest in quintile 3
(42.6%). No evidence of a trend
across quintiles; In 2005, the rate of
being offered smoking cessation
advice was highest in the most
deprived quintile (88.2%) and
declined progressively with
decreasing deprivation to 80.2% in
quintile 1. The increase in smoking
cessation advice rates between the
two time points was not influenced
by deprivation group (adjusted
odds ratio (OR))
Diabetic patients only. Some
suggestion of increased provision
with increased deprivation, though
the relevant statistical analysis to
assess whether this is a statistically
significant result is not available;
no adjustment of the rates in
quintiles for other relevant
variables
Continued on next page
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Table 3.1 – Continued from previous page
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Simpson
2010107;
UK, 2001/2,
2006/7
Townsend
deprivation
index 2001;
comparisons
by quintile
Individual-level
database analysis using
the QRESEARCH
database version 10.
Smoking status and
smoking cessation
provision were
identified using Read
codes
For in-house smoking cessation
advice, in 2001/2 rates of provision
were highest in the most deprived
quintile at 45.12%(95% CIs 44.61,
45.62), with rates generally
declining with decreasing
deprivation. The situation was
similar in 2006/7, though here the
highest rate was in quintile 4 at
84.44%(95% CIs 84.16, 84.72).
Referral to stop smoking services
had a trend towards decreased
provision with decreased
deprivation at both time points. In
2001/2, rates were 1.94%(95% CIs
1.80, 2.08) in the most deprived
quintile declining to 0.52%(95% CIs
0.43, 0.61) in the least; in 2006/7,
the same trend persisted, with
equivalent figures 8.56% (95% CIs
8.37, 8.75) in the least deprived
declining monotonically to 5.25%
(95% CIs 5.04, 5.46) in the least
deprived quintile
This study looked at both in-house
smoking cessation advice given in
primary care, and referrals to
stop-smoking services. All analyses
were univariate, and so the effects
observed may have been explicable
by demographic or comorbidity
changes. Analysis of the trends
across deprivation quintiles are not
presented; in view of the results it
is possible that there is a significant
trend in favour of provision in the
more deprived quintiles
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3.5.2 Medical management of risk factors
In this section of the review I consider interventions that are routinely
used to manage risk factors (or in the case of aspirin to manage CHD
risk) from the point of view of the equity of their provision.
3.5.2.1 Antihypertensives
Italicised name and
date references in
section 3.5.2.1 refer
to papers in table C.1
on page 406
Seventeen studies address inequity in supply of antihypertensives
for the primary prevention of CHD; these papers are summarised
in table C.1, in appendix C. This table also includes studies that do
not allow differentiation of primary and secondary prevention by BP
management and prescription of anti-hypertensive medications. The
picture that emerges from the studies shown in table C.1 is mixed, but
studies predominantly find that both the provision of antihypertens-
ive treatments for primary prevention of CHD and the achievement
of BP targets are not related to socio-economic deprivation or social
class. Five of the studies (Pears 2003108, Ward 2004109, Ward 2005110,
Edwards 2003111, Crawley 2009112) looked at provision of antihypertens-
ives. Fourteen of the studies examined achievement of BP targets as an
outcome (Edwards 2003111, Chen 2003113, Bachman 2003114, Hippisley-
Cox 2004115, Gray 2006116, McLean 2006117, Patel 2006118, Millett, Car
et al119, Saxena 2007104, McGovern 2008120, Ashworth 2008121, Craw-
ley 2009112, Hamilton 2010122, Hammouche 2011123). One study (Pears
2003108) also looked at whether hypertensive patients were ‘under-
review’, ‘treated’, or ‘not-followed-up’ with respect to the management
of their hypertension. Six of the studies analysing equity in primary
prevention by management of BP looked only at diabetic patients: Ed-
wards 2003111, Bachman 2003114, Hippisley-Cox 2004115, Gray 2006116,
Millett, Car et al119, Hamilton 2010122.
Saxena 2007104 found a statistically significant gradient of an in-
creased proportion of hypertensive patients meeting BP targets with
decreased deprivation. Millett, Car et al119 found a mixed picture in
which a smaller proportion of patients achieved targets in the most
deprived practices compared to the least deprived practices, but the
proportion was highest for intermediately deprived practices. Statist-
ical significance could not be assessed for this result. McLean 2006117
found a non-significant decline in the management of hypertension
as deprivation increased. Ashworth 2008121 found that a statistically
significant difference between deprivation groups in 2004-5 (with
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more deprived groups less likely to reach BP control targets) had
disappeared by 2006-7.
The studies that examined prescription of anti-hypertensive med-
ications either found no association with deprivation/social class
(Edwards 2003111, Crawley 2009112) or found a mixed picture. Of those
suggesting a mixed picture, Pears 2003108 suggested that more de-
prived hypertensive patients were less likely to be on thiazide diuretics,
as likely to be on beta-blockers, and more likely to be on Angiotensin-
converting enzyme (ACE) inhibitors and calcium-channel blockers;
Ward 2004109 found patients from deprived practices were less likely
to be on ACE inhibitors and bendrofluazide, and equally likely to be
on beta-blockers; Ward 2005110 found that more deprived practices
prescribed less bendrofluazide, with no effect for ACE inhibitors or
beta-blockers.
The only paper that examined whether hypertensive patients were
‘under-review’,‘treated’, or ‘not-followed-up’ (Pears 2003)108, found
that deprived patients were less likely to be ‘under-review’.
The rest of the studies reviewed found no significant relation-
ship between deprivation/social class and either prescribing of anti-
hypertensive drugs or achievement of BP control targets. Examining
the studies in which findings suggest an element of inequity of provi-
sion of health care compared to those which do not, it is not clear that
studies over a particular time period (either the earlier studies which
cover periods back to the early 1990s or those from a later period up to
2007) are more likely to provide evidence of an association. One paper
(Ashworth 2008)121 found that a relatioship that existed at an earlier
time-point, 2004-5, was no longer observable by the second time-point,
2006-7. Methodologically, there is a suggestion that it is the ecological
studies that demonstrate inequity in provision of anti-hypertensives or
achievement of BP control targets: of those studies suggesting a mixed
picture or inequity in management, only that by Pears 2003108 is an
individual-level analysis. All the studies that provide no evidence of
inequity are individual-level studies.
3.5.2.2 Lipid-lowering medications
Italicised name and
date references in
section 3.5.2.2 refer
to papers in table C.2
on page 413
Seventeen papers examine equity in prescription of lipid-lowering
medications and achievement of cholesterol targets; these papers are
summarised in table C.2. Of these papers, eight deal only with pre-
scription of lipid-lowering medications ( Bradshaw 1998124, Packham
1999125, Packham 2000126, Ward 2004109, Ward 2005110, Ward 2007127,
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Ashworth 2007128, Forde 2011129), seven deal only with achievement of
cholesterol targets ( Bachman 2003114, Hippisley-Cox 2004115, McLean
2006117, Gray 2006116, Millett, Car et al119, McGovern 2008120, Hamilton
2010122), and two deal with both (Edwards 2003111, Crawley 2009112).
Six of the studies look only at diabetic patients ( Edwards 2003111,
Bachman 2003114, Hippisley-Cox 2004115, Millett, Car et al119, McGovern
2008120, Hamilton 2010122).
Of the papers reviewed, five found a positive relationship between
increasing deprivation/social class and reduced lipid-lowering drug
provision or reduced achievement of cholesterol targets (Bradshaw
1998124, Packham 1999125, Packham 2000126, Ward 2004109, and McLean
2006117). The papers that found a positive relationship with lipid-
lowering drug prescribing were ecological studies. Packham 1999125
found that the initial relationship between deprivation and statin-
prescribing in 1996 was no longer significant in 1997-1998 (Packham
2000126). The findings from Ward 2004109 need to be seen in light of
the fact that there is a similar, but better quality study, published sub-
sequently, which largely repeats the earlier study but uses multivariate
rather than univariate analysis (Ward 2005110).
The findings from all the subsequent studies looking at lipid-lower-
ing medication prescribing equity provide no evidence of inequity
of provision. One study suggests a relationship between increased
deprivation and worse achievement of cholesterol targets (Millett,
Car et al119), but CIs are not available for the results of this study,
so the statistical significance is uncertain. All other studies find no
evidence of inequity in the achievement of cholesterol targets between
deprivation groups, though in one of these studies the result is hard
to interpret with apparent contradiction between CIs and the p-value
of the result (Bachman 2003114). In some of the studies reviewed, the
achievement of cholesterol targets appeared to occur more frequently
in more deprived groups (McLean 2006117, McGovern 2008120, Hamilton
2010122).
The results from these studies are only positive (in the sense of
demonstrating inequity of provision by deprivation/socio-economic
status) in older, ecological studies (Bradshaw 1998124, Packham 1999125,
Packham 2000126, Ward 2004109, McLean 2006117). It may be that the
positive results in these studies are a reflection of methodological
weaknesses, though they may also indicate that the inequity of provi-
sion of lipid-lowering medications that they observed had disappeared
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over time; the latter possibility is supported by the findings of Packham
2000126.
3.5.2.3 Anti-platelet medications
Italicised name and
date references in
section 3.5.2.3 refer
to papers in table C.3
on page 420
Nine papers looked at primary prevention of CHD using anti-platelet
therapies, and are shown in table C.3; some papers may deal with a
mixture of primary and secondary prevention, for example Elwood
2005130, Ward 2004109 and Ward 2005110. One paper looked at clopido-
grel provision (Petty 2008131); the others looked at aspirin. One study
(Edwards 2003111) looked at diabetic patients only.
Of the nine studies identified, the majority suggest either that there
is no relationship between deprivation/social class and provision
of anti-platelet medications or that those in more deprived social
groups are more likely to be taking these therapies. Only two studies
(Ward 2005110, Saxena 2007104) found evidence of inequity of provision.
In the Ward 2005110 study, ecological prescribing rates for practices
were modelled on a number of practice characteristics, among them
Low Income Scheme Index (LISI) score. Results suggested that with
increased deprivation there was decreased prescribing of aspirin at
the practice level. This is in an ecological study, which was not able to
take account of whether individuals specifically had a clinical need
for aspirin, as is more possible in individual-level analyses. Instead,
this study used a number of proxies to infer the practice-level clinical
needs that would be expected for the population. The other study
which suggested that anti-platelet medications were prescribed less
in more deprived practices used a similar methodology, with similar
potential limitations (Saxena 2007104).
The remaining studies identified in this review suggested no in-
equity in provision of anti-platelet medications was present, includ-
ing Bedson 2001132, Ward 2004109, and Petty 2008131; indeed a num-
ber of the studies found that individuals in more deprived social
groups were more likely to be receiving anti-platelet therapy with
aspirin (Edwards 2003111, Elwood 2005130, Vinogradova 2009133, and El-
wood 2011134), though CIs were not available for the study by Vino-
gradova 2009133. All of these studies, and in addition the study by
Bedson 2001132 used individual-level data; Ward 2004109 and Petty
2008131 employed ecological methodologies.
Overall, the findings from the review of the equity of provision
of anti-platelet therapies suggest that they are provided equitably
across deprivation groups and social classes. There is no evidence
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of a temporal effect, as the two studies which suggest that a level of
inequity of provision might be occurring covered a time period similar
to that covered by other studies in review.
3.5.2.4 Diabetes management
Italicised name and
date references in
section 3.5.2.4 refer
to papers in table C.4
on page 423
Papers typically do not examine diabetes control from the perspective
of primary prevention, though good-quality glycaemic control is a
key aspect of the primary prevention of CHD (as well as other macro-
and micro-vascular complications); for the purposes of this review
papers addressing the quality of glycaemic control by deprivation or
social class in individuals who do not have CHD have been examined.
The primary prevention component is typically implicit rather than
explicit in these papers.
Fifteen papers for the review examined the management of dia-
betes in individuals without CHD. The majority of papers identified
looked at the achievement of glycaemic-control targets, as measured
by HbA1C. Only two papers (Crawley 2009112, Millett, Saxena et al135)
examined the provision of prescriptions for hypoglycaemic medica-
tion.
A mixed picture emerges, with some papers suggesting that the
achievement of glycaemic-control targets in more deprived social
groups is worse. Weng 2000136, Hippisley-Cox 2004115, Bebb 2005137,
McGovern 2008120, and Wild 2008138 found that patients from more de-
prived social groups tended to have worse glycaemic control. Maclean
2006117 found that when examining QOF data, the standard of dia-
betes management did not differ when exclusions from QOF returns
were not included in the analysis, but found that when such exclu-
sions were included the percentage of patients achieving glycaemic-
controlled targets in more deprived social groups was lower. Millet,
Car et al 2007119 found a gradient in the proportion of patients reaching
the glycaemic-controlled targets according to deprivation and prac-
tice level; a higher proportion of patients in less deprived practices
achieved targets. Crawley 2009112 found that there was no difference
between the manual and non-manual social class groups in the pre-
scribing of oral hypoglycaemic agents, but that achievement of HbA1C
targets was less likely in the manual group in 2003 (when the res-
ult were statistically significant) and in 2006 (when it was not). One
study (Gray 2006), found that patients in the least deprived group
were more likely to achieve HbA1C targets, but that the result was non-
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significant. Millett, Saxena et al135 found no difference in prescribing
of hypoglycaemic agents.
Other papers (O’Kane 2010139, Edwards 2003111, Bachman 2003114,
Millet 2009140, Hamilton 2010122) found that the achievement of glycae-
mic-control targets between social deprivation groups was not system-
atically different, with the implication that the management of these
individuals is not inequitable across these groups.
In situations in which there is an observed, statistically-significant
difference across deprivation groups in the achievement of glycaemic-
control targets, the conclusion that can legitimately be drawn is that
there is an absence of evidence of equity of provision of care, but not
strong evidence of inequity of provision. This is because management
of blood sugar by individuals has a very strong self-care component,
which may act to a large extent independently of the quality of health
care provided to the individual. While this tendency will also operate
with achievement of BP-control targets (where adherence to medica-
tion regimes may vary systematically across deprivation groups), it is
likely to be more pronounced in glycaemic-control management.
3.5.3 Secondary prevention and management of chronic disease
3.5.3.1 Antihypertensives
Italicised name and
date references in
section 3.5.3.1 refer
to papers in table C.5
on page 430
Thirteen papers were identified that address equity of prescription
of anti-hypertensive medications and equity of achievement of blood
pressure targets by deprivation or social class for those with a dia-
gnosis of CHD; the papers are summarised in table C.5. The ma-
jority (eight) of the papers examined equity in provision of anti-
hypertensive medications (Britton 2004141, Simpson 2005142, Harding
2005143, Ramsay 2005144, Murphy 2006145, McGovern 2008120, Mathur
2011146, and Hawkins 2013103); four papers examined both equity of
anti-hypertensive drug provision and equity in achievement of BP
targets (McLean 2006117, Strong 2006106, Saxena 2007104, and Crawley
2009112); one examined only equity in achievement of BP targets (Ash-
worth 2008121).
Overall, the findings from the papers identified suggest that the pro-
vision of anti-hypertensive drugs and the achievement of BP targets are
both equitable in those with CHD. Of the papers identified, only Sax-
ena 2007104 found a unmixed picture of inequity of provision, with a
suggestion that, at practice-level, practices with increased deprivation
tended to have lower prescribing of ACE-inhibitors and beta-blockers
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and to have a decreased proportion of patients with CHD meeting
BP targets. A number of other studies found a slightly mixed picture
(Harding 2005143, Ramsay 2005144, McGovern 2008120, Ashworth 2008121,
Crawley 2009112). Harding 2005143 found that patients in more deprived
communities were less likely to be prescribed calcium-channel block-
ers and diuretics and received fewer anti-hypertensive drugs, but
found that for ACE inhibitor and beta-blocker prescription the gradi-
ent suggested some inequity but was not statistically significant –
potentially suggesting a lack of power to detect a true gradient. Ram-
say 2005144 made numerous comparisons at two time-points for those
with angina and those with a previous MI and for different drugs;
only one of these comparisons suggested inequity, and the positive
results may be a result of multiple comparisons. McGovern120 found
that more deprived groups were more likely to receive ACE inhibit-
ors, but less likely to receive beta-blockers. Ashworth 2008121 found
that an initial inequity in the achievement of BP targets subsequently
disappeared. Crawley 2009112 found that there was no difference in pre-
scribing of anti-hypertensive medications between deprivation groups;
in 2003 there was a non-statistically-significant suggestion of inequity
in achievement of BP targets; in 2006 this result was significant.
Other studies examined found no evidence of inequity of provi-
sion of anti-hypertensive medications (Britton 2004141, Simpson 2005142,
McLean 2006117, Strong 2006106, Murphy 2006145, Mathur 2011146) or
in the achievement of BP targets (McLean 2006117, Strong 2006106).
Hawkins 2013103 found that patients in the more deprived individulas
with angina were more likely to receive ACE inhibitors or angiotensin-
II receptor blockers (ARBs) in 2007 (though not in 1999); in this study,
there was no difference for secondary prevention in primary care or
following an MI.
No clear temporal tendency in the positive results emerges from the
review in this area. Ashworth 2008121 found that an initial difference
in the achievement of BP control by deprivation that was found in
2004-5 had largely disappeared by 2006-7; in contrast, Crawley 2009112
found that a non-significant difference in achievement of BP targets
in 2003 had become statistically significant by 2006 – though the
authors suggest this may be the result of the earlier study being
under-powered.
Whether a study was ecological or individual-level appears not to
be related to its finding evidence of inequity in hypertension man-
agement. Of the papers that examined inequity in achievement of BP
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targets, three out of five found some evidence of inequity (though
in the studies by Ashworth 2008121 and Crawley 2009112 this was equi-
vocal). When looking at inequity of provision of anti-hypertensive med-
ications, only one paper suggested inequity (Saxena 2007104); three
papers suggested that some individual antihypertensives were in-
equitably provided but found that others were equitably prescribed
or favoured more deprived groups (Harding 2005143, Ramsay 2005144,
and McGovern 2008120). This may provide some indication that ‘in-
equity’ in achievement of targets is reliant not only on factors relating
to the quality of service (such as identification of clinical need and
prescription for appropriate medication), but relates also to the extent
to which individuals adhere to any recommended treatment.
3.5.3.2 Lipid-lowering medications
Italicised name and
date references in
section 3.5.3.2 refer
to papers in table C.6
on page 438
Ten papers addressed equity by social class or deprivation in pre-
scribing of lipid-lowering medications to those with CHD; they are
summarised in table C.6. Eight looked only at equity in prescribing of
lipid-lowering drugs (Reid 2002147, Britton 2004141 , Harding 2005143,
Ramsay 2005144, Simpson 2005142, Murphy 2006145, Mathur 2011146, and
Hawkins 2013103), one looked only at achievement of cholesterol targets
(Strong 2006106), and one looked at both (Crawley 2009112).
No studies unequivocally identify inequity in either provision of
lipid-lowering medication or in achievement of cholesterol targets,
though two do provide evidence of a changing picture over time
(Ramsay 2005144 and Simpson 2005142). Ramsay 2005144 examined the
prescription of statins to patients who had CHD. The analysis was
carried out separately for patients with angina and for patients with
a previous MI. Most of the results showed no evidence of inequity
of provision; in 2000 those from the manual social-class group with
angina were less likely to receive a statin (prevalence ratio 0.64 (95%
CIs 0.45, 0.91)). By 2003 this result was no longer statistically signi-
ficant for those with angina – prevalence ratio 0.91 (95% CIs 0.76,
1.09); there was no evidence of inequity of provision in those with a
previous MI, with the results favouring the manual social-class group
in 2000 and in 2003 (though the relationships were not statistically
significant). Simpson 2005142 found that an initial relationship in which
the most deprived group received significantly less statin treatment
than the most deprived observed between 1998 and 2000 was no
longer present between 2001 and 2002. Other studies identified in the
review did not find any evidence of inequity of prescribing of lipid-
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lowering medication (Reid 2002147, Britton 2004141, Harding 2005143,
Murphy 2006145, Mathur 2011146, and Hawkins 2013103 – where there
was some evidence of increased prescribing in more deprived groups),
or inequity in achievement of cholesterol targest (Strong 2006106), or
found neither (Crawley 2009112). One study, Strong 2006106, found a
non-statistically-significant association between increased deprivation
and the percentage of patients achieving cholesterol targets at practice
level.
3.5.3.3 Anti-platelet medications
Italicised name and
date references in
section 3.5.3.3 refer
to papers in table C.7
on page 443
Fifteen papers examined the provision of anti-platelet medications
(aspirin in most cases; Hawkins 2013103 looking in addition at clopido-
grel) to individuals with a previous diagnosis of CHD. These studies
were carried out between 1997 and 2011, with the earliest data for any
of the studies going back to 1985.
Of the studies identified, only one (Saxena 2007104) found any evid-
ence of inequity of provision of anti-platelet medications in patients
with CHD, and the association it found was weak. In the study the
authors found that at a practice level there was an association between
practice-level deprivation (IMD) and the proportion of patients at a
practice treated with aspirin, as returned in QOF data. The strength
of the association was tested using the Kruskal-Wallis test, but was
not examined further using multivariate analysis which might take
account of other covariates relating to practices, though analysis was
performed separately according to practice size. The ecological nature
of this study and the limited nature of the analysis performed, together
with the relatively weak evidence of an association, mean that this
paper provides only weak evidence of inequity of aspirin provision
for secondary prevention.
Other studies in this area did not find evidence of inequity; Ram-
say 2005144 found some suggestion that patients with angina or who
had previously had an MI appeared to be less likely to be treated
with aspirin if they were in the manual social class (compared to the
non-manual social class), but these results did not attain statistical
significance at either of the time-points studied or for either of the pa-
tient groups. Some of the studies in fact found that the more deprived
social group appeared more likely to be treated with aspirin; Trinder
2003148 and Mathur 2011146 found some evidence of this, though the
results were not statistically significant; other papers (Elwood 2005130,
McGovern 2008120, Elwood 2011134) found evidence of such a pattern;
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Hawkins 2013103 also found such a picture, particularly in younger age
groups: this pattern was present in the stable angina group in both
1999 and 2007, in 1999 only in their secondary prevention group, and
was not seen in the MI group (either for aspirin or clopidogrel).
Overall, it is clear that the evidence in this area clearly does not
support the existence of inequity in provision of aspirin (or other
anti-platelet medications) for secondary prevention of CHD.
3.5.4 Revascularisation
Italicised name and
date references in
section 3.5.4 refer to
papers in table C.8
on page 449
Fifteen papers were identified in the review that examined the equity
of provision of revascularisation procedures. The majority of the pa-
pers account provision rates of revascularisation procedures (either
CABG or percutaneous transluminal coronary angioplasty (PTCA));
one paper (Pell 2000149) examined waiting times for procedures.
The results from these papers present a mixed picture of the extent
of inequity of provision of revascularisation procedures. A number
of papers find evidence of inequity of provision, including Payne
1997150, Manson-Siddle 1998151, Manson-Siddle 1999152, Hippisley-Cox
2000153, Lester 2004154, and Cosh 2008155. MacLeod 1999156 found in in-
equitable provision of CABG, and though there was some suggestion
of inequitable provision of PTCA this result was not statistically signi-
ficant, which was attributed to the small number of these procedures
identified in the study. Ben-Schlomo 1995157 found a mixed picture,
with evidence of inequitable provision of revascularisation procedures
(CABG) in men: the second and third deprivation quartiles had the
lowest rate of revascularisations, while mortality, which was used as a
measure of proxy need in the study, increased as deprivation increased.
The paper that examined differences in waiting times for revascular-
isation procedures (Pell 2000149) found that overall patients in more
deprived groups waited longer for surgery, but that when the analysis
was repeated separately for routine and emergency procedures there
was no longer a significant difference between the groups.
The remaining studies that were reviewed did not find evidence
of inequity of provision of revascularisation procedures (Kee 1995158,
Black 1995159, Britton 2004141, Gatrell 2002160). Morris 2005161 found
some suggestion of inequity, but the result was not statistically signific-
ant. Mindell 2008162 found no evidence of inequity in NHS provision
of revascularisation procedures, but did find that provision in the
private sector was inequitable.
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Figure 3.13: Summary of findings from review of smoking cessation
Result
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Strong 2006
n = 12920
Millett, Gray et al 2007
n = 4284
Saxena 2007
n = 3130602
Simpson 2010
n = 300064
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
Study size
l 1000
l 15,000
30,000
50,000+
The majority of the studies identified and included in this review
dated from 2004 or earlier (12 out of 15 papers) with many of the
studies published in the 1990s (6 out of 15 papers). Only one of
the studies found evidence of inequity in revascularisation-provision
data from after 2004 (Cosh 2008), and this paper used data from 1992
through to 2006. There is, therefore, no evidence of inequity and
provision of revascularisation procedures after, at the very latest, the
2000s. Patterns of provision of revascularisation procedures may have
changed substantially since that time, due to the large increases in
capacity that have occurred.
The majority of studies that identified some level of inequity in
provision of revascularisation procedures were carried out using
ecological approaches (Ben-Schlomo157, Payne 1997150, Manson-Siddle
1998151, Manson-Siddle 1999152, Hippisley-Cox 2000153, Lester 2004154,
Cosh 2008155). The only paper showing inequity which used individual-
level data was MacLeod 1999156; this paper utilised data from 1991 to
1995.
Two of the papers included in this section of the review were not
published, peer-reviewed papers (Lester 2004154, Cosh 2008155). Their
findings therefore merit less weight than those from published studies.
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Figure 3.14: Summary of findings from review of primary prevention using
antihypertensive medications
Result
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Bachman 2003
n = 770
Chen 2003
n = 1836
Edwards 2003
n = 5671
Pears 2003
n = 19352
Hippisley−Cox 2004
n = 54180
Ward 2004
n = 353897
Ward 2005
n = 353897
Gray 2006
n = 6035
McLean 2006
n = Large ecological
Patel 2006
n = 6066
Millett, Car et al 2007
n = 1852762
Saxena 2007
n = 3130602
Ashworth 2008
n = Large ecological
McGovern 2008
n = 56561
Hamilton 2010
n = 105065
Hammouche 2011
n = 304
l
l
l
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
Study size
l 1000
l 15,000
30,000
50,000+
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Figure 3.15: Summary of findings from review of primary prevention using
cholesterol-lowering medications
Result
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Bradshaw 1998
n = 545783
Packham 1999
n = Large ecological
Packham 2000
n = Large ecological
Bachman 2003
n = 770
Edwards 2003
n = 5671
Hippisley−Cox 2004
n = 54180
Ward 2004
n = 353897
Ward 2005
n = 353897
Gray 2006
n = 6035
McLean 2006
n = Large ecological
Ashworth 2007
n = Large ecological
Millett, Car et al 2007
n = 1852762
Ward 2007
n = 350000
McGovern 2008
n = 56561
Crawley 2009
n = 5269
Hamilton 2010
n = 105065
Forde 2011
n = 7000
l
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
l Prospective cohort
Study size
l 1000
l 15,000
30,000
50,000+
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Figure 3.16: Summary of findings from review of primary prevention using
antiplatelet medication
Result
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Bedson 2001
n = 5983
Edwards 2003
n = 5671
Ward 2004
n = 353897
Elwood 2005
n = 1386
Ward 2005
n = 353897
Saxena 2007
n = 3130602
Petty 2008
n = Large ecological
Vinogradova 2009
n = Large indiv. level
Elwood 2011
n = 4558
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
l Prospective cohort
Study size
l 1000
l 15,000
30,000
50,000+
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Figure 3.17: Summary of findings from review of diabetes management
Result
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Weng 2000
n = 610
Bachman 2003
n = 770
Edwards 2003
n = 5671
Hippisley−Cox 2004
n = 54180
Bebb 2005
n = 1534
Gray 2006
n = 6035
McLean 2006
n = Large ecological
Millett, Car et al 2007
n = 1852762
Millett, Saxena et al 2007
n = 557
McGovern 2008
n = 56561
Wild 2008
n = 52280
Crawley 2009
n = 5269
Millett 2009
n = 1968
Hamilton 2010
n = 105065
O'Kane 2010
n = 685
l
l
l
l
l
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
l Prospective cohort
Study size
l 1000
l 15,000
30,000
50,000+
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Figure 3.18: Summary of findings from review of secondary prevention using
antihypertensives
Result
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Britton 2004
n = 10308
Harding 2005
n = 8300
Ramsay 2005
n = 857
Simpson 2005
n = 14425
McLean 2006
n = Large ecological
Murphy 2006
n = 9508
Strong 2006
n = 12920
Saxena 2007
n = 3130602
Ashworth 2008
n = Large ecological
McGovern 2008
n = 75495
Crawley 2009
n = 5269
Mathur 2011
n = 10933
Hawkins 2013
n = 117942
l
l
l
l
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
l Prospective cohort
Study size
l 1000
l 15,000
30,000
50,000+
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Figure 3.19: Summary of findings from review of secondly prevention using
cholesterol-lowering medications
Result
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Reid 2002
n = 760
Britton 2004
n = 10308
Harding 2005
n = 8300
Ramsay 2005
n = 857
Simpson 2005
n = 14425
Murphy 2006
n = 9508
Strong 2006
n = 12920
Crawley 2009
n = 5269
Mathur 2011
n = 10933
Hawkins 2013
n = 117942
l
l
l
l
l
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
l Prospective cohort
Study size
l 1000
l 15,000
30,000
50,000+
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Figure 3.20: Summary of findings from review of secondary prevention using
antiplatelet medications
Result
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McCallum 1997
n = 5751
Trinder 2003
n = 6322
Britton 2004
n = 10308
Elwood 2005
n = 1386
Harding 2005
n = 8300
Ramsay 2005
n = 857
Simpson 2005
n = 14425
McLean 2006
n = Large ecological
Murphy 2006
n = 9508
Strong 2006
n = 12920
Saxena 2007
n = 3130602
McGovern 2008
n = 75495
Elwood 2011
n = 4558
Mathur 2011
n = 10933
Hawkins 2013
n = 117942
l
l
l
l
l
l
l
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
l Prospective cohort
Study size
l 1000
l 15,000
30,000
50,000+
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Figure 3.21: Summary of findings from review of provision of revascularisa-
tion
Result
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Ben−Shlomo 1995
n = Large ecological
Black 1995
n = 11600000
Kee 1995
n = 141
Payne 1997
n = 12240
Manson−Siddle 1998
n = Large ecological
MacLeod 1999
n = 36838
Manson−Siddle 1999
n = Large ecological
Hippisley−Cox 2000
n = Large ecological
Pell 2000
n = 26642
Gatrell 2002
n = Large ecological
Britton 2004
n = 10308
Lester 2004
n = Large ecological
Morris 2005
n = 5818
Cosh 2008
n = Large ecological
Mindell 2008
n = Large ecological
l
l
l
l
l
Favours
less deprived
No evidence
of difference
Favours
more deprived
Unclear
Study design
l Ecological
l Individual level
l Prospective cohort
Study size
l 1000
l 15,000
30,000
50,000+
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3.6 discussion
3.6.1 Summary of findings
The findings from the literature review can be summarised as follows.
1. The findings from the papers examining smoking cessation ad-
vice and referral to smoking cessation services are summarised
in figure 3.13. Of the studies, only one out of four found evidence
of inequity; this represents one out of six of the comparisons
made, because two studies made more than one comparison.
The effect found was for provision of smoking cessation advice
only. The effect was found in a large, but ecological study. The
effect was not large
2. Findings for papers for the review of antihypertensives for
primary prevention are summarised in figure 3.14. Of the 17
studies, two favour more deprived individuals (individual-level
studies), three favour the less deprived (all ecological studies),
and 11 studies show no effect. One study has unclear results be-
cause there is a suggestion of inequity, but it is unclear whether
the effect is statistically significant Millett 2007119. One of the
studies classified as showing no effect (Pears 2003)108, in fact had
a mixed picture with more deprived individuals less likely to be
prescribed thiazide diuretics and more likely to be prescribed
ACE inhibitors – overall it is not clear that such a result suggests
inequity ( though I have classified it as doing so in figure 3.14).
No obvious time effects emerge from the studies, though one
study found that evidence of inequity from an earlier time point
subsequently disappeared (Ashworth 2008121)
3. The 17 studies looking at primary prevention using lipid-lowering
therapies are summarised in figure 3.15. Five studies (all eco-
logical) show some evidence of inequity. Three studies favour
more deprived individuals (two of these are individual-level
studies). Seven studies, including one prospective cohort, show
no effect. For one study, the result is unclear because statistical
uncertainty is not taken account of (Millett 2007119). There is
some suggestion of a temporal effect, with all studies suggest-
ing inequity published in or before 2006; in the second of two
similar studies (Packham 2000126), previous evidence of inequity
disappeared at a later time point
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4. The nine studies examining primary prevention using antiplate-
let therapies are summarised in figure 3.16. Of the nine studies
included, two studies (both ecological) found evidence of in-
equity in provision. Three studies (including one prospective
cohort and two individual-level studies) found that provision
was higher in more deprived groups. Four studies did not find
any difference.
5. The 15 studies examining inequity in diabetes management are
shown in figure 3.17. Neither study examining provision of
hypoglycaemic agents found any evidence of inequity. Of the
studies examining differences in outcome, seven out of fourteen
studies found evidence of poor achievement in more deprived
groups. Of these seven, only one was an ecological study, with
one prospective cohort study, and the other five being individual-
level studies. One of the studies (Crawley 2009112) found a sig-
nificant difference in achievement of targets at only one time
point.
6. The 13 studies examining inequity in secondary prevention using
antihypertensives are shown in figure 3.18. Of these, the majority
of papers found no evidence of inequity. Four papers did find
evidence of inequity: Ramsay 2005144 (though here there is a
concern about the number of comparisons made, and evidence
of inequity was limited to prescription of beta-blockers); Harding
2005143 in the achievement of targets; Ashworth 2008121 in the
achievement of targets (though the effect later disappeared); and
Saxena 2007104 for both prescription of antihypertensives and
achievement of targets.
7. The ten papers examining inequity in the provision of lipid-
lowering medications for secondary prevention are shown in
figure 3.19. Eight out of the ten studies show no evidence of in-
equity; the two studies that found evidence of reduced provision
of statins to those in more deprived groups found that the effect
disappeared over the time course of the study
8. The 15 papers examining inequity in the provision of antiplatelet
therapies for the purposes of secondary prevention are shown
in figure 3.20. Only one, poor-quality, ecological study found
evidence of inequity. Two studies found evidence that more
deprived individuals were more likely to be receiving antiplatelet
therapies
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9. The 15 studies examining inequity in the provision of revas-
cularisation procedures are shown in figure 3.21. Eight found
evidence of inequity (only one of which was an individual-level
study). Of the seven studies finding no difference or favour-
ing the more deprived individual, two were individual-level
studies and two were prospective cohort studies. If the non-peer-
reviewed studies are discounted (Lester 2004154, Cosh 2008155),
there is no study showing evidence of inequity after the year
2000
A standout finding from the overall set of results from this literature
review is that most studies find no evidence of differential provision of
health care for CHD across deprivation groups or between individuals
with different levels of deprivation. This overall picture is summarised
in table 3.2. From the total column, 28.4% of studies find evidence of
inequity. Moreover, in compiling these figures, I have credited a study
as having provided evidence of inequity if any component of the study
(including comparisons at different time points or for different types
of intervention within an intervention type, such as antihypertensives
or antiplatelet drugs) provides such evidence. Thus, if all comparisons
made were treated separately, this figure would be lower.
Taken at face value, such results imply that inequity in provision
does not appear to operate systematically (if at all); the effect is, at
most, limited to particular interventions at particular times and in
particular places. Prior to making such conclusions, consideration is
owed to the methodological limitations of studies, including to the
issue of which study type was employed.
In relation to study type, a further clear pattern emerges from the
review: ecological studies tend to find relationships suggestive of an in-
equity of provision more frequently than individual-level or prospect-
ive cohort studies. I illustrate this further in table 3.2. A higher propor-
tion of ecological studies find that provision of healthcare (or proxy
measures of provision of healthcare) favour less deprived groups:
53.7%, compared to 13.1% for individual-level studies, and 21.4% for
prospective cohort studies. Two lines of argument might be invoked
to explain this. The first is based on three considerations that relate to
ecological studies: they are, in general, poorer quality, due to inherent
methodological weakness; they are typically easier to carry out than
studies using individual-level data; they are potentially (as with other
studies) subject to publication bias (the phenomenon whereby positive
results are more likely to result in publication). Therefore one might
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Table 3.2: Findings for different study types in the literature review. The per-
centages indicated show the percentage of studies in the relevant
column with each result type
Eco (%) Ind (%) Pro (%) TOTAL
Favours less deprived 22 (53.7%) 8 (13.1%) 3 (21.4%) 33 (28.4%)
No evidence of difference 15 (36.6%) 42 (68.9%) 9 (64.3%) 66 (56.9%)
Favours more deprived 2 (4.9%) 10 (16.4%) 2 (14.3%) 14 (12.1%)
Unclear 2 (4.9%) 1 (1.6%) 0 (2.7%) 3 (2.6%)
TOTAL 41 61 14 116
Eco = ecological study; Ind = individual-level study; Pro = prospective cohort
study
conceive a scenario in which poorer-quality, ecological studies, which
can be readily carried out, arrive at invalid conclusions (due to meth-
odological weakness), and, due to the existence of publication bias,
disproportionately achieve publication of this result; equally, there
may be a large number of unpublished ecological studies that showed
no evidence of inequity. The differing rates of inequity identified in
individual-level studies might relate to the fact that such studies are
less likely to draw invalid conclusions, so that publication bias has no
(or few) positive studies on which to operate.
The second plausible possibility is that, due to their differing ap-
proaches, ecological and individual-level studies are systematically
gathering different information. Ecological studies typically use a
proxy measure of need, such as the death rate or admission rate for
CHD. In using such an approach, ecological studies may identify need
that is hidden from individual-level studies, because they are inferring
levels of need in populations; this will include need in individuals
who may not themselves have presented to health services nor have
been included in cohort studies. In the event that more deprived in-
dividuals are less likely to present to health services at earlier stages
in the pathway of care for CHD, ecological studies might uncover
an apparent ‘inequity’ that is hidden from individual-level studies,
because ecological studies take account of inferences about the level
of need that might exist, regardless of whether that need results in
presentation to healthcare services.
A further theme that emerges is the possible effect that time may
be having on inequity in provision of CHD services. In a number of
studies an effect was observed at an earlier time point, but later in the
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study period the previously observed effect was not there. It is notable
that the inequity is generally observable at an earlier time period and
disappears later, rather than vice versa. Over the period considered
in the review, organisational and clinical changes are known to have
occurred, for example in the development and implementation of
NSFs and the QOF; such changes may have had an influence on
inequity in provision, as might a generally increased awareness of
its possible existence, or other factors. However, he overall pattern of
findings when comparing different studies does not appear to suggest
that earlier studies are more likely to find evidence of inequity then
later studies.
For ease of visualisation and discussion, I have simply classified
studies as ‘Favours less deprived’ (that is to say provides evidence of
inequity), ‘No evidence of difference’, ‘Favours more deprived’, and
‘Unclear’. Synthesising the findings from different studies using their
individual effect sizes was impractical because of the heterogeneous
nature of the measurements used. The approach taken has the ad-
vantage of simplicity, but fails to convey the magnitude of any effects
uncovered. In this approach, I have only classified as ‘Favours less
deprived’ results which were statistically significant, but statistical
significance depends on study size and gives no information about
whether result is clinically important.
I now consider the magnitude of the effects uncovered in the selec-
ted studies. It is notable that five of the comparisons which provided
results suggestive of inequity arose from one study (Saxena 2007104),
and in each case the effect size was small (comparisons were for
smoking cessation, primary prevention using antihypertensive ther-
apies, primary prevention using antiplatelet therapies, secondary pre-
vention using antihypertensive therapies, and secondary prevention
using antiplatelet therapies). This study used a fairly simple, eco-
logical method. The authors examined practice-level achievement
of QOF-indicators in relation to practice characteristics, including
practice-level deprivation (IMD separated into three bands). While the
patterns across deprivation suggest inequity in the areas mentioned,
the actual percentage difference in achievement is small. Taking the
example of smoking cessation, results (which are divided up by prac-
tice size) show that in practices sized 0 to 2999, the percentage of
individuals CHD offered smoking cessation advice rose from 90.3%,
through 91.4%, to 93.3% from the most to the least deprived third of
practices. Similar magnitudes of effect was seen for other practice sizes.
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Likewise, for achievement of BP targets in those with hypertension,
for the smallest practices the percentage of patients achieving the
target rose from 70.3%, through 72.4%, to 74.0%. For practices sized
5000 to 7999, equivalent figures were 69.8%, 71.9%, and 71.7%; for
the practices sized 10,000 and over, equivalent figures were 70.2%,
71.7%, and 72.0%. Figures for prescription of antiplatelet therapies in
those with a history of CHD, are, for the smallest practices, 87.5%,
88.5%, and 88.9%; for middle sized practices 89.3%, 90.3%, 91.1%; for
the largest practices 90.1%, 90.7%, 91.2%. Though not reproduced
here, the figures for the other comparisons mentioned above (primary
and secondary prevention using antihypertensive therapies) show a
similar pattern. What is notable for these comparisons is that, though
the trend shows an increase in the percentage of patients that achieve
the QOF target as the deprivation level of the practice decreases, these
differences are between one and three percent for almost all of the
comparisons made. All of these differences achieved statistical signi-
ficance using the Kruskal-Wallis test, but, in view of the fact that the
interventions will only be effective in a proportion of cases, even if
they are given, these small percentage differences seem insufficient
to be meaningfully contributing to any difference in outcome. It is
notable that data were collected during the first year after the introduc-
tion of QOF, (2004-2005) a period when most general practices made
rapid and significant changes in the way they collected and reported
data required by QOF, and faced new administrative challenges. It
may be that practices with certain characteristics coped better with
these challenges. For example, the authors suggest that the better per-
formance of larger practices may reflect the wider range of staff roles
they could deploy. It is conceivable that the administrative aspects of
QOF performance in practices in deprived areas were affected by the
additional pressures (such as consulation rates) that such practices
may experience.
Determining the clinical importance of the results of many of the
studies can be very difficult on the basis of the results provided. Fur-
thermore, this makes it impossible to pool the analyses from different
studies. For example, some studies109,110,117,124–126 provide results in
terms of correlation coefficients between prescribing rates and depriva-
tion rates at practice level or area level. It can be hard to infer from such
information the extent to which the correlation coefficients presented
would impact on patients and on the difference in outcomes seen
between deprivation groups.
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It is quite clear from all the studies that, from the outset, a key data
limitation goes some way to undermining all the published studies;
this was alluded to in sections 2.1.1 on page 17 and 2.1.3 page 26: data
are not available on whether or not individuals have been offered an
intervention but turned it down.
The inadequate information about demand for interventions means
that it is very difficult for studies to definitively identify inequity – for
reasons detailed in the earlier discussion of health needs assessment.
A further related issue, is that data generally give little or no in-
formation on adherence. Adherence to treatment, and consequently
the effectiveness of interventions in practice, is known to differ ac-
cording to deprivation (for example in the effectiveness of smoking
cessation and in the quality of blood sugar control in diabetics). When
examining differential outcomes between deprivation groups, studies
are generally unable to determine the extent to which achievement of
outcomes relates to provision or to adherence or other patient-related
factors.
A number of issues relating to the ways in which statistical tech-
niques were employed in the papers arose in the course of the review.
First, in some of the studies a large number of comparisons were car-
ried out, only some of them turning out to be statistically significant in
suggesting inequity. If enough comparisons are made random effects
make it likely that some positive results will emerge. Second, the level
of uncertainty in the result was not always adequately quantified,
particularly in relation to Millett, Car et al119. Further in the paper
by Saxena 2007104, it is not clear that the Kruskal-Wallis test used to
determine statistical significance in terms of the difference between
the groups is adequate.
In a number of studies, even in relation to a particular area such as
provision of antihypertensives, more than one comparison may have
been made, and these results may conflict. Particularly in relation to
the prescription of antihypertensive medications this raises a question:
if a deprived individual or group has inadequate provision of one
particular drug class, but provision for others showed no evidence of
inequity, is this provision unfair overall? There is a recognised ladder
of treatment for the management of hypertension (see appendix B),
and simply measuring the provision of each of the drugs that can
be used in the treatment of hypertension is a blunt mechanism for
assessing the overall equity of provision of such a ladder of treatment.
Clearly, for practical reasons studies have simplified their approach,
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and gaining a really detailed picture of the extent to which treat-
ment meets quite complex treatment recommendations is frequently
impractical.
3.6.2 Strengths and limitations of the review
While, in carrying out this review, I have endeavoured to be com-
prehensive, I was inevitably obliged to leave out some potentially
relevant material. I now justify the decisions made in this respect.
The scope was limited to a subset of available interventions for CHD,
based on a number of considerations: the availability of routine data
relating to that intervention; the exclusion of activities that are not
necessarily, in themselves, risk modifying; the exclusion of studies
addressing inequities in provision of interventions that are no longer
used in routine practice. Furthermore, the final selection in the review
was limited on the basis of other criteria, including the nature of
the inequity under consideration (whether it be by area-based socio-
economic deprivation, individual-level socio-economic deprivation,
race, income, employment, education, or gender), the population in
which the study was carried out, and the time period which the study
covered.
To rationalise the selection of literature summarized in this chapter,
papers have been reviewed only if they address inequity in interven-
tions that are addressed in the subsequent parts of this thesis. Inequity
in other interventions for which adequate information is not available
in routine data, though it does have the potential to influence the
gradient in CHD outcomes observed, is less directly relevant to this
thesis.
A number of activities directed at an individual might be inequitably
provided, but not result in modification of an individual’s risk; such
activities include referral to specialists or investigation of CHD. For
example, it may be that individuals from different area-level socio-
economic deprivation groups are referred to cardiology specialists
at different thresholds. In such a situation, less deprived individuals
might be seeing cardiologists at an earlier stage in their disease. It
would be possible for papers in the published literature to study
whether such phenomena were occurring, but such papers have not
been reviewed in this chapter because the process of being referred to
a specialist is not considered to directly affect the risk of progression
of CHD.
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Behaviour change interventions available to primary care practition-
ers include in-house delivery of advice relating to smoking cessation,
weight loss, diet, and exercise, and referral to specialist services to
provide relevant programmes.
Weight loss, dietary, and exercise interventions are not reliably
recorded in routine data. It is hard to tell, on the basis of the Read
code employed, whether the intervention was truly agentic or part of
a bigger programme. Therefore, in relation to behaviour modification,
I have limited ourselves to considering only differences in smoking
cessation provision.
Smoking cessation advice is a fairly discrete intervention, with a
dedicated service, that operates at an agentic level. Records in routine
general practice data (on the basis of preliminary examination of the
GP data in Wales) are much more substantial than for other behaviour
change interventions. It is possible to look at differences in outcome,
because smoking status is a fairly well recorded variable in GP records.
This thesis specifically looks at area-level socio-economic depriva-
tion. In view of this , only papers which include area-level socio-
economic deprivation or some other measure of social class (either at
individual or area level) as one of the individual characteristics for
assessing equity were selected for detailed review.
The focus of this thesis is the Welsh population and the geographical
area of Wales; papers have, therefore, only been included if they
describe studies carried out in Wales or in other constituent countries
of the UK. I made this decision because, while patterns in other areas
are certainly of interest, it is likely that the extent of any inequity that
exists relates to the organisation of health services.
Likewise, papers of potential relevance have been published over
several decades, with the earliest papers on this theme published in the
1980s. Papers included in this review describe only studies performed
in or after 1995. I judged that evidence about the existence of inequity
or otherwise from early periods is not necessarily generalisable to the
current time.
Papers from the grey literature relating to Wales stimulated my
original interest in the subjects addressed in this thesis, and for this
reason I wished to include them, though I have taken account of their
unpublished nature.
I wanted , as far as possible, to summarise the findings from the
review in such a way as to allow the reader to grasp fairly quickly the
main findings. Because of the differing nature of the studies included,
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I elected to summarise findings purely on the basis of whether the
results did or did not suggest inequity. Using this approach meant
that I left out information about effect size and that, where studies
had mixed results, I classified such studies as demonstrating inequity.
Despite the limitations of the approach I have taken, I believe that the
means used to present the findings will aid the reader in interpreting
the literature.
Carrying out a literature review of this nature is a major undertaking.
I wished to complete the review at a relatively early stage in the time-
period allotted for this thesis. Having done so, I have not attempted
to systematically update the findings, but have tried to take account
of any new information that I have identified subsequently through
non-systematic means, for example the paper by Hawkins et al103.
3.6.2.1 NSFs and QOF
NSFs are policies set by the NHS in the UK to define standards of
care for a number of major medical conditions including CHD, stroke,
cancers, chronic obstructive pulmonary disease, diabetes, kidney dis-
ease, and mental illness. They set clear quality requirements for care
based on the best available evidence, and offer strategies and support
to help organisations achieve these. The NSF for CHD was introduced
in England in 2000, and in Wales in 2001.163–168 The The Wales Na-
tional Framework for Coronary Heart Disease (NSF-2001) set out the
standard of cardiac care that should be provided for the Welsh popu-
lation.163 Subsequently this document was updated with a revision
that also includes non-CHD cardiac disease: The Cardiac Disease Na-
tional Service Framework for Wales (NSF-2009)).163 There is ample
evidence that, in relation to CHD, there was marked in improvement
in both quality of care and in mortality, during the period following
the introduction of the NSFs. It is, of course, impossible to quantify
how much of this improvement is directly attributable to the NSFs.
The Coronary Heart Disease National Service Framework: Building
on excellence, maintaining progress – Progress report for 2008169
details the progress made in implementing the Coronary Heart Disease
National Service Framework in England in the eight years since its
publication. It describes rapid and significant changes during the
period 2000-2008, marked improvements having been seen in resources.
Waiting times for CABG were shorter, and cardiology units were better
resourced and staffed. Smoking rates were lower. CHD mortality had
continued to decline. Hippisley-Cox et al170 reported that there were
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substantial improvements in both the recording of coronary risk factors
and disease control measures following the implementation of the
National Service Framework for Coronary Heart Disease. Ramsay144
reported that between 1998-2001 and 2003, statin uptake and the use
of combined drug treatment in elderly men and women increased
markedly. Campbell171 measured changes in the quality of care for
three major chronic diseases (CHD, asthma, and type 2 diabetes)
between 1998 and 2003. He found substantial improvements relating to
all three, but most marked for CHD. An implication of such evidence
is that standards of CHD care were already significantly improving
before the introduction of QOF in 2004.
The QOF, an unprecedented public health intervention operating
within primary care, is a system for the performance management and
payment of GPs in the NHS in the UK. QOF was introduced in April
2004 as part of a revised contract for GPs. It offered financial incentives
relating to a range of performance indicators including those for CHD.
(A typical clinical indicator would be the proportion of patients with
coronary heart disease who had cholesterol measured in that year.)
In this chapter I have already discussed, in relation to health-
care inequity, a number of studies whose evidence is based on QOF
data.104,106,112,117,121,128 A large volume of literature exists in relation to
other aspects of the impact of QOF and provides evidence of relevance
to this thesis in the following respects.
There was marked improvement in clinical activity indicators (in-
cluding those for CHD) in the early years of QOF. This means that
my study period coincided with a period of rapid change in activity
in primary care in relation to CHD. QOF achievements tended to
plateau after the initial improvement.172–176 During this period of im-
provement there was some evidence of narrowing of the deprivation-
gap.121,174,177 There was little evidence of ‘gaming’ through exception
reporting: this is relevant to the reliability of QOF data used in stud-
ies discussed earlier in this chapter.178 QOF was associated with a
decrease in hospital admissions for incentivized conditions including
CHD.179 There was evidence of limited effects of the characteristics of
a general practice on its QOF achievements.180
3.6.3 Implications for thesis
A number of important influences on my approach to this work arose
from the findings of the literature review.
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First, it is clear that difficulty arises when studies attempt to dis-
entangle true inequity in healthcare provision from patient-related
factors. This is particularly the case when looking at differential
achievement of intermediate outcomes (for example blood pressure or
blood sugar control) between groups, but also applies to other ongo-
ing interventions (for example any long-term drug therapies), where
differential adherence to treatment across groups may lead to differ-
ential outcomes. Empirical evidence of this effect appears to emerge
from the review: a higher proportion of the studies looking at diabetes
management appear to suggest inequity (7/14) – with only one of
these studies being ecological. With the exception of revascularisation
(where all but one of the studies suggesting inequity are ecological),
other areas reviewed do not have such a high proportion of study
suggesting inequity. It is conceivable that this pattern relates to the
fact that there is a very strong patient component in the management
of diabetes.
On this basis, it is clearly important that in subsequent parts of
this thesis, I use caution in ascribing any differences observed to
healthcare inequity, when they might actually be due to healthcare
inequity or patient-related factors, or a mixture of both. Information is
not available in routine data sources to allow accurate determination
of whether a difference in the level of treatment that an individual
receives might relate to differences in demand, or to differences in
adherence. It is inevitable therefore that this thesis will suffer some
of the limitations that studies identified in the review evinced – exact
discrimination of the detail of the nature of the differential staircase of
care (discussed in chapters 2 and 5) would not be possible except using
a bespoke dataset that would be extremely difficult and expensive to
acquire.
In many ways, the overall findings of the literature review are
surprising: evidence for the healthcare inequity in relation to the
NHS and CHD is, except perhaps in relation to revascularisation,
very limited. Even if the possibility of publication bias is discounted,
the majority of published studies do not find evidence of inequity.
Furthermore, in those studies that do, the effect sizes tend to be fairly
small. Additionally, in papers finding evidence of inequity, the extent
to which the effect relates truly to healthcare inequity, rather than to
some combination of healthcare inequity and patient-related factors
are, for the most part, difficult to ascertain.
98 inequity in chd interventions
A further theme that emerges from the literature is the possibility
that a temporal effect may be operating in relation to health care
inequity, CHD, and socio-economic position. There is some suggestion
from the literature that earlier papers may have been more likely to
identify inequity; certainly, a number of papers identified inequity
at an earlier time point, with the observed inequity subsequently
disappearing.
Clearly, if the healthcare inequity is not occurring systematically
in relation to CHD and socio-economic position, this represents an
important finding. The existence of healthcare inequity by deprivation
has implications for health inequalities, in the sense that any agentic
intervention might have the potential to worsen health inequalities
where inequity occurs. In contrast, if this is not the case, as the findings
from the literature reviewed in this chapter seem to imply, this not
only obviates the need for concern that such a phenomenon might
be contributing to health inequalities, but also raises the possibility
that systematic implementation of agentic interventions might in itself
contribute to a reduction in the inequality in outcomes from CHD
seen across deprivation groups.
It is clear that the existing literature on healthcare inequity related to
CHD and socio-economic position is limited in terms of methodology
and scope. Moreover, absence of a clear pattern of inequity in care
for CHD contrasts with what is known about uptake of screening
services by more deprived groups. There is a clear need for a whole-
pathway, population-based approach to systematically address the
existence or otherwise of healthcare inequity related to CHD. In the
next chapter, I discuss the methods employed in this thesis to allow
the accomplishing of this task.
Part III
M E T H O D S

4D ATA P E R M I S S I O N , S P E C I F I C AT I O N ,
E X T R A C T I O N A N D P R O C E S S I N G
4.1 introduction
At the start of this thesis, I developed a research rationale and research
questions that I wished to address. I identified the SAIL databank as
the best source of the data in which to find answers to the research
questions. Having decided to use this data source to underpin the
thesis, a number of challenges immediately presented themselves,
which can be summarised as follows:
1. Obtaining permissions for data access
2. Producing a detailed specification of the dataset required for the
thesis
3. Arranging for the extraction process to be performed within
HIRU
4. Processing the extracted data to make it usable for this project
In this chapter I discuss the means by which I addressed these chal-
lenges: I outline the methods used to move from the aim of using
SAIL data through to the production of a cleaned dataset suitable for
subsequent work.
As well as outlining the nature of the steps taken, I seek, where
necessary, to provide justification for the methods used to achieve the
aims. The problems presented were considerable, and it is certainly the
case that they could have been solved in many different ways. While
at every stage I have attempted to solve problems in the best way
that I could devise (subject to limitations of programming capability
and experience, and to the constraints of working on a remotely-
hosted system), the approaches taken are not necessarily optimal, and
with hindsight I appreciate that many things might have been done
differently. With a view to aiding future research of this type, I also
attempt in the following pages to reflect on the difficulties encountered,
the means employed to circumvent them, and how one might avoid
them were it necessary to perform these processes again.
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In discussing how permissions were obtained to use data and the
way the data required were specified (point 1 and 2 in the above list), I
describe the processes separately. In reality, quite a substantial amount
of crossover existed between the two processes: to obtain permission
to use data requires a specification of what is to be used; specifying
the structure of the dataset has, to a certain extent, to take account
of what is likely to be permissible from an information governance
perspective.
In this chapter, I detail the methods have used to obtain, extract,
clean and appropriately format the data for subsequent use. Further
detail of the methods that I needed to use to address the research
questions is discussed in chapters 5 (where I have looked at the
methods used to examine the data from a pathway perspective) and 6
(where I have set out the analytical and statistical methods used).
4.2 permissions for data access
In the background chapter to this thesis I discussed the Information
Governance processes operated by HIRU in relation to SAIL – dis-
cussed on pages 39 to 40. In interacting with HIRU, I have followed
scrupulously the appropriate Information Governance procedures re-
lating to requesting and using data from SAIL – as outlined in the
background material.
In practical terms, to meet the Information Governance requirements
relating to the SAIL databank, I undertook the following.
1. Preliminary discussions with HIRU to consider the feasibility of
the project
2. Formal application to HIRU to obtain permission to use SAIL
data
3. Permission from the Cardiovascular Research Group – Cymru
(CVRG-C) to use analyst time at SAIL to carry out the data
extraction from the main databank
On the basis of preliminary discussions with HIRU staff over sev-
eral weeks, I refined the data specification that was included in the
subsequent formal request to SAIL. These preliminary approaches
included discussions with the co-director of HIRU and with data
analysts from the HIRU Management Team. In discussing the issues
around the data extract, I examined the detailed structure of the data
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tables relating to general practice data, PEDW data, and mortality
data and discussed the issues relating to extraction from these tables.
I modified the formal application to HIRU before submitting it
for Information-Governance approval in the light of feedback from
preliminary discussions.
Because I intended that a data analyst employed by the CVRG-C
would perform the extraction of the specified data tables from the
main SAIL databank, I also submitted a further application to the
CVRG-C for permission to engage the analyst’s time.
4.3 data specification
In specifying in detail the nature and structure of the data required
for this thesis, I aimed to aid the IGRP in their considerations related
to the CRS to facilitate the data-extraction process.
Specifically in relation to the data extraction from the SAIL databank,
I aimed to facilitate the writing of SQL queries (which was the com-
puter language by which data were retrieved from SAIL). This meant
that I needed to specify the structure of tables, linking fields, and ad-
ditional fields required in each table. For each table, I set out explicit
criteria to allow selection of records for inclusion in that table; because
the extract that I wished to use contained several tables, I specified
the means by which these tables should be linked together.
In summary, I needed to make three things as clear as possible in
this specification:
1. The relationships between the tables
2. The criteria by which I wished data rows within these tables to
be selected and included in the extracted dataset
3. The fields (variables) within each of the three main tables that I
needed
In the remainder of this section, I discuss these aspects of the data
specification in turn.
4.3.1 Table relationships
I specified five tables.
1. Main demographic table
104 data permission, specification, extraction and processing
2. Mortality table
3. PEDW table
4. Primary care table
5. Geography and deprivation look-up table
The specification required that tables 1–4 be linked together on Project-
specific Anonymised Linking-field (PSALF) – a unique individual
identifier within the project. The effect of using this linking field
was to allow the establishment of relationships between the tables,
so that for each individual listed in the main demographic table, it
was possible to identify the associated mortality, PEDW, and primary
care records in tables 2–4 (on the basis of PSALF ). The relationship
between the demographic table and tables 2–4 was a one-to-many
relationship, in the sense that one row in the demographic table could
be linked to many rows in the other tables.
I also linked the the geography look-up table, table 5, to the main
demographic table by an encrypted LSOA code – this being an identi-
fication number specifying one of the 1896 LSOAs in Wales. Using a
similar linking process, where I knew the LSOA area-of-residence for
an individual, I could determine the associated area-based decile for
WIMD 2005 (and thus quintile) and also the Local Authority (LA).
4.3.2 Selection criteria
For each of the required tables, I needed to specify selection criteria
that clarified which records from the main SAIL databank tables
should be included in the tables for the extract.
For table 1, the main demographic table, I requested inclusion of
records for individuals that met the following criteria.
• The individual had a date of birth in or before 1975
• The individual had any primary care data in practices that
submit data to the SAIL databank
For table 2, the mortality table, I requested that records from the
SAIL main mortality table should be included in the data extract if
the PSALF for that record was present in table 1 (the demographic
table for this project). I asked that if the cause of death code was one
of the codes shown in appendix E table E.1 (ICD-10 codes only) the
ICD-10 code retrieved be included unchanged in the extract; if the
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ICD-10 code was not in the list then then I specified that it be recoded
to ‘Non-cardiovascular death’.
For table 3, the PEDW table, I asked for records that met the follow-
ing criteria.
• The PSALF for that record was present in table 1
• The spell in which that record occurred contained a diagnosis or
procedure code from appendix E table E.1 (ICD-10 and Office of
Population Censuses and Surveys Classification of Interventions
and Procedures (OPCS) codes only) in any episode in that spell
in any coding position
For table 4, the primary care table, I asked that records be included
if they met the following criteria.
• The PSALF for that record was present in table 1
• The event code for that record contained one of the Read codes
in appendix E table E.1 (Read codes only)
A very large number of Read codes (over 4000) defined inclusion of
records in the primary care table (those shown in table E.1 in appendix
E. These codes included those relating to primary care diagnosis, in-
vestigation, and treatment of CHD and of its risk factors. I took the
codes themselves from a much larger dataset of Read codes (version
2) for clinical activity and drug prescription. I downloaded the full
set of codes from the Technology Reference Data Update Distribu-
tion (TRUD) website181. I imported the main dataset into an SQLite
database, so that I could extract codes relevant to this thesis. The
aim in selecting Read codes for the data extraction was to maximise
sensitivity, by including as many codes as possible relating to each
particular clinical area, leaving open the possibility for refinement of
the coding definitions of different clinical states at a subsequent time.
Ethnicity data would have been useful in this thesis, partly because
I would have liked to use it for adjustment when examining effects
related to deprivation; partly, because variation by ethnicity in util-
isation of healthcare is of inherent interest. Though Read codes exist
for ethnicity, these are not widely used. Ethnicity availability in GP
systems was insufficient to underpin analysis in this area. I argue that
the impact of the absence of ethnicity data is likely to be very small;
from the most recent census data, 7% of the Welsh population is from
minority ethnic groups. Further, CHD is predominantly a disease of
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older age groups; older age groups have lower proportions of minority
ethnic groups.
I extracted the codes in SQLite using SQL queries that used ‘LIKE’
clauses to identify codes in which the code description matched the
required clinical area. The ‘LIKE’ search terms used are shown in
table 4.1 (the ‘%’ sign is a wildcard character signifying an arbitrary
string of characters of arbitrary length). In a small number of cases
I used two, three, and four digit Read code stems to identify lists
of codes in a particular branch of the Read code version 2 system.
I identified such code stems using the NHS Read Browser software
package, available from TRUD, which allows the Read codes system
to be visualised and navigated.
To identify drug treatment Read codes, I worked back from the
codes for specific drug treatments where the code was known, to allow
searching by broader categories relating to that code. This is possible
using Read codes version 2, because the five-digit code describes a
branching hierarchy. By working back to earlier digits in the five-digit
sequence, I was able to identify the broader category from which the
code derived. For example, the Read code for ramipril 1.25 mg capsules
is ‘bi61.’. From this, using the NHS Read Browser, it is possible to
work up the hierarchy and to identify the code ‘bi...’, which is the
code for ACE inhibitors. The search string ‘bi%’ can then be used in
a ‘LIKE’ statement to identify all the Read codes for ACE inhibitors.
Using this approach, I identified Read codes for the following drug
groups.
• Antihypertensive medications including ACE inhibitors
• Antiplatelet medication
• Oral hypoglycaemic medication
• Insulins
• Statins and other cholesterol-lowering agents
The SQL queries that I ran using these ‘LIKE’ statements yielded a
large number of codes (7894), many of which were not relevant. I then
examined the code descriptions relating to these codes individually
to determine whether or not they should be included. Following this
process, I retained 4155 codes.
At the time of the data specification, I was unsure whether there
might also be some GP activity coded using version 3 Read codes
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Table 4.1: LIKE statements used in searching for Read codes
Description LIKE statements used in SQL
CHD %isch%, %coro%, %cor a%,
%cor th%, %ang%, %myo i%,
%myoc%
Stroke %CVA%, %strok%, %sient
isch%, %H/O: TIA%, %pected
TIA%
Heart and renal failure %fail%, %CKD%, %CRF%,
G58%, K04%, Kyu20
Glomerular filtration rate %glom%, %GFR%, 451A%,
451F%, 451G%, 451J%
Diabetes and HbA1c %diab%, %fast%, %impair%,
%gluc%, %sugar%,%HbA%,
%Hb. A%
Rheumatoid arthritis %rheu%
Family history %FH%, %fam%
Cholesterol and lipids %chol%, %LDL%, %HDL%,
%triglyceride%
BMI and weight management %wt%, %weight%, %bmi%,
%body mass%, 162%
Exercise and exercise
management
%exer%, %acti%, %phys%
Hypertension %hyp%, %press%
Smoking %smok%
Diet %diet%
108 data permission, specification, extraction and processing
or the Systematized Nomenclature of Medicine – Clinical Terms
(SNOMED CT) coding system. Because of the possible existence of
these alternative coding systems within the SAIL GP data, I ‘trans-
lated’ the list of version 2 Read codes into these alternate systems. I
performed the conversion from version 2 Read codes to version 3 Read
codes using the file ‘rctctv3map_uk_20110401000001.txt’ downloaded
from the TRUD website. This file contains a field ‘V2_ConceptID’
(which contains version 2 Read code concepts) and a field ‘CTV3_Con-
ceptID’ (which contains version 3 Read code concepts); I carried out
the conversion in R version 2.12 using the ‘match’ function to match
the version 2 Read codes from the original list to version 3 Read codes.
I then compared the resulting codes in version 3 with the original
codes, and I retained and added to the code list those codes that
were different. I matched Version 2 Read codes to SNOMED CT codes
using the NHS Data Migration file RcMap_uk_20110401000001.txt,
matching on the fields ‘ReadCode’ (version 2 Read code concept) and
‘ConceptId’( SNOMED CT concept). Following this process, the list
of codes included 7379 codes. I added a classification field to this
list that I asked the HIRU analyst to add to the general practice data
when performing the extract. I passed this list to the HIRU analyst
performing the data extraction.
For table 5, I specified that all 1896 rows, one for each LSOA in
Wales, should be included in the extract table.
4.3.3 Data fields
For each of the tables 1–5 above, I requested a number of fields in the
data specification. For the main demographic table, table 1, I specified
the fields PSALF, week and year of birth, sex, encrypted LSOAs on
1 January at yearly intervals (2003 to 2010), and encrypted practice
codes on 1 January at yearly intervals (2003 to 2010). An individual’s
LSOA of residence or practice code can change at any time, and over
a given period can change several times. In order to capture as many
such movements as possible, while at the same time still making the
analysis of the small-area deprivation status of individuals tractable,
I used the approach of requesting the LSOA for individuals on 1
January annually.
For the mortality table, table 2, I specified the fields PSALF, date
of death, place of death, primary cause of death (ICD-10 code), and
underlying cause of death (ICD-10 code).
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For the PEDW table, table 3, I specified the fields PSALF; spell
number; episode number; spell start date; spell end date; episode start
date; episode end date; diagnostic codes (ICD-10) and descriptions,
all 14 positions; procedure codes (OPCS-4) and descriptions, all 6 pos-
itions; admission method; source of admission; referring organisation
code; duration of elective wait; provider unit code; and discharge
destination.
For the primary care table, table 4, I specified the fields PSALF,
event code (Read code), Read-code description, event date, and event
value.
Table 5, the deprivation and geography look-up table, is a table
created as part of an earlier project using the SAIL databank. The
table contains one row for each LSOA in Wales for the 2001 census
(totalling 1896). I asked that, for this thesis, the table contain encrypted
LSOA code, LA code, WIMD 2005 deprivation decile, and Townsend
deprivation decile.
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Figure 4.1: Overview of the database structure for the data used in this thesis
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4.4 data extraction
The data for this thesis were extracted from the SAIL databank, man-
aged by the HIRU team at Swansea University. Two HIRU analysts
performed the data extraction. The first of these wrote the SQL queries
needed to extract the data as set out in the data specification.
Before any data could be made available for research purposes, in
line with SAIL Information Governance procedures, the Encrypted
Anonymised Linking Field (ALF-e), a unique identifier for each indi-
vidual, was re-encrypted with PSALF – a newly-encrypted version of
this identifier, used only for my data extract. Similarly, LSOA codes
were encrypted.
The process of beginning the data extraction brought to light some
issues with the data specification, and as a result I made a number
of changes. First, I identified a number of additional clinical codes
(Read codes and ICD-10 codes) that were not included in the original
data specification. Second, it was not possible to create the primary
care table simply by the use of a simple SQL query, because the large
number of records in the main SAIL GP table and the very large
number of Read codes in the data specification made this approach
programmatically unfeasible. HIRU analysts therefore created used
techniques based on cursors within the IBM DB2 (DB2) framework.
Using this approach I was able to take advantage of the strength of
relational-database software to match the primary care data to the
records in the temporary intermediate table. This did not affect the
file structure of the primary care data.
Data-processing and the data extraction were iterative processes, be-
cause I encountered a number of problems that necessitated revisions.
I discuss these further in section 10.3 on page 329.
4.5 data-processing
I performed the data-processing stages described below with the aim
of producing a usable dataset. Doing so required that a number of
challenges be overcome. These included the difficulty of working on a
remotely-hosted computer, the large size of the dataset, the necessity
to clean the dataset adequately prior to use (from the point of view of
missing, duplicate, and implausible data), and formatting the data for
use. I describe below the means used to address these challenges. In
doing so, I address four areas:
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1. Working on a remote system
2. An overview of the decisions made about the programming
languages and software used
3. An overview of the structure of my software
4. A detailed description of the cardiovascular-dataset-generating
software that I wrote to perform the first stage of the data pro-
cessing
4.5.1 Working on a remote system
Due to information governance regulations set out by the data access
agreement with HIRU, I performed all analytical activity within the
SAIL Gateway – the remote access facility for SAIL projects. Over the
course of the analysis, I used two versions of the Gateway system.
Version 1 was in use throughout 2012 and the first half of 2013. I
switched over to version 2 of the Gateway in June 2013. The principal
difference between systems is that version 2 of the Gateway requires
an additional token, which acts as an electronic one-time pad. This
provides additional security for access to the system.
Although working on the Gateway allowed access to the necessary
data sets in a way that would not have been possible otherwise, I was
subject to a number of practical restrictions on the way data processing
might be accomplished. I discuss these further in section 10.3.
4.5.2 Programming-language choice
Before engaging in any analysis, I had to make a number of decisions
about the likely approach that I would employ. In deliberating, I had
in mind a number of principles: given that at the outset, I was unsure
of the exact nature of the processing needed (as is perhaps inevitable),
I wanted to use an approach that was as flexible as possible; similarly,
I wanted an approach that gave the maximum level of control over
the handling of the data; I wanted an approach that would be able
to handle very large volumes of data, especially as at the start of the
project it was not clear how large the final dataset might be; I wanted
to employ programming languages that I had used before, and with
which I was at least reasonably familiar; I wanted to, if at all possible,
design and produce software that was configurable, thus giving it
4.5 data-processing 113
potential use in future projects other than this one; any software that I
used had to be available within the Gateway.
With these principles in mind, I decided not to use the DB2 database
within which the SAIL data are held. Rather, I exported data from
this system to a separate file structure generated by my software. I
did this for two principal reasons: performing the intricate algorithms
on individual-level data that I had in mind would be very difficult in
SQL (though not necessarily impossible); using my own file structure
would give additional control over the data, as compared to the data
held within DB2 (though I hasten to make clear that this additional
control in no way reduced data security; the data was just put in
a different part of the Gateway). This approach had one obvious
drawback. For very large data handling, DB2 is a highly optimised,
fast approach. Given that most of the processing that I wished to
accomplish would only require running once, rather than multiple
runs in a performance-critical situation, this was a trade-off (some
loss of speed in return for greater control and more straightforward
coding) that I thought worthwhile.
I selected programming languages that I have previously used: C#
(for general programming; I chose this over other general-purpose
programming languages simply because it was familiar); the SQLite
dialect of SQL for writing queries (again because I had used it before,
but also because SQLite is a lightweight relational database software
that can be incorporated into C# fairly readily; I used the dynamic
linked library System.Data.SQLite to do this); R for statistical analysis
and production of graphics.
I considered a number of other possible options before rejecting
them, including using Microsoft Office applications (Excel and Ac-
cess), using SPSS, and using Stata. I also considered using R for the
preprocessing of the data, instead of simply for the analysis of the
processed datasets. While it may have been possible to perform the
necessary processing using these approaches, rather than using the
C#/SQLite/R combination that I used, I think that it would have been
much more difficult. Factors bearing on this decision include speed
considerations, ability to handle large datasets, flexibility and ease
of programming, ability to implement an object-orientated approach,
and greater or lesser familiarity with certain software. Clearly there
was more than one way to approach the task: I believe that, in view
of the uncertainties I faced at the start of this project, the approach
chosen represented a sensible balance of performance and flexibility.
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Having decided which software to use, I then progressed to plan an
overview of the necessary software structure.
4.5.3 Software structure
The raw data produced by the extract, and held in project-specific
tables within the DB2 was not suitable for addressing the research
questions. The data required modifying in a number of respects. The
first set of problems related to the fact that the data had not been
cleaned. Duplicate entries were present in the mortality table (but
quite obviously an individual dies only once), in the general practice
table (where the same Read code for the same individual for the same
date quite frequently occurred, but with a different Read code descrip-
tion), and in the demography table (where some unique individual
identifiers were duplicated). Also in the demography table, some of
the LSOA codes did not relate to Welsh LSOAs, because the residents
registered with a Welsh practice ended up in Welsh Demographic
Service (WDS) data. Further problems arose because some general
practice data contain values for results or readings. In many cases
these values were either missing or were clearly implausible. Thus,
I had to develop an approach to handle these entries. Because I was
unsure of the nature of the distributions of these values, I needed to
visualise them in order to determine meaningful cut-offs.
The second broad category of problems related to the structure of
the data. I wished to get the data to a state where I could use one
master algorithm to cycle through the records for each individual and
derive information on the individual based on these records (a process
described in chapter 5). In order to facilitate this, I generated a cleaned
dataset with an appropriate structure. The raw dataset contained four
tables (and one lookup table) in different formats. Moreover, the PEDW
data was in a ‘long’ format, with one row for each unique combination
of spell, episode, operative code, and diagnostic code – making it more
difficult to use. The data in the separate tables were unsorted, making
it difficult to access all of the data on one individual in turn. To provide
usable data, I restructured the data to two tables: a demography table
and a common format table (containing general practice, mortality,
and the restructured PEDW data in the same format). The lookup
table was unchanged. The data in both of these tables needed to be
sorted by the individual’s unique identification number (PSALF).
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A further problem with the raw data was its size. While there are
only a few hundred thousand mortality records, there were approxim-
ately 2,000,000 entries in the demography table, 40 million entries in
the PEDW table, and 130 million entries in the general practice table.
This meant that I had to write software capable of handling this large
number of records; moreover, at the time of development, I was unsure
of the exact final size of the data set because the extraction process
was ongoing, and because SAIL data are periodically refreshed.
I wished to resolve some of the enormous numbers of clinical
codes (particularly Read codes) into a more tractable set of events.
For example, there are, for many classes of drugs of interest, many
different Read codes relating to that class. Likewise, some diagnoses
may have a number of Read codes associated with them, for example
diabetes. I thus wished to develop the means of adding a classification
to a particular record based on clinical-coding criteria; and in fact
I determined that a two-level system was necessary. For example, I
wanted it to be possible to have a broad category for all the general
practice entries relating to raised blood-pressure, but also to be able
to further classify these entries on the basis of whether they related
to blood-pressure readings, blood-pressure diagnoses, blood-pressure
comments, or blood-pressure treatments. I wanted this to be possible
for all types of general-practice data, but also for mortality and PEDW
data. Given that I knew it was unlikely I would get this classification
right first time, I wished to develop a system which allowed me (and
potentially others) to specify fairly easily the nature of the classification
to be used.
Finally, developing the cardiac-dataset generator provided oppor-
tunities to check the original data extract, allowing me to identify
any associated problems. This inevitably resulted in the processes of
data extraction and creation of the cardiac dataset generator becoming
intertwined and iterative. Such an approach allowed me to identify a
number of problems, which are discussed below in section 10.3.
4.5.4 Dataset processing
In this section, I provide details of the structure and workings of the
cardiac-dataset generator. I discuss the following areas:
1. Overview of the process carried out by the software
2. A discussion of the configurability of the software
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3. The software structure
4. The processing methods used in a number of key areas
5. The visualisation of data necessary for processing general prac-
tice value fields
4.5.4.1 Overview of the process
I begin with a discussion of the processing of the general practice
data. The processing of the other main datasets (demography; mor-
tality; PEDW) was similar though necessarily slightly different. The
differences are discussed below.
The data processing approach taken for the GP data is summarised
in the schematic diagram in figure 4.2, which indicates the main files
used to process the data. Due to the large size of the dataset in question,
I split the data up into subsets. I did this using a classification code
which was specified in the original extract specification and which
allowed each GP data line to be categorised into the broad area to
which it referred on the basis of its Read code. Thus, the first level of
classification of the general practice data that I wished to achieve was
accomplished as part of the extraction process (discussed to above)
using the linkage between the general practice table and the table
of Read codes that I provided to the HIRU analyst performing the
extraction. This allowed me to deal with different types of GP data
separately.
First, I extracted the GP data from the main SAIL databank (¶ in
figure 4.2). I did this for each of the classification types, which included
for example ‘hypertension’, ‘coronary heart disease’, ‘calcium-channel
blocker’ and so on. I then imported each of these extracted raw data
files (· in figure 4.2) into an SQLite database (¸ in figure 4.2) from
where I could further query the data and remove duplicates. I added
a further sub-classification field to the data in the SQLite database by
linking the GP table to a sub-classification table (also imported into
SQLite, and derived from the user-specified classification files). This
allowed extraction of fields based on more detailed descriptions, for
example ‘Hypertension reading’, ‘Hypertension diagnosis’, ‘Coronary
heart disease comment’, and so on.
Once this process was complete, I ran each line of the data through
a C# algorithm (¹ in figure 4.2) which processed it based on its
classification and sub-classification. I kept relevant fields for further
analysis; where readings or results were present, I processed these
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so that the units were standardised, and zero values and implaus-
ible values rejected. This process was, again, based on user-specified
formulae. As a result of this process, I created a set of event files (º
in figure 4.2), which contained processed GP event data, and which
could subsequently be combined with PEDW and ONS mortality data,
in a common format which could store all event types. The event files
contained processed data separated by event classification (‘hyperten-
sion’, ‘coronary heart disease’, ‘glomerular filtration rate’, and so on).
Analysis required examination of data at individual level. Therefore
in the next stage of data processing I ran a C# algorithm against each
of the event files (» in figure 4.2) and categorised events by individual.
Because a single individual file would be too large to be manageable,
there were a number of individual files which each contained pro-
cessed data on a subset of individuals (¼ in figure 4.2). At this stage
I combined the general practice data with mortality and PEDW data
that had been processed along a similar but distinct pathway.
Finally, in order to work properly, the derived dataset generator
required the records in the event files to be sorted in order of ascend-
ing PSALF. I accomplished this by writing an external merge sort
algorithm. This allowed me to produce a set of event files which were
sorted, which contained all the records relevant to a particular indi-
vidual, and through which the derived dataset generator algorithms
could cycle.
Although the algorithms for processing the PEDW data were similar
to those used for the general practice data, there were a number of
differences. The classification system for these data was more straight-
forward, with the higher-level classification set as ‘Admission’ and the
lower-level classification based on the type of admission (for example,
CVA, MI, PCI, and so on). No values were present in these data, so
processing was more straightforward
I substantially restructured the PEDW data. The data in the original
extract contained one row for each combination of individual, pro-
vider unit code ( indicating the hospital site in which the admission
occurred), spell number, episode number, diagnosis number, and pro-
cedure number. For my analysis, I wanted this table to contain one
row per episode. I restructured the data at the stage of importing from
the SAIL DB2 database.
Similarly, the mortality data required less processing than general
practice data. I imported the data through the equivalent system of
files, with the high-level classification code set to ‘Death’, and the low-
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level classification code set to either non-cardiovascular cause of death,
or a specified cardiovascular cause. At this stage, I removed duplicates
from the mortality table, which arose where the same individual had
more than one entry in the table. In each of these cases, the cause of
death code and date of death were identical, and so I removed one of
the entries at random.
Once I had imported and classified the PEDW and mortality data, I
was able to alter the format in line with the common format for the
tables that I had previously used for the general practice data. I then
combined all of these data lines into separate files; each file contained
data relating to a range of PSALFs. I used the external-merge-sort
to sort the files by ascending PSALF. As a result of this process, I
was then able to obtain a set of cleaned, classified, sorted event files,
which contained data derived from the general practice, PEDW, and
mortality tables.
I required the demography table to be available separately. I impor-
ted this table into a file in a separate section of the cardiac dataset file
structure. During this process, I used queries sent from C# to the SAIL
DB2 database to remove non-Welsh LSOA codes. At this stage, during
the process of writing the cardiac dataset generator, I discovered that
there were a number of duplicates in the demography table. I arranged
for the HIRU analyst performing the data extract to remove these du-
plicates in a refreshed extract. I imported into the classification-files
section of the cardiac-dataset file-structure an unchanged version of
the lookup table from LSOA to other LSOA-level variables.
4.5
d
a
ta
-pr
o
c
essin
g
119
Figure 4.2: Schematic representation of data processing of GP data
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4.5.4.2 Configurability
One of my aims in producing the cardiac dataset generator was to
produce a system that could be reused in future to generate similar
datasets, using refreshed data from SAIL and using a different spe-
cification of codes and classifications. With this in mind, I sought,
throughout the process of writing the software, to provide options for
users to specify the nature of the final dataset.
Simple variables that the user may specify include the location of the
file structure, the dataset name, and the file size for processing records.
I wished to make it possible for users to specify which type of records
they wish to select from the raw data, how they want to classify
such records, and how they wish to process values in the general
practice data. To do this, I developed a system whereby the software
checks a directory of Excel spreadsheets (termed the classification
files), to look for user-inputted information. The advantage of this
approach is that most users are familiar with spreadsheet software, and
the specification of the dataset itself does not require programming
knowledge. The classification files are generated on the basis of the
unique types of classification in the raw data. For each classification
file, there is a list of Read codes, Read code descriptions, the number
of entries for that Read code in the raw data, and a field to flag
whether or not that Read code and Read code description is a duplicate
combination. A further field is used to hold formulae that allow users
to define how they wish the value field for that particular Read code
to be handled.
In using the system, the user assigns a sub-classification to each of
the Read codes. The process of such an assignment means the records
related to that Read code will be included in the final data; otherwise
the codes are ignored. For codes where the user will wish to use the
value field (typically this is a measurement reading such as blood
pressure or cholesterol), the user specifies a means of handling this
in the formula field. Here, there are functions available to specify the
handling of the data, which are parsed later by the software. There
are three formulae that I have written, which proved useful for this
project.
• RANGE: This function allows the user to specify a range within
which the value should be retained, and the record used. If
the value falls outside the range, the sub-classification of the
record is changed, by adding the suffix ‘EMPTY OR OUT OF
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RANGE’. The arguments to the function are the lower and upper
boundaries for the range.
• SPLITRANGE: This function allows the user to specify two
ranges, for handling mixed distributions. This situation arises
where the same Read code has value fields whether measure-
ment or reading entered is not always in the same units. The
function converts values within the second specified range into
values within the first specified range using a formula entered
by the user as one of the arguments to the function.
• BLOODPRESSURE: This function allows the user to specify the
handling of blood pressure readings, again using two ranges.
This time the first range is used for diastolic blood pressure and
the second for systolic blood pressure.
For each of these formula types, the formula used for the processing
of any sub-classification is taken from the entry for the first Read code
entry related to that sub-classification. All subsequent Read codes of
the same sub-classification are processed in the same way. This saves
the user having to repeatedly enter formulae.
In using these functions for the processing carried out for this
thesis, I based the decisions made about which ranges to employ
on visualisation of the distributions of the values in the data, and
on discussions with a chemical pathology clinician and a laboratory
technician, based on the graphed distributions.
4.5.4.3 Visualisation of data
I needed to visualise the distributions of raw data within the value
fields of the general practice data at an interim stage, before they had
been processed. I achieved this by writing code in R that extracted the
relevant data from the SQLite event files (using the R package, ‘RSQL-
ite’, available from the Comprehensive R Archive Network (CRAN)
repository). The graphics themselves were produced using the R add-
on package, ‘ggplot2’, also available from CRAN.
I automated this process in such a way as to allow large numbers of
distributions to be generated and exported from SAIL for discussion
with people with expertise in the area, facilitating decision-making
about which ranges to include.
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4.6 conclusions
In this chapter, I have outlined the stages through which it was ne-
cessary to progress in order to produce data appropriate for use in
later parts of this thesis. This has included outlining the processes
by which information governance approval was sought and obtained
from the relevant quarter; I have detailed the process by which the
requisite dataset was specified, such that extraction might take place
and inform information governance procedures; I have outlined the
extraction process undertaken; finally, I have detailed the process by
which the extracted data was processed, formatted, and cleaned.
In carrying out these processes, the aim was to progress the work
to a point at which a suitable dataset was available for the purposes
of subsequent work. These later data-processing and analytical tasks
were in themselves quite detailed programming projects. I describe
them in the next two chapters.
5PAT H WAY O F C A R E F O R C O R O N A RY H E A RT
D I S E A S E
5.1 introduction
When first developing ideas for this thesis, I conceived the idea of a
pathway of care for CHD as illustrated in figure 1.1, and discussed
in chapter 1. In chapter 3, I reviewed the literature around inequity
of healthcare interventions for CHD; I found a mixed picture, and no
studies that attempted to look in a comprehensive way across several
areas of care. In the light of this review, and taking into consideration
the aims of my work, I developed an approach to take account of the
flows and knock-on effects that might potentially operate in the system
of care as a whole. I devised an approach to analysis that focused and
comprehensiveness, with a view to examining systematic effects. The
intention was to develop a detailed approach to the idea of a pathway
of care that was explicit, reproducible, and rigorous. It is this approach
that I discuss in this chapter. I hope to set the methods of this thesis
in the context of previous important concepts in this area, to show
how and why I have extended previous conceptual frameworks, and
to provide a detailed description of the methods used to implement
this approach.
I will examine two areas:
1. An overview of the methodological concepts developed around
a pathway approach
2. The detailed implementation of these concepts to generate the
data to address the research questions
5.2 methodological concepts
In the this section, I discuss what I mean by the pathway of care for
CHD, how I determined what should be included in it, the idea of
indication patterns for individuals the concept of the ‘clinical trigger–
clinical action’ approach taken at each point in the pathway, and the
assumptions and limitations of this approach.
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5.2.1 Pathway of care for CHD
This idea of a pathway of care for CHD, as conceived here, involves
a comprehensive overview of the different components of healthcare
that can be delivered to an individual at different times in managing
CHD. Clearly, the requirements for healthcare activity related to CHD
vary from individual to individual, and from time to time for that
individual. Thus, at any one time an individual will have a specific
indication pattern consisting of the set of components of healthcare
for CHD that are indicated for that person at that time.
5.2.2 Inclusion in pathway
There are a large number of interventions that relate to CHD. (The
concept of interventions here is deliberately broad, ranging from from
simple measures to ascertain CHD risk, through management of risk
factors and chronic disease, to revascularisation. Deciding which of
these to include and which to leave out was a key stage in developing
the pathway. It was necessary to develop an approach that considered
up-to-date interventions that have been shown to be effective, and
which were appropriate during the period studied. I kept a number of
principles in mind:
• I wanted to include in the pathway interventions that had been
shown to reduce mortality from the disease or affect identifica-
tion of individuals so that they could receive such interventions
subsequently. For this reason, for example, I did not look at
therapies that provide symptomatic relief of angina
• I wanted to look at interventions that could be regarded as gener-
ally accepted in practice (allowing that there are always clinical
situations in which clinical judgement will override generic guid-
ance). For this reason, I focused on interventions recommended
in National Institute for Clinical Excellence (NICE) guidance
• The pathway was limited by the data available. I could not
look at all relevant interventions. In particular, I could not look
in any detail at the inpatient management of acute coronary
syndromes (ACSs), because information about prescribing in
secondary care was not available in routine data
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• I limited examination of the pathway to looking at treatments
that were in general use during the period of the cohort. I did
not look at experimental or unusual interventions
• I wanted to look at cessation as well as commencement of pre-
scribing of appropriate medications
With these principles in mind, I then developed the overall principle
of the pathway. In figure 5.1, I illustrate the overview of the pathway
schematically. At the top of the figure is shown the potential progres-
sion of an individual through different stages of CHD. At first an
individual will not have the disease, but may become at high risk of
developing it; they may then progress to have stable angina, unstable
angina and other ACSs. On the left-hand side of the figure, I illustrate
the kinds of healthcare activities that can be appropriate in CHD. This
includes a spectrum of care running from primary care identification
of risk factors and risk, through primary care management of such risk
factors, to medical and surgical management of established disease.
I wished to develop the idea of visualising the pathway of care
for CHD based on figure 5.1. Though this was not straightforward (I
discuss some of the issues with it below), I intended to develop an
approach that allowed consideration of an overview of the pathway of
care, and, in particular, a way to visualise it. The eventual overview
diagram that I developed is detailed in section 5.3 on page 133.
5.2.3 Points in the pathway
Having developed the idea of viewing the pathway in overview, I then
sought to determine how I would address each particular point in the
pathway. In the first instance, I developed an approach to thinking
about what was happening at each of these points, and about what I
would be able to determine from available data with respect to health
care provision at each point.
5.2.3.1 Staircase effect
In chapter 2, I discussed healthcare needs assessment on page 26 and
I also introduced the staircase effect on page 6.
These concepts were important for this thesis. I characterise the de-
livery of a healthcare interventions as a staircase, following Tugwell3,
but with the addition of the idea that at each step in that staircase a
particular factor is involved, either related to need, demand, or supply.
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Figure 5.1: Pathway concepts
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Need-related factors are those that have a bearing on an individual’s
capacity to benefit from intervention; supply-related factors are those
pertaining to health-service considerations; demand-related factors are
those to do with whether an individual seeks an intervention, wishes
to undergo it, consents to it, and, where relevant, adheres to therapy.
In figure 1.2, I have classified different stages in the staircase as
supplied-related, demand-related, or need-related. In this conceptu-
alisation, only a proportion of those reaching any particular stage
will move onto the next, with the drop-off related to the factor in
question. (By drop-off, I mean the proportion who fail to move onto
the next step). Effective delivery of an intervention requires that an
individual passes through each stage. At each stage, the drop-off can
be characterised as related to supply, demand, or need; in figure 1.2, I
have illustrated this by colouring drop-off blue when related to need,
read when related to supply, and green when related to demand.
Thinking about the staircase effect for the intervention in this way
means that one can distinguish, if only in theory, between drop-off
related to supply-related factors (which are principally health-service
related), need-related factors (related to the efficacy of the technology
in a particular population group), and demand-related factors (de-
termined by individual behaviour, but clearly related to health service
and societal influences).
For any intervention, there are several stages that need to be gone
through in a critical pathway, each one of which needs to be met
before the theoretical efficacy of the intervention is brought to bear.
Tugwell et al3 defined stages of awareness, access, diagnosis, targeting,
compliance of providers, and adherence of consumers. The exact
sequence of steps conceived might vary according to intervention
and according to the level of ‘magnification’ required in thinking
about the staircase effect. In figure 1.2, we start with all individuals
in the population with capacity to benefit from the intervention, and
progress through to the proportion of those with this need in whom the
intervention is eventually efficacious. Along the way, we incorporate
drop-offs in a number of individuals identified as having the need
for the intervention, being aware of that need, being identified as
having that need (by the health service), being offered the intervention,
consenting to the intervention, being prescribed the intervention or
being listed for a procedure, collecting the prescription or attending
for a procedure, taking the intervention, and persisting with treatment.
The exact sequence of these steps will vary by intervention.
128 pathway of care for coronary heart disease
In my conceptualisation of the staircase, supply-related factors
would include identification of need, offer of intervention, and pre-
scription of intervention (when the intervention is a drug) – these
principally relate to the activity of the health service; demand-related
factors will include awareness, consent, collection of medications, at-
tendance, and adherence – as these principally relate to individual
choice and behaviour; need-related factors would be limited to the
number of individuals in the population with the need and to the
efficacy of the intervention.
The above theoretical division of the staircase effect is useful, be-
cause it allows one to think about what ‘views’ of the staircase one
is able to get for any one intervention. Typical academic studies of
healthcare inequity examine drop-off across a number of steps in the
staircase – and these steps may be some combination of demand-
related, supply-related, and need-related. They do this because they
have to; data are usually not available on all of the potential drop-offs
in the staircase. This limits the extent to which studies can accur-
ately ascertain the existence of healthcare inequity – where healthcare
inequity is conceptualised as a differential drop-off between social
groups in supply-related steps of the staircase. Where demand-related
and need-related steps exist in the segment of the staircase examined,
the possibility of the drop-off being related to differences in these can-
not be discounted. Again, this is important for studies of healthcare
inequity: if one social group is turning down an intervention at a much
higher rate than another, does this represent healthcare inequity?
The limited extent of routine data means that in this thesis I had
to think carefully about which segments of the staircase I would be
looking across for any one intervention. In an ideal world, routine data
would contain information on identification, offering of interventions,
consent, refusal, and so on. This is not the case in reality. Keeping the
idea of the staircase effect in mind, I determined that I would have to
examine a simplified situation. When looking at a non-drug-related
intervention, the data only allowed one to look at the drop-off from the
proportion of individuals with need to the proportion of individuals
to whom the intervention was given. Clearly, this conflates several
drop-off steps in the staircase: one does not know who is offered
intervention, who consents to it and who refuses it. For most diagnoses,
one does not know whether individuals have been identified as having
the diagnosis. These issues are an inevitable consequence of using
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routine data. Cognizance of the staircase effect allows one, I believe,
to keep these limitations carefully in mind.
For interventions that involved a continuous prescription of a drug,
I was able not only to look at prescription of the drug, but also at
the continuation of prescription. Thus, for such interventions, it was
possible to get to ‘views’ across the staircase. This approach allowed
me to examine another potential differential drop-off in the staircase
between deprivation groups.
While the conception of the staircase effect is necessarily theoretical,
it underpins the way chosen to develop methods for this thesis, and I
hope that the foregoing explanation provides the reader with some
insight into my thought processes.
5.2.3.2 Clinical trigger-action
In considering the pathway of care, I have distinguished two important
concepts: first, the idea of a clinical indication for some action to be
performed; this indication can vary with time, according to the course
of disease for an individual as well as other individual characteristics,
such as age; at one time, an individual may have activated a number
of different clinical indications. Second, I have considered the idea of
a clinical action; while this might typically be thought of as a drug
prescription or procedure, I have extended the idea to include more
general actions such as appropriate referrals, appropriate advice, and
appropriate measurements. In the above discussion, I have referred
interchangeably to interventions, triggers, indications, actions and so
on. In subsequent parts of this chapter and thesis, I have used the
following definitions to cover these concepts:
Clinical trigger The time point at which an individual enters
a state where a particular clinical action (measurement,
investigation, referral, drug prescription, or procedure)
would be recommended for the individual according to
generally accepted practice
Clinical action A particular clinical action that would be
recommended for an individual according to generally ac-
cepted practice on the basis of their current clinical state
Indication period The time-period from the clinical trigger
up to the point at which the clinical action is no longer
indicated
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For example, according to NICE guidance, individuals whose risk
assessment (by any appropriate risk-assessment tool) suggests a CVD
risk over 10 years of greater than 20% ought to be offered a statin
medication. The time point at which that individual is known to be at
high risk is a clinical trigger, subsequent to which a statin is indicated;
initiation of prescription of the statin is the clinical action. I detail each
of the clinical trigger-clinical action combinations examined in section
5.3.
In considering clinical trigger-clinical action combinations, the aim
was to analyse differences that might be occurring between individu-
als from different area-level-based deprivation-groups. In evaluating
differences, I sought to look firstly at the time from the clinical trigger
to the clinical action for different groups. Secondly, in the case of
drug prescriptions, I set out to examine the time from the initiation of
prescription with the medication to the time of cessation. Both of these
means of proceeding would allow use of a time-to-event analytical
approach.
I also wished to develop an alternative concept when looking at
prescription medications: drug-coverage proportion. Here, I would
look at the proportion of the indication period covered by the drugs
prescribed.
5.2.3.3 Further considerations
This approach raised a number of issues. I have discussed these in
principle here, and in detail in the second part of this chapter, section
5.3. Broadly they relate to the fact that the available data only provide
a seven-year window in which to examine activity. Prior to the start
of the study period, some data were available from general practices
and from PEDW. The data therefore sometimes identifies individuals
with a clinical trigger that had initially occurred prior to the period of
the study. Moreover, in some cases the data allowed one to identify
the situation where an individual had received the clinical action
prior to the clinical trigger. I discuss how I handled these issues when
implementing my methods in section 5.3.
5.2.4 Cohort of inclusion
This study was based on a cohort of individuals followed up from
January 1, 2004 to 31 December 2010. For any individual, there was
a defined start point and defined end point (or censoring point),
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demarcating a designated cohort period for that individual. During
that time, any one individual could have several clinical trigger-actions
occurring. It was necessary to develop a conceptual framework to
handle the relationships between an individual’s presence in the cohort
(and therefore capability to contribute time to the analysis) and the
timing of any clinical trigger-actions for that individual.
For example, clinical triggers occurring prior to an individual’s
cohort period could be identified in our data (because there was
data from a lead-in period prior to the start of the study period). I
therefore conceptually differentiated these clinical triggers occurring
before the cohort period of observation for the individual (prevalent
clinical triggers) from clinical triggers occurring during it (incident
clinical triggers). I also needed to ensure that an individual’s cohort
period was taken into account when considering the times for which
a clinical trigger-action could be followed up. I discuss the detailed
implementation of algorithms to address these issues in section 5.3.5.
5.2.5 Assumptions and limitations
Inevitably, in order to simplify my methods for analysing the path-
way of care for CHD, I needed to make a number of assumptions
and simplifications. Such a process provided me with an analytically
tractable problem; potentially, this is at the expense of introducing
some limitations into the analysis.
Ratcheting effect of indication states I made the assumption
that individuals could only move in one direction in the
indication states that they could occupy. For example, in
the case of an individual being at high risk for CVD (this
is discussed further below), I assumed that they could not
subsequently become low risk. Likewise, I assumed that
if an individual with stable angina had a ACS they could
not subsequently have returned to a stable angina state. I
believe that such assumptions do not generally introduce
major limitations into my approach, and they contribute
subsequently to simplifying the analysis.
Overlaps in pathway presentation In seeking to present a
graphical representation of the overview of the pathway of
care, I have simplified the combinations of clinical triggers
and clinical actions displayed, at the expense of producing
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some overlaps. In other words, clinical trigger and clinical
action states illustrated in the pathway diagrams (shown
later in this chapter) do not represent mutually exclusive
states. For example, individuals throughout the pathway
care can combine the first smoking clinical trigger with any
other trigger state. Similarly, the revascularisation clinical
action is a composite of the clinical actions for CABG and
PCI. I have deliberately sacrificed some conceptual rigour
to achieve simpler presentation.
Risk assessment NICE simply states that when assessing risk
for CVD, an appropriate risk tool should be employed. The
more commonly used risk assessment tools, particularly
towards the start of the period covered by our data, were
the Framingham risk assessment tools. I have performed
the main analysis using the Framingham non-laboratory
risk assessment tool, as this requires less information for
completion then other tools – making fewer demands in
the ascertainment of risk factors. This allowed me to make
an assessment of risk on a greater proportion of the study
population, though this does need to be balanced against
the potential disadvantages of using this measure, includ-
ing the lack of inclusion of deprivation and ethnicity data
and the evidence that risk is overestimated for contempor-
ary UK populations.182
Drug cessation By setting the analysis out as I did in order
to examine times to cessation of medication prescription, I
made a further assumption: what does cessation of med-
ication actually mean? Obviously, prescriptions cease at
or after the censoring points for the cohort. To coherently
identify drug cessation during the cohort period, I had to
define a minimum length of time before the cohort end
that would count as cessation of prescription.
Multiple comparisons By setting out multiple points in a
pathway at each of which I examined the possibility of
healthcare inequity, the possibility arose that by making
multiple comparisons one would simply identify some
statistically significant results by chance. While I have not
formally adjusted for this effect, for example the use of
Bonferroni corrections or some similar approach, I have
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born this consideration in mind, and discussed this in de-
tail in chapter 10.
Contraindications and informed dissent Read codes exist that
would allow determination of whether or not individu-
als had contraindications to a particular intervention or
whether they turned intervention down (informed dissent).
QOF business rules take account of such situations. I elec-
ted not to in my analysis, because I was interested in the
population-level implementation of clinical actions, regard-
less of contraindication or dissent. In other words, the
overall aim of the project being to examine the possibility
that differences in intervention utilisation drive population-
level inequalities outcome, I felt it was important to look at
unrestricted population denominators to gain insight into
potential effects of differential healthcare utilisation at a
population level.
In the first section of this chapter, I have outlined the conceptual
underpinnings used when developing a pathway approach to looking
at healthcare inequity. This has been a somewhat abstract discussion
in many places. By contrast, in the next section, I now turn to the
concrete details of the implementation of these concepts.
5.3 implementation
5.3.1 The problem
In chapter 4, I discuss data-processing tasks that produced a cleaned
dataset. The ensuing problem was to derive from this data the neces-
sary dataset with which one could implement the pathway approach
using clinical trigger-actions.
Having completed the processes discussed in chapter 4, I had pro-
duced two main tables (held in a number of separate files because
of their large size): one for demography data; one for the common
format data, containing general practice, mortality, and PEDW data.
To implement the methods described in this chapter, I developed an
additional programme called the the derived dataset generator that
took these tables as input data and produced the data for final analysis
as an output.
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Firstly, I needed to determine which individuals met the inclusion
criteria for the cohort, and to determine their relevant demographic
information. It was necessary to define time-periods of inclusion in
the cohort by examining censoring events.
Having decided which components of the pathway of care to include
in the analysis, I needed, at each point in the pathway, to determine
the important events for each individual, including CVD diagnoses,
risk factors, changes in risk score, and treatments. The core of the
analysis required that I use this information to implement the clinical
trigger-action approach at each point.
5.3.2 Inclusion in the pathway
I determined on a number of broad areas to include in the pathway of
care for CHD:
1. Risk and risk factors attainment
2. Smoking management
3. Blood pressure management
4. High-risk statin management
5. Drug management of chronic CHD
6. Drug management of ACS
7. Revascularisation of chronic CHD
8. Revascularisation of ACS
For each of these I then identified specific clinical trigger-action com-
binations that I wanted to examine. In doing so, I took account of
NICE guidance and of the availability of data to examine each poten-
tial clinical trigger-action combination. I discuss the resulting set of
clinical trigger-actions below.
5.3.2.1 Risk and risk factors attainment
With a view to determining whether identification of individuals at
high risk of CVD differed between area-based deprivation groups, I
sought to examine the group of individuals for whom measurement
of risk factors and ascertainment of overall risk would be important
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in determining the need for treatment, particularly smoking man-
agement, statin treatment, and BP management. I examined clinical
actions following the first identified instance of an individual becom-
ing aged 40 in the absence of any CVD-diagnoses (CHD, diabetes,
CVA or transient ischaemic attack (TIA), or peripheral vascular dis-
ease (PVD)). I refer to these subsequently as ‘high risk diagnoses’.
Saying that would be useful in avoiding misunderstanding in later
text. To identify these diagnoses, I used the diagnostic codes in ap-
pendix E. I looked at both Read and ICD-10 codes; when looking at
the latter, I considered codes in any coding position. For individuals
with this trigger, I wanted to look for a number of clinical actions:
Ascertainment of smoking status I defined the presence of
this clinical action to be indicated by the presence of a
Read code indicating smoking status. The full list of codes
is detailed in appendix E.
Measurement of BMI Defined as the presence of Read codes
for BMI, as shown in appendix E.
Measurement of BP For simplicity, I looked only at systolic
blood pressure, defining the clinical action as being repres-
ented by a systolic blood pressure reading, according to
the list of codes shown in appendix E.
Measurement of cholesterol Defined as the presence of a Read
code for measurement of cholesterol, as shown in the list
of codes in appendix E.
Full cardiovascular risk assessment Defined as the first time Cardiovascular risk
tools are described in
appendix B
point at which a complete set of data points was available
such that an assessment of risk using a risk tool would have
been possible (whether or not this were carried out). For
the main analysis, I used the Framingham non-laboratory
risk assessment tool, which requires (in addition to age and
sex) a BMI, a systolic-BP reading, a known smoking status,
diabetes status, and antihypertensive medication treatment
status. Diabetes status was defined on the presence or ab-
sence of diabetes codes, while age and sex were always
known. Thus, in practice, achievement of this clinical ac-
tion required that an individual had a systolic-BP reading,
a BMI, and a smoking status all recorded. In a sensitivity
analysis, I used the original Framingham risk-assessment
tool, which required left ventricular hypertrophy (LVH) on
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electrocardiogram (ECG) – assumed not to be present for
anybody (because this information was not available), and
a cholesterol-ratio reading; BMI was not required; other
variables are required for both tools. Regardless of the risk-
tool used, I put no time limit on the relevance of variables.
For example, if the final required variable, say smoking
status, was not recorded until three years after the most
recent systolic BP, I considered this BP reading to remain
valid, an assumption discussed in chapter 10.
5.3.2.2 Smoking management
I wished to examine potential differences in smoking management
between deprivation groups in primary care. I identified smokers by
finding the earliest time point in the dataset at which an individual
had a Read code indicating that they smoked. Thus, the clinical trigger
in this case was defined as being the earliest occurrence of one of the
Read codes in chapter E. The indication period for these individuals
was ended by the presence of a Read code for the individual being a
non-smoker, again shown in chapter E (as well as by other censoring
events). I had to take account of the situation in which an individual
was recorded as being a smoker, then recorded as no longer being
a smoker, and then recorded as a smoker again. In this or similar
situations, I looked only at the period from the first trigger to the
first non-smoking code; I disregarded subsequent clinical triggers
and indication periods; using this approach simplified coding. In
subsequent parts of this thesis, this clinical trigger is referred to as
‘First smoking’. In individuals with this clinical trigger, I looked at two
clinical actions.
Provision of stop smoking advice This clinical action repres-
ented advice given by clinicians in primary care to indi-
viduals who smoke, with a view to encouraging smoking
cessation. I defined it using the codes shown in E
Smoking cessation referral In this case, I was looking for re-
ferrals to smoking-cessation services. The clinical trigger is
defined using the code shown in E
5.3.2.3 BP management
I had to decide how to handle different situations in which high BP
needs to be managed. In individuals not otherwise at high risk of
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CVD, the cut-off for managing BP is different from that in those who
are already known to be at high risk (either through diagnosis or
through risk assessment).183 I treated these two situations separately.
Furthermore, I needed to determine how to employ BP readings –
should one use systolic readings only, or also look at diastolic readings?
How many readings should one look at? After consideration, and as far
as possible in line with NICE guidance183, I decided on two separate
clinical triggers for BP management.
BP raised and low-risk This clinical trigger arose in a situ-
ation in which an individual whose risk assessment sugges-
ted that they were low risk, or whose risk assessment was
unknown, had three consecutive blood pressures recorded
each with a systolic value greater than 160. In the event
that the individual subsequently became high risk, the
indication period for this clinical trigger was terminated,
and a separate period initiated classified as ‘BP raised and
high-risk’(see below)
BP raised and high-risk I defined this clinical trigger as
arising when an individual who was known to be a high
risk for CVD, either through risk assessment or the pres-
ence of other high-risk diagnoses, had three consecutive
blood pressure readings recorded where each systolic
blood pressure was greater than 140. Alternatively, if a
high risk individual had a hypertension diagnosis recor-
ded, I initiated this clinical trigger. For simplicity, I did
not differentiate clinical triggers for situations in which an
individual was at high risk as a result of risk assessment
from clinical triggers where an individual was at high risk
due to a high-risk diagnosis
I based assessment of cardiovascular risk on my own algorithm that
calculated risk using the Framingham non-laboratory risk assessment
tool (or for the sensitivity analysis the Framingham 1991 risk assess-
ment tool). This algorithm calculated risks at all possible time-points;
I then determined on the basis of these risk assessments, for any one
individual, the time periods when they were: unknown risk; unknown
low risk; of known high risk based on risk assessment; of known
high risk based on a high risk diagnosis; I used the codes is shown in
appendix E to define high-risk diagnoses. Likewise, the codes used to
search for hypertension readings and hypertension diagnoses are also
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shown in E. Further algorithms combined information on risk and
BP reading to identify these clinical triggers. When referring to these
clinical triggers in the rest of this document, I have used the above
terms For both of these hypertension related clinical triggers, I looked
at prescription of antihypertensive medication. Clinical protocols for
the management of hypertension are quite complicated: there is a lad-
der of treatment, with individuals having additional treatment added
according to action and tolerance of treatment; the order in which
drugs are prescribed for individuals depends on patient characteristics
such as age and ethnicity. Many of the medications that can be used
to treat hypertension can also be used for other conditions. While I
did consider developing algorithms to address the complexities of the
management protocols for hypertension, I ultimately decided to re-
duce the complexity of the investigation and look only at a simplified
’clinical action’. While such an approach overlooks the intricacies of
hypertension management, I hoped that by looking in broad terms at
the provision of antihypertensive medications, I would be in a position
to identify gross levels of inequity in provision of them.
Treatment with antihypertensive medication I defined this clin-
ical action as being indicated by treatment with any one of
a number of antihypertensive medications. The list of codes
used to define this clinical action are shown in appendix E
5.3.2.4 High-risk statin management
In ensuing text of
this thesis and in the
wording of figures
and tables, I refer to
clinical triggers and
clinical actions using
the names shown in
italics section 5.3.2
For statin management, I considered two clinical triggers separately:
one for individuals at high risk due to risk assessment; another for
individuals at high risk due to a high-risk diagnosis. In either case a
statin is indicated, but I wished to differentiate the situations, because
of the likelihood that the levels of clinical action would be different.
When considering high-risk diagnoses, I did not include CHD. I did
this to avoid duplication: I consider the provision of statins to indi-
viduals with CHD when examining clinical triggers at other points in
the pathway ( clinical triggers ‘Stable angina’, ‘Stable angina diabetes’,
‘Old ACS’, ‘Unstable angina’, and ‘MI’).
When Risk assessed high This clinical trigger arose at the
time point at which an assessment of cardiovascular risk
was possible using the Framingham non-laboratory score
and where the result of the risk assessment gave a cardi-
ovascular risk over the next 10 years of greater than 20
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percent. My algorithm to assess cardiovascular risk calcu-
lated the 10-year risk at every possible time point for every
possible individual: possible time points were defined as
being when one of the measurement variables changed (for
example, following a systolic BP reading, the score would
be recalculated); I also recalculated the score annually on
each individual’s birthday.
High-risk diagnosis This clinical trigger arose at the earliest
time-point at which one of the diagnostic codes shown in
chapter E appeared in the patient’s data. CHD diagnostic
codes were not used for this clinical trigger, for reasons
explained above. On the appearance of a CHD diagnostic
code in the data, the indication period for this clinical trig-
ger was terminated, and the relevant CHD clinical trigger
was initiated
5.3.2.5 Drug management of chronic CHD
I defined the two different clinical triggers for the management of
chronic CHD. The first related to stable angina (and other unspecified
diagnoses of CHD); the second relates to stable angina in individuals
with diabetes. I make this distinction because the presence of dia-
betes affects whether or not ACE inhibitors are indicated. The clinical
triggers I looked at for chronic CHD were:
Stable angina This clinical trigger was defined by the pres-
ence Read or ICD-10 codes shown in appendix E. In the
event that an individual developed diabetes the ‘stable
angina’ indication period ended, and a clinical trigger for
‘stable angina and diabetes’ was initiated. I also terminated
the indication period in the event of a clinical code for ACS.
Stable angina and diabetes Defined the same as for ‘stable
angina’ using the same codes, but with the additional re-
quirement that the individual have diabetes. The codes
used to define diabetes are shown in appendix E. I termin-
ated this indication period in the event of a clinical code
for ACS.
For ‘stable angina’, I looked at two clinical actions:
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Statin This clinical action was defined by the presence of a
Read code indicating prescription of the statin, as shown
in appendix E
Aspirin Defined by the presence of a Read code for aspirin,
shown in appendix E
I also examined these two clinical actions for ‘stable angina and dia-
betes’, but in addition, in line with NICE guidance, I examined the
following:
ACE inhibitor Defined by the presence of a Read code for
ACE inhibitor or angiotensin II receptor antagonist, as
shown in appendix E
5.3.2.6 Revascularisation of chronic CHD
In addition to the above medication-related clinical actions for the
chronic CHD clinical triggers, I also looked at revascularisation. For
both the ‘stable angina’ and ‘stable angina and diabetes’ clinical trig-
gers, I examined the following:
PCI This clinical action was defined by the presence in
PEDW records of a code (in any position) indicating that
the individual concerned underwent a PCI. I have listed
the codes used to identify this clinical trigger in appendix
E
CABG Similarly, the CABG clinical action relied on OPCS-4
procedure codes in PEDW. Again, I have included the rel-
evant codes in appendix E
Revascularisation In many instances, a PCI or CABG might
both be used to manage a patient’s disease and achieve re-
vascularisation. I considered the possibility that inequity in
the provision of PCIs and in the provision of CABGs might
interact to obscure the overall picture. For example, by
finding inequity in the use of PCI one might in fact simply
be identifying increased use of CABG in more deprived
groups, with a consequent reduced need for PCI – reflected
in reduced utilisation of PCI. To allow for this possibility, I
also included a composite clinical action defined using the
above codes for PCI and CABG combined
Revascularisation for patients with CHD is performed either where
patients have symptoms unresponsive to optimal medical treatment or
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to improve prognosis in those with a substantial burden of ischaemia.184
CABG is the established treatment, with demonstrated survival be-
nefit; in recent years PCI has increasingly been considered as an
alternative.184
There has been extensive debate about whether PCI should be
considered as equally efficacious (as CABG) in terms of key outcomes
(survival, freedom from MI, and freedom from recurrent angina).184. In
recent years PCI has improved in sophistication (balloon angioplasty,
to bare-metal stents, to drug-eluting stents) and complications from the
procedure have gone down. At the same time outcomes from surgery
have improved, with use of improved medical therapy, anaesthesia,
surgical technique, and technical developments such as off-pump
surgery.184
A 2009 study, which pulled the results from 10 randomised con-
trolled trials, concluded that overall there was no significant difference
in the risk of death between those treated with CABG versus PCI (
hazard ratio (HR) 0.9; p-value 0.12).185 In this study, subgroup ana-
lysis suggested that those over 64 and diabetics did have significantly
improved survival with use of CABG. Evidence from disease registers
consistently suggests benefits of between 4 and 5% for CABG over PCI
at 3 to 5 years.184,186–189 In the recent SYNTAX trial (which compared
treatment in a much less restricted patients), PCI failed to achieve
pre-specified criteria for non-inferiority as compared to CABG.190.
During the time-period covered by the study I present here, the
parity of effectiveness of PCI could have been regarded as a legitimate
conclusion on the basis of findings in the literature. For this reason,
I included this intervention when examining the clinical trigger for
chronic CHD. Clearly, subsequent findings suggest that PCI does not
in fact improve outcomes to the same extent as CABG.
5.3.2.7 Drug management of ACS
When considering ACSs, I defined three clinical triggers. Because of
limitations of the data it was necessary to use as one of these triggers
the diagnosis ‘old MI’. Codes exist in PEDW for old myocardial infarc-
tions; sometimes Read codes for ACSs appear in GP data. For these
situations, I defined a clinical trigger for the situation in which PEDW
data suggested an old MI or in which GP data suggested an ACS in
the absence of a corresponding in-patient record. The possible classi-
fications of ACSs that might be derived from the data are quite numer-
ous, and include unspecified ACS, MI, unstable angina, ST-elevation
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myocardial infarction (STEMI), and non-ST-elevation myocardial in-
farction (NSTEMI). I discuss this further in section 5.3.6.2. After much
exploration of unfeasible alternatives, I settled on a simple three-way
classification of ACSs, as follows:
Old ACS To define this clinical trigger, I used a PEDW
code for old myocardial infarction and Read codes for
ACSs. I have listed the codes used to define these trigger
points in appendix E. The indication period for this clin-
ical trigger ended at the date of any subsequent codes for
MI or unstable angina, again listed in E. In the event that
old ACS codes (those related to old myocardial infarction
or myocardial infarction recorded only in primary care)
occurred after PEDW ACS codes, the implementation al-
gorithm disregarded them. The algorithm also disregarded
Old MI with an indication period less than one month in
duration
MI I initiated this clinical trigger on the appearance, in
any coding position, of a code for MI in a patient’s data. I
did not differentiate between NSTEMI and STEMI. Where
repeat ACSs occurred, I terminated the indication period
for the previous MI or unstable angina clinical trigger and
created a new one. When looking at clopidogrel as an ac-
tion, I terminated the indication period 12 months after
the clinical trigger date, as the drug is no longer indicated
after that time
Unstable angina I defined and implemented this clinical
trigger exactly as for MI, with the exception that I used
different codes. I show the codes in appendix E
Because of the way that I defined the clinical triggers MI and Unstable
angina, it was possible for one individual to have more than one of
these clinical triggers – thus, the unit of comparison here was an MI
or Unstable angina clinical trigger rather than an individual.
For each of the above three clinical triggers, I looked at four clinical
actions. I defined and implemented the first three of these, ‘statin’,
‘aspirin’, and ‘ACE inhibitor’ as described in section 5.3.2.5. The fourth
was as follows:
Beta-blocker The presence of one of the Read codes listed in
appendix E defined this clinical action
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In addition, for ‘MI’ and ‘unstable angina’ I also looked at:
Clopidogrel This clinical trigger was defined by the Read
codes shown in appendix E
5.3.2.8 Revascularisation of ACS
For the three clinical triggers relating to ACS, I also looked at revascu-
larisation clinical actions. These three, ‘PCI’, ‘CABG’, and ‘revascular-
isation’, were defined in the way detailed in section 5.3.2.6
5.3.2.9 Visualisation of the pathway overview
I have summarised the set of trigger-actions that I examined in the
pathway analysis in figure 5.2. This figure is a schematic representation
of the pathway of care for CHD through which an individual might
move. A matrix is shown, with the clinical triggers shown across the
top of the figure, and the clinical actions to the left. Where clinical
trigger-actions combinations are indicated by NICE guidance and
where there is sufficient data to address them, I have marked the
matrix with a green tick. The coloured boxes represent the different
regions of the pathway, as discussed above; the key to these is at the
bottom of the figure. For example, from the figure one can see that an
ACE inhibitor is indicated in those with stable angina and diabetes,
but is not indicated in those with stable angina but no diabetes.
In chapter 9, I have made further use of this approach to summar-
ising the pathway, with a view to aiding presentation of a complex set
of results.
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Figure 5.2: The pathway from the data perspective
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5.3.2.10 Drug cessation clinical trigger-actions
I wished to examine for how long drugs that were clinically indicated
continued to be prescribed. I devised a measure for this, to be struc-
tured like the other trigger-action combinations. I designated the date
of the first prescription as a clinical trigger in order to mark the start
of the period I wished to measure. Obviously, the first prescription
is also a clinical action, but I apply the term clinical trigger here in
this restricted way in order to use the same method of analysis and
nomenclature as for all the trigger-action combinations.
I looked from the time of the drug prescription being initiated to the
last prescription, where this was defined as the point at least 56 days
prior to the cohort censoring date for that individual. Thus, to obtain a
last prescription date, which for drug cessation clinical trigger-actions
counted as the action, I looked for a clear window of at least 56 days
(28 days for the last prescription; 38 days clear) between the date of
the last prescription and the cohort censoring point for the individual.
A schematic overview of the clinical trigger-actions related to drug
cessation is shown in figure 5.3. Here, as before, the diagram represents
a matrix of the possible clinical actions I might have considered; those
examined are marked with a green tick. Once again, I have illustrated
the main regions of the pathway. I did not look at drug cessation for
antihypertensive medication, because I judged that doing so would be
too difficult, given the permutations of drug treatments that might be
used to treat the condition.
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Figure 5.3: The pathway from the data perspective: points in the pathway at which drug cessation was examined
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5.3.2.11 Points not included in the the pathway
Some points in the pathway of care for CHD met many of the criteria
for inclusion, but ultimately were excluded from the analysis. This
was because insufficient data were available in the routine data on
individuals. In particular, I would have liked to examine differences in
the medical management of cases of ACS during hospital admissions.
These data are not available within the PEDW dataset. Likewise, in-
formation on cardiac rehabilitation following ACS was not available
to support an adequate analysis.
5.3.3 Pathway simplifications
While attempting to address the pathway of care for CHD in the
way outlined has advantages, I have made some assumptions and
simplifications. In presenting an overview of the pathway, illustrated
schematically in the previous section, I have made assumptions about
the way in which individuals can move between clinical-trigger states
and about what it means for an individual to be at any one place in
the pathway at a given time.
When an individual activates a clinical trigger, I have defined them
as being in a clinical-trigger state for that trigger from that time point
until any stipulated event occurs to terminate the indication period
for that clinical trigger. I have simplified the allowable states that an
individual might occupy in the following ways:
• An individual’s risk cannot return from high risk to low risk
state; once an individual is assessed as being at high risk they
remain high risk, regardless of subsequent risk assessments
• The clinical trigger ‘risk assessed high’ is superseded by the
clinical trigger high-risk diagnosis and by CHD clinical triggers
• The clinical trigger ‘high-risk diagnosis’ was superseded by
CHD clinical triggers. The list of codes used to define a ‘high-
risk diagnosis’ clinical trigger does not include CHD, although
CHD is a condition which indicates that an individual is a high
risk: I have dealt in detail with CHD related clinical triggers
separately, and to avoid duplication in the analysis, have left
CHD codes out of the ‘high-risk diagnosis’ definition
• ‘Stable angina’ is superseded by ‘stable angina and diabetes’, as
well as by clinical triggers for ACSs
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• ‘Stable angina and diabetes’ is superseded by clinical triggers
for ACSs
• ‘Old MI’ is superseded by ‘unstable angina’ and ‘MI’. An indi-
vidual cannot return to the ‘old MI’ indication state following
clinical triggers for ACSs even if the relevant codes occur
• Each new ACS event initiates a new clinical trigger (for ‘unstable
angina’ or ‘MI’ as appropriate)
Despite efforts to simplify the allowable clinical-trigger states, the
pathway overview would still not place the individual at any one time
at only one point in the pathway. While many of the indications are
mutually exclusive – ‘aged over 40 with no high risk diagnosis’ and the
high-risk clinical triggers or the CHD clinical triggers – others are not.
For example, an individual may simultaneously trigger ‘Aged over
40 with no high-risk diagnosis’, ‘First identified as smoker’, and ‘BP
raised and low-risk’. Likewise, ‘BP raised and high-risk’ can trigger at
the same time as ‘Risk assessed high’, ‘High-risk diagnosis’, and CHD
clinical triggers. With each clinical trigger comes one or more clinical
actions. Thus, any one individual, at any given time, is best conceived
as having a specific indication pattern that might be represented by
a selection of ticks in schematic overview (figure 5.2, rather than as
being at a particular point in the pathway.
5.3.4 Overview of programmatic implementation
I implemented the detail of my approach to clinical-trigger actions
and the CHD pathway in a C# program that I wrote to accomplish the
task, which I refer to as the derived dataset generator. Its role was to
take the cleaned data, generated from the process described in chapter
4, and to run algorithms based on the conceptual methods, details
of the CHD pathway, and clinical trigger-action approach that I have
outlined above. In subsequent sections, I describe the methods used
to accomplish the following:
1. Determine the cohort dates of the individual
2. Extract appropriate clinical trigger-actions for each individual
3. Determine relevant covariates for each clinical trigger-action
I have left discussion of the methods used to analyse the data gener-
ated by this program to chapter 6.
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The derived dataset generator examined the data for each individual
in the dataset in turn, each time making available to its own internal
processing algorithms all available:
• Demographic data
• PEDW data
• GP data
• Mortality data
The outputs of the programme were exported to four tables.
Complete set table This table contained one row for every
individual who had any data in the original datasets, re-
gardless of whether or not they were included in the final
analysis. Keeping such a record was necessary, because in
the extract provided to me information was given on many
individuals who should not have been included in my
dataset. This table contained fields related to the reasons
that individuals were either excluded or included in the
final analysis.
Individual table This table contained one row for every in-
dividual included in the final analysis. It contained fields
related to demographic characteristics of the individual
(age, sex, deprivation), mortality information (whether the
individual died during the cohort period, date of death,
cause of death, and related fields), information about in-
dividual’s LSOA of residence at annual sampling points,
and information about the GP practice with which the in-
dividual was registered at annual sampling points.
Trigger action table This table contained one row for every
clinical trigger-action identified in the analysis. It contained
fields relating to the clinical trigger type, clinical action
type, action times and related variables, and covariate in-
formation at the clinical trigger date.
Risk assessment table This table contained one row for every
time point at which a risk assessment could be updated
on any individual in the final dataset. It contained fields
for the most recent cardiovascular risks available at each
time point, whether or not the individual was treated with
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antihypertensive medications and statin at each time point,
and the results of risk assessments using different risk
assessment tools.
5.3.5 Cohort
On each individual I needed to determine the time period during
which the individual had contributed data to the electronic cohort.
I have illustrated the way in which this process was carried out in
figure 5.4. For each individual I wrote algorithms to limit the period
of observation in line with the available data. I assumed that the
maximum observable period for each individual, which I termed the
cohort period, ran from 1 January 2004 to 31 December 2010. I then
checked to see if the individual had died and, if so, when. In the event
that the individual had died before 1 January 2004 (something that
was possible in my data because I had the lead-in period), I excluded
the individual. If the individual had died, and that death took place
on or before 31 December 2010, I changed the end date of the cohort
period to the date of death and set a variable to register that the reason
that the individual had left the cohort was that they had died.
Similarly, I used the information on an individual’s GP practice
(available on 1 January each year from 2003 to 2010, as discussed in
chapter 4) to determine whether an individual had been registered
with a SAIL practice. Where necessary, I reset the cohort period start
and end dates in line with the available data. As a simplifying assump-
tion, I removed from the analysis individuals with discontinuous GP
practice registrations within SAIL GP.
I also examined the time window during which an individual was
resident in Wales (based on LSOA at annual time points). While
the dates of registration with SAIL practices and LSOA dates were
likely to be the same, there was no theoretical reason why this would
always be the case. Therefore, I examined LSOA separately, using the
approach outlined above for the GP window – this time to produce
an LSOA window.
On the basis of these processes I was able to refine, for each indi-
vidual, the cohort window, a period during which, as illustrated in
figure 5.4, an individual was:
• Alive
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Figure 5.4: Derivation of cohort window
Time
1 January
2004
31 December
2010
Alive window
GP window
LSOA window
Cohort window
• Registered with a SAIL GP (subject to the limitations of the
annual-time-point approach)
• Resident in Wales (again subject to the limitations of the annual-
time-point approach)
I used the cohort window thus derived in subsequent algorithms.
For each individual, reclassified the end of the cohort period according
to whether they reach the end of the study period or whether they
were censored. Censoring occurred either because individuals died
or because they left SAIL GP. Because the demography data were
simplified, such that LSOA-of-residents and GP were available only at
annual time points, some error was inevitably introduced to censoring
times for some individuals.
At this point, I also excluded a small number of individuals from
the final data where there was no valid date of birth or valid sex.
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5.3.6 Clinical trigger-actions
In implementing the clinical trigger-actions approach I needed to
develop the main algorithm which identified and processed clinical
trigger-actions and also processed the covariates at the time of the
clinical trigger. I discuss these separately below.
5.3.6.1 Main algorithms
Firstly, the main algorithms identified clinical triggers and their sub-
sequent indication periods based on the coding definitions and rules
described above. In order to do this, the programme examined each
record for the individual, registering both codes that defined a clinical
trigger and codes that indicated that the indication period for that
trigger had been superseded. In the case of clopidogrel, the algorithm
calculated the date 12 months following the clinical trigger and ended
the indication period at that time.
Secondly, for each clinical trigger-action combination, the algorithm
compiled a table of the relevant clinical actions, together with their
dates of occurrence, to inform subsequent processing.
The above information (indication period, and table of actions)
was, for each clinical trigger-action combination, passed to the main
processing algorithm which then carried out the following:
1. Determined the relationship of the indication period to the co-
hort window
2. Determined the relationship of clinical actions to the indication
period
I show a schematic representation of the first of these processes in
figure 5.5. The processing is based on the relationships between the
start and finish of the cohort window and the start and finish of the
indication period. I illustrate a number of possibilities, and have noted
how I handled them. In the event that both the start and end of the
indication period occurred before the cohort window, I excluded the
clinical trigger-action; where the indication period started before the
cohort window but continued into it, I include the clinical trigger-
action, but classify it as a prevalent indication; where the indication
period started on or after the start of the cohort window, I included it,
this time classified as a incident indication; where the indication period
(whether a prevalent or incident indication) continued beyond the end
of the cohort window, I truncated the indication period by setting its
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Figure 5.5: Relations between the cohort window and the indication period
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end date to the end date of the cohort window; where the start date
for the indication period occurred after the end date of the cohort
window, I excluded the clinical trigger-action.
When looking at drug cessation, I did not look at prevalent triggers,
as all drug initiation clinical triggers were by definition incident. In
other words, I did not look for or analyse the situation in which an
individual had a clinical trigger requiring a drug prior to the initiation
period of the cohort window and had begun treatment with the drug.
In examining the relationship between the indication period and the
clinical actions, I sought a number of bits of information. Paramount
amongst these was the time from the clinical trigger to the first clinical
action (if one occurred during the indication period). For every clinical-
trigger action I updated two bits of information: the IsAction variable,
to indicate whether any actions occurred at all during the indication
period and the ClinicalTriggerActionLength variable, based on the time
from the clinical trigger dates to the first clinical action date, set
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to the length of the indication period if no clinical action occurred.
Where the clinical action was a drug, algorithms also calculated the
proportion of the indication window that the individual could have
taken the drug for, variable termed DrugCoverageProportion. I also
coded variables for the number of clinical actions that occurred during
the indication period, and for the achievement of the clinical action
at various set times throughout the indication period (one week, one
month, three months, six months, one year, and three years). When
examining clinical trigger-actions related to drug cessation, I used an
exactly analogous approach. Here, the clinical trigger was defined
by the time point at which the first prescription for the medication
occurred; the clinical action was defined by cessation times for the
medication. In order to determine the cessation times, I looked for the
last prescription occurring at least a defined time period before the
cohort end date; the period chosen was 56 days, but I also employ
different time periods in sensitivity analysis. The 56 is day figure
allows for a three-month gap and three-month prescription to elapse.
Before discussing the ways in which the algorithms captured in-
formation on covariates, I detail some of the difficulties encountered
in deciding how to handle certain eventualities.
5.3.6.2 Difficulties
NICE guidance gives an involved set of definitions of hypertension.
These do not naturally fit in with the clinical Read codes. I had to take
reasonable steps to identify two situations183:
1. An individual with a high cardiovascular risk and a BP greater
than 140 systolic
2. An individual with a unknown or low cardiovascular risk with
a BP greater than 160 systolic
Available information from Read codes gave systolic blood pressure
readings, hypertension diagnoses (where the criteria for the Read code
are not known), and information on cardiovascular risk factors. In
order to define clinical triggers for hypertension, I needed to decide
which risk assessment tool to use, and how to define a raised blood
pressure. I used the Framingham non-laboratory risk assessment tool
in the primary analysis, but used the older Framingham tool in a
sensitivity analysis. In order for an individual to classify as meeting the
systolic blood pressure cut-offs, it required three consecutive readings
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Figure 5.6: Indication period relations with clinical actions
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above the threshold (140 or 160 systolic). I used the hypertension
diagnostic codes as markers of blood pressure greater than 140.
Available codes within PEDW from the ICD-10 coding system allow
for quite a disparate set of categorisations of CHD. The problem here
is that some codes gave only quite general information, such as that
an individual had unspecified coronary heart disease, or unspecified
acute coronary syndrome; sometimes quite specific categorisation was
possible, for example in classifying partial-thickness MI (NSTEMI). I
simplified the classification to the following four categories:
Stable angina and chronic CHD I included in this category
codes for unspecified CHD, unspecified chronic CHD,
stable angina, and also some non-specific codes relating to
acute CHD where a definitive ACS could not be identified
Old ACS I included in this category PEDW codes for old
MI. I also used Read codes suggesting an ACS, where un-
able to identify a record of ACS from PEDW records
Unstable angina I used unstable angina codes from PEDW
to define this category
MI I use codes for unspecified MI, NSTEMI, and STEMI to
define this category. I also included codes for subsequent
MI in this category
The exact codes used for these definitions are shown in appendix E.
A number of considerations motivated this approach. When consid-
ering some of the ICD-10 codes which appear in the acute section of
the cardiovascular disease chapter, I decided that these codes, though
suggestive of ACSs, were insufficient to definitively identify the con-
dition. On the other hand, I did not wish to dismiss this information
completely, and so classified these individuals as having CHD but
not as having a ACS; I analysed the clinical trigger-actions for these
individuals on this basis.
The ‘old ACS’ category would not be required in an ideal situation.
In reality, indications arose within an individual’s data that suggested
that they had suffered an ACS previously, without the presence of
the record of this event itself within the PEDW data. This either arose
through the presence of an old MI code in PEDW or through the
presence of ACS codes in GP data. While I could not rule out the
possibility that these individuals had recently undergone ACSs and
that codes had not appeared in the PEDW (either through the event
occurring outside Wales, outside the NHS, or through missing data), I
5.3 implementation 157
wished to only examine clinical trigger-actions where data suggested
they were relevant. Using the old MI category allowed me to look at
trigger actions differently for these patients where the date of the ACS
was unknown; in particular, I did not look at clopidogrel prescription
in these patients.
Initially, I wanted to examine NSTEMI and STEMI separately. PEDW
coding did not allow differentiating between the conditions: the ma-
jority of events were coded simply as unspecified MI. I settled upon
the approach of using a catch-all category for MI.
ICD-10 codes make a distinction between MIs and subsequent MIs,
where ’subsequent’ implies that the event took place within 28 days
of the previous one. The preliminary investigation of this situation
suggested that in reality subsequent MI-codes were only preceded by
MI-codes a small proportion of the time (about 7%). After considering
the possibility of dropping these codes entirely, I settled on the ap-
proach of simply using them interchangeably with the non-subsequent
variety of MI-code.
In general, the kinds of difficulties discussed here inevitably arise
when using routine data. When confronted with them, I have tried to
come up with a defensible approach, simplifying where possible, and
making explicit what the approach has been.
5.3.7 Covariates
Above, I discussed the wish to adjust the analysis of clinical trigger-
actions for important covariates that might confound the relationship
between socio-economic deprivation and the delivery of healthcare
interventions. Using a clinical trigger-action approach, I was faced
with decisions about which covariates to include, at which time point
I should ascertain the covariates, and how I should define them. In
the next sections, I discuss how I addressed these issues. Which defer
to chapter 6 discussion of how these covariates were used in statistical
models: in this section my aim is to explain how these variables were
actually obtained from the data.
To simplify implementation, I set up my algorithms within the
derived dataset generated to extract all possible information on covari-
ates, whether or not I would actually employ those covariates for the
model for any given clinical trigger-action. The exception to this was
that I was unable to extract variables relating to the hospital admission
for those clinical triggers that were not based on such an admission.
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5.3.7.1 Time-point of capture
For simplicity, I always extracted the latest available covariates at
the date of the clinical trigger. While it is possible that variables
might have changed between the clinical trigger date and any clinical
action, in other words time-dependent covariates might have been
driving any relationship between socio-economic deprivation and
clinical provision, I did not take this approach because of the analytical
demands that it would have made on an already demanding analysis.
I ascertained the latest available covariates: that meant that, for
example,if a clinical trigger occurred on 1st January 2005, where there
has been no BMI recorded since January 2004, I took that most recent
value to be the value at the date of that clinical trigger. I set no time
limit on the persistence of variables in this way.
5.3.7.2 Demographic covariates
For each clinical trigger-action, I recorded an individual’s sex, storing
the information in a variable related to it. For information on age, my
algorithm calculated the age in years at the time of the clinical trigger,
generated a variable for this value, and created variables based on it for
the 10-year age group and 5-year age group of the individual. I used
age as a categorical variable in this way to avoid the issues around
checking assumptions of linearity. Clearly, this was a compromise,
which involved potentially introducing some bias by collapsing to
categories and under adjusting for age.
When looking at deprivation, I used WIMD 2005. For each clinical
trigger, I identified the nearest LSOA in time. This was necessary
because of the annualised time-points employed for LSOA data. The
algorithm then used a lookup table to determine the deprivation
quintile and decile of this LSOA.
5.3.7.3 Supply-related covariates
I wanted to adjust for some covariates relating to the healthcare sup-
plier for the individual. For GP-related clinical trigger-actions, I looked
at the practice at which the individual was registered at the time-point
closest to the trigger date, and used the anonymised practice codes
that SAIL analysts had provided.
Similarly, for ACS-related clinical triggers, I entered the hospital
(provider site code), for the admission in which the ACS occurred. I
extracted further information on the nature of the admission: emer-
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gency, elective or other admission; the specialty the individual was
admitted under (cardiology; cardiothoracic surgery; medical special-
ties; or other). In addition, the algorithm created a variable for the
type of hospital in which the admission took place: this was a binary
variable, either Cardiac centre, if the admitting hospital was a tertiary
centre for cardiac care, or Other centre, if it was not. I defined tertiary
centres as University Hospital of Wales in Cardiff, Morriston Hospital
in Swansea, and the Liverpool Heart and Chest Hospital.
5.3.7.4 Pathway-history covariates
Figure 5.2 shows that for a number of clinical actions, there are several
different clinical triggers. Moreover, it is possible for an individual,
at different times, to be in more than one trigger state. For example,
the same individual might theoretically have started out with their
cardiovascular risk assessed high, have a CVA – moving them to the
clinical trigger ‘high-risk diagnosis’; subsequently they might develop
stable angina (‘stable angina’ clinical trigger), then diabetes (‘stable
angina and diabetes’ clinical trigger), before having an episode of
unstable angina for which they were admitted to hospital (‘unstable
angina’ clinical trigger), followed by an MI (‘MI’ clinical trigger), with
another MI a year later (initiating another ‘MI’ clinical trigger). For
every one of these clinical triggers, statins would have been indicated.
By the time of the last MI, that individual would have had six previous
clinical triggers to initiate the statin; a statin might have been indicated
for several years by that time. Intuitively, this situation is different
from that in which an individual has their first MI.
I wished to allow for this kind of situation, without using a time-
dependent covariates approach (alluded to above), as many analytical
difficulties would result. Instead, I decided to program my algorithms
to produce pathway history variables: for every clinical trigger action,
two were created, the first numbering the clinical trigger; the second
gave the time for which the clinical action had been indicated prior
to this clinical trigger. I have illustrated the way these variables are
derived in figure 5.7. Here, I have shown three clinical triggers and
their subsequent indication periods, each of which is conceptualised
as pertaining to the same clinical action. As a concrete example, this
might represent an individual with stable angina (clinical trigger 1 –
‘stable angina’), who developed diabetes (clinical trigger 2 – ‘stable
angina and diabetes’), who then had an MI (clinical trigger 3 – ‘MI’).
In each of these situations, guidelines recommend aspirin. The clinical
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Figure 5.7: Derivation of pathway history variables
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trigger actions are numbered according to chronological sequence. In
addition, the algorithm calculates, for every clinical trigger, the time
prior to that clinical trigger for which the clinical action in question
has been indicated.
I felt when developing methods that this approach provided a
more intuitive way of addressing the issue of prior pathway activ-
ity (compared say to time-dependent covariates), while still allowing
appropriate adjustment for previous activity such that like-with-like
comparisons of trigger-action times could be made between depriva-
tion groups. I hoped to capture and allow for knock-on effects in
the pathway by this means. Moreover, such an approach has a pre-
cedent in semi-Markov models, in which the time an individual has
spent in a state is taken account of in calculating probabilities of state
transition.191
5.3.7.5 Previous-action covariates
A further issue that arose with this approach occurred where clinical
actions were observed prior to the clinical trigger period. I illustrate
this schematically in figure 5.8. After thought, I handled this situation
in three different ways, according to clinical action type.
1. For measurement-type clinical actions (measurement of BP,
measurement of BMI, measurement of cholesterol, and a full car-
diovascular risk assessment), I ignored previous clinical triggers
2. For drug-related clinical actions (treatment with antihypertensive
medication, statin, aspirin, ACE inhibitor (including angiotensin
II receptor antagonist), beta-blocker, and clopidogrel), I excluded
clinical trigger-actions where the action had occurred prior to
the clinical trigger date
3. For revascularisation clinical actions (revascularisation, PCI, and
CABG), I programmed my algorithms to generate a variable to
determine the number of previous clinical actions of that type
I discuss in chapter 6, the way in which I used this variable for re-
vascularisation clinical actions when modelling clinical trigger-actions
with a time-to-event approach.
5.3.7.6 Risk and risk factors
A further set of covariates that I obtained via my algorithms centred
around patient cardiovascular risk and risk factors. I obtained, at a
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Figure 5.8: Derivation of variables relating to previous actions
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time point as close as possible to the clinical trigger date, information
on the following:
BP: I wrote an algorithm to classify an individual into one
of the following four categories:
• No hypertension
• Undiagnosed hypertension
• Controlled hypertension
• Uncontrolled hypertension
The presence of hypertension was identified on the basis
of systolic blood pressure measurement and Read codes
for hypertension.
BMI I created a variable based on the most recent read-
ing of BMI at the time of the clinical trigger, placing an
individual in one of the following categories:
• Normal or underweight (BMI less than 25)
• Overweight (BMI 25 or more but less than 30)
• Obese (BMI more than 30)
CVD risk I determined cardiovascular risk from risk factors
where possible, using the Framingham non-laboratory risk
assessment tool. I used the following categories:
• Low risk (cardiovascular risk of less than 20 percent
over 10 years)
• High risk (cardiovascular risk of 20 percent or more
over 10 years)
In determining this information, I used the same approach
as discussed above in section 5.3.2.3.
Smoking status I determined the last known smoking status
of the individual on the clinical trigger date, using the
approach outlined above in section 5.3.2.2. In doing so,
I classified the individual at the trigger date as either a
smoker or non-smoker.
Cholesterol:HDL ratio Using a similar approach, I identified
the last known cholesterol:high-density lipoprotein (HDL)
ratio prior to the clinical trigger date. In doing so, I used
both Read codes for cholesterol:HDL and for cholesterol
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and HDL separately (in which case I calculated the ratio).
I categorised the cholesterol:HDL ratio as:
• Less than 4
• 4 or more
In chapter 6, I discuss the points in the pathway at which I used
these covariates. In the implementation of algorithms, I did not limit
the extent to which I captured covariates – they were ascertained
regardless of whether I would subsequently use them for that clinical
trigger-action.
5.3.7.7 Comorbidity
I also implemented algorithms to extract a number of important
comorbidities for each individual, again at the time point of the clinical
trigger. The variables were binary, indicating the presence or absence
of the condition. I defined the following variables:
CHD I identified the presence of CHD using the presence
of any CHD codes in either PEDW or GP data. The full
set of codes used is shown in appendix E. Where none of
these codes were present, I assumed that the individual
did not have the disease
CVA or TIA I implemented the derivation of this variable
in the same way as for CHD, but with a different set of
codes, again shown in appendix E
Diabetes I again looked for PEDW and GP codes; the list is
shown in appendix E
Other comorbidity I had planned to use the Charlson co-
morbidity score as a variable to indicate the presence of
comorbidities. This score contains CHD, CVA, and dia-
betes in its scoring system. To avoid duplicating the effect
of the presence of these diseases, I redefined a variable
to indicate whether or not any Charlson comorbidities
other than these three were present for the individual at
the time of the clinical trigger. I categorised individuals
either as having or not having other comorbidities on this
basis. Codes used are shown in appendix E.192 Though this
approach simplified the analysis, collapsing the Charlson
comorbidity score to a binary variable involved the loss
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of some information and may have resulted in under ad-
justment and biasing of results. Further, in contrast to the
derived binary variable, the Charlson score is an externally
validated measure.
5.4 summary
In this chapter I have discussed the theoretical underpinnings of
my methodological approach and have discussed in detail how I
implemented algorithms to support this approach. The outputs from
these algorithms were data tables suitable for the kind of analysis
which would allow me to address the research question for this thesis.
In the next chapter, I discuss in detail the nature of that analysis.

6A N A LY T I C A L M E T H O D S
6.1 introduction
In this chapter, I describe the means by which I addressed the research
question using the data tables generated by the processes described in
previous chapters. In addition, I outline my methods of descriptive
analysis, give details of sensitivity analyses performed to check the
impact of major assumptions on the findings, and describe the checks
that performed on processes to identify any errors that might have
undermined the results.
I have covered this information in five sections:
1. Descriptive data
2. Main analysis of clinical trigger-actions
3. Pathway overview analysis, based on clinical trigger-actions
4. Sensitivity analysis and data checks
5. Software considerations
The aim throughout is to provide the reader with a coherent record
of the way in which I performed the analytical processes.
6.2 descriptive data analysis
In presenting descriptive data I aimed to present information on
inclusion and exclusion from the dataset, to convey to the reader the
important characteristics of the study population, to provide simple
summaries of service utilisation in the study population, to present
summaries of cardiovascular risk within the study population, and to
present an overview of the clinical trigger-actions identified for this
population. Carrying out this analysis did not allow me to directly
address the research questions, but rather served as a preliminary
process. It did inform subsequent data analysis, help identify errors
and inconsistencies in the data, and provide an overview of the dataset.
I prepared descriptive tables and figures in order to examine four
important areas:
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1. Exclusion from and inclusion in the final dataset
2. Population characteristics for key variables, including service
utilisation
3. Population distribution of cardiovascular risk
4. Broad scoping of clinical-trigger actions for the study population
6.2.1 Filtering of SAIL extraction
I tabulated the number and proportion of individuals excluded from
the dataset for different reasons (unrealistic date of birth, invalid
sex, and discontinuous GP codes). An exclusion for a discontinuous
GP code arose because of the simplifying assumption made: if an
individual was registered with a SAIL-submitting practice with a gap
in registration (likely to be the result of an individual moving out
of SAIL GP, then back in again), I excluded such individuals. This
considerably simplified my algorithms.
When presenting descriptive data, I defined annual cohorts, based
on the first year of registration for each individual in the cohort. I
prepared simple descriptive summaries of the number of individuals
in each of these cohorts. As a simplifying assumption, in the main
descriptive analysis I used the 2004 cohort; all analyses in subsequent
chapters include all individuals contributing time during the cohort.
I presented summary information on the numbers of people leaving
the 2004 cohort for different reasons (end of follow-up period, died,
and left SAIL GP). Where the cause of an individual leaving the cohort
was death, I analysed the numbers of deaths relating to different broad
categories of cause.
6.2.2 Population characteristics for key variables, including service utilisa-
tion
I performed simple descriptive summaries of demographic variables
for individuals in the 2004 cohort.
I examined the prevalences of major conditions (CHD, Stable angina,
MI, CVA, Diabetes). In order to allow time for diagnostic codes to
accrue, I assessed prevalences in 2008. I looked at the proportion of
the population at a specified time point (1 January 2008) who had a
record of the disease.
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The coding definitions used to identify these diagnostic categories
are shown in appendix E. I have discussed in section 6.2.4 the ways
the prevalences so obtained were used to validate my data against
comparable Welsh data. In addition to examining these diagnostic
categories, I also summarised the ‘other comorbidity’ variable that
I created based on the Charlson comorbidity index192, discussed in
the previous chapter. This was a binary variable indicating either that
individual did or did not have Charlson comorbidities other than
CHD, MI, CVA, or diabetes.
Because NHS-service use was the key focus of my thesis, I also
examined simple descriptive summaries relating to this in my data.
While the main analysis addresses this in far more detail (discussed in
section 6.3,) I also prepared these overviews for descriptive purposes
for hospital spells per individual for any cause, by deprivation quintile
and for the numbers of GP records related to CVD, by deprivation
quintile.
In performing this analysis, I looked at the 2004 cohort, and at the
numbers of the above events between 1 January 2004 and 31 December
2010. Where individuals were not present for the entire period, I
excluded them from these data summaries, as this made the analysis
simpler to perform.
I also used the same approach to look at the mean numbers of
measurements for key cardiovascular risk factors.
6.2.3 Assessment of population cardiovascular risk
I prepared summary information on the cardiovascular risk in the pop-
ulation. The risk assessment table that I created using the derived data-
set generator program contained information on major cardiovascular
risk factors available in my data, treatment with antihypertensive and
statin medications, and calculated risks from risk assessment scores. I
used this table to produce summaries of risk factor information and
cardiovascular risk in the population.
I prepared histograms of population distributions of measured risk
factors in the population. The algorithms used to create the summar-
ies looked at the earliest available measurement or reading for an
individual at a given age.
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6.2.4 Data validation
I carried out a number of descriptive analyses in order to check the
validity of our data. While I had no control over the set of data
processes that resulted in the movement of data from clinical systems
into SAIL, it was important to determine the extent to which these
processes had properly functioned. I undertook two strands of data
checking: the first was intended to demonstrate that our data had been
correctly extracted; the second to check that the subsequent processing
carried out produced results consistent with external sources.
In the first set of checks, I made comparisons between the data
in my tables and compared them with expected volumes of data.
I determined the number of individuals over 20 in 2004 (mid-year
estimate) in Wales according to ONS census data. I then found the
proportion of the Welsh population over 20 present in our dataset
in the demography table. The logic of my checks was based on the
assumption that the proportion of data in the other tables should
reflect this proportion of data: thus, if I had 25% of individuals over
20 in Wales in our dataset, one would expect to have about the same
percentage of mortality, PEDW, and GP data in my extract. I used the
year 2004 for all comparisons.
While I performed checks in this way for the mortality, PEDW, and
GP tables, for GP data, I was limited to looking at drug prescriptions,
as this was the only data for which I had a good external data source
against which to compare numbers (All Wales Prescribing Audit Re-
port data, which gives information on the number of items dispensed
– rather than prescriptions written by GPs); for the main groups of
drugs in our data, I found the proportion of prescriptions for Welsh
residents in 2004 that were present in our data.
This exercise demonstrated initial shortcomings in our data extract,
which I were then able to rectify. The extract initially provided by
SAIL had ≈44% of Welsh individuals in the demography table, ≈40%
of deaths for Welsh individuals, ≈47% of Welsh PEDW episodes, and
only ≈29% of drug prescriptions (the exact percentage varying slightly
around this figure, depending on drug class). After identifying the
causes of these problems, I received a corrected set of tables from SAIL
– a proportion of ≈40% of Welsh data being present in each, suggesting
that linkages had been correctly performed and that expected volumes
of data were present in the underlying datasets in SAIL.
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In the second set of checks, I performed a number of simple com-
parisons against prevalences estimates of clinical conditions in two
Welsh datasets: the Welsh Health Survey (WHS) and Welsh QOF data.
First, I estimated point prevalences in the study population for 2005
and 2009, concentrating on major cardiovascular diagnoses – angina,
CHD, diabetes, MI, and CVA (including TIA) – and on risk factors.
As comparison data sources, I used the WHS (for the years 2005
and 2009) and Welsh QOF data (again for the years 2005 and 2009).193
The WHS is a bespoke survey in which self-report questionnaires
are administered to a sample of Welsh residents;193 QOF is based
on data collated from primary care providers in Wales. I obtained,
where possible, prevalences from these sources for CVDs, diabetes,
and important cardiovascular risk factors, with which I compared
prevalences from our data.
There was a systematic difference in the denominator populations
when calculating the overall prevalence of conditions in the SAIL
data compared to QOF: SAIL contained a denominator population
of individuals aged over 20; QOF contained all age groups in the
denominator. Therefore, I expected slightly higher prevalences in SAIL
because I was looking at conditions and risk factors predominantly
affecting older age groups (meaning that the numerator would be
relatively unaffected).
The WHS contained a question on angina; Welsh QOF did not
contain angina prevalence. I compared MI prevalence between our
data and WHS for 2005 and 2009. Diabetes and CVA comparisons
were possible against both QOF and WHS data, again for 2005 and
2009. Obesity and overweight/obesity prevalences were present in
WHS data (for 2009). Smoking data comparisons were made with
WHS (2005 and 2009) and with Welsh QOF data for 2009. When
examining these data on risk factors, I also determined the proportion
of individuals within the dataset for whom the risk factor status was
known and on which the prevalence calculation was based.
When making comparisons for prevalence of hypertension, the
situation was complicated by the lack of clarity about the definition
of hypertension used in comparison data. Hypertension prevalence
as recorded in QOF and from WHS were available in 2005 and 2009. I
compared prevalences for different hypertension definitions from our
data.
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6.3 main analysis of clinical trigger-actions
6.3.1 General principles
In the previous chapter, I developed the idea of a pathway of clinical
care, and described the make up of it. Clinical trigger-action combina-
tions of interest arose at different points in the pathway. In my main
analysis, I investigated these in detail.
The points of interest within the pathway that I identified were
quite numerous (45 clinical trigger-actions for delivery of healthcare,
as well as another 21 related to cessation of medications). Moreover,
I wished to be capable of checking the main assumptions made, by
performing sensitivity analysis by adjustment (processes that I have
described in section 6.2.4). Each of the checks I might perform could
require the analyses to be repeated at each point in the pathway. In this
situation, I faced a potentially daunting range of analyses to perform.
While limiting this to a smaller subset of the pathway was an option,
I believed that this would undermine one of the key strengths of
this study – my attempt to examine a comprehensive picture of the
pathway of care for CHD. I settled on an alternative solution to the
problem: I used an automated process.
Automation itself presented a number of challenges. It was diffi-
cult to produce code capable of carrying out each of the processes
described below, including preparation of basic statistics, more com-
plex models, and graphical output. More importantly, automating
processes was a double-edged sword: it allowed me to cope with a
large analytical volume, but I knew of the way in which an undiscrim-
inating, algorithmic approach might be too crude to take account of
important subtle differences at a point in the pathway – particularly
when carrying out model-fitting, which can require an element of
human judgement. I was therefore presented with the challenge of
developing an automated process, whose finer points of variation
could be altered by user specification.
I have described the architecture of my overall solution to these
challenges below, involving R and SQL, a settings file in which I was
able to specify details of the automated analysis, a variable-selection
frame which the user modifies in order to specify model structures,
and an automated approach to graphical output.
As for the main descriptive analysis, I took the approach of using
embedded SQL code within R, allowing me to connect to the main
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SAIL DB2 database, and thus to exploit the strengths of DB2 for
manipulation of large datasets while carrying out the statistical and
graphical analysis in R.
Throughout the analysis I handled clinical trigger-actions related to
drug cessation separately. Likewise, I performed separate analyses for
incident and prevalent clinical triggers. While for the most part I was
interested in incident clinical triggers, for the clinical trigger based
on age (‘aged over 40 with no high risk diagnosis’), prevalent results
were also important, and so I examined these as well. The derived
datasets generator program produced three different clinical trigger-
action tables: one based on the use of the Framingham non-laboratory
risk assessment tool (which I used in the main analysis), one where
algorithms employed the Framingham 1991 original risk assessment
tool (instead of the non-laboratory risk assessment tool), and one
where the Townsend index of deprivation was used (as opposed to
WIMD 2005). I included analyses using the second and third of these
tables in my checks on major assumptions, discussed in section 6.2.4.
The main analysis employed the principle of looking at the times
from clinical triggers to clinical actions, and comparing these times
across deprivation quintiles. When doing this, I wished to take account
of important covariates with the potential to influence this relationship,
and to look at supply-related variation from practice and hospital as
random effects within the model. I also wanted to take account of
missing data. In the next two sections discuss the principles I employed
to address these requirements.
6.3.1.1 Principles of frailty models
The statistical problem with which I was presented in this work was to
find an appropriate technique to examine survival times (or times-to-
event), while at the same time taking account of the other requirements
outlined above. The standard approach for survival analysis is to
use the Cox proportional hazards model, a type of survival analysis
that allows that censoring (exit of individuals from the cohort for
reasons other than achievement of the outcome in question) be taken
account of, while allowing that baseline hazard be left unspecified.194
A standard Cox model has the form:
λ(t) = λ0(t)e
Xβ
174 analytical methods
where Xβ represents a vector of fixed effect; λ(t) is the hazard function;
λ0(t) is the baseline hazard function. A further requirement of my
analysis was that I was able to examine effects from variation at
practice and hospital level.195 The Cox model can be extended to
include random effects as well, using the following formula:
λ(t) = λ0(t)e
Xβ+Zb
where β represents fixed effects parameters, Zb represents the random
effects, and where b is assumed to have a Gaussian (normal) distribu-
tion.196 This mixed effects or frailty model is a kind of cross-classified
random effects model that allows modelling of times-to-event with
additional examination of area-level effects, modelled as random vari-
ables.
A number of assumptions are implicit in the model’s use: import-
antly, the assumption of proportionality – whereby instantaneous
hazards for subgroups determined on the basis of each covariate are
proportional over time. This is an assumption of convenience to allow
estimation of a single summary effect for each covariate. This assump-
tion can be tested (using residual diagnostics tests, often based on
Schoenfeld residuals), though for tractability reasons I did not attempt
to do this in this work. (I discussed this decision further in section 10.)
A further important, though effectively untestable assumption, is that
of ‘independent censoring’ – whereby censoring is non-informative
and independent of outcome.
In order to quanitify the variation in survival times attributable
to different model components, I considered for simplicity the trans-
formed scale on which fixed and random effects act additively. On
this scale, partitioning the variance attributable to different random
effects is in principle straightforward, and is independent both of any
modelled fixed effects and of the unknown baseline hazard function.
A mixed-effects Cox model can also be written
H(T) = −Xβ−Zb
where β and b are the fixed and random parameters, respectively,
corresponding to covariates X and Z. Here  is assumed to have a
particular extreme value distribution, and H is an unspecified increas-
ing function that corresponds directly to the (likewise unspecified)
baseline hazard. Assuming  has the standard Gumbel (extreme value)I acknowledge the
help and advice that
I have had from
statisticians in
selecting, using, and
describing the
statistical methods
outlined in this
section
distribution, its variance is pi2/6. In mixed effects models the random
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parameters b are often assumed to have a normal distribution, whose
variance σ2 is to be estimated. This variance can be compared to
the residual pi2/6 in the usual fashion, forming a kind of intraclass
correlation coefficient (ICC), for instance
ICC =
σ2
σ2 + pi2/6
This ICC ranges from 0 to 1, with small values indicating that little
variation is being explained by the random effects. In subsequent part
of this work, I refer to this statistic as the ICC.
The models were implemented using the coxme in R, which allows
for flexible specification of frailty models.
6.3.1.2 Principles of multiple imputation
Problems of missingness arose in our data for two different reasons:
firstly, it is likely that some variables that I defined by the presence
or absence of clinical codes were, on occasion, missing these codes
when they should have been present – resulting in a measurement or
misclassification error, which I did not try to address with statistical
techniques.
The second type of missingness occurred when values that I knew
were relevant for an individual (systolic BP, BMI, cholesterol:HDL
ratio, smoking status, admission specialty, and admission type) were
absent from an individual’s data at a designated time. For these
individuals, I used a multiple imputation technique. By doing so, I
was assuming that imputing these values for these individuals at these
times was meaningful. This assumption seems reasonable in this case,
because, even if unmeasured, these individuals could in theory have
had such values measured.
In using a multiple imputation technique, I was, when confronted
by missing values, trying to express appropriate uncertainty about
what those values were.197 The overarching principle of multiple
imputation is to build up a better picture of the things that you do not
know, based on things that you do. Chained equations are iterative
numerical method that can be used to converge on a valid distribution
of missing variables, from which imputed values can then be sampled
to generate a number of imputed datasets. These individual datasets
are then analysed using standard methods, with pooling techniques
used to synthesise results. In a situation where a likelihood analysis
would be difficult because of missing covariates, multiple imputation
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offers a convenient alternative. It assumes that data are ‘missing-at-
random’ – an assumption that cannot be tested.198 Other assumptions
are also inherited from the underlying models used by the imputation
process’s model-fitting procedures.
When electing to employ multiple imputation, I was aware that
its advantages in allowing appropriate account to be taken of un-
certainty relating to missing values and the ability its minimise bias
arising from missing data had to be balanced against its limitations:
the introduction of additional assumptions, which may be violated;
the introduction of additional complexity for those evaluating inter-
preting the study; the practical difficulties involved in carrying out
the approach. Overall, I judged that, in this situation, the advantages
outweighed the disadvantages.
6.3.2 Analytical stages
6.3.2.1 Overview of analytical stages
In overview, the stages of my analysis at each point in the pathway of
care were:
1. Obtain descriptive summaries of the main variables
2. Obtain simple descriptive indications of the relationships of the
main variables to the outcome (time to clinical action)
3. Create Kaplan-Meier plots for the times-to-event for each of the
deprivation quintiles
4. Fit univariate frailty models, taking account of the practice of
registration and where appropriate hospital at the time of the
clinical trigger, to estimate differences between deprivation quin-
tiles
5. Fit multivariate frailty models, again using practice and hospital
at the time of the clinical trigger as random effects, this time also
adding in age and sex at the clinical trigger as covariates
6. Fit multivariate frailty model, looking at practice and hospital
as random effects, including all other available and appropriate
covariates
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6.3.2.2 Clinical trigger-action descriptive data
I prepared descriptive statistics relating to the clinical trigger-action
at each stage of interest in the pathway. I extracted data from the
main SAIL DB2 at each point, using an SQL query embedded within
R that pulled out data based on the clinical trigger name and the
clinical action name. The R function that performed this process, the
ExtractData function, also performed a number of checks and updates
on the data, including formatting variables to the correct data type
and, where necessary, generating factor variables so that subsequent
models would interpret the variables in the right way.
For each clinical trigger, I determined the number of those with
the trigger and the number undergoing a clinical action within the
indication period. I presented the numbers and percentages of clinical
triggers in each category for each of the variables. I looked at the
binary variables sex, smoking status, cholesterol:HDL >= 4, diabetes,
CVA/TIA, previous ACS, other comorbidities, and, for clinical trigger-
actions where the clinical trigger was MI or unstable angina, whether
the admission was at a cardiac centre.
I looked at numbers and percentages for the other non-binary cat-
egorical variables. I categorised age at the date of the clinical trigger
into five-year age bands, starting with the ‘35 to 39’ category finishing
with ‘85+’. Though there were younger age groups in our data, due to
the very small numbers in these categories, I excluded them from my
analysis in order to make presentation of data and statistical modelling
easier. I looked at deprivation quintile using the WIMD 2005 index: 1
was the least deprived category; 5 the most.
I looked at BMI weight categories (normal or low, overweight, obese,
and missing). I used my hypertension categories as created by the
algorithms in the derived dataset generator: none, undiagnosed (un-
diag.), controlled (contr.), and uncontrolled (uncontr.). For MI and
unstable angina clinical triggers I also examined categories for admis-
sion specialty: cardiology, other medical specialties (med. spec.), other
specialties (other spec.), and missing. Likewise, for these I looked at
admission type categories: elective, emergency, other, and missing.
I also examined descriptive data relating to my history variables,
which were created by the derived dataset generator’s algorithms, and
which allowed me to take account in the models of previous states
that the individual had been in and whether or not the individual
had previously received the clinical action. The derivation of these
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variables is discussed in section 5.3.7.4. I summarised these in the first
instance using histograms, looking at the following variables:
• The indication numbers for the clinical trigger
• Indication days prior to this clinical trigger
• The number of previous clinical actions prior to this clinical
trigger
• The number of days since the most recent previous clinical action
6.3.2.3 Descriptive variable relationships with outcome
I wished to examine the relationships between the main clinical trigger-
action covariates and outcomes. In this context, the outcome was the
time to the first clinical action. I calculated rates using a person-
years-at-risk (PYAR) approach, expressed as the number of actions
per person-year-at-risk. I calculated rates for each of the categories
discussed above in section 6.3.2.2.
When looking at history variables and outcomes, I converted the
history variables from discrete numerical to categorical variables. For
each category for each of these variables, I calculated rates as described
above.
6.3.2.4 Kaplan-Meier plots
I produced Kaplan-Meier plots for each clinical trigger-action. In these
plots, the times to clinical action following a trigger are treated in
terms of survival – here survival indicates ’not yet having had the
clinical action’, rather than true survival. The curves start at 100%, as
initially no one has the clinical action. The steepness in decline of the
curve indicates the rate at which clinical actions are being provided,
taking into account censoring in the data. I presented separates curves
for each of the five deprivation quintiles. I did this for each of the clin-
ical trigger-actions of interest and for incident and prevalent clinical
triggers.
In order to implement the production of Kaplan-Meier plots in R,
I used functions Surv and Survfit from the Survival package. I wrote
additional functions to allow me to generate the graphics themselves
using the package ggplot2.
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6.3.2.5 Univariate modelling
While also taking account of variations in practice and, where relevant,
admitting hospital as random effects, I fitted frailty models with
deprivation quintile as the only covariate, and produced HRs for
each quintile; quintile 1 (the least deprived quintile) was the reference
category. I determined 95% CIs for the HRs.
6.3.2.6 Models with age and sex added
I ran a similar set of models at each point in the pathway, this time
with additional covariates in the model:
• Age-group in five-year age band at the clinical trigger date
• Sex
Again, I determined HRs, with 95% CIs. I calculated the ICC as de-
scribed above. For the five-year age bands, I used the ‘50 to 54’ age
band as the reference category, because taking reference categories at
extremes of the age range led to very large HRs that were difficult to
interpret. I used ‘Male’ as the reference category for sex.
6.3.2.7 ‘Complete models’
I performed a further set of models at each point in the pathway,
this time including every covariate for that particular clinical trigger-
action that might be relevant. I considered the following covariates (in
addition to deprivation quintile, five-year age band, and sex):
• Smoker/non-smoker
• BMI category
• Hypertension category
• Cholesterol:HDL category
• CVA/no CVA (CVA includes TIA)
• Other comorbidities/no other comorbidities
• Diabetes/no diabetes
• Indication number
• Indication years
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• Previous action
• Admission method
• Admission specialty
• Cardiac centre
• Practice
• Hospital
For each of these, I determined whether they were potentially appro-
priate at each point in the pathway. I implemented the approach using
a data object held within R, termed the variable selection frame. This
allowed me to specify, for every point in the pathway, the relevant
covariates. I wrote an R function to generate the model formulae
(which are used in R to control inclusion of covariates in a model)
based on the information in the variable selection frame. In specifying
covariates, I had to keep, for example, the following considerations
in mind: some covariates (admission method, hospital type, specialty)
were only available for MI and unstable angina clinical triggers; I
only used the ‘previous action’ covariate for revascularisation clinical
actions; some clinical trigger-actions could not have an indication
number greater than one or an indication years value other than zero;
some clinical triggers (‘aged over 40 with no high-risk diagnosis’, ‘BP
raised and high-risk’, and ‘Risk assessed high’) implied the absence of
diabetes and CVA.
There is no universally agreed method for selecting variables to in-
clude in regression models, and frequently there is a large component
of human judgement in the way models are selected: commentators
describe model fitting as an art as well as a science. Additional but
analogous complications arise in determining how variables ought
to be included in the model, and in the selection of interaction terms
between variables. In the context of a project in which a large num-
ber of models were envisaged with their performance controlled in
an automated way, such a situation presented considerable difficulty.
The requirement was for a process that made adequate adjustment of
comparison between deprivation quintiles with respect to the outcome
(times to provision of health care); I wished to account for potential
confounders as far as was practicable, but I did not necessarily need
to produce the most parsimonious models. As a result, I determined
on an approach of minimising human input to model fitting (relying
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on specification of covariates whose adjustment made clinical sense),
rather than on producing the most statistically efficient models pos-
sible. This was a conscious trade-off: detailed human-guided model
fitting at every point in the pathway would simply have been im-
practical; limiting my approach to much more circumscribed parts
of the pathway of care would, in my view, have diluted or under-
mined one of the key strengths of my approach, namely its effort at
comprehensiveness.
When producing models based on the available covariates at each
point in the pathway, I did, at one stage, implement a systematic
data-driven approach, based on the idea of producing models for all
possible combinations of available variables, computing the Akaike
information criterion (AIC) statistic for each of these, and choosing the
model structure with the minimum value. Ultimately I discarded this
approach, as the computational implications of it were quite onerous:
for example, where 15 potential variables could be considered for
the model using this approach, I needed to fit 215, or 32,768 models,
models in order to find the optimal one. Moreover, this does not take
account of any interaction terms that might be considered. I settled
instead on a pragmatic selection of clinically-reasonable variables,
and ignored interaction terms. To do this, I considered each model in
turn, and looked at the possible covariates that might be employed.
I ensured that I did not include variables that would be nonsensical
for that particular model. For example, I did not include smoking
status as a variable in ‘First smoking’ clinical triggers or hypertension
category for the hypertension clinical triggers. At all times, I tried to
keep in mind which variables would be clinically plausible as relevant
for each of the models. I inputted the results of deliberations in the
variable selection frame object, from which my analytical code was able
to construct the required model.
Because I had excluded individuals from the dataset with a missing
date of birth, LSOA, or sex, these data were complete for all clinical
trigger-actions. As mentioned above, other variables appeared com-
plete, because they were based on the presence or absence of clinical
codes.
Missing data arose for some variables and I have discussed the
measures used to address this issue in section 6.3.1.2. At each point in
the pathway where data were missing, I imputed 5 datasets, performed
separate analyses on each of these, and pooled the results. When
imputing, I allowed all variables (including the outcome) other than
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practice and hospital to contribute to the imputation. I imputed using
the ‘mice’ function from the MICE package; I pooled data using the
‘pool’ function available within the MICE package in R; this function
does not work automatically on the outputs from ‘coxme’ models;
I therefore wrote functions to extract a variate-covariate matrix and
table of coefficients to pass to this function. To pool the ICC, I took
the mean of the ICCs for each of the imputed datasets.
Making the assumption of linearity for deprivation quintiles, I per-
formed a simple linear regression model of log hazard ratios across
quintiles to derive a slope index of inequality199 for the provision of
clinical actions for particular clinical triggers. I did so using the lm
function in R. I assumed equal weighting for each of the quintiles, jus-
tified on the grounds that the estimated variances across the quintiles
were very similar. I present these results in chapter 8.
6.3.2.8 Presentation of models
The analytical approach generated a large number of models. I wanted
to ensure that these were presented in a consistent way, and in a
manner that made it as easy as possible to recognize the point in the
pathway. When presenting models, I have given HRs with 95% CI
for each variable category. The reference category is always identified
with the word ‘Reference’, with the HR set to 1. The indication years
variable is modelled as a continuous variable. The HR here indicates
the changing risk for each increase of one year in the variable. Other
variables were handled as categorical.
6.4 pathway overview analysis
Because my interest was in the overall pattern of any healthcare
inequity by deprivation, I wished to amalgamate these results in
such a way as to make it possible to look across the pathway of care.
Without doing so, I felt that the overall picture would be overwhelmed
by detail.
To do this, I made comparisons between deprivation quintile 5 and
deprivation quintile 1, using the HR and its p-value, as generated
by the models described above. In other words, I reasoned that sys-
tematic healthcare inequity across the pathway would be likely to be
manifested in a simple comparison between quintile 5 and quintile
1. Moreover, I thought that any general pattern in these comparisons
would be most easily identified using a graphical summary.
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I wrote R functions to store the outputs from frailty models in data
objects within R, which I called the results frames – one of these was
for the main analysis, the other for the drug cessation analysis. For
each clinical trigger-action and for each model (univariate, age-sex-
deprivation, complete model), I entered the quintile 5:quintile 1 HR
and the p-value (as well as some other relevant model outputs) into
the results frames.
I used a separate set of R functions to produce graphical summaries
based on the data held within the result frames and on the pathway
diagrams previously developed to show the points on the pathway
that I was examining.
At each point, I wrote a function that examined the HR and p-
value. Where the p-value was less than 0.05, I entered the HR in the
pathway box relevant to that clinical trigger action; I shaded the box
dark green if the hazard ratio suggested favourable provision of care
in quintile 5; I shaded box dark red if the hazard ratio suggested
favourable provision of care in quintile 1. Where the p-value was
greater than or equal to 0.05, I shaded the box light green if the hazard
ratio suggested favourable provision of care in quintile 5 (at a non-
statistically significant level) and light red if the hazard ratio suggested
favourable provision of care in quintile 1 (again at a nonstatistically
significant level). Using this approach, I was able to generate graphical
summaries of the pathway of care for different model types.
In presenting the results in overview, I employed the pathway dia-
gram, which used a matrix approach to demonstrating the pathway
of care. The approach throughout this chapter was based on using
summary information from the models described in the preceding
chapter and those contained in the appendix to give overviews of
what was happening in the pathway as a whole. For each of these
pathway overviews, I employed a consistent presentation system. I
used a colour-coding system within the pathway-overview diagrams,
with the four colours used indicating the following:
Dark red A statistically significant result for the hazard ratio
comparing quintile 5 with quintile 1 which suggests that
the hazard ratio favours quintile 1 in terms of provision of
healthcare at that point in the pathway
Dark green A statistically significant result for the hazard
ratio comparing quintile 5 with quintile 1 which suggests
that the hazard ratio favours quintile 5 in terms of provi-
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sion of healthcare at that point in the pathway
Orange A non-statistically significant result for the hazard
ratio comparing quintile 5 with quintile 1 which provided
limited evidence that the hazard ratio favours quintile 1
in terms of provision of healthcare at that point in the
pathway
Light green A non-statistically significant result for the haz-
ard ratio comparing quintile 5 with quintile 1 which sug-
gest that the hazard ratio favours quintile 5 in terms of
provision of healthcare at that point in the pathway
Statistical significance throughout was assessed at the 5% level. In
addition, I wanted to look at the HRs themselves, as their size indicated
the meaningfulness of any difference. Where results were statistically
significant for the HR comparison between quintile 5 and quintile
1, I included the HR itself at the relevant point in the pathway (HR
comparing quintile 5 to quintile 1, with quintile 1 as the reference
category).
For the main overview analysis I generated the following summar-
ies:
• Univariate frailty models for main clinical trigger-actions
• Univariate frailty models for drug cessation clinical trigger ac-
tions
• Frailty model for deprivation, age, and sex for main clinical
trigger actions
• Frailty model for deprivation, age, and sex for drug cessation
clinical trigger actions
• Frailty model using the complete set of available variables for
main clinical trigger actions
• Frailty model using the complete set of available variables for
drug cessation clinical actions
For each of these main overview analysis, I used the non-laboratory
Framingham risk-assessment tool. I used incident definitions for clin-
ical triggers. I included practice, and, where appropriate, hospital as
random effects terms in the model.
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6.5 sensitivity analyses
In the analytical processes outlined above, I made several assumptions.
For example, in the main analysis I looked only at incident clinical
triggers, I used a drug cessation definition based on an 56-day lapse, I
used the Framingham non-laboratory risk assessment tool, and so on. I
wished to check the sensitivity of the results to important assumptions.
I did this at the level of the entire pathway, looking at the differences in
graphical summaries across the pathway care when these assumptions
were adjusted.The methods used in the sensitivity analyses were
identical, being implemented with the same code, the only difference
being the changes made to the underlying assumptions.
With respect to checking the effects of examining incident, as distinct
from prevalent, clinical triggers, I was particularly interested in the
effects on clinical trigger-actions in which the clinical trigger was
‘aged 40 and over with no high-risk diagnosis’. Because of the way
this clinical trigger was defined, individuals undergoing an incident
clinical trigger during the period of observation would by definition
always be in the five-year age-band ‘40 to 45’. In examining prevalent
figures as well, I was also able to look at potential differences in
measurement and risk assessment in older age groups.
The choice of risk assessment tool that defined high risk was an
important assumption, because it not only affected the rate of clinical
action (‘full cardiovascular risk assessment’), but also affected the time-
point at which some clinical triggers occurred (‘BP raised and low-
risk’, ‘BP raised and high-risk’, and ‘risk assessed high’). I therefore
ascertained the effect of using a different risk assessment tool in
defining clinical triggers and clinical actions, again with a view to
determining whether such a change would affect my main conclusions.
6.6 software considerations
I performed the analysis using the statistical software package R (ver-
sion 2.13). This software was available within the SAIL Gateway –
the remote access facility for the SAIL databank. This software has
been widely used by researchers in statistics, epidemiology, and re-
lated fields. It is freely available, and comes with a number of user-
contributed add-on packages. In performing my analysis, in addition
to using the base packages that shipped with the main installation of
R, I also used a number of these:
186 analytical methods
RODBC Used for connection from R to the SAIL DB2
databank
Survival; coxme Used for time-to-event analysis and Kaplan-
Meier plots
MICE Used to perform multiple imputation with chained
equations
ggplot2 Used for generating plots
grid; gridExtra Used for the generation of general graphical
output (other than plots)
RColorBrewer; stringr Used for formatting colour and text
output
Reshape2; plyr Used for manipulating data
While R was extremely useful for data manipulation, statistical ana-
lyses, and generation of graphical output, its use did present some
difficulties, the main weakness being handling very large data tables
– something with which I had to contend. With a view to using R in
its areas of strength, while at the same time avoiding this weakness, I
took the approach of extracting data as and when needed from the
SAIL DB2 databank using a direct connection from R – something that
is possible with the RODBC package. This allowed me to write SQL
queries that I embedded in R code enabling me to take advantage of
the superior capabilities of DB2 in manipulating large datasets while
at the same time retaining the advantages of using R.
6.7 summary
In this chapter, I have detailed the methods performed my main
analyses using the data tables generated from the processes described
in the preceding two chapters. In the next three chapters, I present the
findings from this analysis.
7D ATA S E T O V E RV I E W A N D D E S C R I P T I V E S
In this chapter, I have a number of specific objectives, each based
around the presentation of descriptive statistics. Firstly, I provide
an overview of our dataset; here I examine inclusion and exclusion
in our cohort, as well as looking at entry into the cohort and at
censoring events. I then discuss the distinction between observations
of individuals in in this cohort and the actual derivation of clinical
trigger-actions on these individuals.
In subsequent sections of this chapter, I present descriptive analyses
of the characteristics of the individuals included in our cohort and
characterisation of important covariates used in later models, including
examination of risk factors and risk. I examine broad patterns of
healthcare utilisation in different deprivation quintiles. I show the
results of a simple validation of our data against external sources.
In the last section of this chapter, I examine mortality in our data,
particularly with respect to CHD mortality by quintile.
7.1 dataset overview
I make a basic distinction in my analysis between data relating to the
cohort on whom it was possible to make observations, and the data
on clinical trigger-actions identified by observing the individuals in
that cohort. To make what follows readily comprehensible, I outline in
this section the broad overview of the dataset, and seek to make clear
this distinction.
In figure 7.1, I show schematically the means by which our dataset
was filtered, using the algorithms to identify individuals in our cohort
presented in chapter 5. I started with 1,201,399 eligible individuals in
the extract. After removals for implausible date of birth, because sex
was not coded, and because of discontinuous time in SAIL GP, there
were 1,199,342 individuals left in the cohort (as summarised in figure
7.1).
Because of the annualised time-points simplification of underlying
LSOA and practice data, individuals were constrained to enter our
cohort on 1 January of a year between 2004 and 2010. The majority of
individuals were present in 2004 (924,068), with a generally declining
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Figure 7.1: Individuals excluded from the dataset
Remove 202 with implausible
date of birth (0.017%).
Remove 7 with sex not coded
(< 0.0001%)
Remove 1848 with
discontinuous time in SAIL GP
(0.15%)
1,201,399 individuals in data
extract
1,201,190 individuals after
removal of missing data
1,199,342 individuals after
removals for discontinuous
SAIL GP
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addition of individuals at annual time-points thereafter. (As time went
on, the number of individuals moving into areas served by SAIL-
submitting practices was drawn from a decreasing pool of individuals
aged greater than 20 in 2011 – accounting for the decreasing numbers
entering our cohort over time). In table 7.2, I show the number of
Table 7.1: Numbers of individuals who appear in the dataset from different
starting years
Year Number
2004 or earlier 924068
2005 57246
2006 48082
2007 47904
2008 54020
2009 43268
2010 24754
TOTAL 1199342
individuals ending their time in the cohort for different reasons. The
majority, 964,940 (80.4%), reached the end of the designated follow-up
period for the study (31 December 2010); a further 144,576 (12.5%)
left SAIL GP (either because they left a SAIL-submitting practice, left
a Wales LSOA, or both). There were 89,826 (7.4%) individuals in the
cohort that died. By following through time the cohort of 1,199,342
Table 7.2: Number of individuals ending their time in the cohort for different
reasons
Reason for end Number
End of follow-up period 964940
Left SAIL GP 144576
Died 89826
TOTAL 1199342
individuals, using the algorithms described in chapter 5, I could
identify clinical triggers relevant to my analysis of the pathway of care
for CHD. I show the numbers of clinical triggers identified in table 7.3.
For several of these clinical triggers I examined more than one clinical
action – thus my analysis of later chapters actually takes account of
more clinical trigger-actions than there are clinical triggers shown in
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table 7.3. For example, in individuals with the clinical trigger ‘MI’, I
looked at clinical actions ‘Statin’, ‘Aspirin’, ‘ACE’, and others.
In table 7.3, I show the numbers of incident clinical triggers (those
arising during the period of observation) and prevalent clinical triggers
(those already present at the start of the study – identifiable on the
basis of lead-in data). Generally, there are more triggers related to
primary prevention (clinical triggers in individuals who do not have
CHD) than to established CHD. The balance between incident and
prevalent triggers varies according to trigger: in particular, the ‘Aged
over 40 with no high risk diagnosis trigger’ has many more prevalent
triggers, because of the number of individuals already aged 40 or
more at the time the study started. I present the detailed analysis of
the clinical triggers shown in table 7.3 and the relevant clinical actions
in chapters 8 and 9. Here the aim is to make clear that the existence of
these clinical triggers was determined by observing the individuals in
our cohort throughout the period of observation for each individual.
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Table 7.3: Numbers of each different kind of clinical trigger (according to incident and prevalent definitions) for individuals in the final dataset
Clinical trigger Number (incident) Number (prevalent)
Aged over 40 with no high risk diagnosis 122486 491886
First identified a smoker 96422 238181
BP raised and low-risk 14478 14531
BP raised and high-risk 106520 85282
Risk assessed high 120472 102903
High-risk diagnosis 47338 59063
Stable angina 19039 30014
Stable angina and diabetes 8988 7492
Old ACS 4288 19198
Unstable angina 13954 4988
MI 20542 6468
TOTAL 574527 1060006
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7.2 population characteristics for key variables
In this section, I present descriptive results in three main areas:
demographic characteristics, prevalences of major conditions and risk
factors, and simple measures of health care utilisation. For simplicity,
for the first and last of these I have looked only at individuals present
in the dataset from 2004 onwards.
7.2.1 Demography
Table 7.4: Population of the 2004 cohort by age and sex
Age Male (%) Female (%) Person (%)
<20 3325 0.70 3896 0.80 7221 0.80
20–24 46289 10.20 42062 9.00 88351 9.60
25–29 33661 7.40 30993 6.60 64654 7.00
30–34 39920 8.80 38282 8.10 78202 8.50
35–39 43839 9.60 42778 9.10 86617 9.40
40–44 43844 9.60 42267 9.00 86111 9.30
45–49 39298 8.60 38522 8.20 77820 8.40
50–54 39709 8.70 38560 8.20 78269 8.50
55–59 41107 9.00 41051 8.70 82158 8.90
60–64 32913 7.20 33027 7.00 65940 7.10
65–69 28867 6.40 29963 6.40 58830 6.40
70–74 23942 5.30 27030 5.80 50972 5.50
75–79 18690 4.10 24236 5.20 42926 4.60
80–84 12261 2.70 20307 4.30 32568 3.50
85+ 6677 1.50 16752 3.60 23429 2.50
All ages 454342 100.00 469726 100.00 924068 100.00
I show the age and sex distribution of individuals present in our final
dataset from 2004 onwards in table 7.4. I present the same information
graphically in figure 7.2, in the form of a population pyramid. Ages
were shown in five-year age bands. Though our cohort looked at
individuals aged 20 and over, some individuals were younger than
this in 2004, but they would turn 20 before 2011, thus allowing them
to contribute time towards the study later. In all, 924,068 individuals
were present in the dataset by 2004.
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Figure 7.2: Population pyramid showing age and sex breakdown for indi-
viduals in the 2004 cohort
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In table 7.5, I present similar information to that shown in table
7.4, but this time data related to the whole of Wales from mid-2004
(based on mid-year population estimates from ONS). In our cohort,
I had slightly higher proportions of individuals in the younger age
bands (20–24, 25–29, 30–34, 35–39) compared to Wales as a whole.
For example, 9.6% of individuals were in the 20–24 age band in our
SAIL cohort, compared to 8.4% for Wales. As a result, the SAIL cohort
contained a slightly smaller proportion of individuals in the age bands
40–44 and over.
In table 7.6, I show the numbers of individuals in each of the
WIMD 2005 deprivation quintiles. Here, as throughout, quintile 1 was
the least deprived quintile; quintile 5 the most. Fewest individuals
appeared in quintile 5 (171,428). Quintile 3 contained the most indi-
viduals, with 212,059. Quintile 1 had the second largest number of
individuals, with 197,491, followed by quintiles 4 and 2 with 172,995
and 170,095 individuals respectively. In table 7.6, I have also shown
the total numbers in the Welsh population in each of the WIMD 2005
deprivation quintiles according to estimates for 2004. The highest
proportion of individuals are from quintile 3 (35.3%), falling to a min-
imum in quintile 2 (28.4 latex percent). It should be noted that these
figures represent the proportion of the population in each quintile in
the total population of Wales – proportions of the Welsh population
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Table 7.5: Mid-year estimates for the population of Wales for the year 2004,
by five-year age band, and sex
Age Male (%) Female (%) Person (%)
20–24 93833 8.80 92999 8.00 186832 8.40
25–29 79121 7.40 79331 6.80 158452 7.10
30–34 91465 8.60 96209 8.30 187674 8.40
35–39 103582 9.70 108570 9.30 212152 9.50
40–44 103928 9.80 108364 9.30 212292 9.50
45–49 94205 8.80 97525 8.40 191730 8.60
50–54 94134 8.80 96993 8.30 191127 8.60
55–59 101256 9.50 103670 8.90 204926 9.20
60–64 81992 7.70 84548 7.30 166540 7.50
65–69 70416 6.60 74689 6.40 145105 6.50
70–74 57903 5.40 67229 5.80 125132 5.60
75–79 45084 4.20 60034 5.20 105118 4.70
80–84 30615 2.90 51152 4.40 81767 3.70
85+ 16942 1.60 42272 3.60 59214 2.70
All ages 1064476 100.00 1163585 100.00 2228061 100.00
Table 7.6: The number of individuals in each of the WIMD quintiles in the
2004 cohort (quintile 1 is least deprived)
Quintile Number Number in Wales Proportion
1 197491 590392 33.5
2 170095 598291 28.4
3 212059 599943 35.3
4 172995 584487 29.6
5 171428 570350 30.0
TOTAL 924068
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aged 20 and over would obviously be higher. The overrepresentation
from individuals in quintile 3 is a reflection of the lack of geograph-
ical representativeness of the sample with respect to Wales overall,
discussed further below, and shown in table 7.7. These numbers were
broken down into population pyramids, shown in figure 7.3; again, in-
dividuals aged less than 20 were not included as this was a very small
group. Arguably, the more deprived quintiles had a more classic ‘pyr-
amidal’ shape, with a high proportion of individuals in the younger
age groups and a steeper drop-off in numbers with increasing age,
leaving a smaller proportion of individuals in the older age groups;
similarly, the less deprived quintiles maintained more of the bulge in
population in middle-aged age bands.
It was known that different local authority populations were dif-
ferentially represented in the SAIL databank. In table 7.7, I show the
numbers of individuals in the final dataset from each of the local
authority areas in Wales. Swansea local authority area contains the
most individuals (172,628), followed by Neath Port Talbot (102,160),
and Carmarthenshire (88,636). Each of these local authorities had
over ten times as many individuals in the dataset as the two local
authorities with fewest individuals – Monmouthshire (1898) and Den-
bighshire (5097). Other local authorities had intermediate numbers of
individuals in the dataset.
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Figure 7.3: Population pyramids showing age and sex breakdown for indi-
viduals in the 2004 cohort by quintile
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Table 7.7: Number of individuals in the 2004 cohort, by local authority
Local authority Number in SAIL Number in ONS Percentage in SAIL
Swansea 172628 228176 75.70
Neath Port Talbot 102160 317099 32.20
Carmarthenshire 88636 137144 64.60
Cardiff 85158 177487 48.00
Bridgend 79719 131947 60.40
Caerphilly 47566 172361 27.60
The Vale of Glamorgan 47236 75775 62.30
Ceredigion 41917 122101 34.30
Isle of Anglesey 31526 118721 26.60
Gwynedd 30928 233971 13.20
Pembrokeshire 28311 116428 24.30
Conwy 26426 112272 23.50
Powys 23805 68753 34.60
Rhondda Cynon Taff 23061 129568 17.80
Newport 21818 90516 24.10
Torfaen 18176 139316 13.00
Flintshire 13870 149681 9.30
Wrexham 13135 129005 10.20
Merthyr Tydfil 11144 69242 16.10
Blaenau Gwent 9853 56020 17.60
Denbighshire 5097 94010 5.40
Monmouthshire 1898 87829 2.20
TOTAL 924068 2957422 31.20
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In the same table, I also show the number of individuals resident
in each Welsh local authority as indicated by population estimates
for the year 2004. I have also indicated the percentage of this popu-
lation present in our cohort for that year. The local authorities with
the greatest proportion of individuals within our cohort were concen-
trated in south-west Wales: Swansea (75.7%), Bridgend (60.4%), and
Carmarthenshire (64.6%). Coverage in Denbighshire and Monmouth-
shire was lowest, at 5.4% and 2.2% respectively. While the 2004 cohort
represented 31.2% of the Welsh population overall, at local authority
level coverage was disproportionately higher in south-west Wales.
7.2.2 Covariates overview
In this section, I present an overview of the clinical covariates used
in subsequent chapters in order to attain insight into their broad
distribution within the general population. In the below tables the
time point for both the numerator and the denominator was 1 January
2008, a time close to the midpoint of the designated observation period.
For each of the main covariates, I present simple point prevalences
(for categorical variables) or means (for continuous variables).
In addition, I include in the current section a more in-depth de-
scription of the distributions of major cardiovascular risk factors in
our study population, based on information in the risk assessment
table, with a view to informing subsequent discussion of the drivers
of any inequity in CHD outcomes. Because the presentation of risk
factor results was not the main focus of my analysis, I have limited
what I present. For most risk factors (BMI, systolic blood pressure,
and cholesterol:HDL ratio) and for assessed cardiovascular risk, I have
chosen to look at one age band only (60–64). Doing so simplified
the presentation and allowed me to disregard differences in the age-
structure of the different quintile populations as drivers of difference.
Moreover, the patterns for this age-band were reproduced, in broad
terms, for other age-bands. I decided in favour of this approach, as
opposed to an approach using adjustment, to avoid the possibility that
in-depth analysis here would distract from the main analysis for the
project.
7.2.2.1 CHD and comorbidities
In table 7.8, I show the numbers of individuals with CHD of any
type (including previous ACS) by quintile. While the absolute number
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of individuals with CHD was highest in quintile 3 (16,000), taking
account of the different denominator populations, the unadjusted
point prevalence was highest in quintile 5 (7.72%), with a declining
prevalence as deprivation decreased, falling to 5.96% in quintile 1. The
overall prevalence of CHD in the cohort was 6.91%. In table 7.9, I show
Table 7.8: Point prevalence of CHD in 2008, by quintile
Quintile Number Denominator Prevalence (percent)
1 12946 217354 5.96
2 12248 185688 6.60
3 16000 229861 6.96
4 14049 188608 7.45
5 14343 185891 7.72
All quintiles 69586 1007402 6.91
prevalence of CHD by age and quintile in 2008, from which table it
is clear that prevalence increases steeply from age 50 onwards; pre-
valence is higher in more deprived quintiles, with relative differences
quite marked in the middle age-groups (for example prevalence is
double in quintile 5 compared to quintile 1 in the 50 to 59 age-group).
Table 7.9: Point prevalence (%) of CHD in 2008, by age-group and quintile
Age-group 1 2 3 4 5
20–24 <0.05 <0.05 <0.05 0.1 <0.05
25–29 0.1 0.1 0.1 0.1 0.1
30–34 0.1 0.1 0.2 0.2 0.2
35–39 0.2 0.2 0.3 0.3 0.6
40–44 0.5 0.5 0.7 1 1.2
45–49 1.1 1.4 1.6 2.2 3
50–54 2.4 2.7 3.2 4.7 5.5
55–59 4.5 4.9 5.5 7.1 9.1
60–64 7.4 8.8 9.5 11.9 13.6
65–69 12.3 13.5 15.3 17.9 19.1
70–74 17.5 19.6 20.4 22.4 24.3
75–79 22.6 24.3 24.8 27.1 27.6
80–84 26.4 27.3 27 29.7 30.7
85+ 27.9 29.2 28.9 29.2 30.1
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I show in table 7.10 numbers and prevalences for individuals with a
previous ACS. Here, a similar pattern emerged: the highest prevalence
was in quintile 5 (3.62%), declining with decreasing deprivation to a
minimum in quintile 1 (2.71%). Overall, 3.15% of individuals within
the cohort had had an ACS.
Table 7.10: Point prevalence of previous acute coronary syndrome in 2008,
by quintile
Quintile Number Denominator Prevalence (percent)
1 5887 217354 2.71
2 5398 185688 2.91
3 7286 229861 3.17
4 6485 188608 3.44
5 6724 185891 3.62
All quintiles 31780 1007402 3.15
Prevalence by age-group and quintile is shown in table 7.11. As with
CHD overall, prevalence rises steeply from the middle age-groups on-
wards; again prevalences are more than double in quintile 5 compared
to 1 in some middle age-groups.
Table 7.11: Point prevalence (%) of previous acute coronary syndrome in
2008, by age-group and quintile
Age-group 1 2 3 4 5
20–24 <0.05 <0.05 <0.05 <0.05 <0.05
25–29 <0.05 <0.05 <0.05 <0.05 <0.05
30–34 0.1 0.1 0.1 0.1 0.1
35–39 0.1 0.1 0.2 0.1 0.3
40–44 0.3 0.3 0.3 0.6 0.6
45–49 0.6 0.6 0.8 1.1 1.5
50–54 1.2 1.3 1.5 2.3 2.8
55–59 2.1 2.3 2.7 3.5 4.4
60–64 3.4 3.7 4.5 5.3 6.2
65–69 5.2 5.7 6.7 7.9 8.7
70–74 8.2 8.7 9.2 10.3 11.5
75–79 10.3 10.4 11.3 12.5 12.7
80–84 12.1 12.7 12.3 13.5 14.4
85+ 12.3 12.8 13 13.3 13.6
7.2 population characteristics for key variables 201
In table 7.12, I present figures for the number and prevalence of
CVA/TIA in the SAIL cohort. Again, prevalence declined with de-
creasing deprivation: in quintile 5 prevalence was 3.16%, declining to
2.75% in quintile 1. Overall prevalence was 2.98%. From table 7.13, the
Table 7.12: Point prevalence of previous CVA/TIA in 2008, by quintile
Quintile Number Denominator Prevalence (percent)
1 5980 217354 2.75
2 5389 185688 2.90
3 6942 229861 3.02
4 5824 188608 3.09
5 5880 185891 3.16
All quintiles 30015 1007402 2.98
relationship of CVA with age and increasing deprivation emerges –
similar to the pattern seen for CHD. Again, relative prevalences are
substantial when comparing quintile 5 and quintile 1 in the middle
age-groups.
Table 7.13: Point prevalence (%) of CVA in 2008, by age-group and quintile
Age-group 1 2 3 4 5
20–24 <0.05 <0.05 <0.05 0.1 0.1
25–29 <0.05 0.1 0.1 0.1 0.1
30–34 0.1 0.1 0.1 0.2 0.2
35–39 0.1 0.2 0.2 0.2 0.3
40–44 0.2 0.3 0.3 0.4 0.5
45–49 0.4 0.5 0.6 0.8 0.9
50–54 0.8 1 1.1 1.3 1.8
55–59 1.5 1.5 1.7 2.2 2.8
60–64 2.6 2.8 2.9 3.4 4.7
65–69 4.5 4.8 5.4 5.9 6.9
70–74 7 7.5 8.2 9 9.2
75–79 11.1 10.5 11.1 12 12.5
80–84 14.5 14.4 14.4 15.3 15.7
85+ 18.7 19.7 19.1 18.3 17
Table 7.14 shows corresponding figures for diabetes in the study
population. A similar, though more pronounced gradient in preval-
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ence was seen. While the overall prevalence was 6.48%, in quintile
5 there were 7.71% of individuals with diabetes; in quintile 1, the
figure was 5.31%. Figure 7.15 illustrates that diabetes prevalence is
Table 7.14: Point prevalence of diabetes in 2008, by quintile
Quintile Number Denominator Prevalence (percent)
1 11534 217354 5.31
2 11020 185688 5.93
3 15059 229861 6.55
4 13289 188608 7.05
5 14333 185891 7.71
All quintiles 65235 1007402 6.48
generally increase with age, though do decline in the older age-groups,
presumably relating either to cohort effects from changing prevalences
or differential survival aamong diabetics.More deprived quintiles have
higher prevalences.
Table 7.15: Point prevalence (%) of diabetes in 2008, by age-group and quin-
tile
Age-group 1 2 3 4 5
20–24 0.6 0.5 0.7 0.7 0.7
25–29 0.7 0.9 0.9 1.1 1.1
30–34 0.8 1 1.3 1.2 1.6
35–39 1.3 1.5 1.9 1.9 2.5
40–44 1.8 2.2 2.7 3.1 4
45–49 2.8 3.3 3.7 4.5 5.3
50–54 4.2 5.1 5.4 6.7 8.3
55–59 6 6.6 7.2 8.6 10.7
60–64 8 8.6 10.1 12.1 14
65–69 10.9 12.1 13.6 15.6 17.6
70–74 14.4 15.5 16.3 18 21.2
75–79 14.9 16.4 18 20.2 21
80–84 14.4 16.3 15.8 17.7 17.9
85+ 12.6 13.2 13.3 14.3 14.7
The prevalences of individuals in different quintiles with ‘other
comorbidities’ shown in table 7.16, were based on the proportion
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of individuals in the cohort with comorbidities from the Charlson
comorbidity index, excluding those presented above. The prevalence
of other comorbidities was highest in quintile 5 (11.85%). Prevalence
overall of these other comorbidities was 9.88%. From figure 7.17, it is
Table 7.16: Point prevalence of ‘other Charlson comorbidities’ in 2008, by
quintile
Quintile Number Denominator Prevalence (percent)
1 17646 217354 8.12
2 16734 185688 9.01
3 22667 229861 9.86
4 20503 188608 10.87
5 22030 185891 11.85
All quintiles 99580 1007402 9.88
clear that the prevalence of having other Charlson comorbidities rises
with age, again with higher prevalences with increasing deprivation
in all age-groups.
Table 7.17: Point prevalence (%) of other Charlson comorbidities in 2008, by
age-group and quintile
Age-group 1 2 3 4 5
20–24 2.1 2.6 3.5 3.9 4.4
25–29 3 3.3 4.1 4.1 5.2
30–34 3.4 3.5 4.1 4.8 5.2
35–39 3.4 3.7 4.2 5.1 5.7
40–44 3.6 4.2 4.7 5.8 6.4
45–49 4.1 4.8 5.2 6.4 8
50–54 5.5 6.3 7 8.6 10.6
55–59 7.3 8.2 8.8 10.9 13.2
60–64 9.9 10.7 12.2 14.1 16.5
65–69 13 14.6 16.6 18.6 21.3
70–74 17.1 18.4 19.8 22.8 25
75–79 21.4 23.2 25.1 27.5 28.7
80–84 25.9 28 27.2 31.3 33.1
85+ 28.2 30.4 31 33 34.4
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7.2.2.2 Risk factors
In table 7.18, I present the prevalence of smokers in those whose
smoking status was known, by quintile in 2008. I also show the per-
centage of the cohort on which a smoking status was known. The
prevalence of smoking varied markedly between deprivation quintiles:
in quintile 5, the prevalence was 32.76%; this declined as deprivation
decreased to 14.45% in quintile 1. Overall smoking prevalence in the
cohort was 22.31%. The percentage of individuals on whom a smoking
status was known (and on which the prevalence figures were based)
varied little. The highest proportion known was in quintile 3, at 92.83%;
the lowest was in quintile 5, at 92.18%.
Table 7.18: Percentage of individuals in the final dataset with a known
smoking status and the percentage of those individuals that
smoked by quintile at the beginning of 2008
Quintile Percent smokers Percent known
1 14.45 92.63
2 18.20 92.31
3 21.49 92.83
4 26.13 92.69
5 32.76 92.18
All quintiles 22.31 92.55
Table 7.19 shows the smoking prevalence by age-group and quintile.
Two patterns were seen. First, in line with table 7.18, prevalence rates of
smoking were higher in more deprived quintiles. For example, for all
age-groups, the smoking prevalence in quintile 5 was approximately
double that in quintile 1. Second, smoking prevalence was highest in
young and young middle-aged age-groups for all quintiles, with a
general decline with increasing age thereafter. In quintile 1, the peak
prevalence was in the 25–29 age-group (21.1%); in quintile 3, it was
in the 20–24 age-group (30.7%); in other quintiles (4, and 5), the peak
prevalence was in an older age-group – 40–44. The highest smoking
prevalence was in individuals from the 40–44 age-group for quintile 5
(46.9%). The lowest prevalence was in the 85+ age-group quintile 1.
Table 7.20 shows mean BMI by quintile (here not adjusted for age),
and the percentage of individuals on whom a BMI measurement was
known. Mean BMI in the general population was highest in quintile 5,
at 27.68, followed by quintile 4 at 27.65. In the less deprived quintiles,
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Table 7.19: Percentage of individuals with a known smoking status who
smoke, by quintile and age-group, from 2004 to 2010
Age-group 1 2 3 4 5
20–24 19.80 24.60 30.70 34.60 42.20
25–29 21.10 25.40 29.40 34.20 40.70
30–34 19.30 23.80 29.10 34.70 41.90
35–39 18.90 23.90 29.80 36.70 44.90
40–44 19.00 24.70 29.90 37.50 46.90
45–49 18.60 24.40 30.10 36.60 46.40
50–54 18.40 23.60 28.50 35.10 44.00
55–59 16.60 20.80 25.10 31.40 39.70
60–64 14.90 18.10 21.50 27.30 34.90
65–69 12.60 15.30 17.80 22.20 30.20
70–74 10.00 12.80 14.10 18.20 24.60
75–79 8.70 10.10 11.80 14.70 20.20
80–84 7.10 7.90 10.10 11.30 14.60
85+ 4.80 5.10 6.30 6.90 9.50
mean BMI was lower: 26.33 in quintile 1, and 26.84 in quintile 2. The
mean BMI overall was 27.13. Figure 7.21 shows the mean BMI by
Table 7.20: Mean BMI and the percentage of individuals on whom a BMI
was known by quintile for 2008
Quintile Mean BMI Percentage known
1 26.33 78.46
2 26.84 78.84
3 27.24 79.73
4 27.65 79.10
5 27.68 79.04
All quintiles 27.13 79.05
age and quintile. Broadly, patterns showing increased BMI in more
deprived quintiles, with BMIs generally highest in the 50s and early
60s.
In the two figures 7.4 and 7.5, I present the distributions of BMI for
men and women from the 60–64 age-band respectively. The distribu-
tions for the five different deprivation quintiles are shown, with the
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Table 7.21: Mean BMI in 2008, by age-group and quintile
Age-group 1 2 3 4 5
20–24 23.6 24 24.5 25.2 25.3
25–29 24.5 25 25.5 25.8 26.1
30–34 25.3 25.8 26.3 26.8 26.8
35–39 26 26.7 27.1 27.6 27.7
40–44 26.5 27 27.4 28 28.1
45–49 26.8 27.4 27.8 28.5 28.6
50–54 27.3 27.8 28.1 28.8 28.9
55–59 27.5 27.9 28.1 28.9 29
60–64 27.5 27.9 28.3 28.8 28.9
65–69 27.3 27.8 28.2 28.6 28.6
70–74 27.1 27.7 27.9 28.4 28.1
75–79 26.7 27.1 27.4 27.5 27.5
80–84 25.8 26.5 26.4 26.6 26.5
85+ 24.7 25.2 25.2 25.5 25.4
least deprived quintile (1) at the top and the most deprived quintile
(5) at the bottom. The blue vertical lines mark the mean for each
distribution, also shown by the blue annotations.
In each quintile, the distributions are slightly left skewed, with a
longer tail to the right of individuals with high and very high BMIs.
The means in women show a fairly clear pattern of increasing BMI
with increasing deprivation from a low in the least deprived quintile at
27.6 to a high in the most deprived quintile at 29.1. In men, while the
pattern is broadly similar, with increasing mean BMI from quintile 1
(28.1) to quintile 4 (28.6), the BMI in quintile 5 (28.4) is the same as that
in quintile 3. The differences between quintiles are less pronounced
than for women.
In figures 7.4 and 7.5, apparent artifactual peaks in the distribution
occur at BMI 56. This occurred because individuals with a BMI with
categorical BMIs greater than 55 (’high BMI’) were assigned a BMI of
56.
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Figure 7.4: Distribution of BMI in men aged 60–64, by deprivation quintile,
with population mean for quintile
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Figure 7.5: Distribution of BMI in women aged 60–64, by deprivation quintile,
with population mean for quintile
Distribution of BMI in women aged 60−−64,  by quintile
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In figure 7.6, I present the distributions of systolic BP in untreated
men aged 60 to 64, by deprivation quintile. While the distributions
are similar in form, there is a small difference in means between quin-
tiles. The pattern broadly appears to reflect increased mean systolic
blood pressure (SBP) with increasing deprivation, with quintile 5 an
exception – mean SBP here being lower than quintile 3.
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Figure 7.6: Distribution of systolic blood pressure in untreated men aged
60–64, by quintile, with population mean for quintile
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When mean SBP for untreated women in the same age-group is
considered (figure 7.7), it is seen that mean SBP is lower in every
quintile than for the corresponding quintile in men, by three or four
mmHg. Here the pattern across quintiles is more consistent with a
monotonic increase in mean SBP with increasing deprivation.
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Figure 7.7: Distribution of systolic blood pressure in untreated women aged
60–64, by quintile, with population mean for quintile
Distribution of systolic blood pressure in
untreated women aged 60−−64,  by quintile
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The distributions and means of SBP in treated men aged 60 to 64
are shown in figure 7.8. Here mean SBP peaks in deprivation quintile
3 at 151, declining from there as deprivation decreases or increases. In
each quintile, SBP in treated individuals is roughly 10 mmHg higher
than in the corresponding untreated population.
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Figure 7.8: Distribution of systolic blood pressure in treated men aged 60–64,
by quintile, with population mean for quintile
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When considering the distributions and means of SBP in treated
women, the pattern of means by deprivation is equivalent to that seen
in men, with the highest mean SBP in quintile 3, again falling away
as deprivation increases and decreases. The differences are not large
(one or two mmHg). As with men, the treated group has a mean SBP
approximately 10 mmHg higher than in the corresponding untreated
group.
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Figure 7.9: Distribution of systolic blood pressure in treated women aged
60–64, by quintile, with population mean for quintile
Distribution of systolic blood pressure in
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I show mean cholesterol:HDL ratios by quintile in table 7.22. The
percentages known here are lower, 31.8% overall, with a low of 27.24%
in quintile 1. Thus, the mean values are based on a small proportion
of the cohort. The mean cholesterol:HDL ratio did not vary greatly
between quintiles when the population was considered as a whole,
unadjusted for age. Figure 7.23 shows mean cholesterol:HDL ratio by
Table 7.22: Mean cholesterol:HDL ratio and the percentage of individuals on
whom a cholesterol:HDL ratio was known by quintile for 2008
Quintile Mean cholesterol:HDL Percentage known
1 3.63 27.24
2 3.66 32.83
3 3.70 34.31
4 3.67 33.13
5 3.72 31.70
All quintiles 3.68 31.81
age and quintile. Patterns here are less clear-cut, with ratios peaking in
the 40s. In these age-groups, mean ratios are higher in more deprived
quintiles; in older age-groups ratios peak in quintile 3.
Table 7.23: Mean cholesterol:HDL ratio in 2008, by age-group and quintile
Age-group 1 2 3 4 5
20–24 3.4 3.31 3.43 3.49 3.56
25–29 3.5 3.52 3.58 3.69 3.72
30–34 3.7 3.78 3.91 3.89 3.94
35–39 3.87 3.93 3.99 4.02 4.07
40–44 3.94 3.94 4.02 4.08 4.08
45–49 3.91 3.94 3.98 3.99 4.07
50–54 3.89 3.92 3.94 3.93 3.96
55–59 3.8 3.82 3.86 3.83 3.87
60–64 3.68 3.7 3.74 3.69 3.75
65–69 3.58 3.6 3.59 3.56 3.58
70–74 3.46 3.48 3.49 3.43 3.46
75–79 3.34 3.39 3.4 3.34 3.35
80–84 3.26 3.33 3.35 3.24 3.22
85+ 3.23 3.33 3.34 3.23 3.22
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In figure 7.10, I present distributions of cholesterol:HDL ratio in
men in the 60 to 64 age-group who are not treated with statins. The
mean cholesterol:HDL is unvarying across the quintiles, excepting a
slightly lower value in quintile 1.
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Figure 7.10: Distribution of cholesterol:HDL in untreated men aged 60–64,
by quintile, with population mean for quintile
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For untreated women in the same age-group, the mean choles-
terol:HDL was slightly lower for corresponding quintiles. A pattern
of increasing mean cholesterol:HDL with increased deprivation was
present, though differences were not large.
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Figure 7.11: Distribution of cholesterol:HDL in untreated women aged 60–64,
by quintile, with population mean for quintile
Distribution of cholesterol HDL ratio in
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Where possible, based on available data, I calculated assessed cardi-
ovascular risk using the Framingham non-laboratory risk assessment
tool. I show the mean values for this assessed risk in table 7.24, to-
gether with the percentage of individuals on whom such a risk could
be calculated. Because they are unadjusted, these figures provide only
a crude estimate of cardiovascular risk in the general population in
the study. Overall mean risk was highest in quintile 3, with risk then
decreasing and increasing with decreasing deprivation.
Table 7.24: Mean cardiovascular risk and the percentage of individuals on
whom a cardiovascular risk was known by quintile for 2008
Quintile Mean cardiovascular risk Percentage known
1 0.156 61.76
2 0.162 61.40
3 0.165 64.39
4 0.161 64.09
5 0.16 63.42
All quintiles 0.161 63.04
Age is the most important risk factor for CHD and CVD more
generally – and this is reflected in table 7.25 – older age-groups have
higher risk. In general, cardiovascular risk increases with increasing
deprivation.
For men aged 60 to 64, the distributions of risk (based on the
Framingham non-laboratory risk-assessment tool) and population
means for each quintile are shown in figure 7.12. Here, a clear pattern
emerges, with mean risk increasing with increasing deprivation, with
a low of 0.247 in the least deprived quintile rising to 0.287 in the most.
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Figure 7.12: Distribution of cardiovascular risk measured using the Framing-
ham non-laboratory risk assessment tool in men aged 60–64, by
quintile, with population mean for quintile
Distribution f cardiovascular ris  using Frami ham
 non−laboratory risk assessment in men aged 60−−64,  by quintile
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Table 7.25: Mean cardiovascular risk (%), using Framingham nonlaboratory
assessment tool in 2008, by age-group and quintile
Age-group 1 2 3 4 5
20–24 0.6 0.6 0.7 0.7 0.7
25–29 1.1 1.2 1.2 1.3 1.3
30–34 1.9 2.1 2.2 2.3 2.5
35–39 3.1 3.4 3.6 3.8 4.1
40–44 4.9 5.3 5.6 6 6.4
45–49 7.4 8 8.3 9 9.6
50–54 10.8 11.5 12 12.6 13.5
55–59 14.8 15.3 16.1 17.1 18.1
60–64 19 19.8 20.7 21.6 22.7
65–69 23.7 24.5 25.6 26.4 27.1
70–74 28.5 29.5 30.7 30.8 31.3
75–79 33.2 34 34.6 34.5 35.3
80–84 36.8 37.3 37.6 37.4 37.7
85+ 39.5 39.3 39.9 38.8 39.3
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A similar pattern occurred for women aged 60 to 64, as shown
in figure 7.13, though here risk was lower throughout (roughly half
the mean value for men) – sex being an important component of
cardiovascular risk models.
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Figure 7.13: Distribution of cardiovascular risk measured using the Framing-
ham non-laboratory risk assessment tool in women aged 60–64,
by quintile, with population mean for quintile
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7.2.3 Healthcare utilisation
I looked at simple measures of health care utilisation, making com-
parisons of mean levels between deprivation quintiles. For this simple
analysis, I looked at measurements of important risk factors in primary
care, total numbers of cardiovascular-related GP records, and total
numbers of hospital admissions of all types for all causes. I looked
across the whole time period of the study.
Table 7.26: Mean hospital admissions and CVD-related GP contacts during
the study period, by quintile
Quintile Admissions (all causes) GP contacts (CVD-only)
1 2.88 131.46
2 3.02 145.5
3 3.17 152.95
4 3.45 154.26
5 3.67 159.45
All quintiles 3.23 148.44
In figure 7.26, I show the mean number of spells in hospital (ad-
missions) for each of the different deprivation quintiles for the 2004
cohort. For these individuals, those in deprivation quintile 5 had on
average 3.67 admissions to hospital during the study period. As the
deprivation level of the quintiles decreased, the mean number of ad-
missions decreased, falling to 2.88 in quintile 1 (the least deprived
cohort). When looking at the mean number of GP records (table 7.26)
of episodes or contacts relating to cardiovascular disease (including
measurements, readings, symptoms, treatments, and diagnoses), a
similar pattern emerged, with higher average numbers of GP con-
tacts in the most deprived quintile (159.5 on average during the study
period), falling as deprivation levels decreased to 131.5 in the least de-
prived quintile.Figure 7.27 shows mean hospital admissions through
the study period by age-group and quintile. Mean admissions are
higher in older age-groups (peaking in the 80–84 age-group), with
general increases with increasing deprivation.
I present the mean number of BMI measurements in table 7.28.
Quintile 5 had on average 5.9 measurements during the study period.
The mean number of measurements declined as deprivation declined
for the quintile, reducing to 4.5 in the least deprived quintile.
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Table 7.27: Mean number of hospital admissions throughout the study period,
by age-group and quintile
Age-group 1 2 3 4 5
20–24 1.7 1.9 2.3 2.7 3.2
25–29 2.2 2.3 2.5 2.7 3
30–34 2.2 2.2 2.3 2.4 2.5
35–39 1.8 1.9 2 2.1 2.3
40–44 1.7 1.9 1.9 2.1 2.4
45–49 1.9 2.1 2.1 2.4 2.5
50–54 2.3 2.3 2.4 2.8 3
55–59 2.6 2.6 2.9 3.2 3.5
60–64 3.2 3.3 3.4 3.9 4
65–69 4 3.9 3.9 4.3 4.4
70–74 4.5 4.5 4.5 4.7 4.8
75–79 4.7 4.8 4.6 5 5.1
80–84 4.8 4.9 4.8 5 5.4
85+ 4.4 4.8 4.7 4.9 4.6
Table 7.28: Mean numbers of measurements and readings performed in gen-
eral practice during the study period, by quintile
Quintile BMI Systolic BP Cholesterol
1 4.54 15.16 3.69
2 4.98 15.33 3.85
3 5.39 15.68 3.96
4 5.56 15.77 3.87
5 5.9 15.37 3.82
All quintiles 5.26 15.46 3.84
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For blood pressure (shown in table 7.28) the picture was different.
The highest mean number of measurements was in quintile 4, at 15.77,
the lowest number of measurements was in quintile 1, at 15.16. Mean
measurements of cholesterol (table 7.28) were highest in quintile 3, at
3.96, second highest in quintile 4 at 3.87, and lowest in quintile 1 at 3.69.
In table 7.29, we see the mean number of contacts with GP services
for CHD-related activity. Mean numbers of contacts are highest in
those in their 70s; as with admissions, mean numbers increase with
increasing deprivation.
Table 7.29: Mean number of contacts with primary care related to cardiovas-
cular disease throughout the study period, by age-group and
quintile
Age-group 1 2 3 4 5
20–24 30.8 32.9 36 38.1 38.4
25–29 36.4 38.9 42 45 46.5
30–34 44.1 47.1 51 53.6 56.9
35–39 53.3 59.1 64.5 69.2 76
40–44 67.3 74.1 84.6 93.4 104.4
45–49 96.6 108.1 120.4 135.1 151.8
50–54 133.9 149.5 156.4 179.7 203.9
55–59 177.2 200.5 216.8 238.3 263.9
60–64 238.7 265.5 282.3 306 324.3
65–69 299.3 332.3 342.2 351.9 379.5
70–74 342 375 379.1 388.6 403.3
75–79 347.3 389 379.1 386.4 401.4
80–84 343.4 349.2 353.5 353 356
85+ 268.7 294.6 281.6 284 279.8
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In table 7.30, I have summarised the prevalences of angina, CHD,
diabetes, MI, and CVA/TIA from different data sources and different
time-points. Table 7.30 shows angina prevalence in the years 2005 and
2009 in SAIL and in the WHS, but angina prevalence was not available
in QOF. Angina prevalence changed in both data sources: in SAIL
from 4.53% in 2005 to 4.62% in 2009; in the WHS from 5.0% in 2005
to 4.0% 2009. Both time-points had a higher prevalence estimate for
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Table 7.30: Prevalences of major diagnoses by data source and by year
Diagnosis Data source Year Prevalence (%)
Angina SAIL 2005 4.53
Angina WHS 2005 5.00
Angina SAIL 2009 4.62
Angina WHS 2009 4.00
CHD QOF (Wales) 2005 4.30
CHD SAIL 2005 6.74
CHD QOF (Wales) 2009 4.20
CHD SAIL 2009 6.93
Diabetes QOF (Wales) 2005 3.90
Diabetes SAIL 2005 5.51
Diabetes WHS 2005 5.00
Diabetes QOF (Wales) 2009 4.60
Diabetes SAIL 2009 6.79
Diabetes WHS 2009 6.00
MI SAIL 2005 3.02
MI WHS 2005 5.00
MI SAIL 2009 3.18
MI WHS 2009 4.00
Stroke/TIA QOF (Wales) 2005 1.80
Stroke/TIA SAIL 2005 2.90
Stroke/TIA WHS 2005 3.00
Stroke/TIA QOF (Wales) 2009 2.00
Stroke/TIA SAIL 2009 3.01
Stroke/TIA WHS 2009 3.00
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angina from the WHS. Prevalence of CHD was available from QOF
and from SAIL (table 7.30). Prevalence in SAIL was 6.74% in 2005 and
6.93% in 2009. Prevalence was lower in QOF at 4.3% in 2005, falling to
4.2% in 2009. Diabetes prevalence was available from all three sources
(table 7.30). In 2005, diabetes prevalence was 3.9% in QOF, 5.51% in
SAIL, and 5.0% in WHS. In 2009, the diabetes prevalence had risen in
each data source: to 4.6% in QOF, to 6.79% in SAIL, and to 6.0% in
the WHS.
Prevalences of previous MI were present in SAIL and in the WHS.
Contrasting patterns were observed for the two data sources over
time. In SAIL, MI prevalence rose from 3.02% in 2005 to 3.18% in
2009. For the WHS, prevalence of MI fell from 5.0% in 2005 to 4.0% in
2009. Importantly, these two sources of information arrived at these
estimates in entirely different ways: the WHS relied on asking a subset
of the Welsh population whether they had ever had the condition;
the SAIL dataset used hospital data recorded in PEDW relating to
admissions during which an MI occurred.
For both SAIL and QOF the prevalence of CVA/TIA increased
between 2005 and 2009 (table 7.30). For SAIL, the rise was from 2.90%
to 3.01%; for QOF, the rise was from 1.8% to 2.0%. The prevalence in
the WHS was the same for the two time-points at 3.0%.
Overall, prevalences between the data sources were broadly com-
parable. Where prevalences were available from both SAIL and QOF,
prevalences were higher in SAIL. This pattern had been anticipated
due to the differences in denominators. In addition, the more inclusive
approach to labelling CHD taken in this thesis compared to QOF
business rules is also likely to explain some of the difference seen. In
comparisons between SAIL and the WHS, prevalences in the WHS
were higher, except for diabetes where prevalences were higher in
SAIL.
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Table 7.31: Prevalences of smoking, obesity and overweight/obesity by data source and by year. The ‘percentage known’ shows the percentage of
individuals in the SAIL data on whom a reading is available
Risk factor Data source Year Prevalence (%) Percentage known
Obesity SAIL 2005 22.73 68.6
Obesity SAIL 2009 26.45 77
Obesity WHS 2009 21.00
Overweight/obesity SAIL 2005 58.78 68.6
Overweight/obesity SAIL 2009 61.84 77
Overweight/obesity WHS 2009 57.00
Smoking SAIL 2005 26.21 80.8
Smoking WHS 2005 28.00
Smoking QOF (Wales) 2009 19.10
Smoking SAIL 2009 23.92 90.5
Smoking WHS 2009 24.00
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I also looked at the prevalences of some important cardiovascular
risk factors in different data sources, to allow comparison: obesity;
overweight/obesity; smoking; and hypertension. I have summarised
these preferences in table 7.31, and for hypertension in table 7.32. In
2005, the prevalence of obesity in SAIL was 22.73% and this figure
had risen to 26.45% by 2009. Prevalence from the WHS was available
from 2009 only and was 21.0%.
A similar pattern was observed with prevalence of overweight/obes-
ity. This is a prevalence including individuals who are either over-
weight or obese, including everybody with a BMI of 25 or over. Here
the prevalence in SAIL was 58.78% in 2005 rising to 61.84% by 2009;
the prevalence from the WHS from 2009 was 57.0%.
Smoking prevalence was available from SAIL and from the WHS
for 2005. SAIL prevalence at this time was 26.21%; in the WHS the pre-
valence was 28.0%. In 2009, QOF data were also available on smoking
prevalence, at 19.1%; smoking prevalence in SAIL had fallen to 23.92%;
in the WHS, prevalence had fallen to 24.0%.
Prevalences of risk factors in SAIL were based only on a proportion
of the total population of the cohort, because for many individuals
their status with respect to these risk factors was unknown. Moreover,
the individuals on whom these risk factors are ascertained are not
randomly selected from the population of the cohort.
In table 7.32, I have summarised a number of prevalences of hy-
pertension for different diagnostic criteria. I have listed prevalences
of hypertension, as included in QOF and WHS. In 2005, the QOF
prevalence of hypertension was 12.7% rising to 14.9% by 2009. The
equivalent prevalences from the WHS were 19.0% in 2005 and 20.0%
and 2009.
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Table 7.32: Prevalences of hypertension and related measures by data source and by year. The ‘percentage known’ shows the percentage of individuals
in the SAIL data on whom a reading/diagnosis is available
Risk factor Data source Year Prevalence (%) Percentage known
Hypertension QOF (Wales) 2005 12.70
Hypertension QOF (Wales) 2009 14.90
Hypertension WHS 2005 19.00
Hypertension WHS 2009 20.00
3 consecutive BPs > 160 in low-risk person SAIL 2005 1.45
3 consecutive BPs > 160 in low-risk person SAIL 2009 1.18
3 consecutive BPs > 140 in high-risk person SAIL 2005 10.30
3 consecutive BPs > 140 in high-risk person SAIL 2009 13.60
Mean systolic BP > 140 SAIL 2005 37.73 51.2
Mean systolic BP > 140 SAIL 2009 29.70 63.2
Mean systolic BP > 160 SAIL 2005 7.97 50.9
Mean systolic BP > 160 SAIL 2009 4.31 62.7
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For the SAIL data, I had to determine what hypertension actually
constituted. I have cited prevalences in 2005 and 2009 in the SAIL data-
set using different definitions in table 7.32. In the first two definitions,
I followed NICE guidance and looked at the prevalence of individuals
with three consecutive systolic BP measurements greater than 140 in
an individual known to be at high risk of CVD; the prevalence of
individuals meeting this definition was 10.3% in 2005 and 13.6% in
2009. I also considered individuals with three consecutive systolic BP
measurements greater than 160 who were at low-risk of CVD; here
the prevalence was 1.45% in 2005 and 1.18% in 2009. For comparison,
I also looked at a simpler definition, looking at individuals with mean
systolic BPs greater than a designated threshold (140 or 160) from
three readings. Using the 140 threshold, 37.7% of individuals met this
definition in 2005 falling to 29.7% by 2009; with the 160 threshold,
7.97% of individuals met this definition in 2005 falling to 4.31% by
2009.
There was a substantial difference between the prevalences of hyper-
tension using different criteria. While the prevalences from QOF and
the WHS were comparable, this was not the case for the definitions
used to ascertain prevalence in SAIL, which found either substan-
tially lower or substantially higher estimates than the comparison data
sources.
7.4 mortality
In this section I describe the causes of death by broad category for
individuals in our cohort, and have looked at mortality by deprivation
quintile in relation to CHD. One of the key underlying assumptions of
this thesis was that the mortality rate from CHD was higher in more
deprived groups, a pattern which has been observed in numerous
studies. I use this section to present descriptive data that allowed me to
test the validity of this assumption. In table 7.33, I show the numbers
of deaths by different broad categories of cause for individuals in
our cohort. In 67,529 individuals, death was from non-cardiovascular-
related causes. Of the remainder, 15,339 individuals had a cause of
death relating to CHD, representing 17.1% of deaths where the cause
was known. An additional 1708 deaths (1.9% of deaths) were recorded
as due to heart failure; CVA accounted for a further 5248 deaths (5.84%
of deaths). Taking CHD, heart failure, and CVA together to constitute
CVD deaths, CVD accounted for 24.8% of all deaths (22,295 deaths in
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Table 7.33: Breakdown of the broad categories of cause of death for the
individuals in the 2004 cohort who died
Cause of death Number
Other 67529
CHD 15339
Stroke 5248
Heart failure 1708
Unknown 2
TOTAL 89826
all). The codes used to assign deaths to the different categories shown
in figure 7.33 are shown in appendix E.
In table 7.34, I show the death rate from CHD for the different
deprivation quintiles, per thousand person-years at risk within our
cohort.
The rate of death from CHD was highest in quintile 5, 2.68, with a
declining trend as deprivation declined through the quintiles to 1.77. I
Table 7.34: Number of CHD deaths per 1000 person-years-at-risk, by quintile
Quintile PYAR (1000s) CHD deaths CHD deaths per PYAR
1 1452 2576 1.77
2 1233 2605 2.11
3 1536 3647 2.37
4 1261 3172 2.51
5 1249 3345 2.68
illustrate the same pattern in figure 7.14. This is a Kaplan-Meier plot
showing the patterns of mortality from CHD over time. In this figure,
the Y-axis ends at 0.9 as the majority of individuals in the dataset did
not die from CHD during the study period. The lines in figure 7.14 are
coloured by quintile. The pattern shown suggests that, with increased
deprivation, a higher proportion of individuals are dying from CHD.
In table 7.35, I present the results of a Cox proportional hazard
model of death from CHD, showing the HRs with CIs for the different
quintiles. Again, the pattern of increased risk of death with increased
deprivation was shown. Using quintile 1 as the reference category with
HR 1, the HR for quintile 5 was 1.54 (95% CI: 1.46; 1.62), suggesting
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Figure 7.14: Kaplan-Meier plot of death from CHD by quintile
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an increased risk of death of 54% in this quintile. When compared to
quintile 1 other quintiles (2, 3, and 4) had an increased risk of death
from CHD, the size of the HR declining as deprivation declined. I
Table 7.35: Hazard ratios for coronary heart disease death by quintile
Quintile Hazard ratio 95% CI
Quintile 1 1 Reference
Quintile 2 1.17 1.11; 1.24
Quintile 3 1.3 1.24; 1.37
Quintile 4 1.41 1.34; 1.49
Quintile 5 1.54 1.46; 1.62
show a similar set of figures in table 7.36, though this time the HRs
shown are adjusted for age and sex (these being obvious confounders
of the relationship). Doing so has the effect of increasing the HRs in
quintiles 4 and 5 – from 1.41 to 1.50 and from 1.54 to 1.72 respectively.
In quintiles 2 and 3 the HRs changed slightly when the adjustment
was made – from 1.17 to 1.16 in quintile 2 and from 1.30 to 1.32 in
quintile 3. Overall, our results suggested that rates of death from CHD
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Table 7.36: Hazard ratios for coronary heart disease death by quintile, adjus-
ted for age and sex
Quintile Hazard ratio 95% CI
Quintile 1 1 Reference
Quintile 2 1.16 1.1; 1.23
Quintile 3 1.32 1.26; 1.39
Quintile 4 1.5 1.42; 1.58
Quintile 5 1.72 1.63; 1.81
were related to deprivation, with increased rates of death in more
deprived quintiles.
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7.5 summary
In this chapter, I have given an overview of our dataset, specifically
concentrating on the characteristics of the individuals on whom I set
out to identify clinical triggers. I have described our dataset, look-
ing at the demographic characteristics of the cohort as of 1 January
2004; I have presented prevalences for important covariates; I have
summarised healthcare utilisation by deprivation quintile throughout
our study. I have presented results from a simple validation of our
dataset against prevalence estimates from external sources. Because
of the importance of mortality from CHD by deprivation quintile as
an underlying assumption for this work, I have presented results on
CHD mortality differences between quintiles – to demonstrate that
this starting point, incorporated into the rationale for this work in
chapter 1, was justified based on patterns in our data.
Summarising the results from this chapter, I have found that
• Utilisation of healthcare in broad terms appears to be higher
with increasing deprivation
• Risk profiles are often worse as deprivation increases, especially
for smoking
• Mortality from CHD is higher with increasing deprivation
Although, following from the arguments in our rationale in chapter 1,
healthcare inequity might explain some of the differences in outcome
CHD mortality between deprivation groups reported in this chapter,
the risk profiles presented here indicate that more deprived groups
have worse risk factor profiles (particularly in relation to smoking,
where prevalences in the most deprived are approximately double
those in the least deprived quintile). In other words, purely on this
(well-documented) basis, one can argue that it is not necessary to
invoke healthcare inequity to explain differences in outcome. Taken
with the findings of chapter 3, where I found quite equivocal evidence
in the literature for the existence of healthcare inequity for CHD, I
turn to our detailed analysis of clinical trigger-actions having estab-
lished (partly in this chapter, partly on the basis of previous work
reviewed in chapter 3) that the case for healthcare inequity in the
NHS for CHD is fairly weak and is very likely unnecessary to explain
observed differences in outcome. Further, the simple summaries of
healthcare utilisation presented here suggest that, in broad terms,
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deprived groups have more contacts (admissions, CHD-related meas-
urements) with healthcare services.
In the next two chapters, I present analysis of clinical trigger-actions
themselves. Firstly, I examine some exemplar analyses from selected
points in the pathway of care for CHD; secondly, in chapter 9, I present
an overview of our pathway analysis.
8S E L E C T E D PAT H WAY R E S U LT S
In the previous chapter, I presented an overview of our data using
a descriptive approach. In this chapter I report detailed results at
two points on the pathway of care for CHD in order to explain and
illustrate how results will be presented throughout this thesis. Because
of the large volume of results it would have been impractical to present
them all in the main text at this level of detail at every point in the
pathway. An overview of all results appears in the next chapter, and
further detailed results appear in appendix D.
The two pathway points I chose to focus on in this chapter are statin
prescribing in individuals whose risk is assessed as high, and PCI for
individuals who have had an MI. I did not choose these points because
of the specific nature of their results or because their analysis was
somehow different: I performed the same analysis as that presented
in this chapter at every point in the pathway of care for CHD. I hope
that focusing on statins in high-risk individuals will be of interest
to the reader because the subject is topical at the time of writing;
revascularisation with PCI was chosen as a contrast, because it is quite
a different kind of activity to which different considerations apply.
Thus, the aim here is to give maximally informative examples of the
way my analysis was performed.
In presenting the results I have adhered to a consistent framework,
also employed in the further results presented in the appendix. To aid
with orientation in such a large amount of information, I have tried to
make clear the point in the pathway the reader is looking at by using a
frame coloured according to the area of the pathway, with a schematic
overview of the pathway highlighting both the current point and the
broad area of the pathway concerned.
Throughout, I have used single quotes in the titles of figures to
indicate the names of the clinical trigger and clinical action; the name
of the clinical trigger comes first. I present a hierarchy of results for
each pathway point. I start with descriptive summaries of the clinical
trigger-actions, by looking at the main covariates at the clinical trigger
date, and at the history variables discussed in chapter 5. I then present
summaries of the ‘survival times’ for that clinical trigger-action, using
a Kaplan-Meier plot with separate curves for each deprivation quintile.
241
242 selected pathway results
Next I present the hierarchy of models looking at clinical trigger-action
times across quintiles. I present a univariate model looking only at HRs
across quintiles, including practice (and where appropriate hospital of
admission) as a random effects terms in the model. Secondly, I have
included a model that adjusts in addition for the age-group and sex of
the individual at the clinical-trigger date. Thirdly, I have looked at a
model that in addition contains other plausible and relevant covariates,
again containing random effects terms for practice (and hospital if
necessary).
8.1 statin prescription in individuals assessed as being
high risk
I have considered first the clinical trigger-action in which an indi-
vidual is determined as being at high cardiovascular risk (through risk
assessment but not through having a ’high risk diagnosis’) and thus,
in line with NICE guidance, potentially able to benefit from a statin.
The algorithms identified 120,459 individuals for whom this clinical
trigger arose during the observation period of our study (1 January
2004 to 31 December 2010 ), and in whom I looked for prescription of
statins following the date of this clinical trigger. Of those individuals
with a cardiovascular risk that could be assessed as high, 33,226 went
on to receive a statin. The clinical-trigger period was terminated in the
event that an individual developed a ’high risk diagnosis’.
In figure 8.1, I have presented the breakdown of categorical variables
at the clinical trigger date. A clear majority of individuals were men,
71,483 in all, representing 59.3%; this is consistent with the higher
cardiovascular risk at a given age found in men compared to women.
The percentage of smokers was 32.2% (38,788 individuals) at the clin-
ical trigger date. That there was no missing data for smoking was
expected: individuals could only be assessed as having high cardi-
ovascular risk if a smoking status had been available by the clinical
trigger date. The comparatively high smoking prevalence (32.2%), re-
flects its importance in the risk-assessment tool that designated the
individuals as being at high risk. The high proportion of missing data
for the cholesterol:HDL ratio (60.9%) is a reflection of the fact that
this variable is not required for the Framingham non-laboratory risk
assessment tool that I used in my main analysis. Similarly, none of the
individuals were in any of the other diagnostic categories examined
(diabetes, CVA/TIA, CHD, and previous ACS), because such indi-
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viduals were considered separately in the ‘high-risk diagnosis’ clinical
trigger.
Age is the dominant variable in the Framingham non-laboratory
risk-assessment tool. In line with this, the largest number of indi-
viduals designated at high risk were in the 60 to 64 age-band (24,377
representing 20.2% of those with this trigger), and the figure was also
high in the neighbouring age-bands. Younger and older age groups
contained fewer individuals with this clinical trigger: the former be-
cause their risk was genuinely low; the latter because individuals had
either already become high risk in an earlier age group or because
they had a ’high-risk diagnosis’ to disqualify them from this trigger.
Thus, the age distribution seen is in line with expectations.
Deprivation quintile 3 was overrepresented in our entire dataset,
and this was reflected in the numbers for this clinical trigger. For that
quintile, 29,010 individuals had this trigger, representing 24.0% of the
total. The number was lowest in quintile 5, at 21,947, representing
18.2% of the total.
The risk assessment I used included BMI as one of its variables,
and so none of the individuals with this clinical trigger had a missing
value for BMI. Overall more than 70% of these individuals were
either overweight or obese at the time of the clinical trigger. Similarly,
only 64,735 individuals (53.8%) did not have hypertension, 14,649
(12.2%) had undiagnosed hypertension, 23,025 (19.1%) had controlled
hypertension, and 18,032 (15.0%) had uncontrolled hypertension. In these
presentations of
crude rates, I have
not presented CIs
around my estimates
or made formal
comparisons: the
significance of these
relationships is dealt
with in detail later,
with the employment
of appropriate
statistical techniques
In figure 8.2, I have shown crude rates, expressed as the number
of clinical actions per-person-year-at-risk with the clinical trigger, in
this case the number of individuals starting treatment with a statin
during the time in which they have fulfilled the trigger ‘risk assessed
high’. The rate per PYAR in women was 0.123; in men 0.091. The rate
in smokers was 0.091, compared to 0.11 in non-smokers. In those with
a cholesterol:HDL ratio greater than 4, the rate was 0.199, compared
to 0.165 in those whose ratio was less. The rate was slightly higher in
those with other Charlson comorbidities, at 0.107 compared to 0.104
in those without.
With respect to age, the rates at which individuals received statins
were lower at the extremes of age, particularly for the older age bands:
the 85+ age-band had a rate of 0.041 and the ‘80 to 85’ age-band had
a rate of 0.060; this compared to a maximum rate in the ‘65 to 69’
age-band where the rate was 0.122.
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Figure 8.1: Descriptive variables for the clinical trigger-action ‘risk assessed
high’ and ‘statin’
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Rates of provision of statins were lower in quintiles 3 and 4 than in
other quintiles.
BMI categories showed a higher rate of provision in overweight
individuals (rate 0.11) and obese individuals (rate 0.117), as compared
to individuals with normal or low BMI, where the rate was 0.083.
For hypertension categories, the rate of provision was lowest in indi-
viduals with no hypertension (0.071), rising to 0.105 in individuals
with undiagnosed hypertension, to 0.151 in individuals with uncon-
trolled hypertension, and was highest in individuals with controlled
hypertension at 0.178.
Overall, these results, which are a starting point for my analysis,
suggest that overweight and obese individuals, those with hypertens-
ive disease, and those with a raised cholesterol:HDL ratio were more
likely to have received treatment, perhaps reflecting a situation where
treatment was being initiated on the basis of risk factors considered
separately, rather than on overall cardiovascular risk. Women and
those from the mid part of the age range were more likely to receive
treatment.
In figure 8.3, I present the distributions of the derived history vari-
ables. By my definition, the ‘risk assessed high’ clinical trigger would
always be the first indication, given that it was always superseded
by clinical triggers relating to high-risk or cardiovascular diagnoses.
The distribution in the first of the figures, showing the counts for the
different indication numbers, was therefore expected. Likewise, all
individuals were expected to have zero days of previous indication
prior to the clinical trigger date, confirmed in the second graphic
(histogram showing indication days prior to this clinical trigger). The
following graphic shows the distribution of the number of times in-
dividuals had received a statin prior to the clinical trigger date, the
vast majority never having received a statin. For those individuals
who did, I show the distribution of times since that previous statin
in the fourth graphic in figure 8.3 (histogram of days since the most
recent prior clinical action). The distribution is right-skewed, most
individuals having received this treatment within the last 50 days.
In figure 8.4, I show results relating to these same derived variables
relating to patient history, this time including rates of provision of a
statin (expressed as years-per-person-year-at-risk). Only one category
is present for the indication number and indication periods (for reas-
ons given above). The number of previous clinical actions was zero
for 105,301 individuals (in other words, these individuals had never
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Figure 8.2: Relations between categorical variables and times to provision of
statin in those with the clinical trigger ‘risk assessed high’
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Figure 8.3: Frequencies of derived variables relating to an individual’s history
within the pathway for the clinical trigger ‘risk assessed high’ and
’statin’
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had a statin at the time of the clinical trigger). There were 11,029 indi-
viduals who had five or more previous statin prescriptions. Smaller
numbers had had between one and four prescriptions. The rate of
subsequent provision in those with five or more prescriptions was
3.287, compared to 0.066 in those who had had no previous statin: this
is consistent with this group representing individuals already being
treated with the drug. In subsequent analysis, I have only included
the 105,301 individuals with no previous statin prescription. Similarly,
those individuals who had their most recent statin prescription within
one year of the trigger date (shown in last table in figure 8.4), had a
higher rate of subsequent prescription for the drug (3.465) compared
to 0.066 in those who had not previously received it.
In figure 8.5, I show a Kaplan-Meier plot of the prescription of
statins in individuals assessed to be at high risk, for each of the
five deprivation quintiles. At time 0 the proportion of individuals
who have not had a statin is 1; this figure declines with time, as an
increasing proportion of individuals are treated. In all quintiles, there
was an initial quite steep decline, accounting for about 10 to 15% of
individuals receiving the drug. Thereafter, a more gradual decline
persisted through the rest of the observation period. Clear differences
between the quintiles were not apparent.
In figure 8.6 I present findings from a univariate mixed-effects
model (frailty model) looking at HRs for deprivation quintiles, with
quintile 1 as the reference category, and showing 95% CIs. The ICC for
practices is also shown, which gives an indication of the proportion of
the variability in the outcome that can be explained by taking account
of practice-level variability as a random-effect term.
When performing this and subsequent analyses using frailty models
to look at this clinical trigger-action, I included 105,301 individuals
(those individuals who I had identified from the descriptive analysis
as having had no previous statin prescription). Of these individuals
33,226 began a statin during the time-period in which it was indicated
due to their being high risk on risk assessment.
HRs did not vary significantly across deprivation quintiles. While
they were very slightly higher in the other quintiles as compared
to the reference category, for example at 1.01 in quintile 2, the CIs
for these estimates all crossed one, suggesting that the differences
were not statistically significant. Further, the estimated HRs suggested
only a very modest difference between quintiles in their hazard for
receiving a statin (one or two percent). The ICC of 0.090 indicated
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Figure 8.4: History variables and rates of provision for clinical trigger ‘risk
assessed high’ and the clinical action ‘statin’
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patient history for 'risk assessed high' and 'statin'. Incident
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Figure 8.5: Kaplan-Meier plot showing the proportion of individuals who
had not received a statin prescription by time and by deprivation
quintile
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that approximately 9% of the observed variation was explicable on the
basis of practice-level variation.
In the next stage of the modelling, I added the variables age and sex
as covariates, retaining the deprivation quintile variable, and again
including practice as a random-effect term. The HRs and CIs for this
model are shown in figure 8.7. In presenting HRs for age-bands, I took
the ‘50 to 54’ age-band as the reference category, in order to avoid
using an extreme age-band for comparison. Importantly, no evidence
emerged from this model of significant differences across deprivation
quintiles in provision of statins to these patients. The HRs were close
to 1 for quintiles 2 through to 5, and even small differences (HR 1.01
in quintile 2 and 0.98 in quintile 4) were not significant.
Older age categories were less likely to receive a statin based purely
on risk. In the ‘75 to 79’ age-band the HR was 0.65 (95% CIs 0.60; 0.70);
for the ‘80 to 84’ age-band the hazard ratio was 0.44 (95% CIs 0.40;
0.48); in the ‘85+’ age-band it was 0.27 (95% CIs 0.31; 0.39). Other age
bands were significantly more likely to receive the treatment than the
reference category: ‘55 to 59’ age-band, with HR 1.13 (95% CIs 1.08;
1.19); ‘60 to 64’, with HR 1.13 (95% CIs 1.08; 1.19); and ‘65 to 69’, with
HR 1.10 (95% CIs 1.04; 1.16). The model suggested that women were
also significantly more likely to receive the treatment, with a HR of
1.35 (95% CIs 1.31; 1.39), having adjusted for deprivation quintile and
age. The proportion of the variation in outcome related to practice-
level variation increased slightly, as compared to the univariate model,
to 0.093.
Thus, on the basis of this further modelling, which allowed adjust-
ment of the comparison across deprivation quintiles for age and sex,
no evidence of a significant difference emerged in initiation of statin
prescription between deprivation quintiles.
The final model used to examine this clinical trigger action, whose
results are shown in figure 8.8, took the same approach as before,
but with some additional variables (smoking status, BMI, hyperten-
sion category, cholesterol:HDL, and other comorbidities). Again, no
significant differences existed in the quintile comparison. The HRs
rose slightly in quintiles 3, 4, and 5. The HR was highest in quintile
5, 1.01 (95% CI 0.96; 1.07); it was 1.00 (95% CI 0.95; 1.06) in quintiles
1,2,3 and 4. A similar age-related pattern emerged to that seen in the
age-sex-adjusted model. As a result of additional adjustments in this
model, the HR in the ‘45 to 49’ age-band was 0.89 (95% CI 0.83; 0.96);
there was also a significant difference in the ‘70 to 74’ age-band, with
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Figure 8.6: Univariate mixed-effect model for the clinical trigger ‘risk as-
sessed high’ and the clinical action ‘statin’ by deprivation quintiles
and null model
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Figure 8.7: Multivariate mixed-effect model for the clinical trigger ‘risk as-
sessed high’ and clinical action ‘statin’ for deprivation quintiles,
adjusted for age and sex
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clinical trigger
Number of clinical triggers 105301; Number of clinical actions 20661. ICC
for practice = 0.093
254 selected pathway results
a HR of 1.18 (95% CI 1.10; 1.27). Likewise, the pattern seen earlier,
whereby women were more likely to receive a statin in this group
persisted in this model, with a HR 1.29 (95% CI 1.24; 1.33).
Of the other variables included, it was notable that obese individuals
were less likely to receive a statin then those of low or normal weight,
HR 0.92 (95% CI 0.88; 0.96). Those with controlled hypertension –
HR 1.81 (95% CI 1.74; 1.88), uncontrolled hypertension – HR 1.80
(95% CI 1.72; 1.88), and undiagnosed hypertension – HR 1.43 (95% CI
1.37; 1.50) were all significantly more likely to receive a statin than
those with no hypertension, adjusting for the other variables shown.
Likewise, individuals with a cholesterol:HDL ratio greater than or
equal to 4 were over twice as likely to receive a statin, with HR 2.37
(95% CI 2.30; 2.44). Those with Charlson comorbidities (other than
high cardiovascular risk comorbidities) were significantly less likely
to receive treatment, with HR 0.90 (95% CI 0.86; 0.96).
I estimated a slope index of inequality across the hazard ratios of
deprivation for the ’fully adjusted model’. The estimated regression
coefficient for the log hazard ratio was 0.0019, with a p value of
0.561, suggesting no significant slope across quintiles in the hazard of
receiving a statin.
Summarising, the overall pattern that emerged from these findings
for this clinical trigger-action was as follows:
• A fairly small proportion of individuals received the intervention
• Women in this group were more likely to receive a statin
• Older age groups with less likely to receive a statin
• Individuals with hypertension or raised cholesterol:HDL ratio
were more likely to receive a statin in this group, though indi-
viduals who smoked were not
• Approximately 9% of the variation seen in times to receiving a
statin related to variation at practice level
• There was no difference between deprivation quintiles in times
to receiving a statin
• Their work to clear phases in the Kaplan-Meier plot, with an
initial fairly rapid achievement of the clinical action, followed
by subsequent slower population uptake. I discuss this pattern
further in chapter 10, where I also consider results from other
points in the pathway
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Figure 8.8: Multivariate mixed-effect model for the clinical trigger ‘risk as-
sessed high’ and clinical action ‘statin’ for deprivation quintiles,
adjusted for age, sex, and other variables
High risk
statin
management
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          Male
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       No hyp.
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   No oth. co.
     Other co.
HR
    1
 1.01
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 1.01
 1.01
 0.77
 0.94
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    1
 1.20
 1.30
 1.31
 1.19
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 0.56
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    1
 1.28
    1
 1.00
    1
 1.05
 0.92
    1
 1.80
 1.79
 1.43
    1
 2.35
    1
 0.90
95% CI
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  (0.96; 1.06)
  (0.94; 1.04)
  (0.96; 1.06)
  (0.95; 1.07)
  (0.58; 1.03)
  (0.84; 1.06)
  (0.84; 0.96)
   (Reference)
  (1.14; 1.26)
  (1.24; 1.37)
  (1.24; 1.39)
  (1.12; 1.27)
  (0.75; 0.88)
  (0.51; 0.62)
  (0.29; 0.40)
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  (1.24; 1.32)
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  (0.96; 1.03)
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  (1.01; 1.09)
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  (1.73; 1.88)
  (1.71; 1.87)
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   (Reference)
  (2.21; 2.51)
   (Reference)
  (0.85; 0.95)
Mixed−effects model for 'risk assessed high' and 'statin'. Incident
clinical trigger
Number of clinical triggers 105301; Number of clinical actions 20661. ICC
for practice = 0.089. Missing values imputed using MICE.
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8.2 pci in individuals with mi
In figure 8.9, I show descriptive summaries for the main categorical
variables for the clinical trigger-action ‘MI’ and ‘PCI’. I identified
20,467 MIs in our dataset for which I investigated times to provision
of PCI. In 5118 cases, the MI was followed by a PCI. The majority of
individuals having an MI in our dataset were men (12,371, repres-
enting 60.4%); a majority of individuals were non-smokers (14,677,
representing 71.7%), with 4722 (23.1%) smokers – 943 (5.2 %) had
missing smoking data. A majority had a cholesterol:HDL ratio less
than 4 (7029, representing 34.3%); there were 4867 (23.8%) individuals
with a cholesterol:HDL ratio greater than or equal to 4; this value was
missing for 8571 of the MIs, representing 41.9%. By definition, every
MI occurred in an individual who had CHD or an ACS. Of the MIs
examined, 9586 (46.8%) occurred in individuals with other Charlson
comorbidities at the time of the event. Of all the MIs, 3031 (14.8%)
were treated in a cardiac centre.
The majority of MIs occurred in older age groups, despite the
smaller overall populations there, reflecting the powerful effect of age
as a risk factor for CHD. Thus, 3778 (18.5%) of the events occurred in
those in the ‘85+’ age-band, 3120 (15.2%) in the ‘80 to 84’ age-band,
and 2927 (14.3%) in the ‘75 to 79’ age-band. Over half of the events
occurred in those aged 70 and over.
A smaller proportion of events occurred in the less deprived quin-
tiles than in the more deprived. There were 3528 (17.2%) events in
quintile 1, compared to 4788 (23.4%) in quintile 3 and 4294 (21.0%)
in quintile 5. Particularly with respect to quintile 3, this is partly
a reflection of the over-representation of this quintile in the study
population.
Of those MIs that occurred, 6567 (32.1%) occurred in overweight
individuals and 4638 (22.7%) in obese individuals; for 3213 (15.7%) of
the events that occurred the BMI value was missing. When looking at
events in relation to hypertension category, I found that the majority
occurred in individuals with controlled hypertension – 10,587 (51.7%),
perhaps reflecting the older age of these individuals. Uncontrolled
hypertension was present in individuals with an MI in 2835 cases
(13.9%), while 6302 (30.8%) did not have hypertension.
I also looked at the specialty and type of the admission (emergency
or elective) relating to the MI that was the clinical trigger. A large
majority of the admissions had either cardiology, 8207 (40.1%), or
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another medical specialty, 10676 (52.2%), as the clinical specialty; Most
of the admissions were emergency admissions, 16523 (80.7%).
In figure 8.10, I show the crude rates of provision of PCI after MI in
the same way as for the earlier clinical trigger-action (‘risk assessed
high’ and ‘statin’). The rate was higher in men, at 0.280 compared
to 0.152 in women; it was higher in smokers at 0.378, compared to
0.191 in non-smokers, and 0.138 in those whose smoking status was
unknown; it was higher in those with a raised cholesterol:HDL ratio,
at 0.340, compared to 0.181 in those where it was not raised, and
0.209 in those where it was unknown. The crude rate of provision
was lower in diabetics (0.174 compared to 0.243 for non–diabetics), in
those who have had a previous CVA/TIA (0.97, compared to 0.243 in
those who have not), and in those with other Charlson comorbidities
(0.157 compared to 0.277 in those without). Crude rates were also
higher in those treated in a cardiac centre (0.312 compared to 0.211 in
a non-cardiac centre).
Overall, crude rates of provision of PCI seem higher in those with
risk factors that are not also comorbidities (male sex, smoking, and
raised cholesterol:HDL ratio) and lower in those with comorbidities
(some of which are also risk factors) – diabetes, CVA/TIA, and other
Charlson comorbidities. Provision was more likely in those treated at
cardiac centres.
Younger age groups had higher crude rates of provision of PCI
following MI. The highest rate was in the ‘40 to 44’ age-band, 0.55,
falling consistently as age increased to 0.31 for the ‘65 to 69’ age-band
and at a minimum of 0.031 in the ‘85+’ age-band. In view of the known
pattern, whereby more deprived individuals tend to have ACSs at a
younger age, this decreasing rate with age highlighted the importance
of adjusting for this variable in further analyses.
Following MIs in an individual with normal or low BMI, the rate
of provision of PCI was 0.19. Where the individual was overweight
the rate was higher (0.253) and similarly it was higher if the person
was obese (0.276). Those with no hypertension had a rate of provision
of PCI of 0.281; in those with undiagnosed hypertension the rate was
0.289. Rates were lower in those with diagnosed hypertension, whether
it be controlled (0.188) or uncontrolled (0.227).
Where the admission relating to MI was under the cardiology spe-
cialty, rates were substantially higher, 0.495, as compared to 0.111 in
other medical specialties. The rate in other specialties were 0.021. For
admission type, the rate was highest in the ‘other’ category, at 0.366,
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Figure 8.9: Descriptive variables for the clinical trigger-action ‘MI’ and ‘PCI’
Revascularisation
of ACS
Frequencies of categorical variables for 'MI' and 'PCI'. Incident
clinical trigger (triggers = 20467; actions = 5118)
Variable
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Smoker
Chol:HDL >= 4
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CVA/TIA
CHD
Previous ACS
Other comorbidities
Cardiac centre
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 8096
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20467
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 3031
(%)
(39.6)
(23.1)
(23.8)
(23.8)
(16)
(100)
(100)
(46.8)
(14.8)
No
12371
14677
 7029
15596
17189
    0
    0
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(%)
(60.4)
(71.7)
(34.3)
(76.2)
(84)
(0)
(0)
(53.2)
(85.2)
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   0
1068
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   0
   0
   0
   0
   0
   0
(%)
(0)
(5.2)
(41.9)
(0)
(0)
(0)
(0)
(0)
(0)
Number of clinical triggers for binary variables
Age
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40 to 44
45 to 49
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55 to 59
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65 to 69
70 to 74
75 to 79
80 to 84
85+
n
 198
 408
 668
1136
1436
1954
2211
2631
2927
3120
3778
(%)
(1)
(2)
(3.3)
(5.6)
(7)
(9.5)
(10.8)
(12.9)
(14.3)
(15.2)
(18.5)
Number of clinical triggers
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Normal or low
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Obese
Missing
n
6049
6567
4638
3213
(%)
(29.6)
(32.1)
(22.7)
(15.7)
Number of clinical triggers
by BMI
Hypertension
None
Undiag.
Contr.
Uncontr.
n
 6302
  743
10587
 2835
(%)
(30.8)
(3.6)
(51.7)
(13.9)
Number of clinical triggers
by hypertension category
Quintile
1
2
3
4
5
n
3528
3584
4788
4273
4294
(%)
(17.2)
(17.5)
(23.4)
(20.9)
(21)
Number of clinical triggers
by quintile
Specialty
Cardiology
Med. spec.
Other spec.
Missing
n
 8207
10676
 1578
    6
(%)
(40.1)
(52.2)
(7.7)
(0)
Number of clinical triggers
by admission specialty
Admission type
Elective
Emergency
Other
Missing
n
  622
16523
 3294
   28
(%)
(3)
(80.7)
(16.1)
(0.1)
Number of clinical triggers
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8.2 pci in individuals with mi 259
followed by the emergency category at 0.208. Rates were lowest for
those with an elective admission as 0.072.
In figure 8.11, I present the distributions of the derived history
variables for this clinical trigger-action. In the first figure I show
the distribution of indication numbers. Where the MI was the first
indication that the individual had for PCI, the indication number was 1.
In some cases individuals had had previous periods in which they had
stable angina or an ACS, meaning that the MI in question was not their
first indication for PCI. In figure 8.12, I have illustrated the variable
shown in this distribution as a categorical variable, with numbers
and rates for each category – in the first figure ‘Number and rate
for different indication numbers’. The great majority of individuals
having an MI had an indication number of 1 (10,697 individuals), 2
(6165 individuals), or 3 (2225 individuals). There were 603 individuals
for whom the indication number was five or more (meaning that
prior to this MI the individual had had at least four other previous
indications for PCI). The provision rate was highest in those for whom
this was the first indication, at 0.248; where the second indication, the
rate was 0.231; the rate was lowest in those for whom this was the
fourth indication, at 0.152.
Similarly in figure 8.11, I show, in the second graphic, the num-
ber of indication days prior to the MI event under investigation. To
give an example, were it the case that one year prior to that event
the individual had had another MI (for which PCI would also have
been indicated), that individual would register 365 days prior to this
clinical trigger (assuming that no other indication events prior to that
complicated the picture). From the distribution, it was clear that there
was a peak at zero prior indication days, reflecting the individuals
for whom this was indication number 1 (who by definition have no
previous indication days). The distribution of prior indication days
is otherwise very heavily right skewed, shown more clearly in the
second graphic of figure 8.12. There were 14,302 individuals with
prior indication periods less than or equal to one year; also 3920 MIs
occurred in individuals who had already had prior indications for the
procedure for over five years. The crude rate of provision was highest
in those with prior indication times less than one year, at 0.258; longer
prior indication times had lower provision rates for example for those
with prior indication times more than three years and less than or
equal to four years, the rate was 0.170; in those with prior indication
times greater than five years the rate was 0.139.
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Figure 8.10: Relations between categorical variables and times to provision
of PCI in those with the clinical trigger ‘MI’
Revascularisation
of ACS
Categorical variables relationships with outcome for 'MI' and 'PCI'.
Incident clinical trigger (triggers = 20467; actions = 5118)
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The third graphic of figure 8.11, shows the distribution of clinical
actions prior to the date of this clinical trigger. In this context, this
meant how many PCIs the individual with the MI had previously
undergone. The majority had never had a previous PCI; from the third
graphic in figure 8.12, it can be seen that this was 19,458 of the MIs,
compared to 892 for which there had been one previous PCI, 96 for
whom there had been two, and small numbers for whom there had
been at least three. The provision rate was highest in those with two
previous PCIs, 0.594. This compares with a rate of 0.226 in those with
no previous PCI.
The final graphic in figure 8.11, shows how many days had elapsed
since the most recent previous clinical action (PCI in this case). Thus,
had an individual with an MI had a PCI most recently 100 days prior
to that MI, this variable would be 100. There is arguably some con-
centration in the distribution in the 0 to 10 days time period, perhaps
reflecting a tendency to instability of the coronary endothelium for
a period following PCI. In the final graphic in figure 8.12, it is seen
that the 19,458 individuals who had never had a previous PCI had a
rate of 0.226, higher than those individuals who had had a previous
PCI as recently as the last year (with a rate of 0.117), but had lower
rates than individuals who had had previous PCIs longer ago than
that (the numbers in these categories were quite small). For example,
the 58 individuals who had had a PCI between four and five years
previously had a rate of 1.224.
In figure 8.13, I show a Kaplan-Meier plot for this clinical trigger-
action. In this figure, all individuals (the proportion of one) started
out at time zero having not had a PCI; this proportion was adjusted
as individuals underwent the procedure over time, taking account of
the number of individuals censored. A clear feature of the graphic is
that there is a near vertical decline subsequent to time zero, indicating
that a percentage of individuals between 25 and 30% underwent a
PCI very soon after the MI in question – presumably relating to the
provision of primary PCI. It is important to emphasise that there
is an apparent contradiction here with the 80% ‘Emergency’ figures
presented in figure 8.9 in relation to admission type; in fact this
difference is explained by the fact that the 80% ‘Emergency’ figure
relates to the original MI (the clinical trigger), rather than to the PCI
(the clinical action). No difference was evident in this initial decline
between deprivation quintiles. Subsequently, a slower rate of receiving
PCIs occurred to the end of the observation period. During this period,
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Figure 8.11: History variables for clinical trigger ‘MI’ and the clinical action
‘PCI’
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Figure 8.12: History variables and rates of provision for clinical trigger ‘MI’
and the clinical action ‘PCI’
Revascularisation
of ACS
Variable relationships with outcome for derived variables relating to
patient history for 'MI' and 'PCI'. Incident clinical trigger
(triggers = 20467; actions = 5118)
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the line indicating uptake fell most slowly for quintile 2 (reflecting that
PCI was being received more slowly for that group); graphically the
lines indicating uptake in other quintiles were very similar. Overall,
there was not a substantial difference in uptake between quintiles.
In figure 8.14, I present results from a univariate frailty model
modelling times to provision of PCI by deprivation quintile, using the
patient practice and treatment hospital as random-effect terms in the
model. The multilevel model in this case was a cross-classified model
with individuals nested within practices nested within hospitals. I
examined 20,467 MIs, following which 5118 PCIs were provided. The
ICC for the individual’s practice in this case was 0.034. The ICC for
the admitting hospital was at 0.351.
An analogous model, this time with age and sex added as covariates,
but otherwise performed in the same way, has been presented in
figure 8.15. Adjusting for age and sex affected the HRs for the quintile
comparison. Quintile 2 now had a hazard ratio 0.90 (95% CI 0.81; 0.99),
significantly lower than the reference group quintile 1; quintile 5 had
hazard ratio 0.78 (95% CI 0.71; 0.86), suggesting significantly reduced
provision in this group as well. As was the case with crude rates, there
was evidence of a significant age effect, with decreasing provision
with increasing age. For example, the HR was 0.59 (95% CI 0.53; 0.66)
in the ‘65 to 69’ age-band; this fell to 0.26 (95% CI 0.23; 0.29) in the
‘75 to 79’ age-band; the HR was 0.04 (95% CI 0.03; 0.05) in the ‘85+’
age-band. There was also a significant effect of sex, where the HR for
utilisation in women was 0.83 (95% CI 0.78; 0.89) with men as the
reference group. Adjusting for age and sex in this model also reduced
the ICC for practice (to 0.012 from 0.034 in the univariate model), and
the ICC for hospital (to 0.188, from 0.351 in the univariate model).
In figure 8.16, I again show outputs from a frailty model on similar
lines, but this time with a number of additional covariates included.
The pattern across quintiles seen in the previous model persisted here.
This time the HR for quintile 3 was 0.90 (95% CI 0.82; 0.99), suggesting
a lower hazard of receiving PCI than in quintile 1 (the reference group).
Individuals in quintiles 2 to 5 were significantly less likely to undergo
the procedure, with a HR in quintile 5 of 0.83 (95% CI 0.75; 0.92). The
pattern across age groups persisted: HRs in older age groups were
significantly less than one (indicating lower hazard of undergoing PCI
than in the ‘50 to 54’ age-band that was the reference category). The
HR for women was 0.85 (95% CI 0.80; 0.91), indicating, again, that
women were receiving PCIs less than men at any given time.
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Figure 8.13: Kaplan-Meier plot showing the proportion of individuals who
had not received a PCI by time and by deprivation quintile
Revascularisation
of ACS
0.00
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7
Time (years)
Pr
op
or
ti
on
 w
it
ho
ut
 a
ct
io
n
Quintile
1
2
3
4
5
Kaplan−Meier plot for 'MI' and 'PCI'.
Incident clinical trigger (triggers =
20467; actions = 5118)
266 selected pathway results
Figure 8.14: Univariate mixed-effect model for the clinical trigger ‘MI’ and
the clinical action ‘PCI’ by deprivation quintiles and null model
Revascularisation
of ACS
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Figure 8.15: Multivariate mixed-effect model for the clinical trigger ‘MI’ and
clinical action ‘PCI’ for deprivation quintiles, adjusted for age
and sex
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268 selected pathway results
Smokers were significantly more likely to receive PCI, with a HR
of 1.14 (95% CI 1.07; 1.21). Overweight individuals were more likely
to receive a PCI compared to those of normal or low BMI: HR 1.11
(95% CI 1.04; 1.19). Individuals with undiagnosed hypertension were
more likely to receive the intervention, HR 1.15 (95% CI 1.01; 1.31),
compared to those with no hypertension. Provision of PCI was made
less likely by the presence of covariates – CVA, HR 0.67 (95% CI
0.59; 0.75); diabetes, HR 0.82 (95% CI 0.76; 0.88); and other Charlson
comorbidities, HR 0.70 (95% CI 0.65; 0.74). Again, a possible pattern
emerged in which factors conferring high cardiovascular risk made
interventions more likely while comorbidities made it less likely.
In this model, I also adjusted for admission type, hospital type and
specialty. Emergency admission made subsequent PCI more likely
(compared to elective admission), with HR 1.66 (95% CI 1.30; 2.13).
MIs treated at non-cardiac centres (designated ‘Other cen.’ in figure
8.16) were less likely lead to a PCI, with HR 0.56 (95% CI 0.33; 0.93).
MIs admitted under medical specialties other than cardiology – HR
0.43 (95% CI 0.40; 0.46), and other non-medical specialties – HR 0.07
(95% CI 0.05; 0.09) – were all less likely to go on to PCI than patients
admitted under cardiology.
I also adjusted for the derived history variables. Here I found that
MIs occurring in individuals for whom previous indications for PCI
had been present were significantly less likely to receive that interven-
tion, and that the more previous indications the less likely this was. In
those with one previous indication the HR (taking individuals with
no previous indications as the reference category) was 0.84 (95% CI
0.77; 0.90); for those with two previous indications (indication number
3), the HR was 0.68 (95% CI 0.60; 0.78); for those with three previous
indications, the HR was 0.66 (95% CI 0.54; 0.81). Indication years prior
to the current indication was handled as a continuous variable. I also
looked at the number of previous responses (PCIs prior to the trigger
MI). Where the MI occurred in individuals with one or more previ-
ous PCIs, subsequent PCI was less likely, with HR 0.93 (95% CI 0.81;
1.06), compared to those with no previous response as the reference
category.
In this model, the ICC for the variation by practice remained the
almost the same (0.013 compared with , from 0.012 in the previous
model), suggesting that approximately 1.3% of the variation in times
from MI to PCI might have been explained by practice-level variation.
The ICC for hospital also fell: to 0.128, from 0.188 in the previous
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model, suggesting that 12.8% variation related to hospital-level vari-
ation.
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Figure 8.16: Multivariate mixed-effect model for the clinical trigger ‘MI’ and
clinical action ‘PCI’ for deprivation quintiles, adjusted for age,
sex, and other variables
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Again, for this ’fully adjusted model’, I determined a slope index of
inequality across quintiles, with an estimated regression coefficient of
-0.0395, with a p value of 0.036, suggesting a statistically significant
gradient across quintiles of decreasing hazard of receiving PCI with
increasing deprivation, and nearly 4% fall in the chances of having
a PCI by quintile. I checked the plausibility of the assumption of
linearity by examining the log hazard ratios (quintile 2: -0.117; quintile
3: -0.105; quintile 4: -0.139; quintile 5: -0.186).
Below, I present a summary of the main findings relating to the
clinical trigger-action ‘MI’ and ‘PCI’:
• Of the 20467 MIs that I identified in our data, 5118 went on to
have a PCI following that event, representing 25.0%
• Women were significantly less likely to receive a PCI when
adjustments were made for other covariates
• Older age groups were significantly less likely to have a PCI,
again in the adjusted model
• There was evidence that adverse risk factors were more likely to
be present in those receiving PCI (smoking, BMI, hypertension,
and cholesterol:HDL), whereas comorbidities (diabetes, CVA,
and the composite variable relating to other Charlson comorbid-
ities) were less likely to be present, notwithstanding the fact that
some of these comorbidities also increased risk
• Emergency admission to cardiac centres under cardiologists
was associated with a subsequent increased chance of a PCI,
compared to admissions that did not have these characteristics
• If the trigger MI was the first indication that the individual and
had for PCI, subsequent intervention was more likely. Interven-
tion was more likely with increasing time from any previous
PCI that might have occurred. PCI was less likely in those who
had a previoius PCI prior to the trigger MI
• In the fully adjusted model, variation at practice level accounted
for 1.3% of the variation in times to PCI; variation in treating
hospital accounted for 12.8%
• In univariate comparison, there was no significant difference
between deprivation quintiles; when age and sex were adjusted
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for, significantly reduced HRs occurred in more deprived quin-
tiles compared to quintile 1; this pattern persisted in the fully
adjusted model
8.3 summary
In this chapter, I have reviewed detailed results from only two points
in the pathway of care for CHD. When looking at provision of stat-
ins to those in whom a cardiovascular risk assessment suggested the
individual was high risk, I found no significant difference between
deprivation quintiles. This was despite adjusting for available covari-
ates, and taking account of variation at practice level.
I have also reported in detail results relating to the provision of PCI
in patients following MI. Here, though univariate modelling suggested
no difference between deprivation quintiles, I found evidence, when
adjusting for other variables, that individuals in more deprived groups
were less likely to undergo subsequent PCI.
By presenting detailed results for two pathway points I aimed to
give the reader an insight into the nature of the analysis performed
at each point in the pathway of care. It would have been completely
impractical to present detailed results in the same way for all the
analyses performed. Important results relating to other points in the
pathway are included, without accompanying discussion, in appendix
D. For those interested, all of the main results equivalent to those
presented in this chapter can be accessed there.
Because of the focus on comprehensiveness, I needed to develop an
approach to presenting the results based on the pathway as a whole. I
present these results in the next chapter.
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This chapter is concerned with summarising the large number of
results produced from my analysis. While I have described specific
sections of the pathway of care for CHD in the preceding chapter, with
a view to elucidating the approaches used at each specific point on
the pathway, the overall aim in this thesis was to address healthcare
inequity in the pathway of care for CHD as a whole.
Using the approach to presentation described on page 183, I present
summaries of the pathway results using different modelling approaches,
and using different underlying assumptions. In overview, I present
summary results for the following:
1. The main analysis of clinical trigger-actions for the pathway,
components of which were presented in the previous chapter.
This looks at incident clinical triggers using the Framingham
non-laboratory risk assessment tool.
2. The main analysis of clinical trigger-actions for drug cessation for
the part of the pathway where drug treatments were indicated.
3. The main analysis repeated with important underlying assump-
tions changed
There are three main levels of modelling presented, as discussed in
detail in the previous chapter when considering specific components
of the pathway of care for CHD: univariate modelling (looking only
at deprivation quintile, with practice, and, where relevant, hospital, as
random effects); age-sex adjusted multivariate modelling, again with
random-effect terms; multivariate models which adjust for all available,
potentially-relevant covariates, as well as having the above random-
effect terms – referred to throughout as ‘fully-adjusted models’.
9.1 main analysis
The first set of models looked at, univariate models comparing HRs
across deprivation quintiles with adjustment for hospital and practice
as random effects, are summarised in the first of the pathway diagrams,
figure 9.1. To aid discussion, I have divided the pathway into eight
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different regions, corresponding to broad categories of clinical trigger-
action.
In the first of these, ‘Risk and risk factors attainment’, two of the
five clinical trigger-actions significantly favoured the most deprived
quintile (looking at smoking status and BMI). The HR was 1.20 for
smoking status, for example, suggesting that the most deprived group
was 20% more likely to have a smoking status recorded over time.
Measurement of cholesterol and of BP was not significantly different
between the most and least deprived quintiles; time to the availability
of information in GP records sufficient to perform a full cardiovascular
risk assessment was significantly less in the least deprived quintile,
with a HR of 0.97. Thus, when looking at ‘Risk and risk factors at-
tainment’, I found a slightly paradoxical picture in which the most
deprived quintile was more likely to have individual components
of the risk assessment tool measured, but was less likely to have a
complete set of these measurements available to allow calculation of a
risk.
In the second region of the pathway, ‘Smoking management’, it
was found that smokers identified in more deprived quintiles were
significantly more likely to receive smoking-cessation advice and to
be referred to smoking-cessation services.
For the region ‘BP management’, low-risk individuals with a raised
BP and high-risk individuals with a raised BP were both signific-
antly more likely to receive an antihypertensive in the most deprived
quintile compared to the least. In the next region, ‘High-risk statin
management’, there was no significant difference between quintiles.
Next, I looked at provision of drugs. In chronic CHD, defined as
stable angina and stable angina with diabetes, shown in region ‘Drug
management of chronic CHD’, individuals with stable angina in the
most deprived quintiles were significantly less likely to receive a statin
than those in the least deprived quintile, with a HR of 0.86. This was
not the case in the group who had stable angina and diabetes, nor were
there any significant differences in aspirin or ACE inhibitor treatment.
In acute disease, shown in the region ‘Drug management of ACS’, I
found no difference in statin, aspirin, or beta-blocker prescription. In
those with an old ACS, the most deprived quintile were less likely to
receive an ACE inhibitor, with a HR 0.80.
I looked at revascularisation, shown in the two regions ‘Revascular-
isation of chronic CHD’ and ‘Revascularisation of ACS’. Those in the
most deprived quintile with stable angina were less likely to receive
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PCI (HR 0.74) or CABG (HR 0.78), as well as to receive revascular-
isation overall – a composite outcome comprised of PCI and CABG
combined – with a HR of 0.76. For those with stable angina and dia-
betes there was no significant difference in provision of PCI but for
CABG the HR was 0.67 for the most deprived quintile.
Those in the most deprived quintile were significantly less likely
to undergo a PCI or CABG following an episode of unstable angina,
with HR of 0.79 and 0.81 respectively.
For the purpose of summarising these findings, I considered the
first four regions in the pathway (‘Risk and risk factors attainment’,
‘Smoking management’, ’BP management’, and ‘High-risk statin man-
agement’) as primary prevention of CHD. Here one could say that,
aside from being less likely to have all data available for a full cardi-
ovascular risk assessment, achievement of clinical actions in response
to clinical triggers broadly favoured the most deprived quintile. Six of
the points in the pathway here significantly favoured that group; two
other points leant towards it without achieving significance.
In contrast, for clinical triggers related to established CHD, in the
remaining four regions of the pathway considered, where significant
differences arose, they generally favoured the least deprived quintile.
I made 19 comparisons when looking at drug provision: two of these
significantly favoured the least deprived group and one (clopidogrel in
MI) favoured the most deprived. I made 15 comparisons when looking
at revascularisation, though these are not independent because the
revascularisation composite outcome is dependent on the outcomes
PCI and CABG. Here I found nine clinical trigger-actions that signific-
antly favoured the least deprived quintile, and one favouring the most
deprived.
Notwithstanding the issues of multiple comparison, discussed later,
a plausible pattern that emerges from this initial modelling suggests
absence overall of healthcare inequity in primary prevention, with,
in contrast, a suggestion that in established disease provision of care
might not be equitable, particularly with respect to revascularisation
procedures. In order to examine this further, I present below results
from multivariate modelling.
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Figure 9.1: Pathway overview of univariate frailty models
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In figure 9.2, I summarise results from frailty models which include
age and sex as covariates, in addition to deprivation quintile. When I
looked at the pathway region ‘Risk and risk factors attainment’, I found
that, as before, there was a significant difference in ascertainment
of smoking status, and measurement of BMI and BP, favouring the
most deprived quintile. Moreover, HRs had increased slightly, when
compared to the univariate models: 1.20 for smoking status; 1.13 for
measurement of BMI; 1.05 for measurement of BP. The significant
difference for ‘Full cardiovascular risk assessment’ in those ‘Aged 40
and over with no high risk diagnosis’ disappeared in this multivariate
model.
When I looked at ‘Smoking management’, I found a more or less
unchanged pattern: both provision of smoking-cessation advice and
referral for smoking advice were significantly more likely in the most
deprived quintile. ‘BP management’ favoured the most deprived quin-
tile in those who were low risk – HR slightly reduced to 1.23; there
was no longer a significant difference favouring the most deprived
quintile in those who were high risk.
For the region ‘High-risk statin management’, there was, again, no
significant difference between quintiles in provision, either to those
who were high risk based on risk assessment or those who were high
risk based on diagnoses.
When looking at ‘Drug management of chronic CHD’, I found
an unchanged pattern: individuals with stable angina in the most
deprived quintile were less likely to receive a statin, this time with a
slightly lower HR of 0.84 (compared to 0.86); difference in provision of
aspirin was not statistically significant for these individuals. For those
with stable angina and diabetes, there was no significant difference in
provision of statins, aspirin, or ACE inhibitors. For ‘Drug management
of ACS’, those in more deprived quintiles with an old ACS were again
less likely to receive a statin, aspirin or ACE inhibitor. Those with
unstable angina were more likely to receive aspirin.
With revascularisation, for ‘Revascularisation of chronic CHD’, those
in the most deprived quintile with stable angina was again less likely
to receive PCI (HR 0.68, down from 0.79) and revascularisation overall
(HR 0.75, down from 0.78). The HR for CABG was no longer signi-
ficant. For those with stable angina and diabetes, the most deprived
quintile was again less likely to receive revascularisation overall, with
a HR of 0.74, down from 0.76. When looking at the region of the path-
way ‘Revascularisation of ACS’, there was no significant difference,
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as previously, in the provision of revascularisation for those with an
old ACS. As before, those in the most deprived quintile with unstable
angina were less likely to receive PCI, with a HR of 0.72, down from
0.79; and to receive revascularisation overall, with a HR of 0.74, down
from 0.78. In addition, they were less likely to receive a CABG, where
the difference was unchanged with a HR of 0.81. In the univariate
model, there had been little difference in provision for those with
MI. This changed in the age-sex adjusted model; the most deprived
quintile were significantly less likely to receive a PCI, HR 0.78; and
significantly less likely to receive revascularisation overall, HR 0.77.
Summarising again, when employing multivariate models that took
account of the age and sex of the individual in the primary prevention
(the first four regions of the pathway), I found that the previously
observed difference in the chance of an individual having all necessary
variables recorded to allow performance of a full cardiovascular risk
assessment was no longer significant. Overall, for this part of the path-
way, six clinical trigger-actions favoured the most deprived group; in
five there was no significant difference (one tended towards favouring
the most deprived group, without achieving significance; four tended
towards favouring the least deprived group, again without achieving
significance). In this picture, there was no evidence of inequity of
provision for primary prevention.
The picture that emerged for the management of established disease
(the last four regions of the pathway) contrasted with this. Of the
34 comparisons made, 14 suggested that the most deprived quintile
was less likely to receive the clinical action in question. This was less
pronounced in the ‘Drug management of chronic CHD’ where one of
the five comparisons suggested inequity (statin provision in those with
stable angina), and in ‘Drug management of ACS’ where four out of
fourteen comparisons suggested inequity. Again, bearing in mind and
that the ‘Revascularisation’ outcome is not independent of the PCI and
CABG outcomes, I found that nine out of fifteen clinical trigger-actions
relating to revascularisation suggested reduced provision in the most
deprived quintile. Moreover, adjusting for age and sex in these models
tended to reduce the HRs, as well as making more of these results
significantly different.
When considering the age and sex adjusted models in overview,
I found a similar pattern to that observed in the univariate models,
but this time more pronounced: there was no evidence of inequity
in the primary prevention part of the pathway of care; there was a
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suggestion of inequity in drug management of established disease;
there was a much more pronounced suggestion of inequity in provi-
sion of revascularisation. To further investigate this relationship, I now
consider an overview of the models that I refer to as ‘fully-adjusted’.
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Figure 9.2: Pathway overview of age and sex adjusted multivariate frailty models
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In figure 9.3, I show the results from models which used all appro-
priate and available covariates. For the region ‘Risk and risk factors
attainment’, the picture remains largely unchanged from the previous
set of models. ‘Ascertainment of smoking status’, ‘Measurement of
BMI’, and ‘Measurement of BP’ clinical actions were all significantly
more likely in the most deprived quintile (the HR for ‘Measurement of
BP’ fell slightly, from 1.05 to 1.03). As before, there was no significant
difference for ‘Measurement of cholesterol’ and for ‘Full cardiovascular
risk assessment’ the HR was 0.97.
The picture for the region ‘Smoking management’, was also little
changed: in smokers, ‘Provision of smoking-cessation advice’ was
again more likely in the most deprived quintile, HR 1.10. ‘Referral to
smoking-cessation services’ showed no significant difference between
the most deprived and least deprived quintiles.
For the region ‘BP management’, a significant difference, favouring
the most deprived quintile, remained for the provision of antihyper-
tensive medication to those with raised BP who were otherwise at
low risk for CVD; HR 1.22, down slightly from 1.23. There was no
significant difference for individuals who were high risk and had a
raised BP.
There was no significant difference in the provision of statins to in-
dividuals who were at high risk of CVD, whether this high-risk status
arose as a result of risk assessment or whether from the presence of a
high-risk diagnosis. This finding was unchanged from that observed
using the earlier modelling approaches.
When I looked at the region ‘Drug management of chronic CHD’, I
found no substantial difference from the previous pattern of findings:
individuals with stable angina in the most deprived quintile were less
likely to be treated with a statin with HR 0.87, up from 0.84. Otherwise
there was no evidence of significant differences between the most and
least deprived quintiles in this region of the pathway.
When looking at ‘Drug management of ACS’ I found that the pre-
viously identified reduced provision of beta-blockers to those with
MI in the most deprived quintiles was no longer significant. The only
remaining significant difference between the most and least deprived
quintiles was for ACE inhibitors in those with an old ACS, with HR
0.80, up from 0.77.
For ‘Revascularisation of chronic CHD’, I found that the difference
in provision of PCI for those with the clinical trigger ‘Stable angina
and diabetes’ was no longer significant (nor in turn for CABG and
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for revascularisation overall). Differences remained for the ‘Stable
angina’ clinical trigger, both for PCI and for revascularisation overall.
Here, each of the HRs was higher than in the previous model (age-sex
adjusted models): it rose to 0.72 for PCI from 0.68; and to 0.79 from
0.75 for revascularisation overall.
When I looked at ‘Revascularisation of ACS’, I found, as before,
no significant differences for the ‘Old ACS’ clinical trigger. There
was no longer a significant difference for the provision of CABG
between quintiles in those with unstable angina. The difference for
PCI remained significant, with the HR rising to 0.76, having been 0.72
previously. The difference for revascularisation overall in those with
unstable angina was also significant as before, with HR of 0.83, up
from 0.74. The difference between quintiles for individuals with an MI
remained significant for PCI and for revascularisation overall. Here
the HR for PCI rose to 0.83, from 0.78; for revascularisation overall it
rose to 0.83, from 0.77.
When I examined the fully-adjusted models, which were summar-
ised in figure 9.3, I found a broadly unchanged overall picture. In the
first four regions of the pathway, which deal with primary prevention,
there was no evidence that provision of treatment was inequitable,
five significant differences that were uncovered favouring the most
deprived quintile, and one favouring the least deprived. When looking
at drug management, I found a significant difference that favoured the
least deprived quintile for two of the clinical trigger-actions: ‘Stable
angina’ to ‘Statin’ and ‘Old ACS’ to ‘ACE inhibitor’. Thus, of the 19
comparisons made here, two show some evidence of inequity. One
(‘Aspirin’ in ‘Unstable angina’) favoured the most deprived quintile.
Evidence of inequity in provision of revascularisation, particularly
PCI, persisted in the fully-adjusted models. This was the case for the
provision of both PCI and revascularisation overall in those with stable
angina, unstable angina or MI.
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Figure 9.3: Pathway overview of fully-adjusted multivariate frailty models
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9.2 drug cessation analysis
In this section of my analysis, I looked at the times from an individual
initiating treatment with the drug for a particular indication to the time
they stopped taking the drug. Clearly, this was only relevant at stages
in the pathway of care where a drug was being prescribed. I did not
look at drug cessation for the region ‘BP management’, because there
I had looked at prescription of any major antihypertensive medication
– having not specified the medication, examining cessation became
much more difficult. Thus, I addressed three regions of the pathway
when looking at drug cessation: ‘High-risk statin management’, ‘Drug
management of chronic CHD’, and ‘Drug management of ACS’. In this
section, I have considered the findings from these models in overview.
When looking at the findings from these models it was important
to be clear that a situation representing inequity in provision would
be one in which more deprived individuals were stopping taking
their drugs more quickly; in other words were inequity occurring, the
times to the outcome (cessation of the drug) would be shorter; thus,
evidence of inequity would arise where the HR for the comparison of
quintile 5 (most deprived) to quintile 1 (least deprived) was greater
than one, and statistically significant. Clearly, this is the opposite way
around from the situation when I considered the main analysis. In this
section, I have coloured the graphics to take account of this difference:
for example, dark green still indicates a situation in which the most
deprived quintile appears to be receiving healthcare in a favourable
way compared to the least deprived (though the HRs in this instance
would now be less than one, rather than, as before, greater than one).
In figure 9.4, I have summarised the univariate models (taking
account only of deprivation quintile, with practice, and where relevant
hospital, as random effect terms). In the region of the pathway ‘High-
risk statin management’, I considered the persistence of prescription
of statins in individuals who had started taking them either because
they were risk assessed as being at high risk of CVD, or because they
had a high-risk diagnosis. Individuals with a high-risk diagnosis in
the most deprived quintile were significantly less likely to stop taking
a statin ( HR 0.77).
In the region of the pathway ‘Drug management of chronic CHD’,
no significant differences emerged.
9.2 drug cessation analysis 285
For ‘Drug management of ACS’, I made 14 comparisons, only one
showing a significant difference: those with MI in the most deprived
quintile were less likely to stop taking clopidogrel (HR 0.84).
In overview, when I performed univariate modelling to look at
the overall pattern of drug cessation I found only two significant
differences in the 21 comparisons, both favouring the most deprived
quintile.
286
r
esu
lts
o
v
er
v
iew
Figure 9.4: Pathway overview of univariate frailty model of drug cessation
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In the next set of models, I looked again at drug cessation, this time
adding age and sex as covariates in the models. I summarise these
findings in figure 9.5. For the region of the pathway ‘High-risk statin
management’, individuals in the most deprived quintile who were
high risk on the basis of a high-risk diagnosis, were again less likely
to stop taking a statin, the HR rising slightly to 0.80, from 0.77.
In the ‘Drug management of chronic CHD’ region of the pathway
there were again no significant differences.
For the ‘Drug management of ACS’ region, I found that those in the
least deprived quintile with unstable angina or MI, were less likely to
stop taking an ACE inhibitor (HR 1.26 and 1.22 respectively) and those
with MI were less likely to stop taking aspirin (HR 1.21).Individuals in
the most deprived quintile with MI remained less likely to stop taking
clopidogrel, HR 0.84 (unchanged).
When considering drug cessation, adjustment for age and sex re-
vealed the three significant differences described above relating to
those with unstable angina or MI, but overall the picture remained
one in which there was little evidence of inequity.
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Figure 9.5: Pathway overview of multivariate frailty model of drug cessation adjusting for age and sex
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In figure 9.6, I show an overview of the findings from the fully-
adjusted frailty models with which I examined cessation of drug
prescription. These models are therefore analogous to those presented
in the previous figure (figure 9.5), but include additional covariates.
Again, I found, when looking at the region ‘High-risk statin man-
agement’, a pattern suggesting that individuals who were high-risk
through high-risk diagnoses in the most deprived quintile were signi-
ficantly less likely to stop taking statins: the HR was 0.79, down from
0.80.
When looking at ‘Drug management of chronic CHD’ I found no
significant differences.
For the region ‘Drug management of ACS’, three significant findings
favouring the least deprived no longer appeared in the fully-adjusted
model : these related to cessation of aspirin and ACE inhibitors in
ACS. However the finding favouring the most deprived (clopidogrel
cessation in those with MI) persisted.
When looking in overview at drug cessation as a model using fully-
adjusted frailty models, I found no suggestion that individuals from
the most deprived quintile were more likely to stop taking any of the
indicated drugs than those in the least deprived quintile. Of the 21
comparisons made, three showed showed that individuals in the most
deprived quintile were significantly less likely to stop taking the drugs
in question, and none showed that they were more likely to do so. In
summary, there was no suggestion of inequity in the persistence of
prescription of drugs at those points in the pathway of care where
drugs were indicated.
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Figure 9.6: Pathway overview of fully-adjusted multivariate frailty models of drug cessation
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9.3 sensitivity analysis
As alluded to in chapter 6, I was aware that my work was founded
on a number of assumptions, that these assumptions might substan-
tially affect the findings, and that a thorough analysis would check
whether such assumptions might undermine the conclusions. I present
the results of such checks in this section. I examined the following
assumptions, each time looking only at the summary of results from
fully-adjusted models.
1. Using the Framingham 1991 risk assessment tool, as opposed to
the non-laboratory risk assessment tool
2. Making comparisons across 2001 Townsend deprivation quin-
tiles, as opposed to using WIMD 2005
3. Using 20 as opposed to 5 imputations when using multiple
imputation using chained equations (MICE)
4. Prevalent as opposed to incident clinical triggers for the main
analysis
9.3.1 1991 Framingham risk-assessment tool
Findings when using the Framingham 1991 risk-assessment tool (res-
ults summarised in figure 9.7, compared to 9.3) are similar to my main
analysis. The HR for ‘Full cardiovascular risk assessment’ is no longer
significant. The HR for ‘BP raised and low-risk’ and ‘Treatment with
antihypertensive medication’ decreases slightly to 1.16 (from 1.22);
that for ‘BP raised and high-risk’ is now significant, with HR 1.07
(favouring the most deprived quintile). Likewise, ‘Risk assessed high’
and ‘Statin’ is now significant, with HR 1.05.
In the area of the pathway looking at drug management of estab-
lished CHD, results are broadly unchanged, though the result for
‘Statin’ in ‘Old ACS’ and ‘ACE inhibitor’ in ‘Old ACS’ are no longer
significant.
The pattern of results for revascularisation is essentially unchanged
other than some small adjustments to some HRs. Overall, changing
the underlying risk-assessment tool used in the analysis has no pro-
nounced effect on the broad pattern seen.
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Figure 9.7: Pathway overview of fully-adjusted frailty models using the 1991 Framingham risk assessment tool
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9.3.2 Townsend deprivation quintiles
Analysis using the Townsend 2001 deprivation quintiles, rather than
those for WIMD 2005, are shown in figure 9.8 (compared to 9.3). Find-
ings for the ‘Aged 40 and over and no high risk diagnosis’ trigger are
no longer significant for ‘Measurement of BP’, and HRs are slightly re-
duced for ‘Ascertainment of smoking status’ (1.18 from 1.2), ‘Measure-
ment of BMI’ (1.1 from 1.12), and ‘Full cardiovascular risk assessment’
(0.94 from 0.97).
Other findings for clinical triggers in those without established
CHD are essentially unchanged; there is a small increase in HR for
‘Provision of smoking-cessation advice’ in ‘First identified as smoker’
to 1.11 from 1.1.
The part of the pathway dealing with drug management of estab-
lished disease is also largely unchanged. There are small changes in
HRs and the results for ‘Statin’ in ‘Old ACS’ and ‘Aspirin’ in ‘Unstable
angina’ are no longer significant.
Similarly, in the revascularisation part of the pathway, there are
some small changes in HR (for example, ‘PCI’ in ‘Unstable angina’ up
to 0.8 from 0.77; ‘PCI’ in ‘MI’ down to 0.83, from 0.89). The HR for
‘CABG’ in ‘Stable angina and diabetes’ is now significant, at 0.64, as is
that for ‘Revascularisation’ at 0.66.
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Figure 9.8: Pathway overview of fully-adjusted frailty models using Townsend deprivation quintiles
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9.3.3 Imputation number
My original analysis, summarised in figure 9.3 employed five imputed
datasets to manage missing data. I also checked the impact on the
broad conclusions of using a larger number of invitations. The results
of this additional analysis are summarised in figure 9.9.
Firstly, it is clear that in this revised analysis a number of HRs are
slightly different: for ‘Ascertainment of smoking status’ the HR falls
to 1.18 from 1.2; that for ‘Full cardiovascular risk assessment’ drops to
0.94; ‘Statin’ for ‘Stable angina’ rises from the 0.87 to 0.89; beta-blocker
for ‘Old ACS’ falls to 0.72. For ‘Unstable angina’ and ‘PCI’ the HR
rises to 0.83 (from 0.77); for ‘Unstable angina’ and ‘Revascularisation’
to 0.86 (from 0.83). ‘MI’ and ‘PCI’ has an increase in HR from 0.83 to
0.89; ‘MI’ and ‘Revascularisation’ again rises to 0.88 (from 0.83).
Secondly, the statistical significance of some of the results changes.
‘Measurement of BP’, ‘Statin’ and ‘Old ACS’, and ‘Aspirin’ for ‘Un-
stable angina’ are no longer significant. ‘CABG’ for ‘Stable angina and
diabetes’ becomes significant, with HR 0.64, as does ‘Revascularisation’
in ‘Stable angina and diabetes’ with HR 0.66.
Thirdly, these changes do not substantially alter the overall interpret-
ation of these findings. It remains the case that the primary prevention
component of the pathway showed no evidence of healthcare inequity
(with the exception of ‘Full cardiovascular risk assessment’), that there
is some evidence of inequity in the management of established CHD
with drugs, but that, particularly in view of the number of comparis-
ons made, this is far from systematic. For revascularisation, the results
suggest evidence of inequity of utilisation, most obviously with PCI,
but also with revascularisation overall.
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Figure 9.9: Pathway overview of fully-adjusted frailty models using 20 imputations instead of 5
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9.3.4 Prevalent clinical triggers
Making an assumption of the importance of clinical triggers that were
already in place at the start of the observation period has a very
noticeable impact on results (compare figure 9.10 to figure 9.3).
The first important point to bear in mind is that the ‘Aged 40 and
over with low high risk diagnosis’ clinical trigger now includes all
individuals aged 40 and over at the time that they entered the dataset
(that is to say at the start of the cohort period for each individual).
Here, the situation contrasts with incident clinical triggers in that
for ‘Measurement of BP’, ‘Measurement of cholesterol’, and for ‘Full
cardiovascular risk assessment’, there is evidence of some inequity.
HRs for ‘Measurement of BP’ and for ‘Measurement of cholesterol’
are 0.98, suggesting a small effect; the significance here needs to be
seen in the light of the larger number of triggers analysed (491,886)
for these clinical actions.
Another impact on the broad picture from the use of prevalent
triggers arises when considering statin use in individuals at high risk
of CHD, but without established disease. Here significant HRs for
the ‘Risk assessed high’ and ‘High-risk diagnosis’ triggers suggest
inequity in provision of statins in those who were already at high risk
of CHD at the time they entered the study (HRs both 0.94).
Broadly speaking, the results for drug management of individuals
with established CHD are unchanged in the sense that this area of
the pathway does not favour any deprivation group in a systematic
way. The specifics do change: clinical-trigger actions in this part of the
pathway that did show statistically significant evidence of a difference
no longer do so. Two points now suggest a significant difference, with
‘Aspirin’ in ‘Stable angina’ favouring the more deprived quintile (HR
1.14) and ‘Aspirin’ in ‘Old ACS’ favouring the least, with HR 0.78.
With prevalent triggers, the situation in the revascularisation area
of the pathway changes. Previously significant results are no longer
so; there is now evidence of inequity for ‘CABG’ and ‘Stable angina’
with HR of 0.76.
In the region ’revascularisation of chronic CHD’, no differences were
significant other than that CABG in stable angina now favoured the
least deprived (HR 0.76).
In overview, the use of prevalent triggers, which essentially entails
looking at individuals who already had these triggers at the start of
the study, shows no systematic picture of inequity, particularly when
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one considers that the ‘Aged 40 and over with no high risk diagnosis’
trigger, probably due to large numbers, generates HRs which are
significant, but not generally far from 1.
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Figure 9.10: Pathway overview of fully-adjusted frailty models using prevalent clinical triggers
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9.3.5 Comparison of gradients rather than quintile 5:1
In this thesis, I employed the simplified method of examining the HRs
for quintile 5 and quintile 1 as a means of identifying inequity. While
there were clearly several advantages to this simplification, I wanted
to check that the conclusions of the study would not be substantially
altered by the use of an alternative: the slope index of inequality
approach, as outlined in chapter 6.
Table 9.1 shows each of the clinical trigger-actions for which the
fully-adjusted model suggested that a social gradient existed (on the
basis of inspection). For each of these, I show the results: firstly, using
the 5:1 HR approach (showing an estimate of the HR, whether the
result is statistically significant, and noting which social group was
favoured on the basis of the result), secondly using the slope index of
inequality (for which I show comparable information in the table).
As might be expected, the direction of effect does not change for
any of the clinical trigger-actions with use of the different method.
In six of the 20 cases, the statistical significance of the results does
change.
Most commonly, results which significantly favoured the least de-
prived quintile in the 5:1 comparison lost significance when the slope
index of inequality was used. This applied to three of the six results
which changed: old ACS and ACE inhibitor; unstable angina and PCI;
unstable angina and revascularisation. One result which previously
faavoured the most deprived quintile in the 5:1 analysis also lost
significance: unstable angina and aspirin.
There were two results which had previously not been significant
in the 5:1 comparison that became significant when using the slope
index of inequality: MI and CABG (favouring the least deprived);
first identified as a smoker and referral to smoking cessation services
(favouring the most deprived).
In summary, use of the slope index of inequality approach does
lead to a small number of changes in significance of some results.
Broadly, using this approach produce a picture slightly less suggestive
of inequity in health care across the whole pathway of care for CHD.
The overall pattern seen is not markedly affected, and the influence
of these changes on the conclusions that can be drawn about inequity
across the pathway of care is minimal.
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Table 9.1: Comparison of findings for clinical trigger-actions with an apparent social gradient using 5:1 hazard ratio compared to slope index of
inequality
5:1 Hazard Ratio Slope index of inequality
Trigger Action HR Significant Favours Estimate Significant Favours
aged 40+ with no
high-risk diagnosis
ascertainment of
smoking status
1.2 Yes Most
deprived
0.047 Yes Most
deprived
aged 40+ with no
high-risk diagnosis
measurement BMI 1.12 Yes Most
deprived
0.026 Yes Most
deprived
first identified as
smoker
smoking–cessation
advice
1.1 Yes Most
deprived
0.025 Yes Most
deprived
first identified as
smoker
referral to
smoking-cessation
services
1.17 No Most
deprived
0.039 Yes Most
deprived
BP raised and low-risk treatment with
antihypertensive
medication
1.22 Yes Most
deprived
0.043 Yes Most
deprived
unstable angina aspirin 1.24 Yes Most
deprived
0.049 No Most
deprived
old ACS ACE inhibitor 0.8 Yes Least
deprived
-0.047 No Least
deprived
stable angina PCI 0.72 Yes Least
deprived
-0.088 Yes Least
deprived
stable angina CABG 0.87 No Least
deprived
-0.045 No Least
deprived
Continued on next page
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Table 9.1 – Continued from previous page
5:1 Hazard Ratio Slope index of inequality
Trigger Action HR Significant Favours Estimate Significant Favours
stable angina and
diabetes
CABG 0.77 No Least
deprived
-0.043 No Least
deprived
stable angina revascularisation 0.79 Yes Least
deprived
-0.068 Yes Least
deprived
stable angina and
diabetes
revascularisation 0.79 No Least
deprived
-0.039 No Least
deprived
unstable angina PCI 0.76 Yes Least
deprived
-0.05 No Least
deprived
MI PCI 0.83 Yes Least
deprived
-0.04 Yes Least
deprived
old ACS CABG 0.78 No Least
deprived
-0.091 No Least
deprived
MI CABG 0.89 No Least
deprived
-0.026 Yes Least
deprived
unstable angina revascularisation 0.83 Yes Least
deprived
-0.035 No Least
deprived
MI revascularisation 0.83 Yes Least
deprived
-0.04 Yes Least
deprived
high-risk diagnosis statin cessation 0.78 Yes Most
deprived
-0.054 Yes Most
deprived
Continued on next page
9.3
sen
sitiv
ity
a
n
a
lysis
303
Table 9.1 – Continued from previous page
5:1 Hazard Ratio Slope index of inequality
Trigger Action HR Significant Favours Estimate Significant Favours
old ACS statin cessation 0.7 Yes Most
deprived
-0.083 Yes Most
deprived
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9.4 chapter discussion
Particularly with the next chapter in mind, in which I discuss my
findings, I now summarise the results from this chapter.
9.4.1 Quintile comparisons
I characterise the findings according to four broad areas of the path-
way:
1. Risk and risk factors attainment
2. Other primary care management of individuals without estab-
lished CHD
3. Drug management of patients with established CHD
4. Revascularisation
Risk and risk factors attainment The main findings from the
principal investigation are shown in figure 9.3, on page
283. Here, with respect to risk factors and assessment of
full cardiovascular risk, a paradoxical picture emerges. In-
dividuals from the most deprived quintile are more likely
to have their smoking status ascertained, their BMI meas-
ured, and their BP taken; at the same time, they are not
significantly less likely to have their cholesterol:HDL ra-
tio measured. The paradox arises from the fact that they
are significantly less likely to have full information avail-
able to ascertain cardiovascular risk using the Framingham
non-laboratory risk-assessment tool, despite the fact that
smoking status, BMI, and systolic BP are all components
of that score.
Clearly, the paradoxical appearance of this result reflects an
underlying situation in which more deprived individuals
are more likely to have any one of these three risk factors
recorded, but less likely to have recordings for all three:
in other words, ascertainment of one risk factor in the
least deprived quintile is more likely to be accompanied by
corresponding progression to ascertainment of the other
two risk factors.
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This difference is not large, as reflected in the HR of 0.97 for
progression to a full cardiovascular risk assessment. The
pattern is broadly resistant to changes in the underlying
assumptions: when the 1991 Framingham risk assessment
tool is used instead (see figure 9.7 on page 292), the HR
for full cardiovascular risk assessment is no longer signi-
ficant; when Townsend quintiles are used (see figure 9.8
on page 294), the difference in measurement of BP is no
longer significant, while the HR for full cardiovascular risk
assessment is significant, with a HR that has fallen to 0.94.
In part, the significance of these findings relates to the
large sample size: the effect sizes here are small in many
cases.
Particularly in this area, it was important to look also at
prevalent clinical triggers, which also will include indi-
viduals who had already turned 40 at the time of their
entry into the study (see figure 9.10 on page 299) – that is
to say to look also at older individuals. Doing so changes
the picture only slightly, with measurement of BP and
cholesterol:HDL now slightly less likely in the most de-
prived quintile; full cardiovascular risk assessment remains
less likely in the most deprived quintile, with HR of 0.98.
Thus, at this stage of the pathway, the situation in which
risk factor ascertainment broadly favours the most de-
prived quintile, with a picture slightly depending on un-
derlying assumptions, but where ascertainment of full
cardiovascular risk appears less likely in the most deprived
quintiles; the effect does not appear to be large.
Other primary care management of individuals without coron-
ary heart disease There is no evidence here that more de-
prived individuals utilise less care in this part of the path-
way. The only slight proviso is that when prevalent triggers
are examined (that is to say examination of retrospect-
ive clinical triggers that occurred prior to the start of the
study is taken account of), individuals in the most de-
prived group who could in theory have been assessed as
being high risk and individuals with a high-risk diagnosis
were both significantly less likely to receive statins. Not-
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withstanding this finding, the overall picture, even when
changes in the underlying assumptions are considered,
suggests that more deprived individuals do not receive
less care in these clinical situations, and appears to point
to a higher utilisation of care by the most deprived group
in this part of the pathway.
Drug management of patients with established CHD The evid-
ence from the two areas of the pathway concerned with
drug management of CHD is equivocal (see figure 9.3 on
page 283). Most results suggest no significant difference
between the groups; two in the problematic ‘Old ACS’ cat-
egory suggest a reduced likelihood of utilisation in the
most deprived quintile. Use of this clinical trigger may
be best thought of as a means of excluding individuals
who might be classified inappropriately with other clinical
triggers. In view of the number of comparisons made in
these two areas, one would expect one or two significant
results on the basis of random variation alone. Thus, I
have been cautious about not lending undue weight to the
implications of the significant results for ‘Statin’ for the
clinical trigger ‘Stable angina’, and for ‘Aspirin’ for the
clinical trigger ‘Unstable angina’. Overall, I suggest that it
would be over-interpreting the findings to conclude that
there is a substantial difference either way in the utilisa-
tion of drug management for established CHD, in view of
the difficulty in interpreting the ‘Old ACS’ category and
while remaining cognisant of the implications of multiple
comparison.
Revascularisation I found a consistent picture with revascu-
larisation. Firstly, PCIs were significantly less likely in quin-
tile 5 in those with the ‘Stable angina’, ‘Unstable angina’,
and ‘MI’ clinical triggers. This relationship drove a corres-
ponding effect for revascularisation as a whole. Further,
there was a tendency towards inequitable provision of
CABG at each stage, though this did not achieve statistical
significance. This plausibly might reflect a lack of power
to identify a genuine relationship, particularly in view of
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the relatively small numbers of CABGs performed: 1645,
compared to 5118 PCIs in the 20,467 individuals with an
incident-MI trigger. At the very least, one can be sure that
the apparent inequity in PCI is not compensated for by
increased utilisation of CABG.
Overall, I consider that the evidence around revascularisa-
tion suggests that there is inequity in utilisation, partic-
ularly with PCI, but potentially also with CABG as well.
Further, the HRs suggest that this effect is not negligible,
with for example HRs 0.72 for ‘Stable angina’ and ‘PCI’;
0.77 for ‘Unstable angina’ and ‘PCI’; and 0.83 for ‘MI’ and
‘PCI’. While such effects are not present in a systematic
way when looking at provision of revascularisation retro-
spectively (prevalent triggers), the findings are, in broad
terms, unchanged by the adjustment of my other main
assumptions.
I also looked at comparison of drug cessation (see figure 9.6 on page
290),
Drug cessation I found no evidence that deprived groups
stopped receiving prescriptions for indicated medications
more quickly; indeed, there was some suggestion of the
opposite, though given the issue of multiple comparison,
it would be hard to assert this with great certainty (I made
25 comparisons looking at drug cessation in all). This pic-
ture remains essentially unmodified when the results are
repeated with the 1991 Framinghham risk-assessment tool
and when using the Townsend deprivation quintiles. In
short, there is no evidence that differential outcomes relate
to differences in the time for which prescriptions are issued
to individuals from different quintiles – though clearly this
is not the same as actual adherence to treatment protocols.
I have, for practical reasons, deliberately kept presentation of results
here to discussion of those directly relevant to my research questions.
In fact, many other results were produced by my analysis, which it is
beyond the scope of this thesis to consider in detail. I discuss some of
these in section 10.4.
In this chapter, I have presented the results of my overview approach
to examining healthcare inequity across the pathway of care for CHD.
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A number of broad findings emerged, which I have summarised as
follows:
• There is no evidence of inequity of care in the regions of the
pathway relating to primary prevention of CHD
• There is some evidence, which must be regarded as equivocal in
the light of the number of comparisons made, of inequity in the
provision of drug treatments for those with established CHD
• There is persistent evidence of inequity in provision of revascu-
larisation, particularly related to PCI
In the next chapter, I discuss the implications of these findings further,
and set them in the context of previous work.
Part IV
D I S C U S S I O N

10D I S C U S S I O N
In this chapter I will discuss:
• my key findings, offering explanations for them and placing
them in the context of existing literature
• strengths and limitations of the study
• challenges and lessons
• implications for further work
• conclusions and the policy recommendations that can be based
on them
10.1 key findings
As indicated in the previous chapter, the overall pattern of my findings
suggests that in the early part of the pathway (primary prevention)
results tend slightly to favour the more deprived, and in the later part
of the pathway (management of established CHD and revascularisa-
tion) results tend to favour the less deprived. However, it is notable
that of all the comparisons made a majority indicate no significant
difference between quintile 1 and quintile 5. A broad picture of my
results can be seen clearly in figures 9.1, 9.2 and 9.3.
10.1.1 Revascularisation
The clearest difference found in this study was that PCI, and revascu-
larisation overall, were consistently less utilised in quintile 5 than in
quintile 1. Figure 9.3 summarizes the data of the fully adjusted model.
Significant differences (quintile 1 versus quintile 5) were seen in the
following trigger-action combinations:
• stable angina and PCI
• stable angina and revascularisation (composite)
• unstable angina and PCI
• unstable angina and revascularisation (composite)
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• MI and PCI
• MI and revascularisation (composite)
Revascularisation did not appear inequitable in a category of limited
usefulness (‘Old MI’), or in relation to CABG in the fully adjusted
model but it is possible that my analysis of CABG data was under-
powered. Indeed, analysis using a slope index of inequality approach
suggested that the gradient across quintiles for this clinical trigger-
action was significant. Thus, it appears that inequity in revascularisa-
tion in my population during the study period is a valid observation.
This is therefore consistent with evidence in published literature150–156,
although a number of the studies reviewed in chapter 3 showed no
evidence of inequity in revascularisation.141,158–160 It is of concern that
in addition to the deprivation-related differences found there were
also gender differences. For example in the mixed effects model for
stable angina and PCI the HR for females receiving the intervention
was 0.6. For stable angina it was 0.32. Throughout the models relating
to revascularisation and the different triggers there were strikingly
fewer interventions in females. This finding is consistent with other
reports from the published literature.200–204
We did not design this study specifically to identify the causes of
any inequity detected, but my pathway approach enables us to infer
that this revascularisation inequity is not a knock-on effect and is
not related to any general, systematic failure to prevent, recognise
and treat CHD equitably. An explanation of the inequity might be
related to features of the health service, with respect to its structure
and operation, that affect provision of revascularisation. While I have
made an effort to adjust for some such factors in my work, this
adjustment is inevitably incomplete. Revascularisation services rely
on quite different parts of the health service to the earlier parts of the
pathway (secondary and tertiary rather than primary care) and it is
quite plausible that supply-side effects could operate specifically in
relation to revascularisation.
It is notable that immediately before and during my study period
there were very marked increases in numbers of revascularisation pro-
cedures carried out in the UK, even more so in Wales than elsewhere.
Between 2000 and 2012 rates of PCI (all types) increased as follows:
in England from 590 to 1423 per million population; in Wales from
550 to 1363 per million population. During the period 2004 to 2008 the
increase in Wales was from approximately 900 to approximately 1150
PCI procedures per million population. In the UK the proportions of
10.1 key findings 313
PCIs by indication also changed. From 2006 to 2012 the proportion
indicated by STEMI rose from 11% to 24.7 %, and the proportion in-
dicated by stable angina fell from 50% to 34%. There was very marked
increase in provision of primary PCI for STEMI in Wales, rising from
111 per million population in 2009 to 303 per million population in
2012. Comparable figures from England were 230 per million pop-
ulation and 390 per million population.205 Such an increase partly
reflects national policy guidelines such as the NICE guidelines that of-
fer clear protocols for the use of revascularisation in stable angina and
in ACS.206–208 Clearly therefore, during my study period there was a
background of very rapid change in provision of revascularisation. I
will suggest in the final section of this chapter that this emphasizes
the importance of sensitive monitoring of such changes, and that a
distinctive ability of the methodology in my study is that it allows the
detection of ‘knock-on effects’ in relation to revascularisation.
Further explanation of the revascularisation inequity might also
relate to the individuals in the study population. Several papers report-
ing inequity in revascularization postulate that attitudes, expectations,
illness behaviour and consultation thresholds (differing according to
socioeconomic status) may be explanatory.150,152,209,210 This suggestion
has been explored more effectively in qualitative studies, particularly
that of Gardner, who reports that a number of deprivation-linked
attitudes, including fear of hospitals and low expectations, may have
formed a barrier to referral for angiography and subsequent revascu-
larisation.211 Similarly, Tod, in a study based in a relatively deprived
area in Yorkshire, found that comparable social and cultural factors
were likely to deter uptake of CHD care.212 These studies used a qual-
itative approach to examining demand, and, as I have emphasized,
the absence of information about demand in data sources such as ours
greatly limits direct interpretation.
Another possible explanation is that the more deprived individuals
do not have the same capacity to benefit from revascularisation inter-
ventions (or perhaps are not perceived to do so by the health service),
because of characteristics of their clinical state. While I have adjusted
for comorbidity in my study, there is little doubt that such adjustment
is incomplete. Further, when I did so, the evidence for inequity in
revascularisation appeared to weaken (contrast figure 9.2 on page 280
and figure 9.3 on page 283). The reduced provision of revascularisation
that so clearly occurs with increasing age also points to the possible
importance of a comorbidity effect. In view of the pattern seen, while
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the evidence is insufficient from this study, I suggest that differing
levels of comorbidity may act as a significant part of the explanation
for apparent inequity in revascularisation, as evinced by the following
considerations:
• Deprived groups generally have worse risk-factor profiles, in-
cluding with respect to poorly characterised risk factors
• Adjustment for comorbidity appears to improve the picture
(reduce the observed level of inequity in revascularisation)
• Intuitively, complex revascularisation procedures may be more
‘sensitive’ to concerns about comorbidity and patient suitability
than is the case for drug management or, in particular, evaluation
of risk factors and risk
10.1.2 Ascertainment of risk factors
The identification of significant inequity in achievement of full cardi-
ovascular risk assessment (shown in figures 9.1 and 9.3) may represent
a genuine finding, although the effect size is small (HR 0.97). Nonethe-
less, a possible explanation is suggested by the fact that observational
studies have frequently noted reduced attendance by more deprived
social groups at screening arranged by formal invitation.213 Contrast-
ingly, the ascertainment of individual risk factors favoured the more
deprived. For example in the fully adjusted model the HR was 1.2 for
ascertainment of smoking status. The process of assessing smoking,
BMI, and BP in individuals where these risk factors are already re-
cognized or obviously problematic may differ from the more formal
approach required to perform full risk assessment. Measuring and
recording risk factors such as smoking status or BMI is often done
opportunistically in primary care in a piecemeal way during consulta-
tions that may be unrelated to CHD. Therefore the paradox in my
findings conceivably relates to subtle differences in the way primary
care consultations are conducted with individuals from different socio-
economic groups, or to their differing consultation rates. While such
a pattern is speculative, it may mean that, if equity grounds are con-
sidered important, an ad hoc case-finding approach to cardiovascular
risk screening may be more appropriate than a programme of formal
invitation.
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10.1.3 Management of risk factors and medication in primary prevention
The findings of the fully adjusted model showed significant differences
favouring quintile 5 in relation to smoking cessation advice and in
relation to treatment of raised BP in the low-risk group. In addition,
the univariate and the age-sex adjusted models showed differences
favouring quintile 5 in relation to referral to a smoking-cessation
service. In my literature review, I found one study suggesting that
smoking-cessation advice was better provided to the less deprived104,
and three studies showing no difference.105–107 To this extent, my find-
ing on smoking cessation advice is surprising. A possible explanation
could relate to the surge in activity in measuring and recording risk
factors during the early years of QOF, and the higher consulting rates
seen in more deprived areas could conceivably contribute an effect. I
reviewed in detail in section 3.5.2.1 studies reporting on BP treatment
in CHD prevention, and my finding that treatment of raised BP in
the low-risk group favoured quintile 5 contrasts with evidence from
three studies.104,117,119 Most of the studies reviewed showed either no
difference or a mixed picture. Therefore my finding can be regarded
as surprising.
10.1.4 Secondary prevention
My findings in this area gave patchy and slight evidence of inequity.
In relation to medication in established CHD the only significant
differences found in the fully adjusted model favouring quintile 1
were statin use in stable angina and in ‘old ACS’, and ACE inhib-
itor use in ‘old ACS’. In chapter 3, I reviewed studies reporting on
lipid lowering medication in CHD prevention (section 3.5.2.2). Five
studies found some evidence of a social gradient (favouring the less
deprived) in either prescription of lipid lowering drugs or reaching
cholesterol targets. A majority of studies found no significant differ-
ences by deprivation or other socio-economic measures. These studies
are summarised in table C.2.
In the fully adjusted models, I found a difference favouring quin-
tile 5 in aspirin use in unstable angina. In addition, in the age-sex
adjusted model, aspirin use in ‘old ACS’ and beta-blocker use in MI,
favoured quintile 1, whereas aspirin use in unstable angina favoured
quintile 5. Studies reporting on aspirin use in CHD were discussed in
section 3.5.2.3, two papers104,110 showing evidence favouring the less
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deprived, most studies showing no significant differences, and four
studies111,130,134,214 showing evidence favouring the more deprived.
Overall, in relation to secondary prevention, twenty comparisons were
made for medication in established CHD and therefore the majority
(17 out of 20 in the fully adjusted model) did not show significant
differences favouring quintile 1. This is consistent with the result of a
large 2012 study103 that found no evidence of inequity in provision of
major drug treatments for secondary prevention.
10.1.5 Drug cessation analysis
Twenty three comparisons were made using the fully adjusted models.
There were significant differences favouring quintile 5 in three com-
parisons of persistence of prescription: statins in the ‘high risk’ groups,
statins in ‘old ACS’ and clopidogrel in MI. No significant differences
favouring quitile 1 were found for these models. On the basis of this
overall finding, I conclude that patterns of drug-cessation cannot be
driving differences in CHD outcomes (given that outcomes are poorer
in more deprived groups). Indeed, to the extent that prescription-
persistence is better in more deprived groups it may be acting to
reduce inequality in outcome – though I have no strong evidence
that prescription-persistence is a valid indicator of true adherence to
treatment regimes.
10.1.6 Suboptimal care
Determining the extent to which health care delivered is truly optimal
is not straightforward. Sub optimal, as distinct from inequitable care
appears to have been received by some of those in my study popu-
lation. The criteria for optimal care are generally reflected in NICE
guidelines, but it may be difficult exactly to measure performance
against them – as when there is latitude in a prescribing recommend-
ation. For example in NICE guidelines it is clearly recognised that
factors such as a patient’s preference or intolerance to drug would
affect prescribing decisions. Therefore to know whether such care was
optimal in a population one might need complex information about
patient demand, non-compliance, drug intolerance, and so one. In
some cases, this information is available from GP data, but we elected
not to use it in our study, as outlined above, because of our emphasis
on examining the effects of healthcare inequity at a whole population
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level. A more practical way of identifying sub optimal care may lie in
comparison – nationally, regionally, or practice by practice. However,
the problem arises of determining which area is providing optimal
care to benchmark other areas against.
Despite these caveats, a number of findings from the analysis presen-
ted here give a strong suggestion either that sub optimal care was
taking place or that the interventions in question are of limited benefit
when used at population scale. It is important here to remember that I
am talking not about comparisons across quintiles, but about volume
of healthcare, which in itself has implications for healthcare equity (as
discussed in chapter 2).
While in many cases it is difficult to be certain that issues such
as refusal, intolerance, contraindication and so on are not in part
responsible for observed population-level uptake of interventions,
there is a section of the pathway of care where this is much less likely
to be an important factor – namely the part of the pathway dealing
with ascertainment of risk factors and provision of smoking advice.
Thus, I see that for those turning 40 ‘ascertainment of smoking status’,
‘measurement of BMI’, ‘measurement of BP’, and ‘measurement of
cholesterol’ all show declines in the Kaplan-Meier plots which in
an ideal healthcare response should be much steeper. Thus, three
years after turning 40 approximately 30% of individuals do not have
a smoking status recorded, approximately 60% do not have a BMI
recorded, and approximately 40% do not have a BP measured. Only
about 25% have a cholesterol measured.
Similarly, while approximately 60% of those first identified as
smokers receive smoking cessation advice immediately, approximately
40% do not, and by three years approximately 15% of individuals still
have no record of such advice being given. Given the importance of
smoking as a driver of CHD, it is clear that this is suboptimal (either
the provision of the advice or the recording of such provision).
In other parts of the pathway, sub optimal management is harder
to identify with certainty, because of the issues outlined at the start
of this section. Again, notwithstanding these limitations, a number of
important findings emerge. Because I used only the requirement that
at least one BP medication be used for the clinical action ‘BP raised
and low risk’ and ‘BP raised and high risk’, individuals intolerant
of one BP medication could be treated with another and the clinical
action would still be achieved. Further, intolerance to a medication
is identified by a trial of a drug: according to my methodology that
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trial would count as the drugs starting. Thus, for the BP medication,
intolerance of medication is unlikely to be an explanation for the
absence of treatment.
In low-risk individuals with a high BP three years after such a BP
was identifiable from GP records, approximately 25% of individuals
had not started on a BP treatment. For those with high cardiovascular
risk, approximately 30% had not begun treatment at three years. While
the caveats from above obviously apply to statin therapy, it is striking
that for those with high CVD risk but no diagnosis, three years after
this was first identifiable, approximately 75% of individuals had not
started on a statin. The picture with those with a diagnosis was quite
different – at three years approximately 30% had not received a statin.
When looking at secondary prevention of CHD, I identified numer-
ous examples of situations suggestive of suboptimal care, particularly
with beta-blockers, where I found disappointing levels of initiation of
treatment: more than 90% of individuals were not started on treatment
at three years in those with unstable angina or MI.
With revascularisation, identification of suboptimal care is much
more problematic, because of the absence in my data of many bits of
information relevant to whether an individual has a genuine need for
a revascularisation procedure.
Overall, though not the focus of my study, I found several instances
indicative of the existence of suboptimal care for the study population
in the study period. As a comparison, using a different methodology
in a different population, Hawkins et al found, when looking at sec-
ondary prevention of CHD and management of MI, better proportions
of individuals with these indications treated then I identified in my
study. For example at one year follow-up, I identified less than 75% of
those with myocardial infarction being treated with aspirin, compared
to more than 90% in the Hawkins study. This discrepancy may be
explained by the fact that the Hawkins study used the Myocardial
Ischaemia National Audit Project (MINAP) dataset to identify MIs.
This will provide a more valid denominator of MIs and a numer-
ator (individuals treated with aspirin) that included information on
in-hospital management.
With ACE-inhibitor management, I found approximately 70% treated
by one year in those with MI, comparable to the Hawkins figures. With
clopidogrel, Hawkins found substantial differences between 2003 and
2007, with a rise from 42 to 91%. This is broadly consistent with my
finding of approximately 50% treatment at one year, again taking into
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account the fact that inpatient prescribing was not captured in my data.
The very poor rates of prescribing of beta-blockers in our study were
not reflected in the Hawkins paper, and this constitutes a surprising
finding, worthy of further investigation to examine whether this is a
real effect.
10.1.7 Relating these findings to national policy and guidelines
The measurement of health inequalities, which would include meas-
urement of healthcare inequity, has been repeatedly recommended
in the policy documents and reports in the UK.8,215,216 My study has
importance for these recommendations in a number of ways. Firstly
it fulfils these ambitions in a systematic way with respect to health-
care inequity for CHD in Wales. It provides proof of concept that
such an approach can be used to systematically address the exist-
ence of healthcare inequity across a wide range of components of
the pathway of care for a particular condition using an automated
population level approach, in such a way that could be repeated with
a view to monitoring changes in provision. Thus, this work provides
a concrete example of a methodology that could be employed to meet
the recommendations laid out in policy documents and guidelines
in a systematic and repeatable way. Further, I have demonstrated the
detail of an implementation approach and have written programmatic
algorithms that could underpin such work both in relation to CHD
and for other conditions. In addition, the work presented in this thesis
reassures stakeholders that widespread inequity in healthcare is not
occurring with respect to CHD in Wales.
NICE and the NSFs are explicit that major determinants of risk
(smoking, diet, other lifestyle factors, and so on) must be addressed
proportionately. That is to say that undue focus on for example re-
vascularisation is not an appropriate population-level approach to
managing CHD. These recommendations concur with the findings of
my study, which, as I discuss further below, imply that in order to
affect differences in rates of CHD between deprivation groups, the
main focus ought to be on affecting social gradients in the important
determinants of cardiovascular disease.
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10.2 appraisal of study
10.2.1 Strengths
My analysis was based on data from a large number of individuals
(over one million). Using such a large electronic cohort as a basis for
my study meant that I was able to identify large numbers of clinical
triggers for which I ascertained times to clinical action. While the abso-
lute numbers of specified clinical triggers varied markedly according
to type, employment of a large underlying cohort population increased
my chances of identifying sufficient clinical triggers to provide a good
level of precision in my final estimates. Likewise, the large size of
the cohort meant sufficient data were available to adjust for relevant
covariates. Furthermore, one of my key aims in this work was a com-
prehensive examination of healthcare delivery across a pathway of
care at a truly population level; the availability of a dataset based on
such a large number of people allowed me to do that. In undertaking
a pathway-level analysis, I hoped to be able to identify systematic
effects with respect to healthcare inequity, rather than simply identify
its effects at isolated points in the pathway. I consider that, despite
the limitations discussed later in this chapter, my study achieved this
through its key strengths: the the comprehensive view of the pathway
and the development of innovative ways of measuring utilisation,
timeliness and continuation of indicated interventions.
With the exception of the definition of deprivation quintile for an
individual (which is based on inferring an individual’s deprivation
from the small-area geography in which they live), my data were
at individual level. This meant that I was largely able to circumvent
issues arising from ecological biases in our data. Moreover, access to
data of this nature allowed me to employ the chosen methodology
using a survival analysis approach, with adjustments for important
covariates, and a hierarchical model structure (individual–practice–
hospital) taking account of supply-side factors as random variables.
Using a survival approach eliminated the need to decide on a par-
ticular time-period that should be considered important in analysing
outcome. It is widely used and accepted in health research; it allows
appropriate adjustment and, with the use of frailty models, allowed me
to extend my analysis to take account of effects at practice and hospital
level, modelled in a hierarchy. While a ‘glass-half-empty’ perspective
might see the use of random effects within models as only necessary
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where insufficient information is available to determine what charac-
teristics of hospitals or practices are affecting outcome, a more positive
perspective would judge that use of these techniques maximised the
insight that one could gain into the observable relationships with the
available data.
I believe the real strength of this study was in the development of a
simple but novel methodology to address population-level analysis of
healthcare implementation, using the clinical trigger-action approach.
I used a carefully-developed theoretical framework to underpin a
rigorously-defined set of algorithms to identify, classify, and collect
relevant information on these clinical trigger-actions from a large
and unrefined underlying data source. This allowed me to use the
statistical techniques of survival analysis using frailty models to model
my data. Further, I developed the idea of drug cessation, looking at
progress from drug initiation to drug cessation as an additional level
of my analysis, but employing the same survival analysis techniques –
thereby ensuring that the complete analysis could be subsumed within
a consistent theoretical framework.
The real strength of this approach becomes clear when one considers
that it allowed one to look globally at a comprehensive pathway in
such a way as to address potential knock-on effects in individuals’
progress through it. For example, I was concerned at the outset of this
work that examining the management of only those individuals with
an assessed high cardiovascular risk could fail to identify inequity if
assessment of risk itself were inequitable. My approach relieves such
concerns. In other words, in attempting to capture any differences in
management that might exist as individuals flow through the system,
my approach allows me to be sure that progression of individuals
through disease states of increasing severity (no disease; angina and
chronic CHD; ACS) is not facilitated by differential disease manage-
ment at an upstream stage. Without such attention to the nature of
the pathway, differential management lurking in unexamined parts of
the pathway of care could exert inequitable knock-on effects, even if
downstream management were completely equitable.
A further advantage of this approach is in examining the effects of
derived history variables within models. By using available inform-
ation on the length of time for which a particular clinical action had
been indicated for an individual and by looking at the number of
different previous indications that had occurred, I was able, by taking
account of the pathway perspective, to adjust for these elements of an
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individual’s history as potential confounders in my models. Similarly,
I was able to take account of whether an individual had previously
received a clinical action prior to the clinical trigger in question. My
approach focused on taking account of progression of individuals
through an overall system in a way not previously attempted when
examining healthcare inequity.
I made strenuous efforts to validate the data, both by examining its
volume in comparison with expectation and by making prevalence
comparisons against external sources. Without such an approach it
would have been very difficult to identify subtle but critical failings
in the original data extract with which I was supplied. Prevalences of
major conditions and risk factors in my dataset corresponded to those
in the most similar available dataset (Welsh QOF). Available evidence
suggests therefore that the content of our dataset was in line with
expectations from other sources (notwithstanding the difficulties of
defining hypertension).
In my analysis, in addition to looking in a comprehensive way across
the pathway of care for CHD, I looked at the potential effects on my
findings of altering some of the important underlying assumptions of
my analysis, thus allowing one to clarify that such assumptions are
not critical in driving the pattern of relationships encountered. This
allows one to be more certain that the findings are robust, rather than
being highly sensitive to the underlying assumptions in question.
10.2.2 Limitations
10.2.2.1 Limitations related to data sources
Individuals were included in the study on the basis of the GP practice
with which they were registered; about 40% of the Welsh popula-
tion were registered with a SAIL-submitting practice. Any systematic
difference between individuals or the management of individuals
between practices included in and excluded from SAIL might bias the
results. The cohort of individuals included was, for example, not geo-
graphically representative of the Welsh population: SAIL-submitting
practices were disproportionately based in West Wales (as was dis-
played in figure 7.7). Furthermore, the individuals within our dataset
on whom readings and results were available did not represent a ran-
dom sample of our study population. For example, it seems extremely
likely that very overweight individuals will be more likely to have
their BMI recorded than individuals of normal weight; similar effects
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are likely to occur at numerous points in our data. While I have taken
all reasonable steps to use multiple imputation techniques to address
issues of missing data, there is nevertheless an inevitable issue of
representativeness in this study and studies of its kind.
In addition to issues with representativeness of the Welsh popula-
tion, there are also issues that arise when wishing to generalise to the
UK-population. Health service arrangements are distinctive in Wales,
and any generalisation from our population to the population of the
UK needs to take account of this.
Routine data quality is dependent on the way in which data is
entered into the raw datasets. Misclassification and absent data are
problems that inevitably occur in a proportion of records of this
type. As an example of misclassification, it is widely appreciated
that a proportion of deaths are given an incorrect cause; likewise, I
suspect that referrals to smoking cessation services from primary care
are not always accompanied by the entry of the relevant Read code
into clinical systems – resulting in absent data. The classification of
ACSs within the PEDW data was unsatisfactory, given the presence
of codes for old MI and the difficulty of differentiating different
types of ACS. Furthermore, the difficulty of which coding positions
to regard as being relevant within PEDW arises – here I have used
codes in any coding position to define diagnoses. This increased
sensitivity at the expense of specificity. Clearly, in some situations this
was not a problem – for example in relation to risk factor ascertainment.
However, the designation of clinical triggers based on a simplified
three-way classification of ACS, involved use of the MI code at any
coding position and I recognize this as a potential limitation.
There were a number of specific examples within our data that
were poorly coded. Admissions to the Liverpool specialist cardiac
centre (Liverpool Heart and Chest Hospital) were indifferently coded,
such that I had to classify all admissions to the trust as being cardiac
centre admissions; the variable admission type in PEDW data is poorly
coded; the Read codes for referral to smoking cessation services from
primary care are not widely used; the Welsh Demographic Service
administrative information overestimated populations in younger age
groups (a known problem with this data). I would have liked to have
used data on an individual’s ethnicity in the analysis. Though Read
codes are available to code this information, in practice, they are very
rarely used, so I was unable to include this information in our analysis.
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Besides absent data arising because it does not find its way into
datasets appropriately, there are also complete absences within PEDW
at a systematic level: most importantly, it would have been extremely
valuable for this work to have examined the drugs given to patients
from different patient groups as inpatients within hospital following
an ACS; this was not possible, because in-patient drugs are not avail-
able from PEDW records. Not only did this preclude investigation
of an important area of treatment, it also meant that I was unable to
begin my analysis of the period during which an individual received
a medication until after they had returned to being under the care of
their GP. Allowing time for drugs taken home from hospital by the
patient, this meant that I was usually unable to identify initiation of
treatment until 28 days plus the length of the admission had elapsed;
this also meant that admission length might potentially confound
the relationship between deprivation and drug provision. Other data
that were not available to me included data on cardiac rehabilitation,
data on admissions and procedures in the private health sector, and
over-the-counter prescriptions of aspirin and statins. Data relating to
the type of admission (emergency, elective or other) for MI suggests
that the coding gave inadequate detail. For example, in relation to the
trigger-action MI and PCI I have presented figures for admission type:
elective 3%, emergency 80.7% and ‘other’ 16.1%. This seems implaus-
ible; my understanding is that this difficulty may relate to the decision
to use codes to define MI in any diagnostic position, with the result
that some admissions are misclassified as MI-related. Ideally, I would
have had access to a source of data relating to general practices and
hospitals, detailing specific characteristics of each of these such that I
could have investigated in detail the real drivers behind hospital-level
and practice-level effects – thus obviating the need for the random
effects approach used.
A limitation in the use of the LSOA, by which one infers an indi-
vidual’s level of deprivation through small-area geography, is that
health-selection effects (individuals with health problems tending to
‘gravitate’ to poorer areas) and exposure-lag effects (accumulating
effects related to the area on an individual’s health over time) could
not be allowed for.
10.2.2.2 Limitations related to analytical approach
A number of criticisms might legitimately be directed at my analytical
approach. It might be argued that the approach of basing the find-
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ings primarily on the comparison between deprivation quintile 5 and
deprivation quintile 1 constitutes a limitation, though I have tried to
allow for any potential sensitivity of the analysis to this simplification
by re-examining the areas of the pathway for which social gradients
were apparent using a slope in the of inequality approach (section
9.3.5 on page 300).
In modern epidemiology, confidence intervals are preferred to p-
values because of the additional information they provide; in the
overview approach I have focused, for presentational reasons, on
using p-values and HRs. Similarly, the use of HRs might be subject to
criticism in the sense that the statistic is not additively symmetrical –
for example, a HR of 0.8 does not represent an effect size equivalent
(though opposite) to a HR of 1.2. It might be argued that this muddies
the presentation of pathway overviews as presented here, but, after
consideration, I decided that more confusion would be inherent in use
of log HRs as an alternative, especially as most HRs presented were
close to 1.
The covariates were defined at the time-point of the clinical trigger.
I did not analyse subsequent changes in covariates during the clinical
trigger-response period – that is I did not include time-dependent
covariates in the models. While I did consider pursuing this approach,
it proved impractical within the context of the other analytical de-
mands faced. When using age as a covariates in models, I used age
as a categorical rather than continuous variable, because age is often
most appropriate modelled as a non-linear term, something which
would have been difficult using my automation approach.
In my discussion of pathway simplifications in chapter 5, I indicated
that, for reasons of practicability in this study, I regarded an individual
assessed as ‘high risk’ as being unable to return to ‘low risk’, irrespect-
ive of any subsequent risk assessment. I recognised this as a potential
limitation but saw it as unavoidable.
A weakness in the analysis using the pathway approach is an inher-
ent problem with multiple comparison. In very simple terms, using
a significance level of 5% implies that in making 20 comparisons, on
average, one might expect one to be significant purely on the basis of
random variation. In the pathway overview analysis, I have made sub-
stantially more than 20 comparisons. Thus, some significant findings
in overview would be expected on the basis of chance alone in my
analysis. While statistical techniques exist to take account of multiple
comparison (the Bonferroni correction or similar techniques), I did not
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apply them in the context of this study. Instead, I have sought, when
interpreting my results, to keep very clearly in mind the problem of
multiple comparison.
I used multiple imputation, in instances where certain data were
unavailable, as a means of minimising the effect of missing data on
findings. On page 176 in chapter 6, I discuss some of the limita-
tions associated with this approach, for example, the introduction of
additional assumptions, complexity and practical difficulty into the
analysis.
While the study gained much from the ethos of automation of ana-
lysis brought to the work, there were inevitable negative implications.
In a situation in which only one model was being developed, a large
element of human input and judgement would have been used. When
selecting models, though my approach allowed me to specify the
model differently at each point in the pathway, I did this in a prag-
matic way, without pursuing an extensive process of trial and error as
one might have if automation had been unnecessary. Ideally, I would
have liked to have introduced interaction terms into the models, but
the process of automation made it impractical to do so – a further
limitation of this approach. Likewise, I was unable to test some of the
assumptions of my approach in detail, particularly the assumption of
proportional hazards when using frailty models, the assumption that
five imputations were sufficient (though I did test this assumption
in broad terms in the sensitivity analysis), and the assumption of
linearity when using indication years as a continuous term in models.
When looking at survival times in relation to clinical trigger-actions
I was concerned that my approach might be biased by a competing
risks effect from an individual dying. Put simply, I knew that indi-
viduals from more deprived groups had higher age-sex-standardised
death rates; the potential issue was that individuals might die be-
fore contributing time to the models, thus meaning that individuals
who died more quickly were more likely to contribute time to the
denominator but less likely to receive the clinical action (and thus
enter the numerator). After detailed discussions with experts in the
field, I believe the survival approach inherent in using frailty models
takes account of this effect and that no bias is in fact occurring.217
When developing the methods, I made a number of simplifications
that helped make the analysis possible in the face of the problems
presented by a daunting array of clinical codes from which I needed
to define clinical states, an extremely large analytical work load that
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made automation necessary, the comprehensive nature of the pathway
under investigation, and the complexity of the underlying data sources.
Such simplifications might be considered limitations.
I removed individuals from our dataset when they had a discon-
tinuous period of registration within SAIL GP; I analysed our cohort
using annualised time-points of registration, rather than looking at
every time-point of registration change. When considering transfers
between hospitals, I created separate trigger periods for each admis-
sion (hospital transferred from and transferred to). Because of the
structure of my algorithms, the effect of this was to generate some
very short clinical trigger-action periods in which no action occurred,
which were quickly superseded. When examining the management of
hypertension, I considerably simplified the nature of the clinical action
I looked at. In reality, clinical algorithms for managing hypertension
are quite complicated, and producing computer algorithms to ad-
dress the extent to which clinical recommendations were followed in
detail would have been extremely difficult. When examining manage-
ment of hypertension, I looked only at the most routinely used drugs,
excluding others such as spironolactone and alpha blockers. When
examining risk assessment, I assumed that risk-factor measurements
stayed relevant for an indefinite period. Finally, for simplicity, I did
not look at temporal effects within our study period. In other words, I
assumed that any differences in times-to-event would be consistent
over the time-period of this study. This assumption may have been
inappropriate in relation to revascularisation: in the literature review I
found some evidence of a temporal trend in its provision, and during
the study period there were significant increases in the resources to
provide revascularisation in the population studied. When using the
Charlson Index as a covariate to adjust for comorbidity in the analysis,
I collapsed the full index to a binary variable, thereby potentially
weakening the adjustment as compared to an approach using the
validated index itself. My analysis did not consider issues of informed
dissent and contraindications to treatment when looking at achieve-
ment of clinical actions, something which might have been possible
on the basis of available Read codes, but which I did not carry out.
As a further simplification, I used the Framingham non-laboratory
risk assessment tool (though I did test the effect of doing so in sens-
itivity analysis). There are limitations with the non-laboratory risk
assessment approach, as outlined on page
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A number of other limitations have implications for further work
and are therefore discussed under that heading later in this chapter.
These relate to:
• The possible incorporation of CIs round HRs into graphical
summaries to give clearer overviews
• Refining the selection of simplified models
• Extending the statistical analysis so that models included time-
dependent covariates
• The need to check in detail assumptions of proportional hazards
• The need to check for linearity using indication years as linear
term
• Calculating the numbers of imputations needed to account for
variation produced by missing data
• Adjusting formally for effects of multiple comparisons
• Awareness of possible limitations relating to simplifying assump-
tions
10.2.2.3 Limitations and study validity
Clearly, all studies are subject to limitations, and such limitations
predispose study to a greater or lesser extent to issues of bias, con-
founding, chance findings, and reverse causation. Appraising the
extent to which such issues arise for my study is therefore important.
In performing this analysis, I was, in simple terms, looking for
an association between socio-economic deprivation and the time to
achievement of certain clinical actions following clinical triggers at
different points in the pathway of care. A number of methodological
characteristics of the study may have caused biases towards the null,
that is to say made it more difficult to identify a true association
against a background of random variation. For example, the approach
of using a 5:1 HR approach has the potential to bias the results to-
wards the null, because information on the middle three quintiles
in the analysis is not taken into account (though I did examine the
implications of this in our sensitivity analysis). Likewise, the use of
area-based deprivation, age as a categorical variable, the Charlson
index as a collapsed binary variable, and the limitations of routine
coding introducing misclassification, could all act to introduce ‘noise’
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into models and reduce the strength of the ‘signal’ which the study
sought to identify.
Issues of representativeness of the population in the study could
also potentially introduce bias. Were it the case that the population
included in the cohort was systematically different from that excluded,
bias might be introduced. The lack of geographical representativeness
of the population with respect to the population of Wales (and the UK
more generally) makes the existence of such bias more likely.
While I adjusted for potential confounding variables in our models,
it is quite likely that under adjustment for relevant confounders oc-
curred, because some potentially useful variables were not available
(for example ethnicity). Residual confounding within models might
have the effect either of suggesting associations between deprivation
and healthcare utilisation that are not in fact valid or of concealing
true associations.
As discussed above, given the number of comparisons made, the
potential role of chance in underlying identified associations needs to
be carefully borne in mind. While I have tried to take this carefully
into account, I acknowledge the potential effect of chance in producing
spuriously positive results with the methodology employed.
10.3 challenges and lessons
It is tempting when reporting academic activity in a document such
as this – aimed as it is primarily at an academic audience – to gloss
over or put spin on particular difficulties or oversights, and to attempt
to give the impression that the courses of action that were eventually
followed had been intended right from the start: I resist that tempta-
tion here, because other researchers may wish to undertake similar
projects; an honest appraisal of these issues might, I hope, be of use
to them. Moreover, I intended to progress to cover some areas that
time-constraints have relegated to the further work (section 10.4). This
necessity is in part attributable to the difficulties described in this
section. While many of these are, no doubt, common to all projects of
this nature, some are not; in my view, honesty about and description
of such challenges, is important in giving a clear picture of the work
involved in producing a thesis of this nature.
By far the biggest frustration with this work arose from the difficulty
of obtaining an extract from the main SAIL databank that conformed
to my specification. Problems, which stemmed from a range of causes,
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resulted in delays in the project and required that code be significantly
rewritten in places. SAIL is a relatively new framework: it is quite
likely that many of the problems confronted would not occur in
projects started now.
Particular difficulties arose at two stages. Firstly, the process of IGRP
approval for the project took a long time. An initial application that I
submitted was rejected on the basis that the specification of the GP
data was not meaningful in the context of the SAIL GP table. I was
obliged to rewrite and resubmit an application, having spent time
being schooled in the structure of the SAIL GP table by one of the SAIL
analysts. Including the delay for this rewrite, the approval process
took seven months from initiation to granting of formal approval.
Secondly, following approval, the extraction of data itself was ex-
tremely time-consuming and fraught with difficulty. The extraction
required that a complex set of linkages be performed accurately on
several different tables, and in relation to the PEDW data this was
a particularly demanding exercise. It was necessary to undergo nu-
merous cycles of an iterative process, in which I examined the extract
provided by SAIL so as to identify errors, which I then pointed out for
correction. These ranged from quite simple and easy to spot problems
(for example, an entire year missing deaths data; incorrect linkage in
the PEDW) to subtle and difficult to identify problems.
Each error or set of errors that I identified meant that that I had to
point out and characterise the error and wait for it to be identified
in the SQL code relating to the extraction, for the extraction to be
performed, and for a further set of processes to be performed by the
technical team to re-encrypt the data. As a result, any such iteration
introduced a delay of between one and two weeks (sometimes more)
in access to a definitive data extract – which, in turn, I would then
need to run through my own algorithms. The identification and char-
acterisation of problems in this way was extremely time-consuming
and delayed the project on numerous occasions.
The software that I developed to perform my analysis pulled data
out of the DB2 databank and processed it in an external file structure.
I did this in an effort to ‘play safe’, because at the outset of the project
I did not have a clear indication of the extent to which I would be able
to manipulate data within DB2. Were I doing this project again, rather
than relying on C# and SQLite for implementation of my algorithms,
I would consider making much more use of DB2 to store data and to
perform routines on them. It is quite likely that this would result in a
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performance improvement, and might solve some of the difficulties of
running time encountered.
10.4 further work
In considering further work that might be undertaken, I have looked
at four areas:
1. Using an expanded dataset, with the same approach, addressing
the same question
2. Using other methodological approaches
3. Using other definitional starting points, but addressing the same
broad question
4. Generalisation of approach
10.4.1 Using the same approach on an expanded dataset to address the
research question
Further work might be undertaken to look at a different dataset, either
by expanding the current dataset or by looking at an entirely different
data source, but with a focus on the same research question.
Expanding the current dataset might be achieved in a number of
ways. Most simply, data could be re-extracted from SAIL with the
date criteria for the extract extended forward. At the time of writing,
data are available to the end of 2012 (an extension of two years in
the study period). Moreover, the proportion of GP practices in Wales
submitting data to SAIL has increased since the original extract was
performed, meaning that geographical coverage within Wales might
also have increased. Because the SAIL databank is increasingly linked
into other similar sites in the UK, as part of the Farr Institute, it might
potentially be possible in future to obtain an expanded dataset that
included data from those sites. The data extract used in this thesis
was based on demographic information on individuals linked to GP,
PEDW, and mortality data. The dataset might potentially be expanded
by linking into other data sources. For example the MINAP dataset
contains information on individuals in Wales with MIs, separate data
exists for PCI data, and potentially radiology and other datasets might
be linked in as well. Such additional linkage might make available
other useful variables on individuals, potentially allowing additional
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analysis to be refined and making it possible to validate previous
results.
Were it impossible to arrange additional linkage to data from other
parts of the UK, another approach might be to repeat the analysis
on datasets from other areas. Scottish linked hospital discharge and
death data has been used for many years for epidemiological analysis
of CHD and a similar study using this data could clarify the general-
isability of the findings presented here.218 During the time in which
this thesis was prepared, the Cardiovascular Disease Research Using
Linked Bespoke Studies And Electronic Records (CALIBER) dataset
has been established, which contains data similar to that addressed in
this thesis. CALIBER (for example) might be a data source on which
the analysis could be repeated; it has previously been used for work
with a similar emphasis.219 Comparison of the work presented here
with findings from studies employing different data from different
UK populations would be useful in establishing whether the patterns
I have observed are area- and time-specific. Such triangulation would
allow the findings presented here to be set in the context of other
results. Furthermore, while in my analysis I validated prevalences of
important CVD diagnoses and risk factors in our population against
other available data sources, an extension of this process, whereby a
more in-depth validation of our data against other sources in Wales
and in other parts of UK would be an important area for further work.
10.4.2 Using other methodological approaches
The approach in this work is best characterised as an observational
epidemiological study. Other broad classes of study could contribute
greatly to increasing understanding in this area, both with respect to
detailed understanding of the causes of the observed patterns and
their likely impacts.
Qualitative studies in this area, which seek to elucidate the mechan-
isms by which healthcare inequity might be arising, particularly with
respect to revascularisation procedures, could make an important con-
tribution to understanding what is happening at the population level.
While in the current work I have developed an approach that allows
me to examine the pathway in overview, based as it is on routine data,
it cannot provide information about why healthcare inequity specific
to revascularisation might have occurred. Qualitative studies looking
at in-depth analysis of interviews with individuals from different
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deprivation groups and with clinicians could provide this informa-
tion, which could potentially prove invaluable in understanding the
mechanisms by which healthcare inequity arises. Some studies of this
type have previously been performed.209,220,221
10.4.3 Other definitional starting point, but addressing the same question
At the inception of this work, I decided, for reasons discussed in
chapter 2, to base my analysis on identifying healthcare inequity on
the presence of differential utilisation-for-need. As previously pointed
out, this is by no means the only way to approach the subject. Depend-
ing slightly on ideological viewpoint, further work might be directed
at examining differences in expenditure, resource input, access, health
outcome, or healthcare quality between deprivation groups as mark-
ers of healthcare inequity. Further work, at a philosophical level, to
clarify which perspective on healthcare inequity really matters could
contribute to clarity and understanding in the field.
For example, in a seminal 1979 commentary, Julian Tudor Hart pos-
tulated the existence of an ‘inverse care law’.222 He cited examples of
inequity that included number-of-doctors-per-population (resource),
differences in infrastructure (quality), differences in care given (utilisa-
tion), and differences in outcome. Thus, in this influential articulation
of the problem of healthcare inequity, no primary definition of health-
care inequity was identified, and, further, the definitions implicitedly
cited are not necessarily mutually compatible. These issues have been
discussed in academic literature30–36, but it is not clear that consensus
has been achieved.
10.4.4 Generalisation
When designing this work, I mentally designated this project as one
specific implementation based on a particular ethos that could be
extended in a general way: this work, therefore, represents, as much
as an end in itself, proof-of-concept for a class of investigations that
might readily be carried out in several other areas. By carrying out this
work, I believe that I have demonstrated that projects of this kind are
feasible. The ethos that underpins it is based on a very simple principle:
maximise the quality of information available about implementation
of things that work, and do so in a systematic, population-level way;
in other words, work out if we are doing as well as possible the things
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that we already know how to do. The approach uses large linked
routine datasets; relies on a programmatically automated analysis; and
is built upon a rigorous and generalisable set of concepts, built around
the idea of a clinical trigger-action. In performing this work, I believe
that I have demonstrated how such an approach might be pursued,
proving that the implementation of the complex algorithms necessary
to perform it is possible in a reasonable timeframe, demonstrating
the feasibility of prioritising comprehensiveness and a population-
level perspective, and providing pathway figures, such as figure 9.3,
that mean that very complex information can be presented in an
assimilable way.
Insofar as this project has succeeded as a proof-of-concept, I believe
that it points towards a generalised approach that can provide a useful
future contribution in both a research and health service context.
It is of not only academic interest to understand the patterns of
implementation of healthcare interventions of proven benefit. Invest-
igation might focus on equity, as in this work, but might extend to
looking at the population effectiveness of interventions, and the factors
affecting the level of their utilisation. Benchmarking an achievable,
population-level performance, based on real-world activity and con-
trolling for case-mix might be extremely useful to those planning and
directing health services. Further, observational studies could be aug-
mented by modelling approaches that could usefully inform strategic
and policy-level approaches.
In an operational service context, it is clear that detailed information
on service utilisation of the sort envisaged here is likely to be extremely
useful to health service planners and managers, as well as to political
decision-makers. The concepts implemented here could, in some cases,
act as an extension of ad hoc, small-scale, clinical-audit. I envision the
possibility of providing a framework that would provide automated,
population-level audits of implementation along pathways of care. For
example, the code written for this project could quite readily be used
to provide regularly updated feedback on clinical implementation
related to CHD. The approach itself could be generalised much more
widely to other populations and areas of clinical care, particularly
those relating to chronic diseases with complex pathways of care.
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10.4.5 Illustrative example of population effects
It would clearly be valuable to estimate the population benefits if the
findings in this study of inequity and of suboptimal care were effect-
ively addressed. The existing literature provides indications of how
this might be approached. For example, Capewell et al223, used the IM-
PACT model to integrate data on numbers of CHD patients, treatment
uptake, treatment effectiveness, population risk factor trends, and
median survival among US adults. They concluded that modest re-
ductions in the prevalence of several major cardiovascular disease risk
factors accounted for more than twice as many life-years gained as did
treatments, although these gains were partially offset by substantial
increases in obesity and diabetes.
Fidal et al used the IMPACT CHD model to calculate the number of
life-years gained from specific cardiological interventions from 2000
to 2010 in the UK.224 They found that aspirin and beta-blockers for
secondary prevention following MI or revascularisation, for angina
and heart failure were highly cost-effective. Other secondary pre-
vention therapies, including cardiac rehabilitation, ACE inhibitors
and statins, were reasonably cost-effective, as were CABG surgery
and angioplasty. Primary angioplasty for myocardial infarction was
intermediate, and statins in primary prevention were much less cost-
effective. The cost-effectiveness ratios for standard CHD treatments
varied by over 100-fold. They concluded that large amounts of NHS
funding are being spent on relatively less cost-effective interventions,
such as statins for primary prevention, angioplasty and CABG surgery.
Barton et al, in a modelling study225, estimated that a programme
across the entire population of England and Wales that reduced car-
diovascular events by just 1% would result in savings to the health
service worth at least £30m a year compared with no additional in-
tervention. For example, reducing mean cholesterol concentrations or
blood pressure levels in the population by 5% (as already achieved by
similar interventions in some other countries) would result in annual
savings worth at least £80m to £100m. They also estimated reduction
in cardiovascular events and in costs if salt intake and trans-fat intake
were reduced.
To provide an illustrative example, I employ here the sort of ap-
proach use in the IMPACT model to give an idea of the population
impact of some of our findings. Taking the specific example of the
provision of PCI to individuals with an MI, one of the main areas of
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the pathway at which we identified evidence of inequity, I can work
through a simple example of the likely population impact were this
inequity to be addressed.
As a simplification, in this illustrative example I have not considered
the many covariates identified as important in our ‘fully-adjusted’
model, but have used the HRs from that model to indicate the likely
magnitude of effect. The method used to do this is shown in appendix
F. Clearly, there are a number of limitations with this approach, but
it does provide an estimate of the magnitude of the impact of my
findings.
Table 10.1: Numbers of procedures that might have been carried out and
numbers of procedures that might have been prevented or post-
poned had quintile 1 rates of utilisation occurred in other quintiles
throughout the study period
Quintile Difference in procedures Potential deaths saved
1 0 0
2 105 27
3 130 34
4 153 40
5 223 57
Broadly, the approach I have employed here is to apply the quintile
1 rate of utilisation of PCI in those with an MI to the other quintiles.
I did this for rates across the study period for the year following the
MI. Using this approach, it is possible to calculate the number of PCIs
that might have been done in the study period in quintiles 2–5 and
the number of deaths that might have been prevented or postponed.
I show my estimates based on these calculations in table 10.1. Over
the seven years of the study period, 105 additional procedures might
have been utilised by individuals in quintile 2, rising to 223 for those
in quintile 5. The estimates for the number of deaths saved also
suggest that applying these rates to quintiles 2–5 could hypothetically
have reduced deaths in these groups. As an indication of overall
impact, the 57 deaths that might have been prevented or postponed
in quintile 5 represent 7.4% of the total difference in the number of
deaths between quintile 5 and quintile 1 over the study period (769).
These estimates are based on the assumption that it would have been
clinically feasible for some of the individuals in quintile 5 who did not
have the procedure to have it, takes no account of age and comorbidity,
and assumes a relative risk reduction from PCI in the year following
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MI in line with that from primary angioplasty, using the effect size
used in the 2009 study by Capewell et al.226 Each of these assumptions
will tend towards over estimating the number of deaths that might be
prevented or postponed.
It appears that on the basis of these illustrative calculations that
healthcare overall is likely to be responsible for no more than 7.4%
of the difference in the numbers of deaths between quintile 1 and
other quintiles that occurred during the study period. In practice, the
percentage is very likely to be less than this, because of the simplify-
ing assumptions in the model, the fact that this calculation takes no
account of areas of the pathway where healthcare utilisation appears
to favour more deprived groups (especially drug persistence), and
because in other quintiles where there is a large difference in deaths
from quintile 1 (3 and 4) less of the observed difference in deaths
relates to PCI.
Detailed modelling of the likely implications of my findings in
relation to healthcare inequity is beyond the scope of the work in this
thesis, but would likely be a fruitful avenue for further work.
10.5 conclusions
10.5.1 Research question
There are a number of important conclusions from this work:
1. With respect to utilisation adjusted for need, healthcare in the
NHS in Wales is equitable at most points of the pathway of care
for CHD, with the important exception of revascularisation
2. There is evidence of healthcare inequity for revascularisation
with PCI
3. This is likely to contribute only a modest impact on the observed
differences between deprivation groups in CHD outcomes
Points one and two above allow me to address the main research ques-
tion – is there a systematic difference in the utilisation of healthcare
for CHD between different deprivation groups across the pathway
of care for the disease? The answer is a qualified ’yes’, in that while
inequity in revascularisation occurred in my study in what appeared
to be a systematic way, this was a finding essentially confined to one
area of the pathway of care. Inequity was not therefore found to occur
in a generally systematic way or to do so with a law-like tendency.
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The answer to the second research question (To what extent is
any difference in utilisation of healthcare for CHD between different
deprivation groups across the pathway of care contributing to dif-
ferences in CHD mortality between those groups?), again subject to
proviso, is that, while differences (in revascularisation) are likely to
have an effect on differences in CHD mortality, it is likely that this
is modest. Using the results of the illustrative example that I have
presented above is the best estimate available, I suggest that no more
than 7.5% of the difference in the number of deaths observed should
be attributed to differences in PCI provision. Clearly this estimate
itself is subject to uncertainty, and its clarification should be a subject
of further investigation.
While not intuitively surprising, these conclusions imply that the
NHS is not systematically inequitable, but that inequity can arise in
specific areas; it would be of great importance to understand further
why this may be occurring. Notwithstanding this, the implication is
that inequitable utilisation in the NHS is by no means inevitable, and
that in areas where it is identified it may be amenable to remediation.
10.5.2 Proof of concept
Beyond the above specific conclusions related to this work, I can, in
addition, conclude on the basis of the project presented here that
ambitious efforts to understand patterns in healthcare delivery across
pathways of care in a systematic and automated way are feasible based
on routine, linked datasets. Further, such projects are increasingly
favoured by current health service conditions and improved data
resources, and thus it is likely there will be future opportunities
for real, population-level feedback on health service performance
across whole pathways of care to contribute important findings in
future. A frequently heard complaint when considering health service
evaluation is that what is not measured is not improved. If this maxim
holds true, I have an opportunity with projects of this kind to improve
and innovate in the ways health service activity can be observed
and the ways in which feedback can be provided. Potentially such
processes might be invaluable to driving ongoing improvements in the
delivery of care so that outcomes can be influenced by health services
at a truly population level.
10.5 conclusions 339
10.5.3 Recommendations
On the basis of my study, I can make a number of recommendations:
1. The clearest recommendation that emerges from the
work is that, though evidence of healthcare inequity in
the pathway of care for CHD exist, it is not a key driver
of the outcome difference in mortality seen, and therefore
organisations and policymakers should focus instead on
the clear social gradients in cardiovascular risk factors –
particularly smoking – that are likely to be key drivers of
mortality differences between deprivation groups. Reduc-
tions in smoking in such a way as to reduce in both relative
and absolute terms the social gradients in smoking will be
needed if substantial progress is to be made on reducing
differences in outcomes for CHD.
Where agentic approaches are employed, careful efforts
need to be made to monitor effects on inequality using
approaches similar to those employed in this work. My
findings suggest that agentic approaches are not inevit-
ably inequality promoting, but that they can be and this
possibility should be addressed.
It is doubtful that agentic approaches alone can exert suffi-
cient effect. Thus, the continued and expanded emphasis
on structural interventions (social and fiscal policy and
legislation to address risk factors) is important, if poli-
cymakers and stakeholders are serious about reducing
inequalities in outcome from CHD.
2. I recommend that steps are taken to remedy the ap-
parent inequity in revascularisation which would include
taking steps to continue monitoring, using appropriate
methodology along the lines of that employed here, the
social gradients in PCI and CABG provision. Rapid change
has occurred and is occurring in the provision of the ser-
vices in Wales, and an ongoing understanding of social
patterning is important to allow inequities to be addressed.
If gradients persist, investigation of the underlying reasons
should be prioritised.
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3. I recommend ongoing monitoring of components of care
identified in this study as suboptimal. This might be ac-
complished using the algorithms developed for this thesis,
with a view to providing continuing population-scale clin-
ical feedback. Where problems are apparent, local clinical
audit could be used to confirm findings and address short-
comings.
4. In view of my finding relating to risk ascertainment
(section 10.1.2) and evidence from the existing literature, I
tentatively recommend that more deprived groups might
best be screened for cardiovascular risk with an ad hoc
case-finding approach, rather than with a formal screening
approach.
5.The term ‘Inverse Care Law’ is sometimes used in public
health and related disciplines. Evidence from this thesis
and from other available literature suggests that, when
looking at utilisation-by-need for CHD, healthcare inequity
is not appearing in a law-like way. I recommend that the
term may be best avoided when discussing healthcare
inequity, which, rather than appearing as a law or law-like
tendency, is apparent at specific points and times in the
pathways of care for CHD.
6. With respect to the SAIL databank, the experience of
using the facility for the large project undertaken for this
thesis, means that I can make a number of recommend-
ations for improvements to an already excellent system.
I would have recommended that the timescales for the
Information Governance approval be shortened and run
to a formal timescale, but this change has already been
made. I recommend that to facilitate research within SAIL,
serious consideration should be given to the construction
of continuously updated research-ready datasets to exist
as an intermediate additional layer within the databank.
This could be carried out in a number of areas, cardiovas-
cular disease being an obvious one. I also recommend that,
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where possible, extraction procedures be standardised with
a view to preventing the necessity to rewrite difficult bits of
code. This could be achieved with the use of templates and
guides and by making available information on frequently
encountered problems and solutions to them.
7. As mentioned above, to an extent this work was a proof
of concept. Large amounts of data exist within the SAIL
databank and within similar systems. The technical capab-
ility exists for linking these datasets together, and in this
project I have developed what I believe is a robust way
of looking at issues relating to delivery of health care. I
recommend that consideration be given to the carrying
out of an ongoing electronic audit of healthcare delivery
in Wales. This could start with a focus on CHD, employ-
ing the methods and algorithms developed in this thesis.
Potentially, additional data sources might be added (as dis-
cussed above in the further work section). Further, similar
techniques and approaches could be applied to other major
diseases, for example cancers in Wales. A generalisation of
the methodology employed here to achieve a population
level understanding of patterns of delivery of healthcare in
an automated, continuously updated way might prove an
invaluable resource in guiding the delivery of healthcare
in Wales, and I recommend that consideration be given to
pursuing such an approach.
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Part V
A P P E N D I C E S

AT H E W E L S H I N D E X O F M U LT I P L E D E P R I VAT I O N
In this section, I provide additional material relating to WIMD 2005,
which was the principal deprivation measure used in this work.
a.1 indicators used for the income domain
1. Adults and children in income support households
2. Adults and Children in Income-Based Job Seekers Allowance
households
3. Adults and Children in Working Families Tax Credit Households
below a low income threshold
4. Adults and Children in Disability Tax Credit households below
a low income threshold
a.2 indicators used for the employment domain
1. Claimants of Unemployment-related benefits
2. Claimants of Incapacity Benefit
3. Claimants of Severe Disablement Allowance (for women under
60 and men under 65)
4. Participants on New Deal for Young People and Intensive Activ-
ity Period (for New Deal 25+) not included in unemployment-
related benefit counts
a.2.1 Indicators used for education domain
1. Key Stage 2, average point scores
2. Key Stage 3, average point scores
3. Key Stage 4, average point scores
4. Secondary school absence rates
371
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5. Proportion of 16 to 18 year olds not entering further or higher
education
6. Proportion of adults with low or no qualifications
a.2.2 Indicators used for health deprivation domain
1. Limiting long-term illness
2. Standardised all-cause death rate
3. Standardised cancer incidence rate
a.2.3 Indicators used for access to services domain
1. Food shop within 10 minutes
2. GP surgery within 15 minutes
3. Primary school within 15 minutes
4. Post office within 15 minutes
5. Public library within 15 minutes
6. Leisure centre within 20 minutes
7. NHS dentist within 20 minutes
8. Secondary school within 30 minutes
a.2.4 Indicators used for housing deprivation domain
1. Lack of central heating
2. Overcrowding (excluding all student households)
a.2.5 Indicators used for physical environment domain
1. Population averaged estimated air quality for each LSOA in
relation to Air Quality Strategy objectives
2. Population averaged estimated emissions to air per LSOA
3. Proportion of residential population living within 1km from cur-
rent and recent waste disposal sites (landfills and incinerators)
A.2 indicators used for the employment domain 373
4. Proportion of residential population living within 1km from a
significant industrial source (those identified in Part A(1) of The
Pollution Prevention and Control Regulations 2000)
5. Proportion of residential population living in an area with a
significant risk of flooding
Additional information on the technical underpinnings of the WIMD 2005
are available from the Welsh Assembly Government.227

BA D D I T I O N A L B A C K G R O U N D M AT E R I A L
b.1 additional background material relating to inequity,
socio-economic deprivation and healthcare needs as-
sessment
b.1.1 Geographical divisions
This thesis required information on the geographical area of residence
for an individual to assign deprivation-decile to that individual based
on the deprivation-level of the area in which they live. To accomplish
this I utilised a statistical unit of geography called the LSOAs; these
are census-based geographical units developed by the ONS.228 They
were introduced with the aim of reducing the kinds of problems
caused by the inconsistent and unstable electoral ward geography.229
Super output areas themselves are based on output areas (OAs), which
are census-derived small areas of geography, which were developed
with the aim of grouping together postcodes so that OAs had similar
population sizes, had approximately regular shapes and were socially
homogeneous.228 LSOAs based on the 2001 census were first released
in 2004. Their creation was based on the amalgamation of output areas
(typically four to six)229. There are 1896 LSOAs in Wales for the 2001
census data, with approximately 1500 individuals in each.228
b.2 additional background material relating to chd
b.2.1 Pathophysiology
CHD* shares its underlying pathological mechanism, namely ather-
osclerosis, with other major CVDs – see section B.2.5.1. What distin-
guishes the clinical picture of CHD from these others is the anatomical
location of atherosclerotic pathology (in the coronary rather than other
arteries).230
*Coronary heart disease, ischaemic heart disease, and coronary artery disease are,
I believe, interchangeable terms; in this thesis I have used the term coronary heart
disease throughout
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Contemporary models of the pathophysiology of atherosclerosis em-
phasise the response-to-injury hypothesis. Here the initiator of pathology
is thought to be endothelial injury and subsequent dysfunction. Ongo-
ing atheroma development is seen as an attempt at healing in response
to insult with a key role played by the immune system.231 In contrast
to the historical picture of a passive accumulation of lipids and fibrotic
material in the vessel wall232, the newer model emphasises chronic
inflammation as a key driver of atheroma progression.231,233–236
Initial endothelial injury arises from two paramount insults: hyper-
cholesterolaemia231 and haemodynamic disturbance.237 Lesser, though
still important, contributors to endothelial injury include hypertension,
toxins from tobacco smoke, homocysteine91, immune complexes and
inflammatory cytokines.230 There is also some tantalising evidence
of a role for infectious agents in the development of atheroma.238
Genetic evidence suggests that atherosclerosis-related genes are pre-
dominantly involved in mechanisms of inflammation and stem cell
biology239, suggesting that though initial endothelial injury is neces-
sary for atherosclerosis development, it is not sufficient, emphasising
the critical role of the inflammatory response to injury.
This chronic inflammatory process incorporates a number of con-
current and interrelated processes; the most important of these are
summarised schematically in figure B.1. Initial accumulation of low-
density lipoprotein (LDL) in the intima is followed by the oxidation
of component lipids.231 These modified molecules can activate the en-
dothelium, resulting in the recruitment of circulating monocytes and
their adhesion to the endothelial surface, from where they emigrate to
the arterial intima and transform to macrophages; they are joined, in
smaller numbers, by other immune cells, including T lymphocytes and
dendritic cells;231 subsequently these cells help to sustain an immune
response at the site230 with the release of a variety of proinflammatory
mediators. Smooth muscle cells and smooth muscle precursors are
recruited to the intima from both the media and the circulation.230
Macrophages and smooth muscle cells take up oxidised LDL, causing
them to develop into foam cells. Cytokines and growth factors induce
smooth muscle cells to lay down an extracellular matrix composed of
collagen, proteoglycans, and other molecular components.230 Smooth
muscle cells themselves proliferate.
Platelets play a critical role in thrombus formation and ongoing
atheroma progression;240 they bind subendothelium (particularly col-
lagen and von Willebrand factor) in areas where it is exposed due
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to endothelial rupture.241 They subsequently release adenosine di-
phosphate, thromboxane A2, and thombin241, which contributes to
their role in the further activation and recruitment of platelets241, with
subsequent thrombus formation.
Beyond an established role for innate immunity in atherosclerosis,
there is some evidence of an adaptive response with possible antigens
including autoantigens(oxidised-LDL, heat-shock protein 60) or mi-
crobial molecules (possibly chlamydia pneumoniae, cytomegalovirus, or
others);231 components of the adaptive immune response are present
in lesions throughout the course of atherosclerosis.231
A further role in atheroma progression is played by the renin-
angiotensin system, which contributes to atherosclerosis development
by promoting a number of coordinated cellular and molecular events
that occur in the lesion, with angiotensin II known to have a number
of pro-inflammatory actions on the vessel wall that lead to atheroma
progression.242 Patients with chronic kidney disease (CKD) undergo
accelerated atheroma progression, in part related to the activation of
the renin-angiotension system which CKD causes.243
The complex evolution of atheroma, while impossible to characterise
in precise detail, can be seen to give rise to
• Accumulation of extracellular lipids, necrotic cells, and extracel-
lular matrix
• Cellular recruitment and proliferation
• Release of pro-inflammatory cytokines and growth factors
• Predisposition to thrombus formation with further plaque growth
• A possible role for an adaptive immune reponse mediated by B
cells and mast cells
This complex cascade of events gives rise to morphological change
from normal arterial wall structure, through the development of fatty
streaks beneath the endothelial wall, to the emergence of fibrofatty
plaques – characterised by a fibrous cap overlying a lipid core.230 With
continuing progression, such plaques become vulnerable to rupture
or erosion, with such events inducing platelet adhesion around the
site of rupture, thrombosis, and subsequent growth and remodelling
of the plaque.230
The clinical consequences of atherosclerosis emerge by three prin-
cipal means.230 Either progressive plaque growth leads to a critical
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Figure B.1: Morphological and pathophysiological changes of atherosclerosis
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stenosis of the artery, resulting in sufficiently impaired blood flow
to provoke symptoms.230 With plaques in the coronary arteries the
resulting clinical picture is angina pectoris.230 Alternatively, acute
changes244 in the plaque, such as rupture or erosion, with accompa-
nying thrombosis, might result in complete occlusion of the arterial
lumen.230 If occurring at a coronary site, such an event gives rise to the
clinical picture of myocardial infarction, in which complete cessation
of coronary blood flow results in downstream tissue necrosis due to
lack of oxygen, with further injury subsequently arising from reperfu-
sion injury if blood supply is restored.230 Furthermore, embolisation
of thrombus or material from the atheroma can result in occlusion at
sites distant from the plaque itself.230 Finally, weakening of the arterial
wall as a consequence of atheroma progression can result in sudden
rupture and aneurysm of the artery.230
b.2.2 Clinical classification
The permutations of anatomical distribution of atherosclerosis and
progression to critical stenosis, occlusion or aneurysm account for the
range of clinical pictures to which CHD, and more generally CVD,
give rise. In the case of critical stenosis of the artery, in the absence of
acute rupture and thrombosis, a fairly stable clinical condition may
result, in which the inadequacy of coronary blood flow produces
symptoms when the myocardium is exerted – typically patients exper-
ience symptoms during exercise or when under emotional stress; the
relationship of these symptoms to exertion is fairly constant over time;
such a clinical picture is termed stable angina. Symptoms typically in-
volve anterior chest pain, which may radiate into the neck, shoulders,
arms, or jaw.207 In some patients the resultant symptoms are less
typical, and can include gastrointestinal discomfort, breathlessness,
or nausea207. People with stable angina have an increased risk of pro-
gression to acute coronary events207. In some individuals, continuing
anginal symptoms are present yet on angiographic investigation the
coronary arteries appear normal. Such a clinical picture is termed
cardiac syndrome X245.
Acute changes in an atherosclerotic plaque can lead to fast-evolving
and life-threatening clinical pictures, resulting from rapidly narrow-
ing or occluding coronary arteries. Such events are termed ACSs246.
They range from unstable angina, resulting from sudden worsening of
anginal symptoms (either in frequency or intensity), through NSTEMI
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Figure B.2: Schematic representation of the principal coronary arteries; an-
terior view
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that involves myocardial ischaemia together with biochemical evid-
ence of myocardial necrosis, to STEMIs with ST-elevation on ECG –
implying infarction of the full-thickness of the myocardium; the latter
can be further subdivided on the basis of the anatomical region of
myocardium that has infarcted, for example anterior, inferior, pos-
terior, lateral and septal MIs. The anatomy of the principal coronary
arteries is illustrated in figure B.2; exact coronary artery anatomy
varies by individual. The anatomical region of infarction correlates
to the artery in which occlusion has occurred; for example anterior
MI is associated with occlusion of the left coronary artery; inferior
with the right coronary artery; and posterior with the left circumflex
coronary artery or sometimes right coronary artery230 – see figure B.2.
The development of an ACS can result in arrhythmias, catastrophic
compromise of the myocardial architecture, acute left ventricular fail-
ure and sudden cardiac death. Less acutely, survivors of ACS may
rarely develop pericarditis (Dressler’s syndrome) and are predisposed
to the development of chronic heart failure due to myocardial loss.
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b.2.3 Treatments and management
The management of CHD encompasses a number of quite distinct
circumstances in which the aims of management and the precise
means of achieving these aims are different. In these contrasting
situations, a variety of interventions are employed. Fully articulating
the precise details of management in this chapter would involve
presenting material from several clinical guidelines. To circumvent the
impracticality of discussing all such information, I limit myself here
to highlighting the important principles of management under the
major circumstances that arise in relation to CHD183,206,207,245,246,248–266
namely
• Management of stable cardiac pain and secondary prevention of
disease
• Management of acute coronary syndromes and secondary pre-
vention of disease
• Primary prevention
b.2.4 Management of stable cardiac pain
The optimal management of stable angina requires its correct identi-
fication, by clinical means or with the aid of diagnostic tests. NICE
recommend that in individuals with intermittent, stable chest pain
that appears cardiac in nature, if clinical assessment suggests angina
and the likelihood of this is greater than 90% (estimated from the age,
sex and other CVD risk factors), no diagnostic testing is necessary
and an individual can be treated as having stable angina. In other
cases, depending on risk, individuals can be investigated with coron-
ary angiography (risk of angina 61–90%), functional imaging (risk of
angina 30–60%), or computed tomography (CT) calcium scoring (risk
of angina 10–29%)245.
Coronary angiography requires that radio-contrast agent be released
into the coronary arteries to allow x-ray visualisation of blood flow
within the lumen; to achieve this it is necessary to pass a catheter
from a peripheral access site (the radial or femoral artery) through
the arterial circulation to the opening of the coronary arteries. Func-
tional imaging includes a number of procedures: myocardial perfusion
scintigraphy; stress echocardiography; first-pass contrast-enhanced
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magnetic resonance perfusion; and magnetic resonance imaging for
stress-induced wall motion abnormalities245.
Once diagnosis is satisfactorily confirmed, the aims of treatment
are to relieve and reduce symptoms – thereby improving quality of
life – and to optimise secondary prevention (in an effort to reduce
the impact of CHD that is already present)207; Lifestyle advice, drug
treatment and revascularisation are the mainstays of treatment207.
To provide immediate symptomatic relief from anginal symptoms,
individuals with stable angina should be offered a short-acting nitrate.
Further, a regular dose of one or more antianginal drugs should be
initiated with a view to reducing symptoms, administered in line with
the following principles207.
• Use beta-blocker or calcium-channel blocker (CCB) as first line
treatment
• Consider using a beta blocker and CCB if one drug does not
control symptoms
• Where beta-blockers or CCBs or both are not tolerated consider
using one of the following instead: a long-acting nitrate, ivab-
radine, nicorandil, ranolazine
• Do not offer a third drug to those with uncontrolled symptoms
unless they are awaiting revascularisation or unless revascular-
isation is not appropriate
For those in whom it proves impossible to control anginal symptoms
with medical management, revascularisation should be considered
with the choice of treatment between PCI and CABG guided by an-
giographic findings (additional non-invasive or invasive functional
testing may also be required)207. The decision about whether to re-
commend PCI or CABG should be based on the following considera-
tions.207
• The anatomical distribution of disease
• The suitability of the patient to undergo PCI or CABG
• Whether the patient has multivessel disease and has character-
istics that mean that CABG will lead to better survival, namely
diabetes, age over 65 years, or anatomically complex three-vessel
disease
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PCI, often simply known as angioplasty, involves widening of the
artery from within by expanding a balloon to open up the lumen.
Frequently, this is accompanied by the use of a stent – a thin wire-
mesh tube – which is loaded over the angioplasty balloon. As the
balloon inflates, the stent expands and is left in place to hold the
artery open256,264. The stent itself may be bare metal or drug-eluting
(bare metal stents coated with a drug, such as an immunosuppressant,
which is gradually released at the site of stent insertion). Evidence
suggests that drug-eluting stents may reduce the need for repeat
procedures256,264.
CABG is a surgical procedure in which arteries or veins from else-
where in the patient’s body are harvested and grafted to the coronary
arteries to bypass areas affected by atheroma. Surgery is either carried
out by stopping the patient’s heart and maintaining circulation to the
tissues using cardiopulmonary bypass (such ‘on-pump’surgery is the
traditional method), or is performed while the heart is still beating –
so-called ‘off-pump’ CABG262. Regardless of the approach used, ves-
sels commonly used for grafting include the left internal mammary
artery, great saphenous vein, and radial artery.
In those whose angina symptoms are well controlled, there is a
sub-group of patients for whom CABG confers a prognostic advant-
age: those with left main-stem or proximal three-vessel disease. In
these patients, where appropriate, functional or non-invasive ima-
ging techniques can be used to identify individuals who may gain a
survival benefit from undergoing surgery (despite their anginal symp-
toms being well controlled)207. If such investigations suggest that an
individual is in this subgroup, they may progress to angiographic
investigation and then, if appropriate, to surgery.
Finally, a number of preventive treatments can reduce the risk of
progression to ACSs and other CVD events. Secondary prevention in
individuals with stable angina involves lifestyle advice, aspirin 75mg
daily (where appropriate), statin treatment, management of hyperten-
sion and ACE inhibitors (in those with diabetes only)207. In the case
of individuals with established CHD leading to anginal symptoms, no
risk assessment is necessary prior to initiating secondary prevention,
as these individuals are by definition in a high-risk group for the
development of further CVD.
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b.2.5 Management of acute coronary syndromes
As outlined in section B.2.2, acute changes in atherosclerotic plaques
can result in ACS – which includes unstable angina, NSTEMI and MI.
Clinically, patients with each of these conditions present with acute
cardiac chest pain. Where a patient presents with acute chest pain
that is thought to be cardiac (on the basis of clinical history, CVD risk
factors, history of CHD, and previous investigations), management
involves investigation to determine the exact diagnosis and adminis-
tration of treatments to relieve symptoms and improve outcomes. In
clinical reality these processes run in parallel; here I consider them in
turn.
Three main sources of information underpin the decision-making
process that differentiates between different types of ACS and altern-
ative diagnoses: clinical history, biochemical markers of myocardial
injury, and ECG findings. The clinical history is consistent with ACS
where a cardiac-type pain persists for greater than 15 minutes, and
where it is accompanied by nausea, vomiting, sweating, shortness
of breath, palpitations and haemodynamic instability245,267. Abrupt
deterioration in stable angina (with increased frequency of pain, in-
creased duration of pain, or pain on minimal exertion) is also suggest-
ive245. Substantial variation in presentation exists, and even with a
full-thickness infarct some individuals – particularly women, diabetic
or elderly patients – may experience little or no pain267.
A widely-used contemporary definition of MI gives prominence to
the presence of a rise (above the 99th percentile) and subsequent fall
in biochemical markers; troponin I or T is usually used. An MI is dia-
gnosed where this biochemical picture is accompanied by symptoms
of cardiac ischaemia and ECG changes consistent with ischaemia (also
where imaging evidence exists of myocardial damage)268. Biochemical
markers like troponins provide evidence of myocardial damage; they
are therefore important in distinguishing between unstable angina,
in which acute ischaemic chest pain is not accompanied by evidence
of myocardial injury, and MI (either STEMI or NSTEMI). There is a
time-lag in the response of troponin levels to myocardial injury, with
levels peaking approximately 12 hours after damage; clinicians need
to take a delayed troponin sample to account for this (in addition to
an initial measurement)245.
ECG changes indicating a STEMI are ST-segment elevation and new
onset left bundle branch block; subsequently pathological Q-waves
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may develop if blood flow to the affected region is not promptly
restored.245 Patients with NSTEMI and unstable angina may have a
number of changes on their ECG that evince myocardial ischaemia
(but not full thickness infarction); these include ST-segment regional
depression and deep T-wave inversion.245 By definition, ECG findings
allow STEMI and NSTEMI to be distinguished, and in the acute setting
are important in guiding management245.
The diagnostic pathway for the assessment of ACS recommends
that individuals with ST-elevation on ECG are managed as a STEMI
until the diagnosis is confirmed by troponin measurements245. Al-
ternatively, where the ECG shows regional ST-segment depression
or deep T-wave inversion, patients should be managed as unstable
angina or NSTEMI while differentiation between unstable angina and
NSTEMI on the basis of troponin levels is awaited245. Patients with
other changes on the ECG such as Q-wave and T-wave changes, can
be managed as unstable angina or NSTEMI if these conditions ap-
pear likely on the basis of clinical assessment245. Where diagnosis is
difficult, it may be necessary to record and review multiple resting
ECGs245. A normal ECG does not rule out ACS, and where there is
clinical suspicion patients still need monitoring245. The possibility
that symptoms may relate to conditions other than ACS – pulmonary
embolism, aortic dissection, pneumonia, and others – may mean that
other investigations are indicated245.
Initial management of ACS involves pain management with glyceryl
trinitrate (GTN), which may be buccal or sublingual, and, where
necessary, intravenous opioids. All individuals with ACS should be
given aspirin 300 mg, provided they are not allergic to it. Oxygen
should not be routinely administered, but oxygen saturations should
be monitored and, in those without chronic obstructive pulmonary
disease, kept above 94%245 .
In cases of STEMI, restoring the patency of the affected artery
or arteries is vital in minimising the extent of myocardial damage
and in optimising prognosis; this should be done as soon as pos-
sible267. The principal options for achieving this include primary PCI
and fibrinolysis (thrombolysis). In the former, the obstruction is re-
moved mechanically; in the latter, pharmacological agents are used to
break down thrombus and restore blood flow. Evidence suggests that
primary PCI provides better outcomes for this patient group269–274
provided that it can be delivered quickly, though logistic considera-
tions mean that primary PCI is not always available within an appro-
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priate time-frame (120 minutes from the first contact of the patient
with medical services)267. Whichever method of re-perfusion is em-
ployed, the shorter the time to the commencement of therapy the
better, as minimising delay has been shown to improve outcomes267.
Where available, primary PCI is the preferred treatment option.
A number of pharmacological agents are available that influence
clotting – anti-thrombotic medications – and these may be used to
reduce the progression and severity of ACS; they include anti-platelet
drugs (aspirin, clopidogrel, and glycoprotein IIb/IIIa inhibitors such
as tirofiban, eptifibatide and abciximab), heparins (unfractionated hep-
arin, low molecular weight heparin, and synthetic pentasaccharides
such as fondaparinux), and direct thrombin inhibitors (for example
bivalirudin). These bring with them an inherent increased risk of
bleeding. They play a role at different stages in the management of
STEMI and other ACSs.
Beyond intitial management with aspirin, patients with STEMI
should be offered clopidogrel 300 mg, continued at the standard
dose267. Patients undergoing primary PCI should receive adjunct biva-
lirudin in addition to aspirin and clopidogrel257. Patient undergoing
fibrinolysis in situations where primary PCI cannot be performed
within 120 minutes of first medical contact, normally receive anti-
thrombin therapy, the choice of which depends on the fibrinolysis
agent employed, as an adjunct267. It is recommended the fibrinolysis
itself be with fibrin-specific agents (tenecteplase, alteplase, reteplase),
rather than with streptokinase267.
In the absence of ST-elevation on ECG, while waiting for biochemical
evidence of myocardial damage from troponin levels, NSTEMI and
unstable angina are managed according to a common pathway that
differs from that employed in STEMI206. The principle of management
in cases of NSTEMI and unstable angina is to balance the risk of
serious cardiac events against the risk of life-threatening bleeding
associated with anti-thrombotic medications, and to provide drugs to
reduce thrombus formation on the basis of this assessment.
All patients with NSTEMI and unstable angina should remain on
regular aspirin once they have received their 300 mg initial dose206. If
they are not at high risk of bleeding and no angiography is planned
in the next 24 hours they should receive antithrombin therapy with
fondparinux; otherwise, unfractionated heparin should be used, with
dose adjusted to clotting function as appropriate206.
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A risk assessment tool (based on clinical assessment, ECG and blood
tests – for example the GRACE score) can be used to estimate 6-month
mortality for patients with NSTEMI or unstable angina206. Likewise
bleeding risk can be estimated (based on age, known bleeding com-
plications, renal function, and body-weight). These estimates guide
management206. Those at low risk (with predicted 6-month mortality
less than 1.5%) receive less aggressive treatment; where this estim-
ate is 1.5% or more clinicians should offer clopidogrel 300mg and
should continue clopidogrel for 12 months)206. In those with predicted
6-month mortality greater than 3%, adding a glycoprotein IIb/IIIa
inhibitor may add additional benefit, depending on the balance of
mortality and bleeding risks206.
Beyond the provision of such drugs, angiography with the possib-
ility of follow-on PCI should be offered to patients with a predicted
6-month mortality greater than 6% and also to patients at lower risk
with positive ischaemic testing206, within 96 hours of first admission.
Abciximab may be used as an adjunct to PCI in patients not already
on a glycoprotein IIb/IIIa inhibitor206; patients on fondaparinux un-
dergoing PCI should be offered unfractionated heparin206; bivalirudin
should be offered to those with a predicted mortality greater than
3% who are not already on fondaparunix or a glycoprotein IIb/IIIa
inhibitor206.
Following the acute phase, having taken into consideration an-
giographic findings, a multidisiplinary team with expert input should
consider patients for revascularisation, either with PCI or CABG206.
Further considerations arise with regard to the following206,254.
• Assessment of left ventricular function
• Cardiac rehabilitation
• Lifestyle changes
• Management of CVD risk factors for secondary prevention
Cardiac rehabilation offered in the wake of ACS involves the provi-
sion of advice, psychological and social support, and health education
to patients in the period following the acute event254; this should
include an exercise component to support patients in achieving an
appropriate physical activity level254. Lifestyle changes that patients
should be encouraged to make, and which evidence suggests can
reduce risk of subsequent events and improve outcomes (second-
ary prevention), for the most part overlap with those recommended
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for primary prevention. Measures include smoking cessation, weight
management, physical activity, controlling alcohol consumption, and
dietary changes254.
NICE guidance275 suggests that properly trained individuals should
provide tailored advice, counselling and support to those who smoke
(particularly targeted at those from minority ethnic groups and from
deprived communities). Moreover, the guidance suggests that such
groups should be treated at least in proportion to their number of
smokers compared to the general population. Smoking cessation treat-
ments and advice provided on the NHS should employ methods that
have been rigourously evaluated275 and shown to be effective. Such in-
terventions include so-called brief interventions276 (opportunistic dis-
cussions, negotiation, encouragement and potentially referral to more
intensive NHS Stop Smoking services, possibly in combination with
pharmacotherapy), individual behaviour counselling, group behaviour
counselling, self-help materials, and pharmacotherapy.275 Principles
and techniques of smoking cessation are common to primary and
secondary prevention.
Beyond efforts to modify lifestyle, a number of drug treatments are
recommended for secondary prevention:
1. ACE inhibitor
2. aspirin (with clopidogrel continued if it was started in the acute
phase)
3. beta-blocker
4. statin
For some individuals with contraindications or in those unable to tol-
erate the above medications, alternative regimes may be employed254.
In addition, hypertension should be managed to below target levels
where blood pressure is raised254.
Notwithstanding the availability of advanced pharmacological and
technical options to improve outcomes in those with established
CHD, many emphasise the continued need to implement prevent-
ive strategies for the disease – an area which I now address.
b.2.5.1 Primary prevention
In the context of CHD, primary prevention means preventing disease
arising in the first place. Individuals for whom primary prevention is
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relevant may have subclinical vascular pathology, in which a process or
atheroma development is occuring in the coronary (or other) arteries,
but they do not, by definition, have overt clinical disease; rather, the
aim of primary prevention is to avoid or delay the onset of any such
symptomatic pathology. This can be achieved by modification of an
individual’s risk factors for disease development, which in terms of
the pathophysiology of CHD, outlined in section B.2.1, corresponds to
reducing atheroma progression, averting plaque rupture and avoiding
thrombus formation. In terms of practical risk reduction, this entails
mitigating the CHD-risk associated with a number of lifestyle factors –
smoking, poor diet, lack of exercise, binge drinking – as well as with a
number of physiological states to which lifestyle factors, to a greater
or lesser extent, predispose an individual, namely high blood pressure
(hypertension), adverse lipid profiles, diabetes, chronic renal disease
and obesity.
CHD shares many of these lifestyle and physiological risk factors
with a number of other CVDs, and thus primary prevention of CHD
can have a more generalised effect in preventing all forms of CVD. The
major CVDs are cerebrovascular disease (ischaemic stoke and transi-
ent ischaemic attack), peripheral artery disease (PAD), renovascular
disease and aortic atherosclerosis. CHD is also linked to heart failure,
because hypertension and CHD itself predispose to its development.
In seeking to prevent CVD, two broad categories of interventions are
available: structural (or population-level) interventions and agentic (or
individual-level) interventions101. The former seek to modify risk in
whole populations, principally by addressing behavioural risk factors.
Examples include efforts to improve the population diet (reducing salt,
saturated fat and trans fats), to increase population physical activity
and to reduce smoking rates248; approaches to achieving this would
typically include some combination of legislation, regulation, fiscal
policy, and taxation. The individual-level approach seeks to reduce
risk in defined individuals (usually those at higher risk of disease
development); examples include weight-loss, smoking-cessation, and
dietary interventions which can be offered to individuals, as well as
interventions to manage an individual’s physiological risk factors,
such as hypertension, adverse lipid profiles, and blood glucose.
The availability of these two categories of intervention presents
options about the strategic approach to take to implementation. Either
a whole-population or a high-risk approach to primary prevention
might be emphasised213. Structural interventions are by their nature
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more or less limited to whole-population approaches to disease pre-
vention. Agentic interventions are typically targeted at a subset of
the population; it is feasible that they might be used for the whole
population, but this is normally undesirable due to the balance of
risks for some people in the population (for example potential adverse
effects from medications in low-risk individuals) or impractical due to
resource constraints (for example in delivering health improvement
programmes to everyone).
Detailed consideration was first given to these issues by Geoffrey
Rose in a seminal 1981 paper277 and in subsequent work278. Import-
antly, Rose noted that the number of cases of disease resulting from a
risk factor depends on the product of the excess risk that an individual
with the risk factor has and the prevalence of that risk factor in the
population277. From this it follows that achieving substantial risk re-
ductions in high-risk groups may prevent fewer cases of disease overall
than achieving small reductions in risk in the population as a whole.
The former situation involves a large risk reduction multiplied by a
small population, contrasted with the latter situation where a small
risk reduction is multiplied by a large population. Moreover, these
considerations give rise to what Rose termed the ‘prevention paradox’
whereby ‘a measure that brings large benefits to the community offers
little to each participating individual’277, because many individuals at
moderate or low risk might undergo a preventive intervention when
in fact they were not going to develop the disease anyway. Further-
more, this highlights the extreme importance of the long-term safety
of any interventions that are used for population-level prevention, as
only a small proportion of the group of individuals to which such
interventions are given would subsequently have become cases277.
Some commentators have posited that in the time since Rose wrote on
this subject a number of factors, including better risk prediction and
using baseline risk rather than individual risk factors, has changed
the situation in favour of high-risk strategies279,280, though this view
is not universally held281.
In practice, prevention involves the combination of a population
strategy, using population-level interventions, and a high-risk strategy,
which uses individual-level preventive interventions. As Rose com-
mented
“...the conclusion will be that preventive medicine must em-
brace both [population and high-risk approaches], but, of
the two, power resides with the population strategy”278, p 49.
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Structural interventions such as banning of tobacco advertising, bans
on smoking in public place, escalation of tobacco taxation and changes
to food labeling have been employed by UK and devolved govern-
ments of the UK in recent decades, though government commitment
to systematic implementation of such interventions is variable, with
many recommendations in the NICE guideline on prevention of CVD
in populations unaddressed248. Individual-level interventions have
become increasingly sophisticated with, for example, the emergence
of new classes of drugs to treat hypertension and raised cholesterol,
new antiplatelet agents, and the systemisation of the provision of
individual-level behaviour change interventions. All these develop-
ments have been underpinned by numerous clinical trials, review
articles, risk models, clinical guidelines and clinical standards of care,
which mean that clinicians can now offer a number of evidence-based,
preventive interventions to high-risk individuals. Governments at both
the UK- and Wales-level have recently begun to systematise strategy
for prevention in high-risk individuals with the announcement of
programmes for primary prevention282,283.
The focus of this thesis is the quantification of differences between
social groups that arise from agentic or individual-level approaches –
but, in the light of Rose’s observations, such interventions ignore the
low and moderate risk cases; because of the prevention paradox it is
certain that a bulk of social differences in prevention of CHD between
social groups must arise from the different distributions of risk factors
within populations. While I acknowledge this important propensity
from the outset (that is to say the phenomenon whereby effective pop-
ulation prevention requires a mass, rather than high-risk, approach),
differences in mortality between socio-economic groups arising from
systematic differences in the utilisation of agentic interventions might
contribute to the development of some of the disparity seen. Moreover,
I address in this thesis not just preventive approaches, but include
also other components of management, as outlined below, which may
contribute additionally to mortality differences. Thus, it is clear that
the approach taken in this thesis cannot lead to the identification
of the reasons for all of the disparity seen between socio-economic
groups, but it may explain some of it. Furthermore, any such disparity
identified, based as it is on differences in utilisation of agentic inter-
ventions, might be amenable to amelioration by a quite different set of
strategies and policy approaches as compared to disparities arising
from population risk factor distributions.
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The focus of recent primary-prevention strategies at the individual
level is in identifying individuals at a high risk – defined typically as
a the risk of a disease event above a particular threshold, for example
20% risk of a cardiovascular event in the next 10 years – and offering
those individuals interventions to mitigate that risk. For the high-risk
subpopulation it has the potential to prevent disease onset, but such
an approach is heavily dependent on the capacity to identify correctly
those individuals that are at high risk; with a view to achieving this a
number of risk models have been developed over recent decades.
Multivariate risk functions derived from cohort studies and random-
ised control trials underlie the development of such risk prediction
functions and scores284. In principle, development of risk equations
involves following over time groups of individuals on whom data are
available on known and putative cardiovascular risk factors; during
the follow-up period cardiovascular outcomes are recorded; these
data then inform multivariate regression analyses, which produce
the required risk equations (which contain coefficients for each of
the risk factors found to be significant in predicting outcome and
which allow calculation of a risk score). The extent to which such
risk models are able to correctly predict cardiovascular outcomes is
important; overestimating an individual’s risk raises the possibility
that they will be overtreated with the risk of adverse consequences
without the concurrent benefit to justify such risk; underestimating
individual risk can mean that individuals with a capacity to benefit
from treatment miss out.
It is feasible that future developments, or even the systematic ap-
plication of currently available technologies, might provide improved
capacity to predict cardiovascular risk, for example by the use of ima-
ging technologies to identify subclinical atheroma or by the use of
more sophisticated biomarkers. Neither current UK practice nor UK
guidelines advocate such approaches260. For the time being at least,
designation of an individual as being at high risk is accomplished on
the basis of the more traditional approach of using risk scores based
on important known risk factors for CVD.
While each of the available risk scores is based on the same prin-
ciples, the estimates that they produce vary285. A very large number of
these tools are available to clinicians, with a NICE review of such tools
from 2008 finding as many as 110 available260. The best known of such
tools are the risk equations based on the Framingham cohort study.
The first risk equations based on the study were published in 1976,
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with further versions published in 1991, 1998 and 2008. Other risk
scores include the QRISK 2 score, the European SCORE, and ASSIGN.
The important characteristics of the major risk scores are summarised
in table B.1; data in this table and in figure B.3 are taken from the 2011
paper by Liew et al2. The exact outcome events aand the time period
over which these events occur vary between risk models.
Beyond the inherent limitation of a high-risk strategy articulated by
Geoffrey Rose (namely its inability to prevent as many cases as a mass
approach), other issues arise. Concerns have been raised over the cap-
ability of risk scores to predict accurately284, and over the possibility
that, though a risk score may be applicable in one population, it may
perform poorly in another286. It is not clear the adequate comparison
of different models in different populations has been carried out us-
ing appropriate methods286. A related concern with many of the risk
scores available (particularly those based on more recent cohorts) is
that they may not have taken adequate account of those beginning
preventive treatment in the follow-up period, thus biasing the studies
towards underestimating cardiovascular risk2. Furthermore, it has
been argued that risk scores are unnecessary, because the use of age
alone (because it is such a strong risk factor) provides sufficient inform-
ation about risk287. Finally, even assuming an effective tool, it is not
clear that clinicians are comfortable with using risk scores in practice;
possibly due to difficulties using them or a perceived infringement
of clinical autonomy288. While such concerns exist about the use of
specific risk scores and about the wisdom of using risk scores at all,
current UK guidelines advocate their use in clinical practice (though
they do not specify a particular score)260.
Potential problems related to risk scoring methods link to the wider
problems with the high-risk approach to primary prevention of CVD.
Although components of a high-risk prevention strategy have been
subject to randomised trials (for example statins and antihypertensive
medications), the overall effect of a high-risk strategy has not289,290.
Even if a positive effect is assumed, it is not clear that the approach
would be more cost effective than the equivalent expenditure on
structural interventions. High-risk approaches offer ‘treatments’ to in-
dividuals to modify disease risk; but this brings with it the possibility
of treatment failure, limited adherence to treatment, and medicalisa-
tion of healthy individuals (and depending on the nature of measures
adopted, this may apply to large segments of the older population)289.
At lower thresholds for treatment, more individuals need to be treated
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to prevent a case of disease, but for these individuals there is no equi-
valent reduction in the risk of adverse effect; it is therefore difficult to
be sure of an appropriate threshold for treatment291. Critics also point
to the residual risk with which individuals are left – as the available
preventive treatments do not eliminate risk, citing such treatments as
simply ‘sticking plasters’ that do not address the underlying cause of
the disease291,292. A further cause for concern is the possibility that
a high-risk strategy using an agentic approach to prevention might
distract from the potential merits of a structural approach that, for
the reasons outlined by Rose, might have the capacity to substantially
reduce disease101,213,281,293. Finally, and importantly for this thesis, a
high-risk approach with its inherent emphasis on agentic intervention
might widen rather than reduce socio-economic inequalities in CHD
and CVD more generally101,291,294. Critics of a high-risk approach
cite the operation of the inverse care law as evidence that more de-
prived individuals with reduced resource are less able to exploit the
opportunities presented by agentic interventions291,292,294.
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Table B.1: Summary of risk models. All models have age, gender (where applicable), smoking and systolic blood pressure as predictors in addition to
those shown in the table. Data are from Liew 20112; The risk models are shown in order of the start of the time period during which they
collected data
Study Age group Predictors Event predicted
Framingham
1976295
35–64 Serum total cholesterol,
blood/urine glucose, LVH on ECG
CVD events (death from CVD, MI,
ischaemic stroke, angina, PAD,
hypertensive congestive cardiac
failure (CCF))
SCORE
2003296
45–64 Total cholesterol or ratio Fatal CVD events
Framingham
1991297
30–74 Serum total cholesterol, blood
glucose, LVH on ECG
CHD (death from CHD, MI,
angina)
Framingham
1998298
30–74 Serum total cholesterol or LDL,
blood glucose
CHD (death from CHD, MI,
angina)
Framingham
2008299
30–74 Total cholesterol (or BMI in the
non-lab score), antiplatelet
medication
CVD events (CHD death, MI,
ischaemic stroke, haemorrhagic
stroke, TIA, angina, PAD,
hypertensive CCF)
NHEFS
2008300
25–74 Diabetes, BMI CVD events (CHD death, MI,
ischaemic stroke, haemorrhagic
stroke, revascularisation,
hypertensive CCF)
PROCAM
2007301
20–75 LDL, fasting glucose, family
history
CHD (death from CHD, MI)
PROCAM
2002302
35–65 LDL, fasting glucose, family
history
CHD (death from CHD, MI)
Continued on next page
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Study Age group Predictors Event predicted
Progetto
CUORE
2004303
35–69 Total cholesterol, fasting blood
glucose, antiplatelet
CVD events (death from CHD, MI,
ischaemic stroke, haemorrhagic
stroke, revascularisation)
USA-PRC
2006304
39–59 Total cholesterol, fasting glucose,
BMI
CVD events (death from CHD, MI,
ischaemic stroke)
ASSIGN
2007305
30–74 Total cholesterol, diabetes, family
history, socio-economic deprivation
CVD events (death from CHD, MI,
ischaemic stroke, haemorrhagic
stroke, TIA, angina,
revascularisation, hypertensive
CCF
ARIC
2003306
45–64 Total cholesterol, fasting glucose,
antiplatelet medication, ethinicity
CHD (death from CHD, MI)
Personal
HEART
2007307
45–64 Hypercholesterolaemia, diabetes,
family history (men), physical
activity (men), BMI (women)
CHD (death from CHD, MI,
revascularisation)
SHS
2006308
45–74 Total cholesterol or LDL, fasting
glucose, antiplatelet medication,
albuminuria
CHD (death from CHD, MI,
angina, revascularisation)
Reynolds
women
2007309
45+ Total cholesterol, family history,
high-sensitivity C-reactive
protein (hsCRP), HBA1c in
diabetics
CVD events (death from CHD, MI,
ischaemic stroke, revascularisation)
Continued on next page
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Table B.1 – Continued from previous page
Study Age group Predictors Event predicted
QRISK 2
2008182
35–74 Total cholesterol/HDL ratio,
antiplatelet, BMI, ethnicity, family
history, Townsend deprivation,
rheumatoid arthritis, chronic renal
disease, atrial fibrillation
CVD events (CHD death, MI,
ischaemic stroke, TIA, angina)
Reynolds
men 200890
50–80 Total cholesterol, family history,
hsCRP; diabetics exluded at
baseline
CVD events (death from CHD, MI,
ischaemic stroke, haemorrhagic
stroke, revascularisation)
QRISK
2007310
35–74 Total cholesterol/HDL ratio,
antiplatelet, BMI, family history,
Townsend deprivation. Diabetics
excluded at baseline
CVD events (CHD death, MI,
ischaemic stroke, haemorrhagic
stroke, TIA, angina
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Notwithstanding the issues and debates around approaches to
primary prevention in high-risk individuals, current guidelines make
a number of recommendations183,260.
• A systematic strategy should be implemented with a view to
identifying individuals in the 40–74 age range who are likely to
be at high risk of CVD
• Risk equations should be used (where available ) to carry out
formal CVD risk assessments in such individuals, with a 20% or
greater 10-year risk of CVD used as a threshold
• The balance of benefits and risks should be clearly explained to
individuals
• In high-risk individuals, identified by formal risk assessment,
modifiable CVD risk factors should be addressed by encourage-
ment of lifestyle changes (cardioprotective diet, physical activity,
weight management, reduction of alcohol consumption, smoking
cessation) and referral to specialist services where appropriate
• Additionally such individuals should, where appropriate, be
offered antihypertensives, lipid-lowering therapy, have their
blood sugars managed, and their obesity addressed
When providing lipid-lowering therapy for primary prevention, sim-
vastatin 40mg is the recommended dose; there is no target level for
cholesterol. Other lipid-lowering agents can be considered in those
who do not tolerate statins260.
Individuals with a CVD risk greater than 20% should be offered
antihypertensive therapy if they have either stage 1 or stage 2 hy-
pertension183. It is now recommended that suspected hypertension
(blood pressure reading greater than 140/90 mmHg) is confirmed by
ambulatory blood pressure monitoring or home blood pressure monit-
oring183. Using these tests, the cut-offs used are slightly different, with
a blood pressure greater than 135/85 mmHg indicating stage 1 hyper-
tension; greater than 150/95 mmHg indicates stage 2 hypertension.
A staged approach to treatment is recommended, with progression
through stages based on response to therapy – the minimum number
of medications requred to control blood pressure being employed183.
1. In those aged under 55 offer a ACE inhibitor or, if this is not
tolerated, an ARB (or beta-blocker as last resort); those over 55 or
of afro-Caribbean ethnicity should be offered a CCB, or, if this is
not tolerated, a thiazide-like diuretic (chlortalidon, indapamide)
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Figure B.3: Risk models over time. Coloured rectanges indicate the period
of recruitment; black lines show the period to publication; black
points show publication year; rectangles are coloured by location.
Studies are ordered by the start date of data collection
Year
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
l
1950 1960 1970 1980 1990 2000
Framingham 1976
SCORE 2003
Framingham 1991
Framingham 1998
Framingham 2008
NHEFS 2008
PROCAM 2007
PROCAM 2002
Progetto CUORE 2004
USA−PRC 2006
ASSIGN 2007
ARIC 2003
Personal HEART 2007
SHS 2006
Reynolds women 2007
QRISK 2 2008
Reynolds men 2008
QRISK 2007
Location
China
Europe
Germany
Italy
UK
USA
Source: adapted from safe Liew 20112
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2. Progress to treatment with a CCB together with an ACE or ARB.
3. Add thiazide-like diuretic
4. Consider adding a fourth drug (spironolactone, beta blocker, al-
pha blocker), higher doses of a thiazide-like diuretic or obtaining
specialist advice
The target for therapy is a blood pressure of 140/90 mmHg (using
standard blood pressure readings) or lower in those aged under 80
years, and of 150/90 mmHg (using standard blood pressure readings)
in those aged 80 and over183.
Much attention has been paid in the preceding sections to the con-
tent of clinical guidelines that pertain to CHD. I feel that such an
approach was necessary because, though guidelines are not univer-
sally applicable and are not universally agreed with, they are, for the
purposes of this thesis, useful, in that they provide a coherent view of
the standard of care that an individual might expect. Moreover, NICE
guidelines outline the standard of care that an individual might expect
to be offered from the NHS, regardless of their personal characteristics;
such characteristics include an individual’s socio-economic status and
the level of deprivation of the area in which an individual lives; I
discuss these issues next.
b.2.6 Organisation of cardiac services in Wales
Political responsibility for the control of cardiac services in Wales
operates through the WAG. In 2001, it published NSF-2001, which set
out the standard of cardiac care that should be provided for the Welsh
population.163 Subsequently this document has been updated with
a revision that also includes non-CHD cardiac disease: NSF-2009.163
Broadly, these documents set out the expectation that organisations
responsible for the delivery of cardiac services should prepare a local
plan to develop and deliver effective care, aiming to address issues
throughout the ‘patient journey’ and that they should ensure that best
practice is identified and transferred throughout the system.164 To aid
with the delivery of the NSFs, WAG set up three cardiac networks
within Wales (North Wales; Mid and South West Wales; South East
Wales), overseen by a Cardiac Networks Coordinating Group.164
The delivery of care for CHD for the population of Wales is under-
taken by a number of different organisations, according to the type
of care provided. Primary care is delivered by GPs in practices across
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Wales, and for some patients living close to the border by practices in
England. Such care involves the management of risk factors for CVD,
the management of stable disease, and referral of complex cases to
secondary care. Secondary care for CHD involves the management of
complex cases in outpatient departments of District General Hospitals
(or higher-level centres) as well as inpatient treatment of cases – par-
ticularly ACSs. Hospitals involved in the provision of secondary care
for Welsh patients are located across Wales and in areas of England
close to the Welsh border.
Only certain centres have the capacity to provide specialist cardiac
services for Welsh patients. Diagnostic angiography for Welsh patients
has been provided at eight Welsh centres: Ysbyty Glan Clwyd (YGC),
Prince Charles Hospital, Royal Gwent Hospital (RGH), Nevil Hall Hos-
pital, University Hospital of Wales (UHW), Royal Glamorgan Hospital,
Morriston Hospital (MH), and the Princess of Wales Hospital. Two
English centres across the border also provide the service: Liverpool
Heart and Chest Hospital (LHCH), Countess of Chester Hospital.165
PCI has traditionally been provided at three main centres in Wales
(MH, UHW, YGC) as well as at LHCH in England; from June 2011
RGH has also begun providing the procedure.165 Cardiac surgery
for Welsh patients, including CABG, is carried out at three principal
centres: MH, UHW, and LHCH.165
On the basis of original NSFs, target population rates for major
procedures for the treatment of CHD have been set out.166–168 It is
notable that as of the financial year 2010/11, rates of PCI (1112 per
million population) were lower than rates in England (1401 per million
population), but higher than the recommended rates set out in the
original NSF (750 per million population).165 For primary PCI, the
rate of 111 per million population in Wales was substantially lower
than the rate in England (302 per million population).165 For CABG,
the overall rate was 270 per million population for Wales, lower than
the target rate of 754 million population set out in the original NSF.165
b.3 additional background material relating to thesis
methods
b.3.1 Clinical coding
For the purposes of this thesis, three clinical coding systems are
relevant:
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1. ICD-10 – used in PEDW records to code diagnoses and mortality
records to code cause of death
2. OPCS-4 – used in PEDW records to code procedures
3. Read codes – used in GP records to code all primary-care activity
b.3.1.1 ICD-10
ICD-10 is the 10th revision of the International Statistical Classification
of Diseases and Related Health Problems. It is a medical classification
system developed by the WHO.311 The 10th revision was developed
between 1983 and 1992, building on earlier versions of the classifica-
tion.311,312 The original function served by the International Statistical
Classification of Diseases and Related Health Problems (ICD) was in
classifying causes of death at registration.312 It is now the interna-
tional standard diagnostic classification for general epidemiological
and many health-management purposes.311,312 As well as classification
of diseases, ICD can be used to classify signs, symptoms, abnormal
findings, complaints, and social circumstances.311,312
ICD-10 can be used either at a three- or four-digit level, with three-
digit codes providing the core classification, mandatory for reporting
to the WHO mortality database, and four-digit codes allowing more
detailed specification where required.311,312 The classification itself is
divided into 21 chapters.311,312 The first character in each code is a
letter associated with a chapter (except for letters ‘D’ and ‘H’, which
are associated with more than one chapter).311,312 Thus, chapter IX,
entitled ‘Diseases of the circulatory system’, contains codes beginning
with the letter ‘I’.311,312 Each of the chapters in the classification con-
tains sufficient three-digit codes to cover all its content.311,312 Not all
available codes are used, to allow space for addition and revision.311,312
Chapters themselves are divided into blocks of homogenous three-
character subcategories.312 For most of these three-character blocks,
an additional, fourth numeric-character can be used to create up to
10 subcategories for that block.312 The ICD-10 codes relevant to this
thesis are shown in appendix E.
b.3.1.2 OPCS-4
Coding of procedures in PEDW is carried out using the OPCS-4 coding
system. This is a procedural coding system for classifying operations,
procedures, and interventions.313 The original classification was de-
veloped by the Office of Population Censuses and Surveys in 1992.313
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Since that time there have been a number of revisions; current respons-
ibility for maintaining and revising the classification lies with NHS
Connecting for Health.313
The coding system for OPCS-4 uses a four-character alphanumeric
system, similar to that employed by the ICD-10.313 Codes are com-
posed of a letter and three numeric characters.313 Codes in the OPCS-4
are divided into chapters as with ICD-10, though the chapters in the
two systems do not correspond.313 The OPCS-4 codes relevant to this
thesis are shown in appendix E.
b.3.1.3 Read codes
Read codes are the standard clinical terminology used in primary
care in the UK to encode primary-care activity.314,315 Multiple pa-
tient phenomena can be captured using the system, including patient
characteristics, signs, symptoms, observations, laboratory tests and
results, diagnoses, procedures, and administrative items.315 The first
version of the Read code system was developed by a Loughborough
GP, Dr James Read. Two further versions of the Read code system
have subsequently been developed, version 2 and version 3.314,315
The vast majority of primary care data used for this thesis were
coded using Read code version 2.314,315 This version was released in
the early 1990s. It uses an alphanumeric code with five digits.314,315
The TRUD maintains the Read code version 2 classification system,
as well as providing NHS Data Migration datasets, which allow the
conversion of version 2 Read codes into version 3 Read codes and
SNOMED CT codes (which was necessary in this thesis – see chapter
4).316 Recent releases of Read codes version 2 contain in excess of
80,000 codes.316 A co-publication with Read codes version 2 is the
drug and appliance dictionary, which contains in excess of 50,000
codes relating to medications and medical devices, organised along
the same lines as Read codes version 2. This additional set of codes is
used to record the use of medications and medical devices in primary
care.

CL I T E R AT U R E R E V I E W TA B L E S
On the following pages, we include tables relevant to the literature
review presented in a chapter 3. The format of the tables that follow
is equivalent to that used in table 3.1. We include these tables here
with a view to providing necessary supporting detail for chapter 3
while at the same time seeking to avoid overloading the reader with
information.
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Table C.1: Summary of papers examining inequity of provision of antihypertensives for primary prevention
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Pears
2003108;
Scotland,
1998
Carstairs and
Morris Index
of deprivation
1991
Cross-sectional study
using GP
administrative data.
19,352 patients with
hypertension-related
Read code could be
assigned deprivation
category. Outcome was
‘under-review’, ‘treated’
or ‘not-followed-up’.
Multiple logistic
regression
Patients from deprived areas less
likely to be under review, adjusted
odds ratio 0.7 (95% CIs 0.7, 0.8),
compared to least deprived
patients. Odds ratios adjusted for
sex age, and comorbidities for most
deprived compared to least
deprived (reference group):
thiazide diuretics 0.7 (95% CIs 0.7,
0.8); ACE inhibitors 1.2 (95% CIs
1.0, 1.3); calcium-channel blockers
1.3 (95% CIs 1.2, 1.4)
The odds of being on any treatment
for hypertension are not available
from the study. More deprived
hypertension patients are less
likely to be on thiazide diuretics, as
likely to be on beta-blockers, and
more likely to be on ACE
inhibitors and calcium-channel
blockers compared to the least
deprived patients
Edwards
2003111;
Salford,
UK, 1993-4
and 2000-1
Townsend
deprivation
1991
Data from Diabetes
Information System
used to analyse
individuals for
attainments of targets
for diabetes treatment
at two time-points.
In 1993-4, 30.5% in the least
deprived quintile met SBP target;
compared to 31.1% in the most
deprived quintile ; p-value for
trend across fifths 0.862. In 2000-1,
47.1% (least deprived); 46.5%
(most) met SBP target; p-value for
trend 0.466. In 1993-4, 18.9% (least
deprived); 19.8% (most) received
anti-hypertensive treatment;
p-value for trend 0.810. In 2000-1,
50.5% (least deprived); 51.1%
(most) received anti-hypertensives;
p-value for trend 0.0071
Diabetic patients only. No evidence
of differential achievement of BP
targets. No evidence of differencial
BP treatment
Continued on next page
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Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Chen
2003113;
Scotland,
1986 to
1995
Carstairs and
Morris Index
of deprivation
1991
Data from the Glasgow
MONICA study –
cross-sectional surveys.
Study examined the
difference in
proportion of
individuals with
hypertension identified,
treated and controlled.
Multivariate logistic
regression
Multivariate analysis hypertension
control was not significantly
related to socio-economic
deprivation in this population
(p-value 0.238)
No evidence of association between
deprivation status and quality of
BP control
Bachman
2003114;
Avon and
Somerset,
UK, 1998 to
2000
Income Questionnaire of
patients with diabetes.
74% response rate
No significant difference between
income groups in the mean SBP.
Adjusted slope index of inequality
-0.25 (95% CIs -5.1, 4.6)
Diabetic patients only
Ward
2004109;
Four
Primary
Care Trusts
(PCTs) in
North-West
England,
1999 and
2000
Age; ethnicity;
LISI score
(deprivation);
Townsend
score
Ecological study at
practice level.
Univariate
relationships between
LISI score and
prescribing rate.
Associations examined
using Spearman’s rank
correlations
Townsend score correlation
coefficient for ACE inhibitors -0.405
(significant at the 0.01 level) across
all PCTs and for bendrofluazide
-0.275 (significant at the 0.01 level).
Correlation coefficients for
beta-blockers not significant
Univariate analysis does not take
account of each of the different
proxies of need when considering
their relationships with prescribing
rates
Continued on next page
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Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Hippisley-
Cox
2004115;
UK, 2004
Townsend
2001
QRESEARCH database.
54180 patients with
diabetes. Outcome was
adjusted odds ratio for
main outcome
indicators from general
medical services
contract. Comparisons
between most deprived
and least deprived
fifths of deprivation
Achievement of blood pressure
target (<145/85 mmHg) not
statistically different between the
two most extreme deprivation
groups. Odds ratio (most deprived
compared to least deprived) 0.96
(95% CIs 0.90, 1.03)
Diabetic patients only. No
systematic difference in
achievement of blood pressure
target between deprivation
categories
Ward
2005110;
Four PCTs
in
North-West
England,
1999; 2000
Age; ethnicity;
LISI score
Ecological: prescribing
rates for practices,
modelled on a number
of proxies for CHD
need for practices
Multivariate regression analysis.
No association between LISI score
ACE inhibitors or between LISI
score and beta-blockers. Negative
association between LISI score and
bendrofluazide prescription rate,
implying that increased
bendrofluazide prescribing is
associated with less deprived
practices. Beta coefficient in
regression model -0.261; R2 x 100 =
13.1, suggesting that 13.1% of the
prescribing rate for bendrofluazide
can be attributed to this
relationship
Does not consider need at an
individual level; uses a limited list
of cardiovascular drugs; not
possible to differentiate between
primary prevention and secondary
prevention in this study
Continued on next page
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Author
Year;
Setting
Inequity
dimension
Study type Results Comment
McLean
2006117;
Scotland,
2005
SIMD 2004 –
income
domain;
Practice-level
analysis using
average
deprivation
Retrospective analysis
of GP QOF data. 1024
general practices.
Examined relationship
between practice
deprivation and
delivered care. Linear
regression
The regression coefficient for
control of hypertension was -0.05
(p-value 0.14) for payment quality
and -0.08 (p-value 0.01) for
delivered quality. For diabetic
blood-pressure control the
payment quality regression
coefficient was 0.31 (p-value <0.001)
and the delivered quality
regression coefficient was 0.16
(p-value <0.001)
Regression coefficients in this study
indicate the change in quality
associated with a one-point
increase in the percentage of
deprived individuals. Payment
quality analysis removes
individuals who, for various
reasons, are excluded from
payment calculations. Delivered
quality includes these individuals.
The regression coefficient suggests
a non-significant decline in the
management of hypertension
generally as deprivation increases;
for diabetic patients, management
of hypertension improves as
deprivation increases
Patel
2006118;
UK, 1998 to
2001
Social class
(manual
verses
non-manual)
Data from British
Women’s Heart and
Health Study and the
British Regional Heart
Study. Cross-setional
analysis. Multiple
logistic regression
Social class is not associated with a
difference in the quality of blood
pressure control in multivariate
analysis, odd ratio manual vs
non-manual 1.19 (95% CIs 0.94,
1.50)
Suggests manual group may have
better blood pressure control,
though not statistically significant.
Continued on next page
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Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Gray
2006116;
Wandsworth,
London,
2003
IMD Population-based
cross-sectional survey
using electronic GP
records. Examined
success rate for
diabetes quality
indicators. Logistic
regression. n=6035
Patients in the most deprived
groups were less likely to meet the
target for blood pressure, but this
result did not reach statistical
significance – odds ratio of
achieving target least deprived
compared to most deprived (1.18
(95% CIs 0.92, 1.52)
Diabetic patients only
Millett, Car
et al
2007119;
England
and
Scotland,
2004
IMD linked to
practices via
postcode
Study uses QOF data
from England and
Scotland. Practice-level
data. Studies the effect,
at practice-level, of
deprivation on
achievement scores
In the most deprived group of
practices 69.5% of patients met BP
control targets; in the intermediate
practices 72.2% and in the least
deprived practices 71.4% of
patients met targets. No CIs
presented
This study only considers diabetic
patients. Ecological study using
QOF data
Saxena
2007104;
UK, 2004,
2005
IMD 2004.
Grouped into
three bands
Ecological study using
QOF data. Large
number of GP practices
in the UK. Examination
of practice performance
in relation to a number
of practice
characteristics,
including practice size,
deprivation
Some indication of a gradient of
increased proportion of
hypertensive patients meeting
target blood pressure with
decreased deprivation. Groups
statistically different using Kruskal
Wallis exact test p-value <0.0001
Ecological data
Continued on next page
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Author
Year;
Setting
Inequity
dimension
Study type Results Comment
McGovern
2008120;
Scotland,
UK, 2004,
2005
Carstairs and
Morris Index
of deprivation
1991
Study of a number of
quality indicators of
diabetic care in diabetic
patients. Logistic
regression with
covariates gender, age,
diabetes co-morbidities
and deprivation
category
In the logistic regression,
deprivation was not a significant
covariate for blood pressure control
in 2004, with adjusted odds ratio
1.10 (95% CIs 0.94, 1.30), or 2005,
with adjusted odds ratio 1.13 (95%
CIs 0.98, 1.31)
Multiple comparisons were made;
in most comparisons deprivation
was not a statistically significant
covariate. This study looks only at
diabetic patients
Ashworth
2008121;
England,
2005 to
2007
IMD Retrospective
longitudinal survey.
Deprivation analysed
at practice level.
Practice-level analysis.
Relationship between
deprivation and six
QOF indicators related
to blood pressure.
In those with hypertension, the gap
between the least and most
deprived in the proportion with
blood pressure controlled
narrowed over the study period. In
2004-5, 72.4 (95% CIs 71.9, 72.9) in
the least deprived group met
control targets compared to 69.1
(95% CIs 68.6, 69.6); in 2006-7, the
percentages were for least deprived
78.0 (95% CIs 75.5, 76.3) and for the
most deprived 77.4 (95% CIs 77.1,
77.7)
This study suggest that there may
be a narrowing in the disparity in
control of blood pressure and those
with hypertension over the study
period. Practice-level analysis
Continued on next page
412
liter
a
tu
r
e
r
ev
iew
ta
bles
Table C.1 – Continued from previous page
Author
Year;
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Inequity
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Study type Results Comment
Hamilton
2010;
UK, 1997
and 2005
IMD 2004 Patients with type 1 or
type 2 diabetes. Study
looked at achievement
of HbA1C <7.0%, blood
pressure <140/80
mmHg, and total
cholesterol (<5
mmol/L)
In 1997, adjusted odd ratio (for age
and sex) for achievement of BP
target (most versus least deprved
quintile) was 1.03 (95% CIs 1.01,
1.05). Fourth most deprived
quintile versus least deprived
quintile 1.04 (95% CIs 1.02, 1.06).
Other quintile comparisons not
significant. By 2005 the adjusted
odds ratio (most versus least) was
1.03 (95% CIs 0.99, 1.06). Other
quintile comparisons not
statistically significant
Diabetic patients only. Some
suggestion that more deprived
patients are more likely to achieve
BP target
Hammouche
2011123;
18 general
practices in
Norfolk,
UK, 2003
and 2005
IMD Individual level data
extracted from general
practice records. 304
patients. Achievement
of quality for
indications by
deprivation assessed in
univariate and
multivariate analysis
The achievement of quality
indicators for hypertension either
did not vary with geographic
deprivation, or was higher in
patients from more deprived
localities.
Individual level data. Small
numbers.
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Table C.2: Summary of papers examining inequity of provision of lipid-lowering medications for primary prevention
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Bradshaw
1998124;
Gwent,
Wales, 1997
Townsend 1991 Ward-level analysis.
Correlation coefficient for
ward-level deprivation
and statin-prescribing
rate.
No association at ward-level between
the rate of statin prescribing and the
Townsend deprivation quintile (r =
-0.15; p-value = 0.09)
The papers argues that patients in
areas of greater deprivation are likely
to have greater need for statins; the
absence of a correlation might
represent evidence of inequity of
provision of statins
Packham
1999125;
Nottingham,
UK, 1996
Townsend 1991;
Jarman ‘Under-
privileged Area
Score’
Statin prescribing in
relation to deprivation in
general practices.
Ecological analysis at
practice level
There was a statistically significant
inverse relationship between the rate
of statin prescribing and deprivation
score, with p-value <0.0001
This study does not directly take
account of the level of need for
lipid-lowering medications in the
different practices examined, but
assumes that there will be a higher
level of need in more deprived areas,
which, in an equitable situation, ought
to be reflected in higher prescribing
rates
Packham
2000126;
Nottingham,
UK, 1996 to
1998
Townsend 1991 Analysis of general
practice data looking for
practice-level
relationships between
statin-prescribing and
practice-level deprivation.
Multiple linear regression
adjusting for other
practice characteristics
In each year practices in the most
deprived areas had lower rates of
statin prescribing. In 1996 this
relationship was statistically
significant (p-value <0.0005. In 1997
and 1998, proportionately larger
increases in the more deprived
practices meant that no significant
relationship existed between
deprivation and practice prescribing
Initial relationship between
deprivation and statin-prescribing is
not statistically significant after 1996
Continued on next page
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Inequity
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Study type Results Comment
Edwards
2003111;
Salford, UK,
1993-4 and
2000-1
Townsend
deprivation
1991
Data from Diabetes
Information System used
to analyse individuals for
attainments of targets for
diabetes treatment at two
time-points.
No evidence of significant trend across
deprivation fifths in treatment with
lipid-lowering medication or in
achievement of cholesterol targets in
either 1993-4 or 2000-1
Diabetic patients only. No indication
of systematic difference based on
deprivation
Bachman
2003114;
Avon and
Somerset,
UK, 1998 to
2000
Income Questionnaire of patients
with diabetes. 74%
response rate
Results for this paper seem
inconsistent. The adjusted slope index
of inequality (derived from the linear
regression line) is 0.6 (95% CIs 0.2, 0.9),
with a P-value of 0.39
Diabetic patients only
Ward
2004109;
Four PCTs
in
North-West
England,
1999 and
2000
Age; ethnicity;
LISI score
(deprivation);
Townsend score
Ecological study at
practice level. Univariate
relationships between
LISI score and
prescribing rate.
Associations examined
using Spearman’s rank
correlations
The Spearman’s rank correlation
coefficient for the association between
prescribing rates for statins and the
Townsend score was -0.237, which was
statistically significant at the 0.01 level.
When the LISI score was used instead
of Townsend, the correlation
coefficient was -0.326, and was
statistically significant at the 0.01 level.
The findings suggest that as
deprivation increases the prescribing
rate for statins decreases.
Methodological limitations of this
study, including the ecological nature,
and the failure to correct for important
covariates limit the weight that can be
given to this finding
Continued on next page
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Author
Year;
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Inequity
dimension
Study type Results Comment
Hippisley-
Cox
2004115;
UK, 2004
Townsend 2001 QRESEARCH database.
54180 patients with
diabetes. Outcome was
adjusted odds ratio for
main outcome indicators
from general medical
services contract.
Comparisons between
most deprived and least
deprived fifths of
deprivation
Cholesterol target <5 mmol/L
achievement does not differ between
deprivation fifths. Odds ratio (most
deprived to least deprived) 0.99 (95%
CIs 0.92, 1.06)
Diabetic patients only. No suggestion
that the achievement of cholesterol
target is systematically different
between deprivation groups. Statin
prescription is not analysed in this
study
Ward
2005110;
Four PCTs
in
North-West
England,
1999; 2000
Age; ethnicity;
LISI score
Ecological: prescribing
rates for practices,
modelled on a number of
proxies for CHD need for
practices
This study used multivariate
regression modelling and examined
whether deprivation (represented by
LISI score) was a predictor of statin
prescribing. Deprivation dropped out
of the model as is was not a significant
predictor of statin prescribing
No evidence of a relationship between
deprivation and statin prescribing. Not
possible to separate analysis by
primary and secondary prevention.
Individual need is not considered.
McLean
2006117;
Scotland,
2005
SIMD 2004 –
income domain;
Practice-level
analysis using
average
deprivation
Retrospective analysis of
GP QOF data. 1024
general practices.
Examined relationship
between practice
deprivation and delivered
care. Linear regression
The regression coefficient for
achievement of cholesterol control was
-0.13 (p = 0.01) for payment quality; for
delivered quality the regression
coefficient was -0.12 (p = 0.01)
Regression coefficients in this study
indicate the change in quality
associated with a one-point increase in
the percentage of deprived individuals.
Payment quality analysis removes
individuals who, for various reasons,
are excluded from payment
calculations. Delivered quality
includes these individuals. Increasing
practice-level deprivation is reflected
in poorer levels of cholesterol control
in those with CHD, both for payment
and delivered quality.
Continued on next page
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Inequity
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Study type Results Comment
Gray
2006116;
Wandsworth,
London,
2003
IMD Population-based
cross-sectional survey
using electronic GP
records. Examined
success rate for diabetes
quality indicators.
Logistic regression.
n=6035
No significant difference in
achievement of cholesterol target of
less than or equal to 5mmol/L, odds
ratio least deprived versus most
deprived 1.02 (95% CIs 0.81, 1.28)
There is no information in this study
on prescribing of cholesterol-lowering
medication
Millett, Car
et al 2007119;
England and
Scotland,
2004
IMD linked to
practices via
postcode
Study uses QOF data
from England and
Scotland. Practice-level
data. Studies the effect, at
practice-level, of
deprivation on
achievement scores
In most deprived practices, 69.9% of
patients met cholesterol targets; in the
intermediate group of practies 72.7%;
in the least deprived practices 73.3% of
patients met the cholesterol target. CIs
not presented.
This is a study using QOF data.
Diabetic patients only.
Ashworth
2007128;
England,
2004-5
IMD Practice-level analysis of
prescribing of statins in
general practice, looking
at covariates associated
with increased
prescribing
Statin prescribing was higher in more
deprived communities. IMD was
statistically significant in predicting
statin prescribing, with increased
deprivation associated with increased
prescribing in univariate and
multivariate analysis with p-values
<0.001
Ecological study at practice level.
Continued on next page
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Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Ward
2007127;
Four PCTs
in
North-West
England,
1999, 2000
LISI score Cross-sectional ecological
study at practice level to
look at possible inequity
in provision of statins in
primary care.
Multivariate regression
analysis looking at
practice-prescribing rate
as dependent variable.
LISI score is a covariate
in the model
LISI score explained 11% of the
variation in prescribing rates seen
between practices, with a
beta-coefficient of -0.327, for only one
of the PCT. Overall, LISI score was not
significant in predicting
practice-prescribing rate for statins
and dropped out of the multiple
regression model
Some suggestion of reduced
prescribing of statins with increased
deprivation in one PCT, but no overall
relationship. Ecological study
McGovern
2008120;
Scotland,
UK, 2004,
2005
Carstairs and
Morris Index of
deprivation
1991
Study of a number of
quality indicators of
diabetic care in diabetic
patients. Logistic
regression with covariates
gender, age, diabetes
co-morbidities and
deprivation category
In 2004 , prior to introduction of the
new contract, the adjusted odds ratio
for management of cholesterol less
than or equal to 5 mmol/l was 1.17
(95% CIs 0.93, 1.46). After the new
contract (in 2005), the odds ratio was
1.17 (95% CIs 1.02,1.34), suggesting
that diabetics from deprived areas had
better cholesterol control
Multiple comparisons were made; in
most comparisons deprivation was not
a statistically significant covariate. This
study looks only at diabetic patients
Continued on next page
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Author
Year;
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Inequity
dimension
Study type Results Comment
Crawley
2009112;
England,
2003; 2006
Social class
(collapsed to
manual and
non-manual
groups)
Health Survey for
England data, 2003 and
2006; patient groups:
diabetics (n= 611 in 2003),
CHD (n=861 in 2003),
hypertensives (n= 3717 in
2003). Management and
prescribing targets for
hypertension, diabetes
and cholesterol. Logistic
regression; adjusted for
age, gender, BMI, disease
duration and treatment
For diabetic patients, the manual to
non-manual adjusted odds ratio for
reducing cholesterol below 5 was 1.13
(95% CIs 0.68, 1.87) in 2003 and 0.86
(95% CIs 0.48, 1.54) in 2006. The
manual to non-manual adjusted odds
ratio for lipid-lowering prescription
was 1.30 (95% CIs 0.87, 1.91) in 2003
and 0.96 (95% CIs 0.70, 1.31) in 2006.
These findings suggest that the
management of cholesterol and the
prescription of lipid-lowering agents
does not vary significantly across
social class groups. This study only
used two groups for comparison of
deprivation, collapsing analysis into
manual and non-manual. This may
masked differences in outcome
between respondents at either end of
the spectrum. The relatively small
number of individuals with diabetes
examined in this study may mean that
numbers were insufficient to
demonstrate an effect of social class in
2006.
Hamilton
2010;
UK, 1997
and 2005
IMD 2004 Patients with type 1 or
type 2 diabetes. Study
looked at achievement of
HbA1C <7.0%, blood
pressure <140/80 mmHg,
and total cholesterol (<5
mmol/L)
In 1997, the adjusted odd ratio (for age
and sex) for meeting the cholesterol
target (most deprived versus least
deprived quintile) was 1.03 (95% CIs
0.99, 1.07). Other comparisons between
quintiles not significant either. In 2005,
most versus least adjusted odds ratio
was 1.14 (95% CIs 1.02, 1.28)
Diabeteic patients only. In 2005, more
deprived patients were more likely to
achieve the cholesterol target
Continued on next page
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Table C.2 – Continued from previous page
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Forde
2011129;
Whitehall
civil
servants,
2005–2007
Socio-economic
group (British
civil service
grade);
ethnicity
Whitehall II, prospective
cohort study; nearly 7000
participants at baseline;
No difference in prescribed
lipid-lowering drug use between
employment grades in either moderate
or low risk groups. Odds ratio
adjusted for age and sex for those at
moderate risk was for the intermediate
to high employment grade 0.74 (95%
CIs 0.55, 1.01) and for the low to high
employment grade 0.89 (95% CIs
0.49,1.75). In those at high risk, the
odds rate for the intermediate to high
employment grade was 0.99 (95% CIs
0.83, 1.19) and for the low to hight
employment grade was 1.06 (95% CIs
0.78, 1.43)
Prospective cohort study does not
suggest inequity in provision. Does
not include extreme deprivation
groups, for example those not in
employment. Detailed and repeated
assessments of clinical need
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Table C.3: Summary of papers examining inequity of provision of anti-platelet medications for primary prevention
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Bedson
2001132;
North
Stafford-
shire, UK,
Not clear
Townsend 1991 Cross-sectional analysis,
using individual-level GP
data. 5983 patients with
cardiovascular disease
identified
Some suggestion that more affluent
individuals were taking more aspirin,
but the trend across the deprivation
categories is not statistically significant
(p-value 0.445). Odds ratio moderately
deprived to most deprived 1.05 (95%
CIs 0.89, 1.24); moderately affluent to
most deprived 1.10 (95% CIs 0.93,
1.31); most afflent to most deprived
1.06 (95% CIs 0.90, 1.26)
Edwards
2003111;
Salford, UK,
1993-4 and
2000-1
Townsend
deprivation
1991
Data from Diabetes
Information System used
to analyse individuals for
attainments of targets for
diabetes treatment at two
time-points.
The p-value for trend across
deprivation fifths not significant in
1993-4 or 2000-1. Substantial
improvement over study period. By
2000-1 24.9% of least deprived and
25.5% of most deprived quintile were
treated with anti-platelet drug
Diabetic patients only.
Ward
2004109;
Four PCTs
in
North-West
England,
1999 and
2000
Age; ethnicity;
LISI score
(deprivation);
Townsend score
Ecological study at
practice level. Univariate
relationships between
LISI score and
prescribing rate.
Associations examined
using Spearman’s rank
correlations
Spearman’s rank correlation coefficient
between aspirin and Townsend score
was 0.041; the result was not
statistically significant at the 0.05 level.
When the LISI score was used as an
alternative to the Townsend score, the
Spearman’s rank correlation coefficient
was -0.128; again not significant at the
0.05 level
No evidence of a relationship between
aspirin prescribing and deprivation
level. Does not take account of
individual need. Univariate analysis
does not take account of each of the
different proxies of need when
considering their relationships with
prescribing rates. This study is largely
superseded by Ward 2005, which used
similar methodology and data sources
but employed multivariate analysis.
Continued on next page
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Study type Results Comment
Ward
2005110;
Four PCTs
in
North-West
England,
1999; 2000
Age; ethnicity;
LISI score
Ecological: prescribing
rates for practices,
modelled on a number of
proxies for CHD need for
practices
In the multivariate regression model,
the LISI score was a significant
predictor of aspirin prescribing. The
beta coefficient was -0.261 (suggesting
that increased deprivation is
associated with decreased prescribing),
with 10.4% of the variation explained.
Not possible to separate into primary
and secondary prevention. The need of
individuals for aspirin is not
considered; the analysis is
amalgamated to practice level. Aspirin
alternatives are not considered.
Elwood
2005130;
Wales, 2003
Social class
(manual,
non-manual)
Stratified sample of 16
general medical practices
in Wales. Cross-sectional
study of individuals with
high vascular-risk or
cardio-vascular
conditions
The proportion of patients in manual
social classes who stated that they
were taking aspirin regularly (59%)
was significantly greater (p <0.025)
than the proportion in non-manual
classes (53%)
Primary and secondary prevention
were indistinguishable in this study
Saxena
2007104;
UK, 2004,
2005
IMD 2004.
Grouped into
three bands
Ecological study using
QOF data. Large number
of GP practices in the UK.
Examination of practice
performance in relation
to a number of practice
characteristics, including
practice size, deprivation
Weak association with increased
deprivation of practice associated with
decreased proportion of patients being
prescribed anti-platelet medication.
Groups statistically different using
Kruskal Wallis exact test p-value
<0.0001
Ecological data. In this comparison,
patients all had a previous history of
CVA; provision of antiplatelet
therapies in this group might not
legitimately be regarded as primary
prevention of CHD
Petty
2008131;
152 PCTs in
the UK, 2006
IMD at PCT
level
PCT-level analysis using
precribing data.
Ecological study
Deprivation was a statistically
significant explanatory variable for the
level of clopidogrel prescribing at PCT
level.
Ecological study; results hard to
intepret. Need for clopidogrel is
inferred from population
characteristics rather than from
individual-level data
Continued on next page
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Inequity
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Study type Results Comment
Vinogradova
2009133;
UK, 2003 to
2007
Townsend
deprivation
2001
QRESEARCH database to
examine aspirin in use in
relation to deprivation
and co-morbidity. 459 GP
practices
Use was higher in deprived compared
to affluent areas (11.8% in lowest
quintile versus 8.6% in highest quintile
in 2003, 15.9% and 12.5% in 2007)
There is also a increased risk of
gastrointestinal bleeding associated
with increased aspirin use in more
deprived groups. Aspirin use
increased between 2003 and 2007
Elwood
2011134;
Caerphilly,
South Wales,
2008
Social class
(manual and
non-manual)
Representative sample of
population on the NHS
Administrative
Register (NHSAR). 4558
respondents (53%
response rate). Looking at
aspirin prescribing rates
in those with and without
a history of vascular
events
In those respondents without a
previous vascular event, 26% (95% CIs
24, 28) in the manual social classes and
21% (95% CIs 19, 23) in the
non-manual were taking aspirin
Cross-sectional analysis.
Representative sample of population.
Includes over-the-counter and
presribed medication. Clopidogrel not
considered in responses
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Table C.4: Summary of papers examining inequity of diabetes managment in patients without coronary heart disease requiring primary prevention
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Weng
2000136;
London,
1995
Jarman ‘Under-
privileged Area
Score’
Outcomes of diabetes
care for Cohort recruited
between 1982 and 1985
were examined in 1995.
Analysed relationship
between diabetes care
and material deprivation
score
Mean HbA1C for patients in deprived
wards was significantly higher than
that of patients from less deprived
wards. For most deprived wards, the
mean was 10.5 (95% CIs 10.1, 10.9); for
intermediate it was 9.9 (95% CIs 9.5,
10.4); for least deprived it was 9.1 (95%
CIs 8.2, 10.0); p-value for trend 0.003.
This difference arose primarily from a
difference in glycaemic control across
groups for those treated with insulin
The patients in the study were
recruited in the 1980s
Edwards
2003111;
Salford, UK,
1993-4 and
2000-1
Townsend
deprivation
1991
Data from Diabetes
Information System used
to analyse individuals for
attainments of targets for
diabetes treatment at two
time-points.
The percentage of diabetic patients
achieving the HbA1C target in 1993-4
was 30.5% in the least deprived and
31.1% in the most deprived quintile
with p-value for trend across quintiles
0.862. In 2000-1 for the least deprived
quintile this rose to 28.1% and for the
most 25.8%, with a p-value for the
trend across fifths of 0.420
No evidence of differential
achievement of HbA1C target across
deprivation quintiles
Bachman
2003114;
Avon and
Somerset,
UK, 1998 to
2000
Income Questionnaire of patients
with diabetes. 74%
response rate
No significant difference in the mean
HbA1C between the income groups;
p-value 0.22 for adjusted estimate of
slope index of inequality
Continued on next page
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Inequity
dimension
Study type Results Comment
Hippisley-
Cox
2004115;
UK, 2004
Townsend 2001 QRESEARCH database.
54180 patients with
diabetes. Outcome was
adjusted odds ratio for
main outcome indicators
from general medical
services contract.
Comparisons between
most deprived and least
deprived fifths of
deprivation
The odds ratio (most deprived
compared to least deprived) of
achieving the <7.5% target for HbA1C
was 0.88 (95% CIs 0.82, 0.95). For the
<10% target, the odds ratio was 0.70
(95% CIs 0.64, 0.77)
Statistically significant worse
achievement of glycaemic control
targets in most deprived category
compared to least deprived
Bebb 2005137;
Nottingham,
UK, 2001
and 2002
Townsend 2001 1534 patients with type 2
diabetes from general
practices. Patient
characteristics assessed
by a clinical interview,
case note review; practice
characteristics by
questionnaire. Outcome
measure HbA1C.
Two-level random effects
linear regression
Patients registered at the most
deprived practices had higher HbA1C
values than those in the least deprived
practices (mean difference 0.42%, 95%
CIs 0.14, 0.71)
The authors note a ‘threshold effect’
rather than a ‘dose-response effect’,
noting ‘the effect of deprivation only
becoming important where
deprivation is most extreme’
Continued on next page
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McLean
2006117;
Scotland,
2005
SIMD 2004 –
income domain;
Practice-level
analysis using
average
deprivation
Retrospective analysis of
GP QOF data. 1024
general practices.
Examined relationship
between practice
deprivation and delivered
care. Linear regression
For those with diabetes, the regression
coefficient was 0.21, with the p-value
less than 0.001 for achievement of
HbA1C less than 7.4% for payment
quality. For delivered quality, the
regression coefficient was -0.15 with
p-value less than 0.001.
Regression coefficients in this study
indicate the change in quality
associated with a one-point increase in
the percentage of deprived individuals.
Payment quality analysis removes
individuals who, for various reasons,
are excluded from payment
calculations. Delivered quality
includes these individuals. These
results for diabetes management
suggest that in those practices with a
higher proportions of deprived
patients, a higher percentage of
patients achieve criteria for payment,
but when exclusions are taken account
of the percentage of patients achieving
targets is actually worse.
Gray
2006116;
Wandsworth,
London,
2003
IMD Population-based
cross-sectional survey
using electronic GP
records. Examined
success rate for diabetes
quality indicators.
Logistic regression.
n=6035
Patients in the least deprived group
may be more likely to achieve HbA1C
targets though the differences are not
statistically significant. Odds ratio
least deprived compared to most
deprived for less than 7.4% HbA1C
target 1.10 (95% CIs 0.87,1.38); odds
ratio for less than 10.0% target 1.27
(95% CIs 0.97, 1.65)
Some suggestion of worse diabetic
control in those from more deprived
areas.
Continued on next page
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Millett, Car
et al 2007119;
England and
Scotland,
2004
IMD linked to
practices via
postcode
Study uses QOF data
from England and
Scotland. Practice-level
data. Studies the effect, at
practice-level, of
deprivation on
achievement scores
Practices located in deprived areas
performed less well on quality
measures. The proportions of patients
reaching the target for diabetics of an
HbA1C less than or equal to 7.4% was
57.3% in the most deprived group of
practices, 59.1% in the intermediate
group, and 60.1% in the least deprived
group. CIs not presented.
The effect of deprivation was more
pronounced in smaller practices
This is an ecological study using QOF
data.
Millett,
Saxena et al
2007135;
England,
1998 to 2004
Social class
(manual,
non-manual)
Secondary analysis of the
HSE. Comparing national
treatment targets for
blood glucose, blood
pressure and cholesterol
and use of medications in
survey respondents with
diabetes.
No evidence of adverse gradient of
insulin or oral diabetic medication
between diabetics from the two social
classes groups. In 1998, 59.6% of the
manual group and 57.9% of the
non-manual group were on oral
dabetic medication. In 2003 this had
risen to 65.8% in the manual group
and 64.2%in the non-manual group. In
1998, 17.7% in the manual group were
on insulin, compared to 17.5% in a
manual groups; by 2003 this rose to
23.3% in the manual group and 18.8%
in the non-manual group
Individual-level data from HSE. CIs
not available
Continued on next page
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Study type Results Comment
McGovern
2008120;
Scotland,
UK, 2004,
2005
Carstairs and
Morris Index of
deprivation
1991
Study of a number of
quality indicators of
diabetic care in diabetic
patients. Logistic
regression with covariates
gender, age, diabetes
co-morbidities and
deprivation category
In 2004, the odds ratio for deprivation
fifth 5 (compared to 1) of achieving
HbA1C target less than or equal to
7.4% was 0.90 (95% CIs 0.71, 1.15). The
odds ratio of achieving target less than
or equal to 10.0% 0.57 (95% CIs 0.37,
0.87)
In 2005, the odds ratio for the less than
7.4% target was 0.87 (95% CIs 0.76,
1.00) and for the less than 10.0% target
was 0.58 (95% CIs 0.39, 0.84)
Multiple comparisons were made; in
most comparisons deprivation was not
a statistically significant covariate
Wild 2008138;
Glasgow
and Lothian,
UK, 2005
and 2006
SIMD Cross-sectional study of
52280 people in diabetes
registers linked to
hospital admissions data.
Logistic regression
Diabetes more prevalent in the most
deprived quintile 3.3% versus 2.3%
age-adjusted prevalence. There was a
gradient of increasing HbA1C (>7.5%)
with increasing deprivation: least
deprived quintile 46%, most deprived
quintile 47%, p-value 0.01
The study also finds that, beyond the
mild gradient in glucose control, most
deprived groups are more likely to
smoke compared to least deprived
(32% versus 13%, p-value <0.0001) and
to be overweight (51% versus 38%,
p-value <0.0001) and obese (9.8%
versus 4.9% <0.0001)
This study also includes individuals
with CHD. Individual level data
Continued on next page
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Setting
Inequity
dimension
Study type Results Comment
Crawley
2009112;
England,
2003; 2006
Social class
(collapsed to
manual and
non-manual
groups)
Health Survey for
England data, 2003 and
2006; patient groups:
diabetics (n= 611 in 2003),
CHD (n=861 in 2003),
hypertensives (n= 3717 in
2003). Management and
prescribing targets for
hypertension, diabetes
and cholesterol. Logistic
regression; adjusted for
age, gender, BMI, disease
duration and treatment
In diabetic patients comparison was
made between manual and
non-manual groups for achievement of
HbA1C less than 7.5%. Here the
manual to non-manual adjusted odds
ratio was 0.47 (95% CIs 0.28, 0.80) in
2003 and was 0.66 (95% CIs 0.37, 1.15)
in 2006. Comparison was also made
for prescription of oral hypoglycaemic
agents. The manual to non-manual
adjusted odds ratio was 1.18 (95% CIs
0.84, 1.66) in 2003 and 1.34 (95% CIs
0.68, 1.23) in 2006
This study only used two groups for
comparison of deprivation, collapsing
analysis into manual and non-manual.
This may have masked differences in
outcome between respondents at either
end of the spectrum. Findings from
the study show that the difference in
prescribing of oral hypoglycaemic
agents between social classes is not
significant. The achievement of HbA1C
targets was significantly less likely in
the manual group in 2003. The odds
ratio and confidence intervals for 2006
suggest a possible effect might exist
that the study may be insufficiently
powered to uncover.
Millett
2009140;
Southwest
London,
2000 and
2005
Primarily
ethnicity; IMD
Longitudinal model
studying the quality of
diabetes care. Outcome
measures were HbA1C
and mean blood pressure.
Multilevel regression
model
The impact of pay for performance on
blood pressure and blood glucose
levels was not found to vary
significantly with neighbourhood
socio-economic status (SES), either at
the patient or practice level.
Individual level data. Looks primarily
at the impact of pay-for-performance
on disparities in ethnic groups
O’Kane
2010139;
Northern
Ireland, UK,
2003
N. Ireland
income
deprivation
measure;
educational
achievement
Cross-section study of
stratified random sample
of patients diabetes
service database. 685
patients. Individual
questionnaire interview.
Linear regression
HbA1C level not significantly related
to deprivation in regression.
Individual level data; area-level
deprivation. Fairly small study. No
evidence of worse diabetes care in
more deprived groups
Continued on next page
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Hamilton
2010;
UK, 1997
and 2005
IMD 2004 Patients with type 1 or
type 2 diabetes. Study
looked at achievement of
HbA1C <7.0%, blood
pressure <140/80 mmHg,
and total cholesterol (<5
mmol/L)
In 1997, the adjusted odd ratio (for age
and sex) for achieving the HbA1c
target (most deprived versus least
deprived quintile) was 0.96 (95% CIs
0.90, 1.01). Other comparisons between
quintiles not significant either. In 2005,
most versus least adjusted odds ratio
was 1.06 (95% CIs 0.94, 1.21)
No evidence of differential glycaemic
control between deprivation groups
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Table C.5: Summary of papers examining inequity of provision of antihypertensives for secondary prevention
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Britton
2004141;
20 civil
service
departments
in the UK,
1985 to 1999
Civil service
employment
grade
Prospective study with
follow up over 15 years.
10308 participants at
baseline. Need for cardiac
care was determined by
the presence of angina,
myocardial infarction,
and coronary risk factors.
Outcome: cardiac
procedures and drugs.
Age adjusted prevalence of use of
beta-blockers among participants who
attended phase 5 and had a history of
myocardial infarction or angina were
similar across three grades (low 18%,
medium 16%, high 14%), with p-value
for trend 0.22
For ACE inhibitors, prescription rates
were again similar across grades (low
10%, medium 10%, high 10%), with
p-value for trend 0.91
No suggestion of differencial use of
beta-blockers or ACE inhibitors across
social class groups in those who have
a history of MI or angina. Does not
include more extreme social class
groups
Harding
2005143;
English
Midlands,
1999 – 2000
Census based
deprivation at
community
level
Comparison of
prescribing between
communities with
contrasting levels of
deprivation (based on
census data). Baseline
analysis of deprivation,
and age, sex, and burden
of CHD. Prescribing
information from NHS
prescription analysis and
cost (PACT) data.
Chi-squared test to
compare proportions;
t-tests for continuous
measures
Patients in the more deprived
community were less likely to be
prescribed calcium channel blockers,
odds ratio 0.43 (95% CIs 0.24, 0.79),
and a diuretic, odds ratio 0.57 (95%
CIs 0.34, 0.96). Comparisons for
beta-blockers, 32% prescribed among
more deprived compared to 39% for
less deprived (p-value 0.18) and ACE
inhibitors, 18% prescribed in the more
deprived compared to 28% in the less
deprived (p-value 0.07), were not
significant
Patients in the more deprived
community were less likely to be
prescribed calcium-channel blockers
and diuretics, and received on average
fewer hypertension drugs. The greater
burden of CHD that might be
expected in the more deprived
community was not found; possible
under-ascertainment of cases in the
more deprived community.
Non-significant results for ACE
inhibitors and beta-blockers may
reflect a lack of power. Analyses
relating to antihypertensive
medications include all cardiovascular
disease, not just CHD
Continued on next page
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Ramsay
2005144;
UK, 1998 to
2000 and
2003
Social class
(manual and
non-manual)
Prospective cohort study
using patient information
on medication use.
Subjects had a diagnosis
of myocardial infarction
or angina. British
Regional Heart Study
data. Response rate
appoximately 80%.
For angina, in 2000, the prevalence
ratio (manual to non-manual) for
taking an ACE inhibitor was 0.72 (95%
CIs 0.48, 1.08); for beta-blockers, 0.99
(0.75, 1.32). In 2003, for ACE inhibitors
0.78 (0.60, 1.03); beta-blockers 1.07
(0.85, 1.36)
For MI, in 2000, for ACE inhibitors the
ratio was 1.17 (0.81, 1.69); for
beta-blockers 0.73 (0.54, 0.99). In 2003,
for ACE inhibitors 0.98 (0.76, 1.25);
beta-blockers 1.07 (0.85, 1.36)
Multiple comparisons were made.
Most of which were not statistically
significant. The finding that in those
who have had an MI those in the
manual social class are less likely to
take a beta-blocker needs to be
considered in the light of the numbers
of comparisons made
Simpson
2005142;
Scotland,
1997 and
2002
Carstairs and
Morris Index of
deprivation
1991
Cross-sectional study
based on GP morbidity
and prescribing data
(continuous morbidity
recording project). 14425
patients with CHD
No difference between deprivation
groups in the prescribing of ACE
inhibitors or beta-blockers
Individual-level data
Continued on next page
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McLean
2006117;
Scotland,
2005
SIMD 2004 –
income domain;
Practice-level
analysis using
average
deprivation
Retrospective analysis of
GP QOF data. 1024
general practices.
Examined relationship
between practice
deprivation and delivered
care. Linear regression
The regression coefficient in those
with CHD having their blood pressure
controlled was -0.02 with a p-value of
0.53 for payment quality. For delivered
quality, the regression coefficient was
-0.04 with a p-value of 0.28.
The regression coefficient for those
with CHD being treated with a
beta-blocker was -0.06 with a p-value
of 0.21 for payment quality and 0.03
with a p-value of 0.2 for delivered
quality
Regression coefficients in this study
indicate the change in quality
associated with a one-point increase in
the percentage of deprived individuals.
Payment quality analysis removes
individuals who, for various reasons,
are excluded from payment
calculations. Delivered quality
includes these individuals. In relation
to both the control of blood pressure
achieved and the prescription of a
beta-blocker (which controls blood
pressure among other effects) this
paper does not find a statistically
significant relationship between
practice-level deprivation and
practice-level performance
Continued on next page
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Strong
2006106;
Rotherham
Primary
Care Trust,
United
Kingdom,
2003 – 2004
data
Mean IMD
(England) 2004;
calculated at
practice level
Practice-level analysis;
mean practice-level index
of multiple deprivation.
Looks at the Quality and
Outcomes Framework
CHD registered patients,
standardised indirectly
for age and sex.
Spearman’s rank
correlation coefficient for
standardised CHD
against practice
deprivation for
quality-of-care indicators
This study examined three measures
of blood pressure management quality,
and for each looked at the correlation
between these measures and the mean
practice level deprivation. The
percentage of patients with the last
blood pressure reading less than
150/90 mmHg increased with
increased deprivation with a
Spearman’s rank correlation coefficient
of 0.19, the result was not statistically
significant. Spearman’s rank
correlation coefficient for the
percentage of patients treated with
beta-blocker and deprivation was 0.13,
and again the result was not
statistically significant. The
Spearman’s rank correlation coefficient
for patients with previous MI treated
with an ACE inhibitor was 0.10; the
result was not statistically significant
This study suggest that there is, at a
practice level, no evidence of increased
quality of hypertension management
in those with CHD and no evidence of
increased prescribing of beta-blockers
and ACE inhibitors as levels of
deprivation decrease
Continued on next page
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Murphy
2006145;
Scotland,
2001 to 2002
Carstairs and
Morris Index of
deprivation
1991
General morbidity and
prescribing data in the
Continuous Morbidity
Recording database.
Study examined
individuals with angina.
Logistic regression to
examine prescribing of
drugs
In univariate analysis, with increasing
deprivation, patients with angina were
less likely to be prescribed a
beta-blocker (p-value for trend 0.018),
but more likely to be presribed an
ACE inhibitor (p-value for trend 0.02)
In multivariate analysis, patients in
most deprived category were 25%
more likely to be prescribed a
calcium-channel blocker; 51% more
likely to be prescribed an ACE
inhibitor, angiotensin-receptor blocker
or both. The difference in beta-blocker
precription was not significant
No suggestion of inequity in provision
according to need, with those in more
deprived groups prescribed more
(other than for beta-blockers)
Saxena
2007104;
UK, 2004,
2005
IMD 2004.
Grouped into
three bands
Ecological study using
QOF data. Large number
of GP practices in the UK.
Examination of practice
performance in relation
to a number of practice
characteristics, including
practice size, deprivation
Weak association with increased
deprivation of practice associated with
decreased ACE inhibitor and
beta-blocker prescribing, and with
decreased proportion of patients
meeting target BP. Groups statistically
different using Kruskal Wallis exact
test p-value <0.0001
Ecological data
Continued on next page
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McGovern
2008317;
Scotland,
2004 and
2005
Carstairs and
Morris Index of
deprivation
1991
Individuals with CHD
were identified from GP
records. Individual-level
data. Logistic regression.
More deprived groups were more
likely to receive ACE inhibitors: in
2004 the odds ratio (most deprived
compared to least deprived) was 1.64
(95% CIs 1.18, 2.28); in 2005 the odds
ratio was 1.67 (95% CIs 1.34, 2.10).
More deprived groups were less likely
to receive beta-blockers: in 2004 the
odds ratio was 0.87 (95% CIs 0.77,
0.97); in 2005 the ratio was 0.84 (95%
CIs 0.76, 0.92)
Multiple comparisons related to
deprivation, only some of which are
statistically significant.
Ashworth
2008121;
England,
2005 to 2007
IMD Retrospective
longitudinal survey.
Deprivation analysed at
practice level.
Practice-level analysis.
Relationship between
deprivation and six QOF
indicators related to
blood pressure.
Over the study period the gap between
the least and most deprived groups
decreased for those with CHD. In the
least deprived group in 2004-5 85.1%
(95% CIs 84.7, 85.6) met BP targets
compared to 81.8% (95% CIs 81.3, 82.3)
in the most deprived group. By 2006-7
the least deprived figure was 89.4%
(95% CIs 89.1, 89.7) and the most
deprived figure was 88.4% (88.2, 80.7)
Initial evidence of a disparity in blood
pressure control between deprivation
groups in the first year of the study
subsequently disappeared.
Practice-level analysis
Continued on next page
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Crawley
2009112;
England,
2003; 2006
Social class
(collapsed to
manual and
non-manual
groups)
Health Survey for
England data, 2003 and
2006; patient groups:
diabetics (n= 611 in 2003),
CHD (n=861 in 2003),
hypertensives (n= 3717 in
2003). Management and
prescribing targets for
hypertension, diabetes
and cholesterol. Logistic
regression; adjusted for
age, gender, BMI, disease
duration and treatment
In patients diagnosed with CHD, the
manual to non-manual adjusted odds
ratio for successful management of
SBP to less than 150/90 mmHg was
0.95 (95% CIs 0.26, 3.51) in 2003 and
0.44 (95% CIs 0.21, 0.90) in 2006. For
prescription of antihypertensives, the
odds ratios were 1.28 (95% CIs 0.97,
1.70) in 2003, and 0.80 (95% CIs 0.64,
1.00) in 2006
This study only used two groups for
comparison of deprivation, collapsing
analysis into manual and non-manual.
This may mask differences in outcome
between respondents at either end of
the spectrum. The odds ratios
presented suggest no significant effect
of social class on anti-hypertensive
prescribing. In 2006, the manual group
was significantly less likely to achieve
the target blood pressure, though in
2003 this difference had not been
significant. This study carried out 24
comparisons between social classes
and found only two to be statistically
significant. This multiple comparison
may mean that random effects explain
this and the other statistically
significant result from this study.
Mathur
2011146;
East London,
2009 – 2010
Area-level
socio-economic
deprivation
Routinely collected data
from 98 GP practices.
Cross-sectional study.
10933 patients with CHD.
Logistic regression
looking at prescribing of
CHD drugs by age, sex,
ethnicity, socio-economic
deprivation, co-morbidity
and contra-indications
No difference in prescribing rates by
social deprivation was found.
Adjusted odds ratio for beta-blockers
most deprived compared to least
deprived 0.90 (95% CIs 0.75, 1.09).
Comparisons with other deprivation
quintiles were also not significant. For
ACE inhibitors the most to least
adjusted odds ratio was 1.10 (95% CIs
0.91, 1.32); again comparisons with
other deprivation were not statistically
significant
No evidence of inequity in utilisation
of beta-blockers or ACE inhibitors for
secondary prevention
Continued on next page
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Hawkins
2013103;
England,
1999; 2003;
2007
IMD;
comparisons by
quintile
Cross-section
observational analysis
using data from MINAP
and the General Practice
Research
Database (GPRD).
Looked at provision of
intervention into three
groups: MI patients,
examined using data
from MINAP; patients
requiring secondary
prevention – including
patients with previous MI
or revascularisation
(GPRD); chronic angina
(GPRD).
In comparison of ACE inhibitors and
ARBs, there was no statistically
significant difference in the
comparison of age-sex-standardised
rates between quintile 5 and quintile 1,
either in 2003 or in 2007 – rate ratio
1.00 (95% CIs 0.92; 1.10) in 2003 and
1.08 (95% CIs 0.98; 1.19) in 2007 .
Likewise, in the secondary prevention
group there was no difference in 1999 –
rate ratio 1.08 (95% CIs 0.84; 1.37) – or
in 2007 – rate ratio 1.02 (95% CIs 0.79;
1.32). In the stable angina group, the
rate ratio favoured quintile 5 (most
deprived) in 2007, at 1.25 (95% CIs
1.09;1.43), but not in 1999, rate ratio
1.11 (95% CIs 0.94; 1.30). Using the
same method to compare beta-blocker
prescription, there were no statistically
significant differences between groups.
The rate ratios in the MI group were
1.00 (95% CIs 0.94; 1.06) in 2003 and
1.05 (95% CIs 0.96; 1.14) in 2007. For
the secondary prevention group, the
rate ratio was 1.02 (95% CIs 0.55; 1.90)
in 1999 and 1.06 (95% CIs 0.80; 1.39) in
2007
Comparison between quintiles and
three distinct groups. In the MI group,
initiation of treatment as an inpatient
following MI was examined. In the
secondary prevention and stable
angina groups, prescription in primary
care in the same calendar year as the
diagnosis was examined
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Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Reid 2002147;
England,
1998
Social class
(non-manual
and manual)
Cross-sectional analysis
of HSE data. Outcome
was treatment with
lipid-lowering therapy
Adjusted odd ratio of lipid-lowering
treatment in those with CHD
(non-manual versus manual) 1.24 (95%
CIs 0.85, 1.82)
No association between lipid-lowering
therapy and social class.
Britton
2004141;
20 civil
service
departments
in the UK,
1985 to 1999
Civil service
employment
grade
Prospective study with
follow up over 15 years.
10308 participants at
baseline. Need for cardiac
care was determined by
the presence of angina,
myocardial infarction,
and coronary risk factors.
Outcome: cardiac
procedures and drugs.
Age adjusted prevalence of use of
lipid-lowering agents among
participants who attended phase 5 and
had a history of myocardial infarction
or angina were similar across three
grades (low 19%, medium 14%, high
14%), with p-value for trend 0.41
No suggestion of differential use of
lipid-lowering agents across social
class groups in those who have a
history of MI or angina. Does not
include more extreme social class
groups
Harding
2005143;
English
Midlands,
1999 – 2000
Census based
deprivation at
community
level
Comparison of
prescribing between
communities with
contrasting levels of
deprivation (based on
census data). Baseline
analysis of deprivation,
and age, sex, and burden
of CHD. Prescribing
information from PACT
data. Chi-squared test to
compare proportions;
t-tests for continuous
measures
Results for statin prescription only
presented for those less than 74 years
of age. In those with a history of MI,
52.8% were prescribed a statin in the
more deprived community compared
to 47.5% in the less deprived
community. The p-value for the
difference was 0.65.
For those with angina, 48.2% of those
in the more deprived community were
prescribed a statin, compared to 39.3%
in less deprived community. The
p-value for the difference was 0.72
No evidence from the study of an
increased prescription of
lipid-lowering medications to less
deprived communities for individuals
with a history of MI or angina
Continued on next page
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Ramsay
2005144;
UK, 1998 to
2000 and
2003
Social class
(manual and
non-manual)
Prospective cohort study
using patient information
on medication use.
Subjects had a diagnosis
of myocardial infarction
or angina. British
Regional Heart Study
data. Response rate
appoximately 80%.
For patients with angina, in the year
2000 the prevalence ratio (manual
compared to non-manual) for taking a
statin was 0.64 (95% CIs 0.45, 0.91); in
2003, it was 0.91 (95% CIs 0.76, 1.09)
For patients with MI, in 2000, the
prevalence ratio was 1.08 (95% CIs
0.77, 1.52); in 2003 it was 1.14 (95% CIs
0.97, 1.35)
For those who have had an MI, there
is some suggestion that the manual
group is more likely to take a statin,
though the results do not achieve
statistical significance. For those with
angina, there is a statistically
significant reduced likelihood of
taking a statin in the manual social
class in 2000, but this association is no
longer statistically significant in 2003
Simpson
2005142;
Scotland,
1997 and
2002
Carstairs and
Morris Index of
deprivation
1991
Cross-sectional study
based on GP morbidity
and prescribing data
(continuous morbidity
recording project). 14425
patients with CHD
Comparisons were made in
multivariate analysis for multiple
years. 1997–2002. In 1998, the most
deprived group received significantly
less statin treatment than the most
deprived, odds ratio 0.6 (95% CIs 0.5,
0.8); this difference continued until
2000, odds ratio 0.6 (95% CIs 0.5, 0.8).
In other years there was no difference
between most and least deprived
quartiles
The apparent different between most
extreme deprivation groups between
1998 and 2000 disappears by 2001.
Individual-level data
Continued on next page
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Strong
2006106;
Rotherham
Primary
Care Trust,
United
Kingdom,
2003 – 2004
data
Mean IMD
(England) 2004;
calculated at
practice level
Practice-level analysis;
mean practice-level index
of multiple deprivation.
Looks at the Quality and
Outcomes Framework
CHD registered patients,
standardised indirectly
for age and sex.
Spearman’s rank
correlation coefficient for
standardised CHD
against practice
deprivation for
quality-of-care indicators
The Spearman’s rank correlation
coefficient between the percentage of
patients in a practice with CHD with
total cholesterol less than 5 mmol/l
and the mean practice deprivation
score was -0.07. This result was not
statistically significant, though an
exact p-value is not given
Evidence from this study suggest that
there is no statistically significant
difference in the quality of
lipid-lowering management according
to deprivation and practice level.
Information on the correlation
between the percentage of these
patients prescribed a statin and mean
deprivation score is not available
Murphy
2006145;
Scotland,
2001 to 2002
Carstairs and
Morris Index of
deprivation
1991
General morbidity and
prescribing data in the
Continuous Morbidity
Recording database.
Study examined
individuals with angina.
Logistic regression to
examine prescribing of
drugs
There were no differences in
prescribing of statins, with the odds
ratio in the most deprived compared
to the least deprived group 0.92 (95%
CIs 0.77, 1.10)
No inequity in statin prescription
Continued on next page
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Crawley
2009112;
England,
2003; 2006
Social class
(collapsed to
manual and
non-manual
groups)
Health Survey for
England data, 2003 and
2006; patient groups:
diabetics (n= 611 in 2003),
CHD (n=861 in 2003),
hypertensives (n= 3717 in
2003). Management and
prescribing targets for
hypertension, diabetes
and cholesterol. Logistic
regression; adjusted for
age, gender, BMI, disease
duration and treatment
In patients diagnosed with CHD, the
manual to non-manual adjusted odds
ratios for successful management of
cholesterol to less than 5 were 0.71
(95% CIs 0.18, 2.81) in 2003 and 0.86
(95% CIs 0.36, 2.05) in 2006. For
prescription of lipid-lowering drugs,
the odds ratio was 0.80 (95% CIs 0.56,
1.10) in 2003 and 0.85 (95% CIs 0.64,
1.14) in 2006.
This study only used two groups for
comparison of deprivation, collapsing
analysis into manual and non-manual.
This may have masked differences in
outcome between respondents at
either end of the spectrum. The
evidence presented suggests no
statistically significant difference in the
mangement of cholesterol or in
prescribing rates between social
classes. Outcomes inproved
significantly in all groups between
2003 and 2006, with manual groups
having a better increase in statin
prescribing.
Mathur
2011146;
East London,
2009 – 2010
Area-level
socio-economic
deprivation
Routinely collected data
from 98 GP practices.
Cross-sectional study.
10933 patients with CHD.
Logistic regression
looking at prescribing of
CHD drugs by age, sex,
ethnicity, socio-economic
deprivation, co-morbidity
and contra-indications
Odds ratio of treatment with
lipid-modifying drug in most versus
least deprived quintile 1.03 (95% CIs
0.78, 1.36). Comparisons with other
quintiles were also not statistically
significant
No evidence of inequity of provision
of lipid-lowering therapy for
secondary provision in this study
Continued on next page
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Hawkins
2013103;
England,
1999; 2003;
2007
IMD;
comparisons by
quintile
Cross-section
observational analysis
using data from MINAP
and the GPRD. Looked at
provision of intervention
into three groups: MI
patients, examined using
data from MINAP;
patients requiring
secondary prevention –
including patients with
previous MI or
revascularisation (GPRD);
chronic angina (GPRD).
Statin prescription was compared for
the secondary prevention and stable
angina groups in 1999 and 2007. In the
secondary prevention group, there was
no evidence of a significant difference
in prescription between quintile 5 and
quintile 1, with the rate ratio 0.67 (95%
CI 0.45; 1.01) in 1999 and 0.91 (95% CIs
0.71; 1.17) in 2007. In the stable angina
group, prescribing favoured quintile 5
at both time points: rate ratio 1.18 (95%
CI 1.02; 1.36) in 1999; rate ratio 1.37
(95% CIs 1.25; 1.50) in 2007
Comparison of rate ratios of
age-sex-standardised rates between
quintile 5 (most deprived) in quintile 1
(least deprived)
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Table C.7: Summary of papers examining inequity of provision of anti-platelet medications for secondary prevention
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
McCallum
1997318;
UK, 1992
Social class
(manual and
non-manual)
British Regional Heart
Study data. 5751 men
with cardiovascular
disease completing
questionnaires on aspirin
use
The proportion of individuals with
cardiovascular disease was very
similar in the manual and non-manual
groups (39%)
No difference between social class
groups in the proportion taking
aspirin.
Trinder
2003148;
North
Stafford-
shire, UK,
Not clear
Townsend Cross-sectional
population study carried
out on a stratified
random sample of 10000
adults aged over 35.
Response rate 67%.
Examined aspirin
prescription
The chance of being on aspirin was
increased for those living in more
deprived areas, though the result was
not statistically significant. The
adjusted odds ratio most deprived to
least deprived was 1.69 (95% CIs 0.99,
2.89); for intermediate group
compared to least deprived the
adjusted odds ratio was 1.48 (95% CIs
0.87, 2.53)
Some suggestion that more deprived
individuals with cardio-vascular
disease are more likely to take aspirin,
though this is not statistically
significant.
Britton
2004141;
20 civil
service
departments
in the UK,
1985 to 1999
Civil service
employment
grade
Prospective study with
follow up over 15 years.
10308 participants at
baseline. Need for cardiac
care was determined by
the presence of angina,
myocardial infarction,
and coronary risk factors.
Outcome: cardiac
procedures and drugs.
Age adjusted prevalence of use of
aspirin among participants who
attended phase 5 and had a history of
myocardial infarction or angina were
similar across three grades (low 31%,
medium 26%, high 24%), with p-value
for trend 0.33
No suggestion of differencial use of
aspirin across social class groups in
those who have a history of MI or
angina. Does not include more
extreme social class groups
Continued on next page
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Harding
2005143;
English
Midlands,
1999 – 2000
Census based
deprivation at
community
level
Comparison of
prescribing between
communities with
contrasting levels of
deprivation (based on
census data). Baseline
analysis of deprivation,
and age, sex, and burden
of CHD. Prescribing
information from PACT
data. Chi-squared test to
compare proportions;
t-tests for continuous
measures
In the more deprived community
83.1% of those with a history of MI
were prescribed antithrombotic
medication compared to 84.3% in the
less deprived community. The p-value
for the chi squared test was 0.85. In
those with a history of angina, 70.0%
were prescribed an antithrombotic
medication in more the deprived
community compared to 70.9% in the
less deprived community. The p-value
for the difference was 0.54
This study provides no evidence of a
difference in antithrombotic
prescribing rates between the more
and less deprived community in either
those with a history of MI or angina
Ramsay
2005144;
UK, 1998 to
2000 and
2003
Social class
(manual and
non-manual)
Prospective cohort study
using patient information
on medication use.
Subjects had a diagnosis
of myocardial infarction
or angina. British
Regional Heart Study
data. Response rate
appoximately 80%.
For patients with angina, in 2000 the
prevalence ratio (manual versus
non-manual) was 0.91 (95% CIs 0.80,
1.04); in 2003 it was 0.93 (95% CIs 0.84,
1.04)
For patients with MI, in the 2000 the
prevalence ratio was 0.93 (95% CIs
0.84, 1.03); in 2003 it was 0.97 (95% CIs
0.88, 1.06)
Some suggestion that more deprived
groups take less aspirin, but the results
do not attain statistical significance
Simpson
2005142;
Scotland,
1997 and
2002
Carstairs and
Morris Index of
deprivation
1991
Cross-sectional study
based on GP morbidity
and prescribing data
(continuous morbidity
recording project). 14425
patients with CHD
No significant difference between
deprivation groups in the presciption
of secondary anti-platelet medication.
Individual-level data
Continued on next page
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Elwood
2005130;
Wales, 2003
Social class
(manual,
non-manual)
Stratified sample of 16
general medical practices
in Wales. Cross-sectional
study of individuals with
high vascular-risk or
cardio-vascular
conditions
The proportion of patients in manual
social classes who stated that they
were taking aspirin regularly (59%)
was significantly greater (P <0.025)
than the proportion in non-manual
classes (53%)
Not possible to tell if there are social
class differences in primary and
secondary preventative treatment with
aspirin
McLean
2006117;
Scotland,
2005
SIMD 2004 –
income domain;
Practice-level
analysis using
average
deprivation
Retrospective analysis of
GP QOF data. 1024
general practices.
Examined relationship
between practice
deprivation and delivered
care. Linear regression
The regression coefficient for
prescribing aspirin or equivalent
medication for those with CHD was
0.01, p-value 0.78 for payment quality.
For delivered quality the regression
coefficient was 0.03, with p-value 0.2
Regression coefficients in this study
indicate the change in quality
associated with a one-point increase in
the percentage of deprived individuals.
Payment quality analysis removes
individuals who, for various reasons,
are excluded from payment
calculations. Delivered quality
includes these individuals. These
result suggest that there is not a
statistically significant trend of
prescribing of anti-platelet medications
in more deprived practices.
Continued on next page
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Strong
2006106;
Rotherham
Primary
Care Trust,
United
Kingdom,
2003 – 2004
data
Mean IMD
(England) 2004;
calculated at
practice level
Practice-level analysis;
mean practice-level index
of multiple deprivation.
Looks at the Quality and
Outcomes Framework
CHD registered patients,
standardised indirectly
for age and sex.
Spearman’s rank
correlation coefficient for
standardised CHD
against practice
deprivation for
quality-of-care indicators
The Spearman’s rank correlation
coefficient between practice-level mean
deprivation and the percentage of
patients with CHD treated with
anti-platelet medication or
anticoagulant was -0.04. This result
was not statistically significant, though
an exact p-value is not given
Results suggest that there is no
relationship at a practice level between
increased deprivation and decreased
provision of anti-platelet medication in
those diagnosed with CHD
Murphy
2006145;
Scotland,
2001 to 2002
Carstairs and
Morris Index of
deprivation
1991
General morbidity and
prescribing data in the
Continuous Morbidity
Recording database.
Study examined
individuals with angina.
Logistic regression to
examine prescribing of
drugs
In multivariate analysis, the odds ratio
(most deprived groups compared to
least deprived group) of anti-platelet
treatment was 1.08 (95% CIs 0.89, 1.32)
No evidence of inequity of antiplatelet
prescribing in those with angina
Saxena
2007104;
UK, 2004,
2005
IMD 2004.
Grouped into
three bands
Ecological study using
QOF data. Large number
of GP practices in the UK.
Examination of practice
performance in relation
to a number of practice
characteristics, including
practice size, deprivation
Weak association with increased
deprivation of practice associated with
decreased use of anti-platelet
medications. Groups statistically
different using Kruskal Wallis exact
test p-value <0.0001
Ecological data
Continued on next page
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McGovern
2008317;
Scotland,
2004 and
2005
Carstairs and
Morris Index of
deprivation
1991
Individuals with CHD
were identified from GP
records. Individual-level
data. Logistic regression.
More deprived groups with CHD
were more likely to be treated with
antiplatelet medications. In 2004, the
odds ratio (most deprived quintile
versus least deprived quintile) was 1.11
(95% CIs 0.95, 1.28); in 2005, the odds
ratio was 1.14 (95% CIs 1.00, 1.22)
Multiple comparisons related to
deprivation, only some of which are
statistically significant.
Elwood
2011134;
Caerphilly,
South Wales,
2008
Social class
(manual and
non-manual)
Representative sample of
population on the
NHSAR. 4558
respondents (53%
response rate). Looking at
aspirin prescribing rates
in those with and without
a history of vascular
events
Sixty-seven percent of those in manual
social classes were taking aspirin,
compared to 56% in the non-manual
social classes
Cross-sectional analysis.
Representative sample of population.
Includes over-the-counter and
presribed medication. Clopidogrel not
considered in responses
Mathur
2011146;
East London,
2009 – 2010
Area-level
socio-economic
deprivation
Routinely collected data
from 98 GP practices.
Cross-sectional study.
10933 patients with CHD.
Logistic regression
looking at prescribing of
CHD drugs by age, sex,
ethnicity, socio-economic
deprivation, co-morbidity
and contra-indications
Odds ratio of treatment with aspirin in
the most versus least deprived quintile
1.20 (95% CIs 0.96, 1.50). Comparisons
with other quintiles were also not
statistically significant
No evidence from this study of
inequity of aspirin use for secondary
prevention
Continued on next page
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Hawkins
2013103;
England,
1999; 2003;
2007
IMD;
comparisons by
quintile
Cross-section
observational analysis
using data from MINAP
and the GPRD. Looked at
provision of intervention
into three groups: MI
patients, examined using
data from MINAP;
patients requiring
secondary prevention –
including patients with
previous MI or
revascularisation (GPRD);
chronic angina (GPRD).
In the MI group, there were no
significant differences in the rate ratios
of prescribing rates for either aspirin
or clopidogrel at either time point. For
aspirin, the rate ratio was 1.00 (95%
CIs 0.96; 1.04) in 2003 and 0.98 (95%
CIs 0.97; 1.00) in 2007; for clopidogrel,
the rate ratio was 0.94 (95% CIs 0.70;
1.25) in 2003 and 0.96 (95% CIs 0.93;
1.00) in 2007. Rate ratios suggested
increased relative aspirin prescription
in the secondary prevention group
favouring quintile 5 in 1999, with the
rate ratio 1.28 (95% CIs 1.08; 1.53), but
not in 2007, 1.01 (95% CIs 0.76; 1.34).
For the stable angina group, relatively
higher aspirin prescription was
observed both in 1999 – 1.63 (95% CIs
1.46; 1.82) – and in 2007 – 1.65 (95%
CIs 1.48; 1.83).
Comparison of rate ratios of
age-sex-standardised rates between
quintile 5 (most deprived) in quintile 1
(least deprived). The increased relative
provision of aspirin to angina patients
was particularly pronounced in
younger age groups
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Table C.8: Summary of papers examining inequity of provision of revascularisation
Author
Year;
Setting
Inequity
dimension
Study type Results Comment
Ben-Shlomo
1995157;
London,
1991
Townsend 1981 Ecological comparison of
operation rates for CABG
for 1991 with CHD
mortality 1981-85
CHD mortality showed steady,
significant increase with increasing
area deprivaiton score. For women,
CABG rate ratios increased as
deprivation increased. For men, there
was a U-shaped relationship, with
lowest values for the second and third
quartiles
Some suggestion of inequity of
revascularisation provision in men
Kee 1995158;
Nothern
Ireland, 1993
Townsend 1991 Analysis of waiting times
for revascularisation
surgery in patients
undergoing angiography
Townsend deprivation was not
associated with waiting time for
coronary artery surgery
No evidence of an association.
Individual-level data. Waiting times
Black
1995159;
UK, 1992-93
Jarman;
Department of
the
Environment
social
deprivation
index
Cross-sectional ecological
study
More socially deprived districts had
higher rates of revascularisation
procedures
The authors note that this finding may
be confounded by the proximity of
more deprived patients to specialist
centres. Includes private hospitals.
Univariate analysis which did not
correct for distance from specialist
centre
Payne
1997150;
Sheffield,
UK, 1991 to
1995
Townsend
deprivation
1991
A stratified random
sample of patients
registered with GPs
(12240 respondents; 79%
response rate) was used
to determine the
proportion of patients
with symptoms of angina.
Ward-level analysis
There was a relationship between the
prevalence of angina symtoms and
deprivation (r = 0.79; p-value <0.001).
No relationship between the
revascularisation rate and deprivation.
There was a relationship between the
ratio of revascularisations to the
number in an electoral ward estimated
to have symptoms of angina (r= -0.67;
p-value <0.001)
Ecological analysis at ward level;
suggests that the supply of
revascularisations is inequitable
Continued on next page
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Manson-
Siddle
1998151;
Yorkshire,
UK, 1992 to
1994
Super Profile
multidimen-
sional
categorisation
of
socio-economic
disadvantage
Cross-sectional ecological
study at
enumeration-district level.
CHD standardised
mortality ratio as a proxy
for need. Subjects with a
primary diagnosis of
CHD aged 25 and over
Gradient in the utilisation of
revascularisation procedures across
the deprivation groups, though the
gradient does not reflect the gradient
in standardised mortality ratio. This
effect is more pronounced in those
aged 65 to 74 than in those <65
Ecological evidence of an inequity in
supply between deprivation groups
Manson-
Siddle
1999152;
South
Humberside,
UK, 1992 to
1994
Super Profile
multidimen-
sional
categorisation
of
socio-economic
disadvantage
Cross sectional ecological
study of revascularisation
rates, using the Super
Profile classification of
enumeration districts and
CHD standardised
mortality ratios as a
proxy for need. Analysis
was performed before
and after resource
investment in cardiac
services in the area
Decreasing trend for revascularisation
across the Super Profile Lifestyle
groups, with more deprived groups
having lower rates of procedures (the
ratio of revascularisation rates in the
least to most deprived groups was 1.53
: 1 (CIs not provided). After
investment, the apparent inequity in
provision diminished, with the ratio of
revascularisation rates 0.71 : 1, though
the trend across all the deprivation
categories was not improved
Investment in cardiac services, with an
overall increased in revascularisation
rates, reduced the inquity between the
most extreme deprivation groups; a
trend of increased provision with
increased affluence remained
MacLeod
1999156;
Scotland,
1991 to 1995
Carstairs and
Morris Index of
deprivation
1991
Individual-level analysis
of the proportion of
patients admitted with
MI undergoing PTCA
and CABG over the
following two years.
36838 patients. Multiple
logistic regression.
Socio-economic deprivation was
associated with a reduced likelihood
of CABG. Adjusted odd ratio for the
most deprived versus the least
deprived group was 0.70 (95% CIs 0.53,
0.92). The difference between
deprivation groups in progression to
PTCA was not significant.
Small numbers of PTCAs may mean
that this study was underpowered to
demonstrate a genuine association
Continued on next page
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Hippisley-
Cox
2000153;
Nottinghamshire,
1997
Jarman ‘Under-
privalaged Area
Score’
Practice-level analysis.
Poisson regression,
examining utilisation
rates with deprivation as
a covariate (as well as
admission rates for CHD)
In multivarate Poisson regression,
adjusted for a number of practice
characteristics, increased deprivation
was associated with reduced
utilisation of revascularisation
procedures; adjusted rate ratio 0.955
(95% CIs 0.985, 0.991)
Practice-level analysis. CHD
admission rate as a proxy of need
Pell 2000149;
Scotland,
1986 to 1997
Carstairs
deprivation
category
Retrospective analysis of
waiting list data in
Scotland. 26642 patients.
Multivariate logistic
regression
Patients in the most deprived
categories waited about three weeks
longer for surgery than those in the
least deprived category: mean
difference 24 days (95% CIs 15, 32).
Deprived patients had an odds ratio of
0.5 (95% CIs 0.46, 0.61) for having
operations classified as urgent
compared with the least deprived.
When urgent and routine cases were
considered separately, there was no
significant difference in waiting times
between the most and least deprived
categories
This study looks at waiting times, not
revascularisation rates
Gatrell
2002160;
North-West
England,
1993–1996
Carstairs and
Morris Index of
deprivation
1991
Small-area level analysis
of rates of utilisation of
angiography, angioplasty
and bypass surgery.
Poisson regression to
examine explanatory
variables, including
deprivation. CHD
mortality was used as a
proxy for need
For CABG, the risk ratios (adjusted for
need and travel time) for treatment
rose across deprivation quartiles,
indicating that those living in more
deprived areas were receiving more
treatments. The trends across quartiles
were statistically significant. Numbers
for PTCA were too small to allow
precision of estimates, but showed
increased provision with increased
material deprivation
Small-area level study; no suggestion
of inequity of provision at small area
level. CHD mortality used as a proxy
for need
Continued on next page
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Lester
2004154;
Wales, 2000
to 2002
Townsend
deprivation
from 2001
Cross-sectional ecological
study involving a
retrospective analysis of
routinely collected
hospital activity statistics
in relation to need
Persons in the most deprived fifth are
less likely to undergo investigation by
coronary angiogram compared to least
deprived fifth (OR 0.88, 95% CI
0.83-0.92);
Persons in the most deprived fifth are
less likely to undergo treatment by
coronary revascularisation compared
to least deprived fifth (OR 0.84, 95% CI
0.79-0.89)
For persons living in the most
socio-economically deprived fifth of
electoral divisions in Wales, provision
of coronary angiography and
revascularisation is inequitable.
Ecological study; does not take
account of co-morbidity and other
covariates. Not a peer-reviewed study
Britton
2004141;
20 civil
service
departments
in the UK,
1985 to 1999
Civil service
employment
grade
Prospective study with
follow up over 15 years.
10308 participants at
baseline. Need for cardiac
care was determined by
the presence of angina,
myocardial infarction,
and coronary risk factors.
Outcome: cardiac
procedures and drugs.
After correction for smoking, systolic
and diastolic blood pressure, total
cholesterol, body mass index, diabetes,
ethnicity, and family history using
logistic regression the odds ratio for
revascularisation in those with CHD
in the low employment grade group
compared to high was 1.14 (95% CIs
0.57, 2.30); for medium employment
grade the figure was 1.24 (95% CI CIs
0.83, 1.85)
Reverse gradient in use of
revascularisation after correction for
risk factors. Does not take account of
extremes of social groups. Small
numbers in some groups
Morris
2005161;
24 medium
sized British
towns, 1992
to 1996
Registrar
general’s
classification of
social class
Prospective population
based study. British
Regional Heart Study
In multifactorial analysis, which
included adjustment for incidence of
major coronary heart disease or
angina, a lower incidence of
revascularisation was found among
men with manual occupations (0.73,
95% CIs 0.53 to 1.02)
Evidence of lower incidence in men
with manual occupations; not
statistically significant
Continued on next page
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Cosh
2008155;
Wales, 1992
to 2006
Townsend
deprivation
2001
Ecological database
analysis comparing
revascularisation rates
with proxies of need
(CHD deaths and
admissions)
Fewer angiographies per 1000
admissions in the more deprived
groups. Flat gradient of
revascularisation across deprivation
fifths, despite the gradient of increased
(proxy) level of need as deprivation
increases
Overall pattern of apparent horizontal
inequity in CHD investigation and
treatment across Wales. Not a
peer-reviewed study
Mindell
2008162;
London,
2001 to 2003
2004 IMD; Gini
coefficients
Analyses of hospital
episodes statistics and
private-sector data by age,
sex and primary care
trust of residence. Gini
coefficients were derived
to provide an index of
inequality across
subpopulations, with
parametric bootstrapping
to estimate confidence
intervals.
NHS-funded admission rates were not
related to deprivation or
age-standardised deaths rates from
CHD. Privately funded admission
rates were lower in more deprived
PCTs. NHS provision was significantly
more egalitarian (Gini coefficient 0.12)
than the private sector (0.35).
Including all procedures was
significantly less equal (0.13) than
NHS funded care alone.
Suggests the NHS funded provision is
more equitable than privately-funded
care

DA D D I T I O N A L R E S U LT S
d.1 main analysis
In the analysis in the following pages, I present to graphics for each
of the points in the pathway of care for CHD using the same means
of presentation as that employed in chapter 8. I provide at each point
in the pathway:
• A Kaplan-Meier plot for that clinical trigger-action
• The results of the ‘fully-adjusted model’ for that clinical trigger-
action
These figures correspond to figures 8.5 and 8.8 in chapter 8. On request,
I can make available additional graphics relating to these points in
the pathway, again corresponding to each of the figures presented in
chapter 8. These graphics are currently contained in the SAIL Gateway,
so providing them would entail delays while they were exported,
and would be subject to review by HIRU in line with information
governance procedures.
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Kaplan−Meier plot for 'aged 40+ with
no high risk diagnosis' and
'ascertainment of smoking status'.
Incident clinical trigger (triggers =
122486; actions = 72291)
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Mixed−effects model for 'aged 40+ with no high risk diagnosis' and
'ascertainment of smoking status'. Incident clinical trigger
Number of clinical triggers 122486; Number of clinical actions 72291. ICC
for practice = 0.041. Missing values imputed using MICE.
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Kaplan−Meier plot for 'aged 40+ with
no high risk diagnosis' and
'measurement of BMI'. Incident
clinical trigger (triggers = 122486;
actions = 46235)
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Mixed−effects model for 'aged 40+ with no high risk diagnosis' and
'measurement of BMI'. Incident clinical trigger
Number of clinical triggers 122486; Number of clinical actions 46235. ICC
for practice = 0.133. Missing values imputed using MICE.
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Kaplan−Meier plot for 'aged 40+ with
no high risk diagnosis' and
'measurement of BP'. Incident
clinical trigger (triggers = 122486;
actions = 64312)
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Mixed−effects model for 'aged 40+ with no high risk diagnosis' and
'measurement of BP'. Incident clinical trigger
Number of clinical triggers 122486; Number of clinical actions 64312. ICC
for practice = 0.125. Missing values imputed using MICE.
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Kaplan−Meier plot for 'aged 40+ with
no high risk diagnosis' and
'measurement of cholesterol'.
Incident clinical trigger (triggers =
122486; actions = 28652)
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Mixed−effects model for 'aged 40+ with no high risk diagnosis' and
'measurement of cholesterol'. Incident clinical trigger
Number of clinical triggers 122486; Number of clinical actions 28652. ICC
for practice = 0.055. Missing values imputed using MICE.
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Kaplan−Meier plot for 'aged 40+ with
no high risk diagnosis' and 'full
cardiovascular risk assessment'.
Incident clinical trigger (triggers =
122486; actions = 84969)
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       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
   No oth. co.
     Other co.
HR
    1
 1.00
 1.00
 0.98
 0.97
    1
 2.21
    1
 1.96
 2.24
 2.22
    1
 1.38
95% CI
   (Reference)
  (0.98; 1.03)
  (0.97; 1.02)
  (0.95; 1.00)
  (0.95; 1.00)
   (Reference)
  (2.18; 2.24)
   (Reference)
  (1.89; 2.02)
  (2.11; 2.37)
  (2.12; 2.32)
   (Reference)
  (1.34; 1.42)
Mixed−effects model for 'aged 40+ with no high risk diagnosis' and
'full cardiovascular risk assessment'. Incident clinical trigger
Number of clinical triggers 122486; Number of clinical actions 84969. ICC
for practice = 0.166. Missing values imputed using MICE.
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Kaplan−Meier plot for 'first
identified as smoker' and 'provision
of smoking−cessation advice'.
Incident clinical trigger (triggers =
55161; actions = 45926)
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Smoking
management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 1.02
 1.05
 1.08
 1.10
 0.96
 0.98
 1.02
    1
 1.01
 1.01
 0.98
 0.93
 0.92
 0.82
 0.80
    1
 1.06
    1
 0.99
 1.01
    1
 1.19
 1.22
 1.02
    1
 1.08
    1
 1.10
    1
 1.06
    1
 1.03
95% CI
   (Reference)
  (0.99; 1.06)
  (1.02; 1.09)
  (1.05; 1.12)
  (1.06; 1.14)
  (0.92; 0.99)
  (0.95; 1.02)
  (0.99; 1.06)
   (Reference)
  (0.98; 1.05)
  (0.97; 1.05)
  (0.94; 1.03)
  (0.88; 0.98)
  (0.86; 0.97)
  (0.77; 0.89)
  (0.73; 0.88)
   (Reference)
  (1.03; 1.08)
   (Reference)
  (0.96; 1.01)
  (0.98; 1.04)
   (Reference)
  (1.15; 1.23)
  (1.16; 1.28)
  (0.97; 1.08)
   (Reference)
  (1.03; 1.13)
   (Reference)
  (1.04; 1.17)
   (Reference)
  (1.02; 1.10)
   (Reference)
  (0.98; 1.08)
Mixed−effects model for 'first identified as smoker' and 'provision
of smoking−cessation advice'. Incident clinical trigger
Number of clinical triggers 55161; Number of clinical actions 45926. ICC
for practice = 0.056. Missing values imputed using MICE.
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Kaplan−Meier plot for 'first
identified as smoker' and 'referral
to smoking−cessation services'.
Incident clinical trigger (triggers =
55161; actions = 2514)
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Smoking
management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 1.06
 1.10
 1.14
 1.17
 0.97
 1.02
 0.98
    1
 0.99
 1.01
 0.99
 0.66
 0.41
 0.17
 0.13
    1
 1.12
    1
 0.99
 1.05
    1
 1.43
 1.27
 1.10
    1
 1.11
    1
 1.02
    1
 1.46
    1
 1.20
95% CI
   (Reference)
  (0.90; 1.23)
  (0.93; 1.29)
  (0.97; 1.33)
  (0.99; 1.38)
  (0.85; 1.12)
  (0.89; 1.18)
  (0.85; 1.13)
   (Reference)
  (0.85; 1.15)
  (0.85; 1.19)
  (0.81; 1.20)
  (0.52; 0.85)
  (0.29; 0.58)
  (0.09; 0.33)
  (0.05; 0.34)
   (Reference)
  (1.02; 1.23)
   (Reference)
  (0.90; 1.10)
  (0.93; 1.19)
   (Reference)
  (1.25; 1.64)
  (1.03; 1.57)
  (0.86; 1.40)
   (Reference)
  (0.75; 1.65)
   (Reference)
  (0.77; 1.37)
   (Reference)
  (1.26; 1.69)
   (Reference)
  (0.99; 1.46)
Mixed−effects model for 'first identified as smoker' and 'referral to
smoking−cessation services'. Incident clinical trigger
Number of clinical triggers 55161; Number of clinical actions 2514. ICC
for practice = 0.533. Missing values imputed using MICE.
469
BP management
0.00
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7
Time (years)
Pr
op
or
ti
on
 w
it
ho
ut
 a
ct
io
n
Quintile
1
2
3
4
5
Kaplan−Meier plot for 'BP raised and
low−risk' and 'treatment with
antihypertensive medication'.
Incident clinical trigger (triggers =
13814; actions = 9899)
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BP management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
 BMI low/norm.
    Overweight
         Obese
  Chol:HDL < 4
 Chol:HDL >= 4
   No oth. co.
     Other co.
HR
    1
 1.08
 1.14
 1.11
 1.22
 0.96
 1.16
 1.09
    1
 0.89
 0.80
 0.95
 1.08
 1.09
 1.15
 0.93
    1
 0.95
    1
 1.03
 1.03
    1
 1.08
    1
 1.08
95% CI
   (Reference)
  (1.00; 1.15)
  (1.06; 1.22)
  (1.04; 1.20)
  (1.13; 1.31)
  (0.87; 1.06)
  (1.07; 1.25)
  (1.01; 1.17)
   (Reference)
  (0.82; 0.95)
  (0.74; 0.87)
  (0.87; 1.05)
  (0.98; 1.19)
  (0.99; 1.20)
  (1.04; 1.28)
  (0.83; 1.05)
   (Reference)
  (0.90; 0.99)
   (Reference)
  (0.97; 1.09)
  (0.96; 1.11)
   (Reference)
  (0.99; 1.17)
   (Reference)
  (1.00; 1.17)
Mixed−effects model for 'BP raised and low−risk' and 'treatment with
antihypertensive medication'. Incident clinical trigger
Number of clinical triggers 13814; Number of clinical actions 9899. ICC
for practice = 0.052. Missing values imputed using MICE.
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Kaplan−Meier plot for 'BP raised and
high−risk' and 'treatment with
antihypertensive medication'.
Incident clinical trigger (triggers =
106079; actions = 75797)
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BP management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
 BMI low/norm.
    Overweight
         Obese
  Chol:HDL < 4
 Chol:HDL >= 4
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indic. years
HR
    1
 1.01
 1.00
 1.00
 1.00
 0.88
 1.09
 1.06
    1
 0.83
 0.71
 0.64
 0.60
 0.57
 0.55
 0.51
    1
 1.30
    1
 1.10
 1.17
    1
 0.97
    1
 0.95
    1
 1.93
 1.01
95% CI
   (Reference)
  (0.99; 1.04)
  (0.97; 1.02)
  (0.97; 1.03)
  (0.98; 1.03)
  (0.81; 0.96)
  (1.03; 1.15)
  (1.02; 1.10)
   (Reference)
  (0.80; 0.85)
  (0.69; 0.73)
  (0.62; 0.65)
  (0.58; 0.62)
  (0.55; 0.59)
  (0.53; 0.57)
  (0.49; 0.53)
   (Reference)
  (1.28; 1.32)
   (Reference)
  (1.08; 1.12)
  (1.15; 1.19)
   (Reference)
  (0.96; 0.99)
   (Reference)
  (0.93; 0.97)
   (Reference)
  (1.85; 2.00)
  (1.01; 1.02)
Mixed−effects model for 'BP raised and high−risk' and 'treatment with
antihypertensive medication'. Incident clinical trigger
Number of clinical triggers 106079; Number of clinical actions 75797. ICC
for practice = 0.046. Missing values imputed using MICE.
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Kaplan−Meier plot for 'risk assessed
high' and 'statin'. Incident clinical
trigger (triggers = 120459; actions =
33226)
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High risk
statin
management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
   No oth. co.
     Other co.
HR
    1
 1.01
 0.99
 1.01
 1.01
 0.77
 0.94
 0.90
    1
 1.20
 1.30
 1.31
 1.19
 0.82
 0.56
 0.34
    1
 1.28
    1
 1.00
    1
 1.05
 0.92
    1
 1.80
 1.79
 1.43
    1
 2.35
    1
 0.90
95% CI
   (Reference)
  (0.96; 1.06)
  (0.94; 1.04)
  (0.96; 1.06)
  (0.95; 1.07)
  (0.58; 1.03)
  (0.84; 1.06)
  (0.84; 0.96)
   (Reference)
  (1.14; 1.26)
  (1.24; 1.37)
  (1.24; 1.39)
  (1.12; 1.27)
  (0.75; 0.88)
  (0.51; 0.62)
  (0.29; 0.40)
   (Reference)
  (1.24; 1.32)
   (Reference)
  (0.96; 1.03)
   (Reference)
  (1.01; 1.09)
  (0.88; 0.96)
   (Reference)
  (1.73; 1.88)
  (1.71; 1.87)
  (1.36; 1.49)
   (Reference)
  (2.21; 2.51)
   (Reference)
  (0.85; 0.95)
Mixed−effects model for 'risk assessed high' and 'statin'. Incident
clinical trigger
Number of clinical triggers 105301; Number of clinical actions 20661. ICC
for practice = 0.089. Missing values imputed using MICE.
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Kaplan−Meier plot for 'high−risk
diagnosis' and 'statin'. Incident
clinical trigger (triggers = 45601;
actions = 29135)
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High risk
statin
management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
  Chol:HDL < 4
 Chol:HDL >= 4
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indic. years
HR
    1
 0.97
 1.01
 1.02
 1.01
 0.55
 0.79
 0.92
    1
 1.06
 1.11
 1.10
 1.10
 0.96
 0.74
 0.48
    1
 1.09
    1
 1.12
    1
 1.06
 0.99
    1
 1.49
    1
 0.72
    1
 1.15
 1.00
95% CI
   (Reference)
  (0.92; 1.02)
  (0.96; 1.07)
  (0.97; 1.08)
  (0.96; 1.07)
  (0.50; 0.61)
  (0.73; 0.85)
  (0.86; 0.98)
   (Reference)
  (1.00; 1.13)
  (1.04; 1.18)
  (1.04; 1.18)
  (1.02; 1.17)
  (0.90; 1.03)
  (0.68; 0.80)
  (0.44; 0.52)
   (Reference)
  (1.06; 1.13)
   (Reference)
  (1.08; 1.17)
   (Reference)
  (1.01; 1.11)
  (0.93; 1.04)
   (Reference)
  (1.40; 1.59)
   (Reference)
  (0.70; 0.75)
   (Reference)
  (1.10; 1.20)
  (1.00; 1.01)
Mixed−effects model for 'high−risk diagnosis' and 'statin'. Incident
clinical trigger
Number of clinical triggers 34387; Number of clinical actions 19389. ICC
for practice = 0.062. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina'
and 'statin'. Incident clinical
trigger (triggers = 18934; actions =
11230)
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Drug
management of
chronic CHD
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indication 3
  Indic. years
HR
    1
 0.96
 1.04
 0.99
 0.87
 0.40
 0.67
 0.87
    1
 1.08
 1.08
 1.00
 0.85
 0.66
 0.50
 0.24
    1
 0.96
    1
 0.95
    1
 1.06
 0.88
    1
 0.91
 1.09
 1.28
    1
 1.44
    1
 1.13
    1
 0.63
    1
 1.21
 1.10
 1.00
95% CI
   (Reference)
  (0.87; 1.07)
  (0.94; 1.15)
  (0.89; 1.10)
  (0.79; 0.97)
  (0.27; 0.58)
  (0.54; 0.84)
  (0.74; 1.03)
   (Reference)
  (0.95; 1.23)
  (0.95; 1.24)
  (0.88; 1.14)
  (0.74; 0.97)
  (0.57; 0.76)
  (0.43; 0.58)
  (0.20; 0.29)
   (Reference)
  (0.90; 1.03)
   (Reference)
  (0.88; 1.03)
   (Reference)
  (0.98; 1.15)
  (0.80; 0.97)
   (Reference)
  (0.85; 0.98)
  (0.99; 1.19)
  (1.15; 1.44)
   (Reference)
  (1.27; 1.63)
   (Reference)
  (0.99; 1.30)
   (Reference)
  (0.59; 0.68)
   (Reference)
  (1.11; 1.31)
  (0.85; 1.42)
  (0.99; 1.01)
Mixed−effects model for 'stable angina' and 'statin'. Incident
clinical trigger
Number of clinical triggers 11104; Number of clinical actions 4660. ICC
for practice = 0.04. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina
and diabetes' and 'statin'. Incident
clinical trigger (triggers = 8956;
actions = 6588)
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Drug
management of
chronic CHD
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
HR
    1
 0.96
 1.09
 1.07
 0.97
 0.94
 0.96
 1.15
    1
 0.88
 0.88
 0.83
 0.76
 0.64
 0.50
 0.24
    1
 1.08
    1
 0.93
    1
 1.01
 0.96
    1
 1.01
 1.38
 1.34
    1
 1.52
    1
 0.98
    1
 0.73
    1
 2.34
 2.41
 1.15
95% CI
   (Reference)
  (0.75; 1.21)
  (0.86; 1.36)
  (0.85; 1.35)
  (0.77; 1.23)
  (0.52; 1.71)
  (0.56; 1.65)
  (0.76; 1.72)
   (Reference)
  (0.63; 1.24)
  (0.64; 1.21)
  (0.60; 1.13)
  (0.56; 1.04)
  (0.47; 0.88)
  (0.36; 0.70)
  (0.16; 0.36)
   (Reference)
  (0.94; 1.24)
   (Reference)
  (0.77; 1.12)
   (Reference)
  (0.82; 1.24)
  (0.79; 1.16)
   (Reference)
  (0.86; 1.19)
  (1.13; 1.68)
  (0.99; 1.82)
   (Reference)
  (1.29; 1.78)
   (Reference)
  (0.78; 1.23)
   (Reference)
  (0.63; 0.84)
   (Reference)
  (1.51; 3.63)
  (1.53; 3.79)
  (0.38; 3.49)
  Indic. years
HR
 1.00
95% CI
  (0.99; 1.01)
Mixed−effects model for 'stable angina and diabetes' and 'statin'.
Incident clinical trigger
Number of clinical triggers 2457; Number of clinical actions 968. ICC for
practice = 0.067. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina'
and 'aspirin'. Incident clinical
trigger (triggers = 18934; actions =
10703)
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Drug
management of
chronic CHD
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
HR
    1
 0.95
 1.02
 1.00
 0.98
 0.49
 0.95
 0.97
    1
 1.18
 1.19
 1.06
 0.96
 0.90
 0.89
 0.71
    1
 0.86
    1
 1.06
    1
 1.00
 0.90
    1
 0.91
 1.03
 1.26
    1
 1.13
    1
 0.81
    1
 0.64
95% CI
   (Reference)
  (0.85; 1.06)
  (0.91; 1.14)
  (0.89; 1.12)
  (0.88; 1.10)
  (0.34; 0.72)
  (0.76; 1.18)
  (0.81; 1.15)
   (Reference)
  (1.03; 1.35)
  (1.04; 1.36)
  (0.92; 1.22)
  (0.83; 1.12)
  (0.77; 1.04)
  (0.76; 1.05)
  (0.59; 0.85)
   (Reference)
  (0.80; 0.92)
   (Reference)
  (0.97; 1.16)
   (Reference)
  (0.93; 1.09)
  (0.82; 0.98)
   (Reference)
  (0.84; 0.98)
  (0.93; 1.13)
  (1.11; 1.44)
   (Reference)
  (0.99; 1.28)
   (Reference)
  (0.70; 0.94)
   (Reference)
  (0.59; 0.69)
Mixed−effects model for 'stable angina' and 'aspirin'. Incident
clinical trigger
Number of clinical triggers 9433; Number of clinical actions 3923. ICC for
practice = 0.056. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina
and diabetes' and 'aspirin'. Incident
clinical trigger (triggers = 8956;
actions = 5472)
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Drug
management of
chronic CHD
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indic. years
HR
    1
 0.88
 1.09
 0.96
 1.01
 1.12
 1.14
 1.07
    1
 1.10
 1.00
 0.88
 0.94
 0.93
 0.99
 0.81
    1
 0.87
    1
 1.00
    1
 1.11
 0.99
    1
 0.93
 1.18
 1.22
    1
 1.21
    1
 0.90
    1
 0.69
    1
 0.44
 1.01
95% CI
   (Reference)
  (0.70; 1.12)
  (0.87; 1.37)
  (0.77; 1.20)
  (0.81; 1.27)
  (0.60; 2.10)
  (0.72; 1.81)
  (0.71; 1.59)
   (Reference)
  (0.80; 1.50)
  (0.74; 1.36)
  (0.65; 1.20)
  (0.69; 1.27)
  (0.68; 1.28)
  (0.70; 1.39)
  (0.55; 1.20)
   (Reference)
  (0.75; 0.99)
   (Reference)
  (0.83; 1.21)
   (Reference)
  (0.90; 1.38)
  (0.80; 1.22)
   (Reference)
  (0.79; 1.10)
  (0.97; 1.44)
  (0.87; 1.73)
   (Reference)
  (1.00; 1.47)
   (Reference)
  (0.71; 1.16)
   (Reference)
  (0.60; 0.80)
   (Reference)
  (0.36; 0.54)
  (0.99; 1.03)
Mixed−effects model for 'stable angina and diabetes' and 'aspirin'.
Incident clinical trigger
Number of clinical triggers 2736; Number of clinical actions 919. ICC for
practice = 0.066. Missing values imputed using MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
HR
    1
 1.12
 1.20
 1.06
 1.12
 0.87
 0.70
 0.74
    1
 0.81
 0.82
 0.88
 0.92
 0.73
 0.88
 0.60
    1
 0.91
    1
 0.92
    1
 1.10
 1.27
    1
 1.36
 2.72
 1.61
    1
 1.21
    1
 1.16
    1
 0.88
95% CI
   (Reference)
  (0.89; 1.40)
  (0.97; 1.48)
  (0.86; 1.31)
  (0.91; 1.39)
  (0.41; 1.82)
  (0.42; 1.19)
  (0.49; 1.13)
   (Reference)
  (0.60; 1.10)
  (0.61; 1.09)
  (0.66; 1.16)
  (0.70; 1.23)
  (0.54; 0.99)
  (0.64; 1.21)
  (0.42; 0.88)
   (Reference)
  (0.80; 1.03)
   (Reference)
  (0.77; 1.09)
   (Reference)
  (0.90; 1.34)
  (1.05; 1.54)
   (Reference)
  (1.18; 1.57)
  (2.27; 3.26)
  (1.26; 2.05)
   (Reference)
  (1.05; 1.39)
   (Reference)
  (0.96; 1.40)
   (Reference)
  (0.77; 1.01)
Mixed−effects model for 'stable angina and diabetes' and 'ACE
inhibitor'. Incident clinical trigger
Number of clinical triggers 3361; Number of clinical actions 1092. ICC for
practice = 0.03. Missing values imputed using MICE.
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Kaplan−Meier plot for 'old ACS' and
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(triggers = 4256; actions = 2763)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.74
 0.89
 0.94
 0.79
 0.51
 0.61
 0.73
    1
 0.77
 0.83
 0.70
 0.72
 0.56
 0.39
 0.30
    1
 1.07
    1
 1.10
    1
 0.90
 0.96
    1
 0.89
 1.09
 1.10
    1
 1.66
    1
 0.91
    1
 0.52
    1
 0.77
95% CI
   (Reference)
  (0.59; 0.93)
  (0.72; 1.10)
  (0.75; 1.17)
  (0.64; 0.99)
  (0.22; 1.20)
  (0.41; 0.92)
  (0.53; 1.01)
   (Reference)
  (0.57; 1.05)
  (0.61; 1.12)
  (0.52; 0.94)
  (0.54; 0.97)
  (0.41; 0.75)
  (0.29; 0.53)
  (0.22; 0.41)
   (Reference)
  (0.93; 1.25)
   (Reference)
  (0.93; 1.31)
   (Reference)
  (0.74; 1.09)
  (0.79; 1.17)
   (Reference)
  (0.76; 1.05)
  (0.87; 1.35)
  (0.84; 1.44)
   (Reference)
  (1.31; 2.10)
   (Reference)
  (0.72; 1.17)
   (Reference)
  (0.44; 0.61)
   (Reference)
  (0.61; 0.98)
Mixed−effects model for 'old ACS' and 'statin'. Incident clinical
trigger
Number of clinical triggers 2112; Number of clinical actions 963. ICC for
practice = 0.042. Missing values imputed using MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.12
 1.18
 1.03
 1.03
 0.72
 0.75
 1.02
    1
 1.16
 1.35
 1.26
 1.14
 0.96
 0.87
 0.70
    1
 0.81
    1
 1.16
    1
 1.20
 1.18
    1
 0.91
 1.08
 1.13
    1
 1.02
    1
 0.83
    1
 0.71
    1
 0.87
    1
 1.14
95% CI
   (Reference)
  (0.96; 1.32)
  (1.01; 1.38)
  (0.88; 1.21)
  (0.88; 1.20)
  (0.44; 1.18)
  (0.56; 1.01)
  (0.80; 1.30)
   (Reference)
  (0.94; 1.44)
  (1.09; 1.66)
  (1.01; 1.57)
  (0.92; 1.42)
  (0.77; 1.21)
  (0.70; 1.10)
  (0.55; 0.88)
   (Reference)
  (0.74; 0.90)
   (Reference)
  (1.03; 1.30)
   (Reference)
  (1.06; 1.36)
  (1.03; 1.36)
   (Reference)
  (0.82; 1.01)
  (0.94; 1.25)
  (0.91; 1.40)
   (Reference)
  (0.90; 1.16)
   (Reference)
  (0.70; 0.97)
   (Reference)
  (0.64; 0.78)
   (Reference)
  (0.76; 1.00)
   (Reference)
  (0.88; 1.46)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 1.48
    1
 0.76
    1
 0.53
 0.41
    1
 1.26
 1.22
 0.87
 0.57
 1.00
95% CI
  (1.13; 1.93)
   (Reference)
  (0.62; 0.94)
   (Reference)
  (0.48; 0.59)
  (0.34; 0.50)
   (Reference)
  (1.12; 1.43)
  (1.04; 1.43)
  (0.66; 1.15)
  (0.36; 0.91)
  (0.99; 1.01)
Mixed−effects model for 'unstable angina' and 'statin'. Incident
clinical trigger
Number of clinical triggers 4462; Number of clinical actions 2178. ICC for
practice = 0.079. ICC for hospital = 0.011. Missing values imputed using
MICE.
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(triggers = 20467; actions = 11376)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.02
 1.00
 1.04
 0.97
 1.21
 1.08
 1.26
    1
 1.03
 1.02
 0.95
 0.86
 0.78
 0.66
 0.38
    1
 0.93
    1
 1.04
    1
 1.15
 1.05
    1
 0.97
 1.05
 1.03
    1
 1.18
    1
 0.77
    1
 0.68
    1
 0.86
    1
 1.28
95% CI
   (Reference)
  (0.92; 1.13)
  (0.90; 1.11)
  (0.94; 1.15)
  (0.87; 1.08)
  (0.97; 1.51)
  (0.91; 1.28)
  (1.09; 1.46)
   (Reference)
  (0.91; 1.17)
  (0.90; 1.15)
  (0.84; 1.08)
  (0.76; 0.98)
  (0.68; 0.89)
  (0.58; 0.76)
  (0.33; 0.44)
   (Reference)
  (0.87; 0.99)
   (Reference)
  (0.97; 1.11)
   (Reference)
  (1.06; 1.24)
  (0.96; 1.14)
   (Reference)
  (0.90; 1.03)
  (0.96; 1.16)
  (0.91; 1.16)
   (Reference)
  (1.09; 1.27)
   (Reference)
  (0.68; 0.87)
   (Reference)
  (0.64; 0.72)
   (Reference)
  (0.78; 0.94)
   (Reference)
  (1.05; 1.56)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 1.44
    1
 0.84
    1
 0.64
 0.40
    1
 1.16
 1.13
 1.09
 0.93
 1.00
95% CI
  (1.17; 1.77)
   (Reference)
  (0.62; 1.14)
   (Reference)
  (0.60; 0.69)
  (0.35; 0.46)
   (Reference)
  (1.08; 1.26)
  (1.02; 1.26)
  (0.90; 1.32)
  (0.66; 1.32)
  (0.99; 1.00)
Mixed−effects model for 'MI' and 'statin'. Incident clinical trigger
Number of clinical triggers 10442; Number of clinical actions 5372. ICC
for practice = 0.095. ICC for hospital = 0.041. Missing values imputed
using MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.75
 0.98
 0.77
 0.81
 0.85
 0.68
 0.65
    1
 0.69
 0.75
 0.67
 0.89
 0.66
 0.63
 0.68
    1
 1.05
    1
 1.29
    1
 1.00
 1.02
    1
 0.86
 1.08
 1.23
    1
 1.39
    1
 0.58
    1
 0.56
    1
 0.95
95% CI
   (Reference)
  (0.59; 0.94)
  (0.79; 1.22)
  (0.62; 0.96)
  (0.65; 1.01)
  (0.42; 1.71)
  (0.47; 0.98)
  (0.46; 0.91)
   (Reference)
  (0.52; 0.92)
  (0.57; 1.00)
  (0.51; 0.89)
  (0.67; 1.17)
  (0.48; 0.89)
  (0.46; 0.85)
  (0.49; 0.94)
   (Reference)
  (0.89; 1.23)
   (Reference)
  (1.10; 1.51)
   (Reference)
  (0.83; 1.21)
  (0.84; 1.25)
   (Reference)
  (0.73; 1.02)
  (0.86; 1.34)
  (0.94; 1.62)
   (Reference)
  (1.04; 1.86)
   (Reference)
  (0.44; 0.77)
   (Reference)
  (0.48; 0.66)
   (Reference)
  (0.78; 1.17)
Mixed−effects model for 'old ACS' and 'aspirin'. Incident clinical
trigger
Number of clinical triggers 1794; Number of clinical actions 915. ICC for
practice = 0.051. Missing values imputed using MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.08
 1.26
 1.15
 1.24
 0.91
 0.68
 0.90
    1
 1.03
 1.18
 1.03
 1.01
 0.81
 1.03
 0.90
    1
 0.78
    1
 1.20
    1
 0.95
 1.05
    1
 1.00
 1.26
 1.32
    1
 1.05
    1
 0.78
    1
 0.75
    1
 0.93
    1
 0.92
95% CI
   (Reference)
  (0.91; 1.28)
  (1.06; 1.48)
  (0.97; 1.35)
  (1.05; 1.46)
  (0.57; 1.46)
  (0.51; 0.90)
  (0.71; 1.15)
   (Reference)
  (0.85; 1.25)
  (0.97; 1.43)
  (0.83; 1.26)
  (0.81; 1.25)
  (0.65; 1.02)
  (0.82; 1.28)
  (0.71; 1.13)
   (Reference)
  (0.71; 0.86)
   (Reference)
  (1.07; 1.36)
   (Reference)
  (0.83; 1.09)
  (0.92; 1.20)
   (Reference)
  (0.90; 1.12)
  (1.09; 1.44)
  (1.05; 1.64)
   (Reference)
  (0.85; 1.31)
   (Reference)
  (0.64; 0.94)
   (Reference)
  (0.68; 0.83)
   (Reference)
  (0.82; 1.06)
   (Reference)
  (0.72; 1.19)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 1.68
    1
 0.77
    1
 0.66
 0.58
    1
 0.80
 0.64
 0.51
 0.43
 0.99
95% CI
  (1.29; 2.19)
   (Reference)
  (0.59; 0.99)
   (Reference)
  (0.59; 0.74)
  (0.48; 0.71)
   (Reference)
  (0.71; 0.91)
  (0.51; 0.79)
  (0.35; 0.74)
  (0.27; 0.68)
  (0.98; 1.00)
Mixed−effects model for 'unstable angina' and 'aspirin'. Incident
clinical trigger
Number of clinical triggers 4172; Number of clinical actions 2041. ICC for
practice = 0.084. ICC for hospital = 0.021. Missing values imputed using
MICE.
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Kaplan−Meier plot for 'MI' and
'aspirin'. Incident clinical trigger
(triggers = 20467; actions = 11007)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.98
 1.01
 0.98
 0.99
 1.12
 1.10
 1.10
    1
 1.00
 0.98
 0.98
 0.83
 0.78
 0.68
 0.61
    1
 0.85
    1
 1.06
    1
 1.08
 1.03
    1
 0.98
 1.02
 1.06
    1
 1.15
    1
 0.56
    1
 0.72
    1
 0.88
    1
 1.13
95% CI
   (Reference)
  (0.88; 1.09)
  (0.91; 1.12)
  (0.88; 1.09)
  (0.89; 1.10)
  (0.90; 1.39)
  (0.93; 1.29)
  (0.95; 1.26)
   (Reference)
  (0.89; 1.13)
  (0.87; 1.11)
  (0.87; 1.11)
  (0.73; 0.94)
  (0.68; 0.90)
  (0.58; 0.79)
  (0.52; 0.71)
   (Reference)
  (0.79; 0.90)
   (Reference)
  (0.98; 1.15)
   (Reference)
  (1.00; 1.16)
  (0.95; 1.13)
   (Reference)
  (0.92; 1.05)
  (0.93; 1.11)
  (0.94; 1.20)
   (Reference)
  (1.00; 1.31)
   (Reference)
  (0.48; 0.66)
   (Reference)
  (0.67; 0.77)
   (Reference)
  (0.80; 0.96)
   (Reference)
  (0.92; 1.39)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 1.35
    1
 0.85
    1
 0.72
 0.46
    1
 0.97
 0.86
 0.67
 0.49
 0.98
95% CI
  (1.08; 1.67)
   (Reference)
  (0.65; 1.12)
   (Reference)
  (0.66; 0.77)
  (0.40; 0.52)
   (Reference)
  (0.89; 1.06)
  (0.73; 1.01)
  (0.48; 0.95)
  (0.26; 0.92)
  (0.97; 0.99)
Mixed−effects model for 'MI' and 'aspirin'. Incident clinical trigger
Number of clinical triggers 9577; Number of clinical actions 5098. ICC for
practice = 0.107. ICC for hospital = 0.031. Missing values imputed using
MICE.
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Kaplan−Meier plot for 'old ACS' and
'ACE inhibitor'. Incident clinical
trigger (triggers = 4256; actions =
2440)
500
Drug
management of
ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.86
 0.98
 0.84
 0.80
 0.82
 0.72
 0.96
    1
 0.77
 0.85
 0.69
 0.93
 0.69
 0.89
 0.61
    1
 0.75
    1
 1.19
    1
 1.01
 1.20
    1
 1.00
 1.50
 1.44
    1
 1.36
    1
 0.85
    1
 0.59
    1
 1.02
95% CI
   (Reference)
  (0.69; 1.08)
  (0.79; 1.21)
  (0.68; 1.05)
  (0.64; 1.01)
  (0.40; 1.70)
  (0.48; 1.09)
  (0.69; 1.35)
   (Reference)
  (0.56; 1.06)
  (0.63; 1.13)
  (0.51; 0.93)
  (0.70; 1.23)
  (0.50; 0.95)
  (0.65; 1.22)
  (0.43; 0.87)
   (Reference)
  (0.64; 0.87)
   (Reference)
  (1.01; 1.41)
   (Reference)
  (0.85; 1.20)
  (0.98; 1.46)
   (Reference)
  (0.85; 1.18)
  (1.18; 1.90)
  (1.12; 1.85)
   (Reference)
  (0.90; 2.06)
   (Reference)
  (0.67; 1.07)
   (Reference)
  (0.50; 0.70)
   (Reference)
  (0.84; 1.26)
Mixed−effects model for 'old ACS' and 'ACE inhibitor'. Incident
clinical trigger
Number of clinical triggers 2215; Number of clinical actions 881. ICC for
practice = 0.028. Missing values imputed using MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.06
 1.21
 1.19
 1.06
 0.71
 0.70
 1.03
    1
 1.04
 1.26
 1.24
 1.51
 1.23
 1.27
 1.03
    1
 0.80
    1
 1.35
    1
 1.05
 1.07
    1
 1.20
 1.52
 1.26
    1
 1.03
    1
 0.98
    1
 0.76
    1
 1.17
    1
 1.51
95% CI
   (Reference)
  (0.90; 1.25)
  (1.04; 1.42)
  (1.01; 1.39)
  (0.91; 1.25)
  (0.41; 1.23)
  (0.51; 0.97)
  (0.79; 1.33)
   (Reference)
  (0.84; 1.29)
  (1.02; 1.56)
  (1.00; 1.53)
  (1.21; 1.89)
  (0.98; 1.55)
  (1.00; 1.60)
  (0.80; 1.31)
   (Reference)
  (0.72; 0.88)
   (Reference)
  (1.21; 1.51)
   (Reference)
  (0.93; 1.18)
  (0.93; 1.24)
   (Reference)
  (1.08; 1.33)
  (1.30; 1.78)
  (1.02; 1.55)
   (Reference)
  (0.84; 1.27)
   (Reference)
  (0.84; 1.14)
   (Reference)
  (0.69; 0.84)
   (Reference)
  (1.02; 1.34)
   (Reference)
  (1.20; 1.88)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 2.27
    1
 0.75
    1
 0.55
 0.52
    1
 1.15
 0.96
 1.03
 0.57
 0.96
95% CI
  (1.79; 2.86)
   (Reference)
  (0.57; 0.97)
   (Reference)
  (0.49; 0.62)
  (0.43; 0.62)
   (Reference)
  (1.01; 1.30)
  (0.75; 1.22)
  (0.70; 1.51)
  (0.35; 0.92)
  (0.93; 1.00)
Mixed−effects model for 'unstable angina' and 'ACE inhibitor'.
Incident clinical trigger
Number of clinical triggers 5287; Number of clinical actions 1967. ICC for
practice = 0.039. ICC for hospital = 0.024. Missing values imputed using
MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.05
 1.01
 1.02
 1.02
 0.86
 1.01
 1.09
    1
 0.96
 1.04
 0.98
 0.83
 0.84
 0.78
 0.46
    1
 0.89
    1
 1.05
    1
 1.22
 1.20
    1
 1.02
 1.19
 1.12
    1
 1.10
    1
 0.82
    1
 0.73
    1
 1.05
    1
 1.26
95% CI
   (Reference)
  (0.95; 1.16)
  (0.91; 1.12)
  (0.92; 1.12)
  (0.91; 1.13)
  (0.69; 1.07)
  (0.86; 1.19)
  (0.94; 1.25)
   (Reference)
  (0.85; 1.08)
  (0.92; 1.17)
  (0.86; 1.11)
  (0.73; 0.94)
  (0.74; 0.96)
  (0.69; 0.90)
  (0.40; 0.54)
   (Reference)
  (0.83; 0.94)
   (Reference)
  (0.98; 1.12)
   (Reference)
  (1.13; 1.31)
  (1.10; 1.31)
   (Reference)
  (0.95; 1.09)
  (1.08; 1.32)
  (1.00; 1.25)
   (Reference)
  (1.01; 1.20)
   (Reference)
  (0.73; 0.91)
   (Reference)
  (0.68; 0.77)
   (Reference)
  (0.96; 1.15)
   (Reference)
  (1.04; 1.53)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 1.45
    1
 1.04
    1
 0.69
 0.38
    1
 1.04
 0.99
 0.91
 0.83
 0.94
95% CI
  (1.19; 1.77)
   (Reference)
  (0.82; 1.32)
   (Reference)
  (0.64; 0.74)
  (0.34; 0.44)
   (Reference)
  (0.95; 1.14)
  (0.84; 1.18)
  (0.61; 1.36)
  (0.41; 1.70)
  (0.91; 0.96)
Mixed−effects model for 'MI' and 'ACE inhibitor'. Incident clinical
trigger
Number of clinical triggers 10595; Number of clinical actions 5270. ICC
for practice = 0.048. ICC for hospital = 0.024. Missing values imputed
using MICE.
505
Drug
management of
ACS
0.00
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7
Time (years)
Pr
op
or
ti
on
 w
it
ho
ut
 a
ct
io
n
Quintile
1
2
3
4
5
Kaplan−Meier plot for 'old ACS' and
'beta−blocker'. Incident clinical
trigger (triggers = 4256; actions =
332)
506
Drug
management of
ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.86
 0.82
 1.07
 1.00
 0.00
 0.76
 0.51
    1
 0.76
 0.66
 0.57
 0.83
 0.59
 0.48
 0.10
    1
 1.01
    1
 1.20
    1
 1.05
 1.09
    1
 1.10
 1.14
 1.44
    1
 1.43
    1
 0.31
    1
 0.31
    1
 0.77
95% CI
   (Reference)
  (0.47; 1.56)
  (0.46; 1.45)
  (0.61; 1.86)
  (0.57; 1.74)
   (0.00; >99)
  (0.31; 1.88)
  (0.20; 1.31)
   (Reference)
  (0.38; 1.54)
  (0.33; 1.35)
  (0.28; 1.18)
  (0.43; 1.62)
  (0.28; 1.24)
  (0.21; 1.07)
  (0.02; 0.43)
   (Reference)
  (0.68; 1.51)
   (Reference)
  (0.79; 1.83)
   (Reference)
  (0.64; 1.74)
  (0.61; 1.95)
   (Reference)
  (0.71; 1.69)
  (0.64; 2.05)
  (0.72; 2.88)
   (Reference)
  (0.77; 2.66)
   (Reference)
  (0.12; 0.77)
   (Reference)
  (0.19; 0.51)
   (Reference)
  (0.47; 1.25)
Mixed−effects model for 'old ACS' and 'beta−blocker'. Incident
clinical trigger
Number of clinical triggers 3538; Number of clinical actions 124. ICC for
practice = 0.044. Missing values imputed using MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.60
 0.83
 0.86
 0.91
 0.85
 1.80
 0.73
    1
 1.11
 0.80
 0.58
 0.79
 0.64
 0.87
 0.34
    1
 1.03
    1
 0.79
    1
 0.94
 0.78
    1
 1.64
 2.38
 1.72
    1
 1.12
    1
 0.98
    1
 0.40
    1
 0.75
    1
 1.53
95% CI
   (Reference)
  (0.39; 0.92)
  (0.57; 1.21)
  (0.59; 1.26)
  (0.63; 1.32)
  (0.20; 3.68)
  (0.94; 3.46)
  (0.35; 1.56)
   (Reference)
  (0.66; 1.86)
  (0.46; 1.36)
  (0.33; 1.02)
  (0.46; 1.36)
  (0.36; 1.12)
  (0.50; 1.51)
  (0.17; 0.66)
   (Reference)
  (0.80; 1.32)
   (Reference)
  (0.57; 1.10)
   (Reference)
  (0.67; 1.33)
  (0.53; 1.15)
   (Reference)
  (1.21; 2.22)
  (1.66; 3.41)
  (0.94; 3.16)
   (Reference)
  (0.73; 1.70)
   (Reference)
  (0.67; 1.44)
   (Reference)
  (0.30; 0.53)
   (Reference)
  (0.55; 1.04)
   (Reference)
  (0.87; 2.70)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 1.66
    1
 0.86
    1
 1.21
 1.33
    1
 0.75
 0.68
 0.24
 0.27
 0.92
95% CI
  (0.91; 3.05)
   (Reference)
  (0.30; 2.47)
   (Reference)
  (0.88; 1.67)
  (0.84; 2.11)
   (Reference)
  (0.53; 1.07)
  (0.36; 1.26)
  (0.06; 1.03)
  (0.06; 1.19)
  (0.80; 1.08)
Mixed−effects model for 'unstable angina' and 'beta−blocker'.
Incident clinical trigger
Number of clinical triggers 10405; Number of clinical actions 285. ICC for
practice = 0.093. ICC for hospital = 0.292. Missing values imputed using
MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.93
 0.76
 0.81
 0.83
 1.06
 1.70
 1.18
    1
 0.83
 0.95
 0.87
 0.60
 0.56
 0.58
 0.24
    1
 1.07
    1
 0.77
    1
 1.10
 0.98
    1
 1.40
 1.56
 0.83
    1
 1.55
    1
 0.75
    1
 0.39
    1
 1.00
    1
 0.54
95% CI
   (Reference)
  (0.66; 1.30)
  (0.54; 1.07)
  (0.58; 1.13)
  (0.59; 1.17)
  (0.49; 2.30)
  (1.00; 2.88)
  (0.71; 1.96)
   (Reference)
  (0.53; 1.31)
  (0.62; 1.47)
  (0.55; 1.35)
  (0.37; 0.97)
  (0.34; 0.92)
  (0.35; 0.96)
  (0.13; 0.44)
   (Reference)
  (0.84; 1.35)
   (Reference)
  (0.59; 1.02)
   (Reference)
  (0.85; 1.44)
  (0.70; 1.36)
   (Reference)
  (1.09; 1.80)
  (1.13; 2.14)
  (0.48; 1.45)
   (Reference)
  (1.01; 2.37)
   (Reference)
  (0.49; 1.15)
   (Reference)
  (0.30; 0.52)
   (Reference)
  (0.76; 1.32)
   (Reference)
  (0.29; 0.98)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
HR
 0.48
    1
 0.69
    1
 1.32
 0.53
    1
 0.85
 0.59
 0.21
 0.00
 1.00
95% CI
  (0.25; 0.92)
   (Reference)
  (0.26; 1.84)
   (Reference)
  (1.00; 1.75)
  (0.29; 0.95)
   (Reference)
  (0.60; 1.19)
  (0.29; 1.20)
  (0.03; 1.55)
   (0.00; >99)
  (0.85; 1.17)
Mixed−effects model for 'MI' and 'beta−blocker'. Incident clinical
trigger
Number of clinical triggers 16639; Number of clinical actions 363. ICC for
practice = 0.021. ICC for hospital = 0.305. Missing values imputed using
MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.99
 1.08
 1.01
 1.02
 0.88
 0.83
 0.98
    1
 0.93
 0.97
 0.98
 0.96
 0.83
 0.90
 0.80
    1
 0.84
    1
 1.15
    1
 1.05
 1.04
    1
 1.04
 1.02
 1.17
    1
 1.18
    1
 1.06
    1
 0.96
    1
 1.07
    1
 1.03
95% CI
   (Reference)
  (0.90; 1.10)
  (0.98; 1.18)
  (0.92; 1.11)
  (0.93; 1.12)
  (0.62; 1.24)
  (0.67; 1.03)
  (0.83; 1.16)
   (Reference)
  (0.81; 1.06)
  (0.86; 1.10)
  (0.86; 1.11)
  (0.84; 1.09)
  (0.72; 0.94)
  (0.79; 1.03)
  (0.70; 0.92)
   (Reference)
  (0.79; 0.89)
   (Reference)
  (1.07; 1.24)
   (Reference)
  (0.97; 1.13)
  (0.96; 1.12)
   (Reference)
  (0.97; 1.11)
  (0.93; 1.12)
  (0.99; 1.40)
   (Reference)
  (1.08; 1.29)
   (Reference)
  (0.98; 1.13)
   (Reference)
  (0.91; 1.01)
   (Reference)
  (1.01; 1.14)
   (Reference)
  (0.91; 1.16)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.36
    1
 0.69
    1
 0.64
 0.33
95% CI
  (1.19; 1.55)
   (Reference)
  (0.53; 0.91)
   (Reference)
  (0.60; 0.68)
  (0.29; 0.38)
Mixed−effects model for 'unstable angina' and 'clopidogrel'. Incident
clinical trigger
Number of clinical triggers 13907; Number of clinical actions 5783. ICC
for practice = 0.04. ICC for hospital = 0.035. Missing values imputed
using MICE.
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Kaplan−Meier plot for 'MI' and
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10132)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.04
 1.05
 1.06
 1.03
 0.93
 1.00
 1.03
    1
 0.90
 0.86
 0.81
 0.69
 0.63
 0.59
 0.49
    1
 0.99
    1
 1.03
    1
 1.14
 1.08
    1
 1.01
 1.06
 1.02
    1
 1.03
    1
 0.91
    1
 0.85
    1
 0.97
    1
 1.13
95% CI
   (Reference)
  (0.96; 1.12)
  (0.97; 1.13)
  (0.99; 1.15)
  (0.95; 1.11)
  (0.77; 1.12)
  (0.87; 1.15)
  (0.92; 1.16)
   (Reference)
  (0.82; 0.99)
  (0.79; 0.95)
  (0.74; 0.89)
  (0.63; 0.76)
  (0.57; 0.69)
  (0.54; 0.65)
  (0.44; 0.54)
   (Reference)
  (0.94; 1.03)
   (Reference)
  (0.98; 1.09)
   (Reference)
  (1.08; 1.20)
  (1.02; 1.15)
   (Reference)
  (0.96; 1.06)
  (1.00; 1.13)
  (0.92; 1.13)
   (Reference)
  (0.96; 1.11)
   (Reference)
  (0.86; 0.97)
   (Reference)
  (0.81; 0.88)
   (Reference)
  (0.92; 1.02)
   (Reference)
  (0.99; 1.30)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.24
    1
 0.88
    1
 0.67
 0.27
95% CI
  (1.08; 1.43)
   (Reference)
  (0.73; 1.06)
   (Reference)
  (0.64; 0.70)
  (0.24; 0.31)
Mixed−effects model for 'MI' and 'clopidogrel'. Incident clinical
trigger
Number of clinical triggers 20467; Number of clinical actions 10132. ICC
for practice = 0.05. ICC for hospital = 0.015. Missing values imputed
using MICE.
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Kaplan−Meier plot for 'stable angina'
and 'PCI'. Incident clinical trigger
(triggers = 18934; actions = 1172)
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of chronic
CHD
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
No prev. acti.
1+ prev. acti.
HR
    1
 0.97
 0.91
 0.78
 0.72
 1.07
 1.27
 1.22
    1
 0.99
 1.03
 0.84
 0.75
 0.35
 0.24
 0.07
    1
 0.60
    1
 0.97
    1
 1.00
 0.82
    1
 1.02
 1.26
 1.30
    1
 1.75
    1
 0.53
    1
 0.61
    1
 0.00
95% CI
   (Reference)
  (0.80; 1.17)
  (0.75; 1.09)
  (0.64; 0.96)
  (0.58; 0.88)
  (0.61; 1.87)
  (0.89; 1.79)
  (0.92; 1.61)
   (Reference)
  (0.79; 1.26)
  (0.82; 1.29)
  (0.67; 1.07)
  (0.59; 0.96)
  (0.26; 0.47)
  (0.16; 0.35)
  (0.04; 0.15)
   (Reference)
  (0.53; 0.68)
   (Reference)
  (0.84; 1.13)
   (Reference)
  (0.85; 1.18)
  (0.69; 0.96)
   (Reference)
  (0.88; 1.17)
  (1.07; 1.49)
  (1.04; 1.63)
   (Reference)
  (1.50; 2.04)
   (Reference)
  (0.40; 0.70)
   (Reference)
  (0.52; 0.71)
   (Reference)
   (0.00; >99)
Mixed−effects model for 'stable angina' and 'PCI'. Incident clinical
trigger
Number of clinical triggers 18934; Number of clinical actions 1172. ICC
for practice = 0.084. Missing values imputed using MICE.
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518
Revascularisation
of chronic
CHD
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indic. years
No prev. acti.
HR
    1
 0.71
 0.82
 0.69
 0.84
 1.12
 1.35
 1.29
    1
 0.90
 0.73
 0.65
 0.65
 0.28
 0.09
 0.14
    1
 0.69
    1
 0.87
    1
 1.54
 1.47
    1
 1.13
 1.14
 1.46
    1
 0.97
    1
 0.91
    1
 0.67
    1
 0.40
 0.95
    1
95% CI
   (Reference)
  (0.47; 1.06)
  (0.57; 1.19)
  (0.47; 1.01)
  (0.59; 1.21)
  (0.39; 3.19)
  (0.66; 2.77)
  (0.73; 2.28)
   (Reference)
  (0.58; 1.42)
  (0.46; 1.14)
  (0.42; 1.03)
  (0.41; 1.02)
  (0.16; 0.50)
  (0.03; 0.25)
  (0.05; 0.40)
   (Reference)
  (0.53; 0.88)
   (Reference)
  (0.63; 1.21)
   (Reference)
  (0.99; 2.40)
  (0.95; 2.27)
   (Reference)
  (0.83; 1.52)
  (0.80; 1.64)
  (0.80; 2.66)
   (Reference)
  (0.72; 1.31)
   (Reference)
  (0.62; 1.33)
   (Reference)
  (0.51; 0.88)
   (Reference)
  (0.27; 0.60)
  (0.90; 1.00)
   (Reference)
1+ prev. acti.
HR
 1.46
95% CI
  (0.58; 3.68)
Mixed−effects model for 'stable angina and diabetes' and 'PCI'.
Incident clinical trigger
Number of clinical triggers 8956; Number of clinical actions 300. ICC for
practice = 0.09. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina'
and 'CABG'. Incident clinical trigger
(triggers = 18934; actions = 1150)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
No prev. acti.
1+ prev. acti.
HR
    1
 0.93
 0.79
 0.78
 0.87
 0.64
 0.36
 0.93
    1
 1.22
 1.45
 1.70
 1.68
 1.57
 0.78
 0.19
    1
 0.32
    1
 0.88
    1
 0.91
 0.71
    1
 1.24
 1.31
 1.35
    1
 1.49
    1
 0.75
    1
 0.74
    1
 0.00
95% CI
   (Reference)
  (0.77; 1.12)
  (0.66; 0.96)
  (0.64; 0.96)
  (0.71; 1.06)
  (0.26; 1.60)
  (0.17; 0.74)
  (0.62; 1.38)
   (Reference)
  (0.90; 1.64)
  (1.09; 1.94)
  (1.28; 2.25)
  (1.26; 2.24)
  (1.16; 2.11)
  (0.55; 1.11)
  (0.10; 0.36)
   (Reference)
  (0.28; 0.37)
   (Reference)
  (0.75; 1.04)
   (Reference)
  (0.77; 1.08)
  (0.59; 0.85)
   (Reference)
  (1.08; 1.43)
  (1.10; 1.55)
  (1.07; 1.69)
   (Reference)
  (1.27; 1.75)
   (Reference)
  (0.61; 0.93)
   (Reference)
  (0.64; 0.85)
   (Reference)
   (0.00; >99)
Mixed−effects model for 'stable angina' and 'CABG'. Incident clinical
trigger
Number of clinical triggers 18934; Number of clinical actions 1150. ICC
for practice = 0.072. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina
and diabetes' and 'CABG'. Incident
clinical trigger (triggers = 8956;
actions = 385)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indic. years
No prev. acti.
HR
    1
 0.83
 0.96
 0.91
 0.77
 0.41
 0.20
 0.83
    1
 1.57
 1.51
 1.54
 1.55
 1.40
 0.63
 0.21
    1
 0.44
    1
 0.57
    1
 0.90
 0.79
    1
 1.20
 1.10
 0.85
    1
 1.58
    1
 0.87
    1
 0.66
    1
 0.39
 0.97
    1
95% CI
   (Reference)
  (0.59; 1.18)
  (0.69; 1.34)
  (0.65; 1.28)
  (0.54; 1.09)
  (0.05; 3.10)
  (0.03; 1.51)
  (0.36; 1.89)
   (Reference)
  (0.93; 2.64)
  (0.91; 2.52)
  (0.93; 2.54)
  (0.94; 2.56)
  (0.83; 2.36)
  (0.33; 1.21)
  (0.07; 0.63)
   (Reference)
  (0.35; 0.56)
   (Reference)
  (0.40; 0.81)
   (Reference)
  (0.65; 1.26)
  (0.57; 1.11)
   (Reference)
  (0.91; 1.57)
  (0.79; 1.52)
  (0.44; 1.65)
   (Reference)
  (1.22; 2.03)
   (Reference)
  (0.64; 1.20)
   (Reference)
  (0.52; 0.83)
   (Reference)
  (0.27; 0.55)
  (0.93; 1.00)
   (Reference)
1+ prev. acti.
HR
 0.00
95% CI
   (0.00; >99)
Mixed−effects model for 'stable angina and diabetes' and 'CABG'.
Incident clinical trigger
Number of clinical triggers 8956; Number of clinical actions 385. ICC for
practice = 0.138. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina'
and 'revascularisation'. Incident
clinical trigger (triggers = 18934;
actions = 2298)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
No prev. acti.
1+ prev. acti.
HR
    1
 0.96
 0.86
 0.78
 0.79
 0.90
 0.91
 1.12
    1
 1.07
 1.18
 1.15
 1.08
 0.79
 0.42
 0.11
    1
 0.43
    1
 0.93
    1
 0.98
 0.77
    1
 1.11
 1.29
 1.34
    1
 1.57
    1
 0.65
    1
 0.67
    1
 0.00
95% CI
   (Reference)
  (0.84; 1.10)
  (0.75; 0.99)
  (0.68; 0.90)
  (0.68; 0.92)
  (0.56; 1.46)
  (0.67; 1.23)
  (0.89; 1.41)
   (Reference)
  (0.89; 1.29)
  (0.99; 1.41)
  (0.96; 1.38)
  (0.90; 1.30)
  (0.64; 0.96)
  (0.33; 0.55)
  (0.07; 0.18)
   (Reference)
  (0.39; 0.47)
   (Reference)
  (0.83; 1.04)
   (Reference)
  (0.88; 1.09)
  (0.67; 0.89)
   (Reference)
  (1.01; 1.23)
  (1.14; 1.45)
  (1.14; 1.57)
   (Reference)
  (1.42; 1.74)
   (Reference)
  (0.54; 0.77)
   (Reference)
  (0.60; 0.74)
   (Reference)
   (0.00; >99)
Mixed−effects model for 'stable angina' and 'revascularisation'.
Incident clinical trigger
Number of clinical triggers 18934; Number of clinical actions 2298. ICC
for practice = 0.074. Missing values imputed using MICE.
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Kaplan−Meier plot for 'stable angina
and diabetes' and
'revascularisation'. Incident
clinical trigger (triggers = 8956;
actions = 676)
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of chronic
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
  Indication 1
  Indication 2
  Indic. years
No prev. acti.
HR
    1
 0.75
 0.88
 0.81
 0.79
 0.83
 0.87
 1.12
    1
 1.13
 1.00
 0.96
 0.95
 0.68
 0.29
 0.16
    1
 0.54
    1
 0.70
    1
 1.12
 1.02
    1
 1.16
 1.10
 1.13
    1
 1.30
    1
 0.87
    1
 0.65
    1
 0.39
 0.96
    1
95% CI
   (Reference)
  (0.57; 0.98)
  (0.68; 1.13)
  (0.62; 1.04)
  (0.61; 1.03)
  (0.33; 2.10)
  (0.45; 1.68)
  (0.70; 1.80)
   (Reference)
  (0.80; 1.58)
  (0.72; 1.40)
  (0.69; 1.33)
  (0.68; 1.33)
  (0.47; 0.97)
  (0.17; 0.48)
  (0.07; 0.34)
   (Reference)
  (0.45; 0.64)
   (Reference)
  (0.55; 0.88)
   (Reference)
  (0.86; 1.46)
  (0.78; 1.32)
   (Reference)
  (0.95; 1.42)
  (0.86; 1.41)
  (0.72; 1.76)
   (Reference)
  (1.11; 1.53)
   (Reference)
  (0.68; 1.11)
   (Reference)
  (0.54; 0.78)
   (Reference)
  (0.30; 0.51)
  (0.93; 0.99)
   (Reference)
1+ prev. acti.
HR
 0.53
95% CI
  (0.27; 1.04)
Mixed−effects model for 'stable angina and diabetes' and
'revascularisation'. Incident clinical trigger
Number of clinical triggers 8956; Number of clinical actions 676. ICC for
practice = 0.104. Missing values imputed using MICE.
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Kaplan−Meier plot for 'old ACS' and
'PCI'. Incident clinical trigger
(triggers = 4256; actions = 290)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
No prev. acti.
1+ prev. acti.
HR
    1
 1.21
 1.47
 0.90
 1.33
 0.68
 0.83
 0.71
    1
 0.68
 0.69
 0.54
 0.58
 0.25
 0.22
 0.05
    1
 0.71
    1
 1.30
    1
 1.13
 1.04
    1
 0.98
 1.27
 1.16
    1
 1.50
    1
 0.55
    1
 0.63
    1
 0.76
    1
 0.77
95% CI
   (Reference)
  (0.81; 1.82)
  (1.02; 2.14)
  (0.59; 1.36)
  (0.91; 1.95)
  (0.21; 2.21)
  (0.47; 1.47)
  (0.41; 1.21)
   (Reference)
  (0.44; 1.06)
  (0.45; 1.06)
  (0.35; 0.85)
  (0.37; 0.89)
  (0.14; 0.44)
  (0.12; 0.41)
  (0.02; 0.17)
   (Reference)
  (0.54; 0.93)
   (Reference)
  (0.98; 1.72)
   (Reference)
  (0.81; 1.56)
  (0.74; 1.45)
   (Reference)
  (0.74; 1.29)
  (0.89; 1.81)
  (0.69; 1.94)
   (Reference)
  (1.01; 2.22)
   (Reference)
  (0.34; 0.89)
   (Reference)
  (0.48; 0.83)
   (Reference)
  (0.55; 1.04)
   (Reference)
  (0.45; 1.30)
Mixed−effects model for 'old ACS' and 'PCI'. Incident clinical
trigger
Number of clinical triggers 4256; Number of clinical actions 290. ICC for
practice < 0.005. Missing values imputed using MICE.
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Kaplan−Meier plot for 'unstable
angina' and 'PCI'. Incident clinical
trigger (triggers = 13907; actions =
2130)
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.83
 0.88
 0.87
 0.76
 0.81
 0.53
 1.00
    1
 0.83
 0.82
 0.75
 0.73
 0.52
 0.40
 0.17
    1
 0.74
    1
 1.16
    1
 1.08
 0.97
    1
 0.87
 1.03
 0.79
    1
 1.37
    1
 0.71
    1
 0.72
    1
 0.85
    1
 0.94
95% CI
   (Reference)
  (0.72; 0.97)
  (0.76; 1.00)
  (0.76; 1.00)
  (0.66; 0.88)
  (0.52; 1.27)
  (0.39; 0.72)
  (0.81; 1.23)
   (Reference)
  (0.70; 0.99)
  (0.69; 0.97)
  (0.63; 0.89)
  (0.61; 0.87)
  (0.42; 0.63)
  (0.32; 0.50)
  (0.12; 0.24)
   (Reference)
  (0.67; 0.81)
   (Reference)
  (1.03; 1.29)
   (Reference)
  (0.96; 1.23)
  (0.85; 1.11)
   (Reference)
  (0.78; 0.97)
  (0.90; 1.19)
  (0.59; 1.05)
   (Reference)
  (1.21; 1.54)
   (Reference)
  (0.61; 0.82)
   (Reference)
  (0.66; 0.80)
   (Reference)
  (0.76; 0.95)
   (Reference)
  (0.79; 1.13)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
No prev. acti.
1+ prev. acti.
HR
 1.81
    1
 0.53
    1
 0.31
 0.05
    1
 0.96
 0.87
 0.72
 0.69
 1.00
    1
 1.40
95% CI
  (1.52; 2.17)
   (Reference)
  (0.32; 0.86)
   (Reference)
  (0.28; 0.35)
  (0.04; 0.08)
   (Reference)
  (0.86; 1.08)
  (0.75; 1.02)
  (0.58; 0.89)
  (0.55; 0.86)
  (0.99; 1.01)
   (Reference)
  (1.22; 1.60)
Mixed−effects model for 'unstable angina' and 'PCI'. Incident
clinical trigger
Number of clinical triggers 13907; Number of clinical actions 2130. ICC
for practice < 0.005. ICC for hospital = 0.115. Missing values imputed
using MICE.
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Kaplan−Meier plot for 'MI' and 'PCI'.
Incident clinical trigger (triggers =
20467; actions = 5118)
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Revascularisation
of ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.89
 0.90
 0.87
 0.83
 0.77
 0.90
 0.90
    1
 0.90
 0.80
 0.78
 0.56
 0.43
 0.24
 0.08
    1
 0.86
    1
 1.15
    1
 1.11
 1.08
    1
 0.99
 1.04
 1.14
    1
 1.18
    1
 0.67
    1
 0.70
    1
 0.82
    1
 1.67
95% CI
   (Reference)
  (0.80; 0.98)
  (0.82; 0.99)
  (0.79; 0.95)
  (0.75; 0.91)
  (0.62; 0.95)
  (0.77; 1.05)
  (0.79; 1.03)
   (Reference)
  (0.81; 1.01)
  (0.71; 0.89)
  (0.70; 0.87)
  (0.50; 0.63)
  (0.37; 0.48)
  (0.20; 0.28)
  (0.07; 0.10)
   (Reference)
  (0.80; 0.91)
   (Reference)
  (1.08; 1.23)
   (Reference)
  (1.01; 1.22)
  (0.98; 1.18)
   (Reference)
  (0.92; 1.06)
  (0.95; 1.13)
  (1.00; 1.30)
   (Reference)
  (1.09; 1.28)
   (Reference)
  (0.59; 0.75)
   (Reference)
  (0.65; 0.74)
   (Reference)
  (0.75; 0.88)
   (Reference)
  (1.30; 2.13)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
No prev. acti.
1+ prev. acti.
HR
 1.97
    1
 0.56
    1
 0.43
 0.07
    1
 0.84
 0.68
 0.67
 0.65
 1.00
    1
 0.93
95% CI
  (1.53; 2.53)
   (Reference)
  (0.34; 0.92)
   (Reference)
  (0.40; 0.46)
  (0.05; 0.09)
   (Reference)
  (0.77; 0.91)
  (0.60; 0.78)
  (0.55; 0.82)
  (0.50; 0.84)
  (0.99; 1.01)
   (Reference)
  (0.81; 1.06)
Mixed−effects model for 'MI' and 'PCI'. Incident clinical trigger
Number of clinical triggers 20467; Number of clinical actions 5118. ICC
for practice = 0.013. ICC for hospital = 0.127. Missing values imputed
using MICE.
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Revascularisation
of ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
No prev. acti.
1+ prev. acti.
HR
    1
 1.01
 1.06
 0.67
 0.78
 0.00
 0.18
 0.70
    1
 1.03
 1.42
 1.39
 1.64
 0.82
 0.47
 0.00
    1
 0.48
    1
 0.84
    1
 1.23
 0.90
    1
 1.15
 1.45
 2.02
    1
 1.45
    1
 0.62
    1
 0.61
    1
 1.33
    1
 0.00
95% CI
   (Reference)
  (0.62; 1.64)
  (0.67; 1.68)
  (0.39; 1.14)
  (0.47; 1.29)
   (0.00; >99)
  (0.02; 1.39)
  (0.24; 1.99)
   (Reference)
  (0.48; 2.19)
  (0.71; 2.83)
  (0.70; 2.77)
  (0.84; 3.22)
  (0.38; 1.75)
  (0.19; 1.16)
   (0.00; >99)
   (Reference)
  (0.33; 0.72)
   (Reference)
  (0.54; 1.30)
   (Reference)
  (0.78; 1.93)
  (0.55; 1.48)
   (Reference)
  (0.78; 1.71)
  (0.89; 2.34)
  (1.12; 3.63)
   (Reference)
  (0.73; 2.90)
   (Reference)
  (0.35; 1.09)
   (Reference)
  (0.42; 0.88)
   (Reference)
  (0.92; 1.92)
   (Reference)
   (0.00; >99)
Mixed−effects model for 'old ACS' and 'CABG'. Incident clinical
trigger
Number of clinical triggers 4256; Number of clinical actions 159. ICC for
practice < 0.005. Missing values imputed using MICE.
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Revascularisation
of ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.02
 0.95
 1.00
 0.97
 0.52
 0.54
 0.48
    1
 1.25
 1.21
 1.54
 1.49
 1.30
 0.57
 0.04
    1
 0.55
    1
 0.77
    1
 1.02
 0.95
    1
 1.30
 1.63
 1.33
    1
 1.47
    1
 0.78
    1
 0.60
    1
 1.20
    1
 1.15
95% CI
   (Reference)
  (0.83; 1.25)
  (0.78; 1.15)
  (0.82; 1.22)
  (0.79; 1.17)
  (0.19; 1.44)
  (0.30; 0.98)
  (0.29; 0.79)
   (Reference)
  (0.93; 1.68)
  (0.91; 1.61)
  (1.16; 2.04)
  (1.12; 1.97)
  (0.97; 1.74)
  (0.41; 0.81)
  (0.02; 0.09)
   (Reference)
  (0.48; 0.63)
   (Reference)
  (0.66; 0.91)
   (Reference)
  (0.85; 1.21)
  (0.80; 1.14)
   (Reference)
  (1.11; 1.53)
  (1.34; 1.98)
  (0.93; 1.91)
   (Reference)
  (1.27; 1.69)
   (Reference)
  (0.64; 0.94)
   (Reference)
  (0.52; 0.68)
   (Reference)
  (1.05; 1.37)
   (Reference)
  (0.95; 1.39)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
No prev. acti.
1+ prev. acti.
HR
 1.63
    1
 0.67
    1
 0.77
 8.10
    1
 1.37
 1.55
 1.30
 0.95
 0.99
    1
 0.03
95% CI
  (1.33; 1.99)
   (Reference)
  (0.43; 1.04)
   (Reference)
  (0.65; 0.92)
  (6.94; 9.47)
   (Reference)
  (1.17; 1.61)
  (1.27; 1.89)
  (0.99; 1.70)
  (0.69; 1.29)
  (0.98; 1.00)
   (Reference)
  (0.01; 0.11)
Mixed−effects model for 'unstable angina' and 'CABG'. Incident
clinical trigger
Number of clinical triggers 13907; Number of clinical actions 1155. ICC
for practice = 0.031. ICC for hospital = 0.075. Missing values imputed
using MICE.
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Revascularisation
of ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.98
 0.94
 0.95
 0.89
 0.33
 0.70
 0.80
    1
 1.31
 1.57
 1.61
 1.61
 1.06
 0.49
 0.06
    1
 0.57
    1
 0.85
    1
 1.09
 1.17
    1
 1.12
 1.31
 1.12
    1
 1.09
    1
 0.76
    1
 0.59
    1
 1.22
    1
 2.89
95% CI
   (Reference)
  (0.82; 1.16)
  (0.80; 1.11)
  (0.80; 1.13)
  (0.74; 1.06)
  (0.14; 0.75)
  (0.45; 1.08)
  (0.57; 1.13)
   (Reference)
  (1.03; 1.67)
  (1.25; 1.97)
  (1.29; 2.03)
  (1.28; 2.02)
  (0.84; 1.36)
  (0.37; 0.65)
  (0.03; 0.10)
   (Reference)
  (0.50; 0.64)
   (Reference)
  (0.75; 0.96)
   (Reference)
  (0.95; 1.24)
  (1.01; 1.35)
   (Reference)
  (0.98; 1.27)
  (1.13; 1.52)
  (0.87; 1.43)
   (Reference)
  (0.96; 1.25)
   (Reference)
  (0.64; 0.90)
   (Reference)
  (0.53; 0.66)
   (Reference)
  (1.08; 1.37)
   (Reference)
  (2.14; 3.89)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
No prev. acti.
1+ prev. acti.
HR
 3.35
    1
 0.67
    1
 0.98
 8.78
    1
 1.28
 1.36
 1.37
 1.09
 1.01
    1
 0.04
95% CI
  (2.45; 4.59)
   (Reference)
  (0.46; 0.98)
   (Reference)
  (0.86; 1.13)
 (7.64; 10.09)
   (Reference)
  (1.13; 1.46)
  (1.13; 1.62)
  (1.04; 1.82)
  (0.76; 1.55)
  (1.00; 1.02)
   (Reference)
  (0.01; 0.15)
Mixed−effects model for 'MI' and 'CABG'. Incident clinical trigger
Number of clinical triggers 20467; Number of clinical actions 1645. ICC
for practice = 0.05. ICC for hospital = 0.06. Missing values imputed using
MICE.
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Revascularisation
of ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
No prev. acti.
1+ prev. acti.
HR
    1
 1.09
 1.30
 0.77
 1.10
 0.55
 0.70
 0.70
    1
 0.76
 0.87
 0.72
 0.79
 0.34
 0.25
 0.04
    1
 0.62
    1
 1.12
    1
 1.15
 0.98
    1
 1.06
 1.28
 1.34
    1
 1.47
    1
 0.55
    1
 0.62
    1
 0.89
    1
 0.44
95% CI
   (Reference)
  (0.79; 1.49)
  (0.97; 1.74)
  (0.55; 1.07)
  (0.81; 1.49)
  (0.17; 1.79)
  (0.41; 1.21)
  (0.43; 1.14)
   (Reference)
  (0.52; 1.12)
  (0.61; 1.24)
  (0.50; 1.05)
  (0.55; 1.13)
  (0.22; 0.53)
  (0.15; 0.42)
  (0.01; 0.12)
   (Reference)
  (0.49; 0.77)
   (Reference)
  (0.87; 1.43)
   (Reference)
  (0.86; 1.53)
  (0.74; 1.31)
   (Reference)
  (0.85; 1.34)
  (0.96; 1.71)
  (0.90; 1.99)
   (Reference)
  (1.07; 2.02)
   (Reference)
  (0.38; 0.79)
   (Reference)
  (0.50; 0.78)
   (Reference)
  (0.70; 1.14)
   (Reference)
  (0.28; 0.70)
Mixed−effects model for 'old ACS' and 'revascularisation'. Incident
clinical trigger
Number of clinical triggers 4256; Number of clinical actions 441. ICC for
practice < 0.005. Missing values imputed using MICE.
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Revascularisation
of ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.90
 0.92
 0.92
 0.83
 0.70
 0.53
 0.89
    1
 0.93
 0.90
 0.93
 0.88
 0.69
 0.41
 0.11
    1
 0.64
    1
 1.01
    1
 1.09
 0.96
    1
 0.98
 1.23
 0.93
    1
 1.41
    1
 0.70
    1
 0.66
    1
 0.96
    1
 1.01
95% CI
   (Reference)
  (0.80; 1.02)
  (0.82; 1.04)
  (0.82; 1.04)
  (0.74; 0.94)
  (0.47; 1.06)
  (0.40; 0.70)
  (0.73; 1.08)
   (Reference)
  (0.80; 1.08)
  (0.77; 1.04)
  (0.80; 1.08)
  (0.76; 1.02)
  (0.59; 0.81)
  (0.34; 0.49)
  (0.08; 0.15)
   (Reference)
  (0.59; 0.70)
   (Reference)
  (0.92; 1.11)
   (Reference)
  (0.99; 1.21)
  (0.85; 1.08)
   (Reference)
  (0.90; 1.07)
  (1.10; 1.38)
  (0.74; 1.16)
   (Reference)
  (1.25; 1.60)
   (Reference)
  (0.62; 0.79)
   (Reference)
  (0.61; 0.71)
   (Reference)
  (0.88; 1.04)
   (Reference)
  (0.89; 1.15)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
No prev. acti.
1+ prev. acti.
HR
 1.88
    1
 0.49
    1
 0.36
 1.17
    1
 1.14
 1.19
 1.02
 0.86
 0.99
    1
 0.73
95% CI
  (1.64; 2.15)
   (Reference)
  (0.31; 0.77)
   (Reference)
  (0.33; 0.40)
  (1.04; 1.31)
   (Reference)
  (1.04; 1.25)
  (1.06; 1.35)
  (0.86; 1.21)
  (0.71; 1.03)
  (0.99; 1.00)
   (Reference)
  (0.65; 0.82)
Mixed−effects model for 'unstable angina' and 'revascularisation'.
Incident clinical trigger
Number of clinical triggers 13907; Number of clinical actions 3230. ICC
for practice = 0.01. ICC for hospital = 0.104. Missing values imputed
using MICE.
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Revascularisation
of ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.89
 0.90
 0.87
 0.83
 0.68
 0.87
 0.89
    1
 0.97
 0.89
 0.89
 0.69
 0.49
 0.25
 0.07
    1
 0.74
    1
 1.10
    1
 1.13
 1.10
    1
 1.04
 1.12
 1.12
    1
 1.17
    1
 0.67
    1
 0.65
    1
 0.90
    1
 2.14
95% CI
   (Reference)
  (0.82; 0.97)
  (0.83; 0.97)
  (0.80; 0.95)
  (0.77; 0.91)
  (0.55; 0.83)
  (0.75; 1.01)
  (0.78; 1.00)
   (Reference)
  (0.87; 1.07)
  (0.81; 0.98)
  (0.80; 0.98)
  (0.62; 0.76)
  (0.44; 0.55)
  (0.22; 0.28)
  (0.05; 0.08)
   (Reference)
  (0.70; 0.78)
   (Reference)
  (1.04; 1.16)
   (Reference)
  (1.06; 1.21)
  (1.02; 1.19)
   (Reference)
  (0.97; 1.10)
  (1.04; 1.21)
  (1.00; 1.26)
   (Reference)
  (1.10; 1.24)
   (Reference)
  (0.61; 0.74)
   (Reference)
  (0.61; 0.69)
   (Reference)
  (0.84; 0.96)
   (Reference)
  (1.76; 2.60)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
  Indication 1
  Indication 2
  Indication 3
  Indication 4
 Indication 5+
  Indic. years
No prev. acti.
1+ prev. acti.
HR
 2.73
    1
 0.51
    1
 0.47
 0.95
    1
 0.99
 0.92
 0.94
 0.92
 1.00
    1
 0.55
95% CI
  (2.24; 3.34)
   (Reference)
  (0.30; 0.87)
   (Reference)
  (0.44; 0.50)
  (0.85; 1.06)
   (Reference)
  (0.92; 1.06)
  (0.83; 1.03)
  (0.80; 1.12)
  (0.75; 1.14)
  (0.99; 1.01)
   (Reference)
  (0.49; 0.62)
Mixed−effects model for 'MI' and 'revascularisation'. Incident
clinical trigger
Number of clinical triggers 20467; Number of clinical actions 6649. ICC
for practice = 0.007. ICC for hospital = 0.142. Missing values imputed
using MICE.
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546 additional results
d.2 drug-cessation analysis
The analysis presented in subsequent pages related to drug cessation
was performed using the same conceptual underpinnings as that for
our main analysis. As before I present Kaplan-Meier plots and the
summary of results from ‘fully-adjusted models’. It is important to
note when considering these that the HRs operate in a different direc-
tion, because the phenomenon under investigation here is the time to
the prescriptions for a drug ceasing to be issued: it is assumed that
this happening more quickly in the most deprived quintile compared
to the least would constitute evidence of inequity.
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Kaplan−Meier plot for 'risk assessed
high' and 'statin'.  Drug cessation
(triggers = 33228; actions = 5378)
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High risk
statin
management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
   No oth. co.
     Other co.
HR
    1
 1.00
 1.00
 0.96
 0.95
 0.64
 0.91
 0.92
    1
 0.92
 1.00
 0.97
 1.29
 1.43
 1.99
 3.26
    1
 1.03
    1
 1.13
    1
 0.94
 0.92
    1
 0.77
 0.82
 0.94
    1
 1.07
    1
 1.29
95% CI
   (Reference)
  (0.91; 1.10)
  (0.91; 1.10)
  (0.87; 1.06)
  (0.86; 1.05)
  (0.26; 1.55)
  (0.68; 1.21)
  (0.78; 1.08)
   (Reference)
  (0.82; 1.03)
  (0.90; 1.12)
  (0.87; 1.09)
  (1.14; 1.45)
  (1.25; 1.63)
  (1.70; 2.33)
  (2.71; 3.93)
   (Reference)
  (0.97; 1.10)
   (Reference)
  (1.05; 1.21)
   (Reference)
  (0.88; 1.01)
  (0.85; 0.99)
   (Reference)
  (0.71; 0.82)
  (0.77; 0.89)
  (0.85; 1.03)
   (Reference)
  (1.00; 1.14)
   (Reference)
  (1.19; 1.40)
Mixed−effects model for 'risk assessed high' and 'statin'.  Drug
cessation
Number of clinical triggers 33228; Number of clinical actions 5378. ICC
for practice = 0.115. Missing values imputed using MICE.
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Kaplan−Meier plot for 'high−risk
diagnosis' and 'statin'.  Drug
cessation (triggers = 29208; actions
= 4041)
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High risk
statin
management
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
  Chol:HDL < 4
 Chol:HDL >= 4
   No oth. co.
     Other co.
HR
    1
 0.89
 0.91
 0.85
 0.78
 1.44
 1.30
 1.08
    1
 1.06
 1.09
 1.18
 1.34
 1.81
 2.36
 3.51
    1
 1.01
    1
 1.10
    1
 0.86
 0.84
    1
 0.94
    1
 1.36
95% CI
   (Reference)
  (0.80; 1.00)
  (0.82; 1.02)
  (0.76; 0.96)
  (0.70; 0.88)
  (1.13; 1.82)
  (1.06; 1.58)
  (0.90; 1.29)
   (Reference)
  (0.91; 1.24)
  (0.94; 1.26)
  (1.02; 1.37)
  (1.15; 1.55)
  (1.56; 2.10)
  (2.02; 2.76)
  (2.97; 4.14)
   (Reference)
  (0.95; 1.08)
   (Reference)
  (1.01; 1.19)
   (Reference)
  (0.78; 0.95)
  (0.76; 0.92)
   (Reference)
  (0.83; 1.06)
   (Reference)
  (1.27; 1.46)
Mixed−effects model for 'high−risk diagnosis' and 'statin'.  Drug
cessation
Number of clinical triggers 29208; Number of clinical actions 4041. ICC
for practice = 0.133. Missing values imputed using MICE.
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    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
HR
    1
 1.17
 1.20
 1.00
 1.06
 2.84
 1.51
 1.43
    1
 1.21
 1.36
 1.42
 1.58
 2.09
 2.42
 3.83
    1
 1.20
    1
 0.98
    1
 0.88
 0.87
    1
 0.84
 0.82
 0.93
    1
 0.99
    1
 0.79
    1
 1.42
95% CI
   (Reference)
  (1.00; 1.37)
  (1.02; 1.42)
  (0.84; 1.19)
  (0.88; 1.26)
  (1.49; 5.40)
  (0.99; 2.30)
  (1.02; 2.01)
   (Reference)
  (0.92; 1.59)
  (1.05; 1.78)
  (1.10; 1.85)
  (1.22; 2.06)
  (1.60; 2.73)
  (1.83; 3.20)
  (2.85; 5.16)
   (Reference)
  (1.08; 1.33)
   (Reference)
  (0.85; 1.13)
   (Reference)
  (0.77; 1.01)
  (0.76; 0.99)
   (Reference)
  (0.75; 0.94)
  (0.71; 0.95)
  (0.74; 1.17)
   (Reference)
  (0.83; 1.17)
   (Reference)
  (0.69; 0.92)
   (Reference)
  (1.28; 1.58)
Mixed−effects model for 'stable angina' and 'statin'.  Drug cessation
Number of clinical triggers 11231; Number of clinical actions 1711. ICC
for practice = 0.125. Missing values imputed using MICE.
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  Age 35 to 39
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  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
HR
    1
 0.99
 0.85
 0.99
 0.84
 1.60
 0.89
 0.51
    1
 0.99
 1.08
 1.48
 1.65
 2.33
 2.91
 5.83
    1
 1.07
    1
 1.07
    1
 0.79
 0.85
    1
 0.90
 0.80
 0.97
    1
 1.09
    1
 1.08
    1
 1.54
95% CI
   (Reference)
  (0.77; 1.27)
  (0.66; 1.10)
  (0.77; 1.27)
  (0.65; 1.09)
  (0.56; 4.64)
  (0.36; 2.16)
  (0.22; 1.16)
   (Reference)
  (0.62; 1.57)
  (0.70; 1.69)
  (0.97; 2.25)
  (1.09; 2.52)
  (1.53; 3.54)
  (1.88; 4.49)
  (3.71; 9.14)
   (Reference)
  (0.92; 1.24)
   (Reference)
  (0.86; 1.33)
   (Reference)
  (0.64; 0.98)
  (0.69; 1.04)
   (Reference)
  (0.75; 1.08)
  (0.63; 1.01)
  (0.62; 1.51)
   (Reference)
  (0.91; 1.30)
   (Reference)
  (0.90; 1.30)
   (Reference)
  (1.33; 1.79)
Mixed−effects model for 'stable angina and diabetes' and 'statin'.
Drug cessation
Number of clinical triggers 6588; Number of clinical actions 782. ICC for
practice = 0.172. Missing values imputed using MICE.
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    Quintile 3
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    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
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  Age 50 to 54
  Age 55 to 59
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  Age 65 to 69
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  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
HR
    1
 1.03
 1.04
 0.93
 1.01
 1.42
 1.46
 1.03
    1
 1.10
 0.96
 0.99
 1.09
 1.26
 1.47
 1.41
    1
 1.19
    1
 0.91
    1
 0.84
 0.91
    1
 0.91
 0.77
 0.83
    1
 0.89
    1
 0.85
    1
 1.42
95% CI
   (Reference)
  (0.90; 1.18)
  (0.91; 1.19)
  (0.81; 1.07)
  (0.88; 1.17)
  (0.81; 2.48)
  (1.08; 1.98)
  (0.79; 1.36)
   (Reference)
  (0.89; 1.35)
  (0.79; 1.18)
  (0.81; 1.21)
  (0.89; 1.33)
  (1.02; 1.54)
  (1.19; 1.81)
  (1.13; 1.75)
   (Reference)
  (1.09; 1.29)
   (Reference)
  (0.81; 1.02)
   (Reference)
  (0.75; 0.93)
  (0.81; 1.02)
   (Reference)
  (0.83; 0.99)
  (0.68; 0.87)
  (0.69; 1.01)
   (Reference)
  (0.79; 0.99)
   (Reference)
  (0.75; 0.96)
   (Reference)
  (1.31; 1.55)
Mixed−effects model for 'stable angina' and 'aspirin'.  Drug
cessation
Number of clinical triggers 10704; Number of clinical actions 2590. ICC
for practice = 0.1. Missing values imputed using MICE.
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  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
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          Male
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    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
HR
    1
 0.97
 0.75
 0.86
 0.86
 2.16
 0.99
 1.01
    1
 1.10
 1.33
 1.58
 1.60
 2.12
 2.36
 3.25
    1
 1.12
    1
 1.05
    1
 0.88
 0.91
    1
 0.98
 0.89
 0.99
    1
 0.98
    1
 0.97
    1
 1.66
95% CI
   (Reference)
  (0.78; 1.20)
  (0.60; 0.94)
  (0.70; 1.07)
  (0.69; 1.08)
  (0.94; 4.94)
  (0.47; 2.08)
  (0.57; 1.79)
   (Reference)
  (0.73; 1.66)
  (0.91; 1.96)
  (1.09; 2.29)
  (1.10; 2.32)
  (1.46; 3.08)
  (1.60; 3.48)
  (2.17; 4.86)
   (Reference)
  (0.99; 1.28)
   (Reference)
  (0.88; 1.26)
   (Reference)
  (0.74; 1.06)
  (0.76; 1.09)
   (Reference)
  (0.84; 1.15)
  (0.72; 1.09)
  (0.67; 1.47)
   (Reference)
  (0.81; 1.19)
   (Reference)
  (0.82; 1.15)
   (Reference)
  (1.46; 1.89)
Mixed−effects model for 'stable angina and diabetes' and 'aspirin'.
Drug cessation
Number of clinical triggers 5472; Number of clinical actions 1056. ICC for
practice = 0.138. Missing values imputed using MICE.
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    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
HR
    1
 0.91
 1.15
 1.17
 1.10
 0.84
 0.53
 0.77
    1
 0.85
 0.95
 1.47
 1.27
 1.89
 3.16
 3.34
    1
 1.01
    1
 1.29
    1
 0.70
 0.71
    1
 0.63
 0.51
 0.85
    1
 0.93
    1
 1.20
    1
 1.67
95% CI
   (Reference)
  (0.70; 1.19)
  (0.89; 1.48)
  (0.91; 1.51)
  (0.85; 1.41)
  (0.25; 2.81)
  (0.16; 1.76)
  (0.38; 1.56)
   (Reference)
  (0.54; 1.35)
  (0.61; 1.46)
  (0.97; 2.22)
  (0.84; 1.92)
  (1.25; 2.85)
  (2.07; 4.82)
  (2.14; 5.22)
   (Reference)
  (0.88; 1.17)
   (Reference)
  (1.05; 1.59)
   (Reference)
  (0.57; 0.86)
  (0.58; 0.88)
   (Reference)
  (0.52; 0.77)
  (0.40; 0.64)
  (0.52; 1.37)
   (Reference)
  (0.80; 1.09)
   (Reference)
  (1.01; 1.43)
   (Reference)
  (1.45; 1.92)
Mixed−effects model for 'stable angina and diabetes' and 'ACE
inhibitor'.  Drug cessation
Number of clinical triggers 5620; Number of clinical actions 827. ICC for
practice = 0.177. Missing values imputed using MICE.
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    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.97
 0.87
 0.86
 0.70
 2.87
 0.96
 0.98
    1
 0.56
 0.94
 1.51
 1.51
 2.11
 3.18
 7.18
    1
 0.90
    1
 1.30
    1
 0.88
 1.08
    1
 0.88
 0.94
 1.13
    1
 1.42
    1
 1.12
    1
 1.79
    1
 1.30
95% CI
   (Reference)
  (0.69; 1.36)
  (0.62; 1.21)
  (0.61; 1.20)
  (0.49; 0.98)
 (0.82; 10.06)
  (0.39; 2.35)
  (0.43; 2.23)
   (Reference)
  (0.28; 1.12)
  (0.52; 1.72)
  (0.87; 2.61)
  (0.87; 2.62)
  (1.22; 3.66)
  (1.83; 5.54)
 (4.05; 12.72)
   (Reference)
  (0.73; 1.11)
   (Reference)
  (0.99; 1.71)
   (Reference)
  (0.68; 1.13)
  (0.82; 1.41)
   (Reference)
  (0.69; 1.12)
  (0.67; 1.32)
  (0.66; 1.95)
   (Reference)
  (1.00; 2.01)
   (Reference)
  (0.87; 1.43)
   (Reference)
  (1.45; 2.21)
   (Reference)
  (1.02; 1.64)
Mixed−effects model for 'old ACS' and 'statin'.  Drug cessation
Number of clinical triggers 2764; Number of clinical actions 422. ICC for
practice = 0.216. Missing values imputed using MICE.
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    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
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  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.02
 1.07
 0.89
 1.04
 1.79
 2.44
 1.37
    1
 1.14
 1.39
 1.17
 1.82
 1.91
 2.90
 4.83
    1
 1.03
    1
 1.00
    1
 0.91
 0.75
    1
 0.79
 0.80
 1.09
    1
 1.04
    1
 1.16
    1
 1.46
    1
 1.05
    1
 1.12
95% CI
   (Reference)
  (0.83; 1.25)
  (0.87; 1.30)
  (0.73; 1.10)
  (0.84; 1.27)
  (0.80; 4.01)
  (1.50; 3.95)
  (0.86; 2.18)
   (Reference)
  (0.79; 1.64)
  (0.98; 1.95)
  (0.82; 1.66)
  (1.30; 2.54)
  (1.36; 2.68)
  (2.07; 4.07)
  (3.44; 6.79)
   (Reference)
  (0.92; 1.16)
   (Reference)
  (0.85; 1.18)
   (Reference)
  (0.78; 1.06)
  (0.63; 0.88)
   (Reference)
  (0.69; 0.91)
  (0.66; 0.97)
  (0.75; 1.58)
   (Reference)
  (0.82; 1.32)
   (Reference)
  (1.01; 1.33)
   (Reference)
  (1.30; 1.64)
   (Reference)
  (0.92; 1.19)
   (Reference)
  (0.87; 1.45)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.03
    1
 1.18
    1
 1.15
 1.18
95% CI
  (0.77; 1.38)
   (Reference)
  (0.86; 1.61)
   (Reference)
  (1.00; 1.33)
  (0.94; 1.49)
Mixed−effects model for 'unstable angina' and 'statin'.  Drug
cessation
Number of clinical triggers 9211; Number of clinical actions 1341. ICC for
practice = 0.159. ICC for hospital = 0.021. Missing values imputed using
MICE.
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  Age 45 to 49
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          Male
        Female
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        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.92
 1.12
 0.96
 0.97
 2.13
 1.56
 1.02
    1
 1.25
 1.45
 1.81
 2.38
 2.73
 3.92
 5.47
    1
 1.02
    1
 0.94
    1
 0.92
 0.80
    1
 0.99
 0.91
 0.92
    1
 1.14
    1
 1.12
    1
 1.69
    1
 1.20
    1
 1.39
95% CI
   (Reference)
  (0.77; 1.11)
  (0.94; 1.34)
  (0.80; 1.16)
  (0.80; 1.18)
  (1.23; 3.69)
  (0.96; 2.54)
  (0.63; 1.65)
   (Reference)
  (0.87; 1.81)
  (1.03; 2.04)
  (1.30; 2.52)
  (1.73; 3.28)
  (1.98; 3.77)
  (2.85; 5.41)
  (3.95; 7.58)
   (Reference)
  (0.92; 1.13)
   (Reference)
  (0.81; 1.09)
   (Reference)
  (0.81; 1.05)
  (0.69; 0.93)
   (Reference)
  (0.88; 1.12)
  (0.77; 1.09)
  (0.67; 1.27)
   (Reference)
  (1.00; 1.31)
   (Reference)
  (0.98; 1.27)
   (Reference)
  (1.53; 1.88)
   (Reference)
  (1.07; 1.35)
   (Reference)
  (1.03; 1.88)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.19
    1
 1.13
    1
 1.11
 1.19
95% CI
  (0.86; 1.64)
   (Reference)
  (0.80; 1.60)
   (Reference)
  (0.98; 1.26)
  (0.96; 1.47)
Mixed−effects model for 'MI' and 'statin'.  Drug cessation
Number of clinical triggers 11380; Number of clinical actions 1642. ICC
for practice = 0.144. ICC for hospital = 0.036. Missing values imputed
using MICE.
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    Overweight
         Obese
       No hyp.
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 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.96
 0.87
 0.96
 0.79
 3.11
 1.22
 0.83
    1
 0.75
 0.91
 1.26
 1.45
 1.68
 1.97
 2.52
    1
 1.12
    1
 1.18
    1
 0.83
 1.01
    1
 0.91
 0.91
 1.00
    1
 1.00
    1
 1.08
    1
 1.47
    1
 1.37
95% CI
   (Reference)
  (0.72; 1.29)
  (0.65; 1.15)
  (0.72; 1.28)
  (0.59; 1.06)
  (1.06; 9.13)
  (0.60; 2.51)
  (0.42; 1.67)
   (Reference)
  (0.44; 1.29)
  (0.55; 1.50)
  (0.79; 2.01)
  (0.92; 2.29)
  (1.07; 2.66)
  (1.24; 3.14)
  (1.56; 4.07)
   (Reference)
  (0.93; 1.35)
   (Reference)
  (0.93; 1.51)
   (Reference)
  (0.65; 1.05)
  (0.77; 1.32)
   (Reference)
  (0.73; 1.12)
  (0.68; 1.21)
  (0.62; 1.60)
   (Reference)
  (0.79; 1.26)
   (Reference)
  (0.86; 1.36)
   (Reference)
  (1.23; 1.77)
   (Reference)
  (1.11; 1.70)
Mixed−effects model for 'old ACS' and 'aspirin'.  Drug cessation
Number of clinical triggers 2692; Number of clinical actions 537. ICC for
practice = 0.122. Missing values imputed using MICE.
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  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
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     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.92
 0.95
 0.95
 0.85
 1.28
 1.25
 0.98
    1
 1.02
 0.92
 1.00
 1.39
 1.45
 1.81
 2.06
    1
 1.05
    1
 0.95
    1
 0.92
 0.86
    1
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 0.91
 0.83
    1
 1.04
    1
 1.03
    1
 1.39
    1
 0.94
    1
 1.15
95% CI
   (Reference)
  (0.77; 1.10)
  (0.80; 1.14)
  (0.79; 1.13)
  (0.71; 1.02)
  (0.64; 2.58)
  (0.81; 1.92)
  (0.66; 1.45)
   (Reference)
  (0.77; 1.35)
  (0.70; 1.21)
  (0.76; 1.31)
  (1.07; 1.80)
  (1.11; 1.89)
  (1.39; 2.37)
  (1.56; 2.71)
   (Reference)
  (0.95; 1.17)
   (Reference)
  (0.82; 1.10)
   (Reference)
  (0.80; 1.06)
  (0.73; 1.01)
   (Reference)
  (0.72; 0.92)
  (0.77; 1.08)
  (0.58; 1.17)
   (Reference)
  (0.91; 1.19)
   (Reference)
  (0.90; 1.18)
   (Reference)
  (1.26; 1.54)
   (Reference)
  (0.84; 1.06)
   (Reference)
  (0.92; 1.45)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 0.91
    1
 1.10
    1
 1.21
 0.96
95% CI
  (0.70; 1.17)
   (Reference)
  (0.88; 1.37)
   (Reference)
  (1.07; 1.38)
  (0.77; 1.19)
Mixed−effects model for 'unstable angina' and 'aspirin'.  Drug
cessation
Number of clinical triggers 8663; Number of clinical actions 1654. ICC for
practice = 0.134. ICC for hospital = 0.008. Missing values imputed using
MICE.
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         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.00
 1.20
 1.09
 1.13
 1.02
 1.30
 0.82
    1
 0.92
 1.04
 1.53
 1.83
 1.91
 2.81
 3.16
    1
 0.95
    1
 1.04
    1
 0.90
 0.93
    1
 1.06
 1.00
 0.82
    1
 0.86
    1
 1.07
    1
 1.60
    1
 1.20
    1
 1.09
95% CI
   (Reference)
  (0.84; 1.19)
  (1.01; 1.42)
  (0.92; 1.29)
  (0.94; 1.35)
  (0.58; 1.80)
  (0.87; 1.97)
  (0.54; 1.23)
   (Reference)
  (0.67; 1.26)
  (0.78; 1.40)
  (1.16; 2.01)
  (1.39; 2.40)
  (1.45; 2.51)
  (2.14; 3.69)
  (2.40; 4.17)
   (Reference)
  (0.86; 1.05)
   (Reference)
  (0.91; 1.18)
   (Reference)
  (0.81; 1.01)
  (0.80; 1.07)
   (Reference)
  (0.95; 1.19)
  (0.85; 1.17)
  (0.60; 1.12)
   (Reference)
  (0.75; 0.98)
   (Reference)
  (0.95; 1.22)
   (Reference)
  (1.46; 1.77)
   (Reference)
  (1.07; 1.33)
   (Reference)
  (0.85; 1.40)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 0.84
    1
 0.88
    1
 1.13
 1.19
95% CI
  (0.64; 1.10)
   (Reference)
  (0.63; 1.24)
   (Reference)
  (1.00; 1.27)
  (0.98; 1.45)
Mixed−effects model for 'MI' and 'aspirin'.  Drug cessation
Number of clinical triggers 11011; Number of clinical actions 1889. ICC
for practice = 0.132. ICC for hospital = 0.037. Missing values imputed
using MICE.
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 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.98
 1.13
 0.99
 1.10
 1.42
 1.18
 1.88
    1
 0.70
 1.41
 2.39
 1.76
 2.43
 5.57
 6.18
    1
 0.98
    1
 1.35
    1
 0.95
 0.96
    1
 0.83
 0.77
 0.90
    1
 1.12
    1
 1.21
    1
 1.73
    1
 1.15
95% CI
   (Reference)
  (0.70; 1.36)
  (0.82; 1.55)
  (0.72; 1.38)
  (0.80; 1.52)
 (0.18; 11.23)
  (0.44; 3.16)
  (0.85; 4.12)
   (Reference)
  (0.32; 1.51)
  (0.73; 2.72)
  (1.29; 4.45)
  (0.95; 3.28)
  (1.30; 4.53)
 (3.03; 10.21)
 (3.29; 11.63)
   (Reference)
  (0.81; 1.20)
   (Reference)
  (1.03; 1.77)
   (Reference)
  (0.75; 1.22)
  (0.73; 1.25)
   (Reference)
  (0.65; 1.06)
  (0.56; 1.05)
  (0.49; 1.67)
   (Reference)
  (0.88; 1.42)
   (Reference)
  (0.96; 1.53)
   (Reference)
  (1.42; 2.11)
   (Reference)
  (0.92; 1.44)
Mixed−effects model for 'old ACS' and 'ACE inhibitor'.  Drug
cessation
Number of clinical triggers 2441; Number of clinical actions 466. ICC for
practice = 0.173. Missing values imputed using MICE.
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 Chol:HDL >= 4
        No CVA
           CVA
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     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 1.03
 0.98
 1.16
 1.14
 0.41
 1.16
 1.20
    1
 1.08
 1.30
 1.26
 1.84
 2.66
 3.54
 5.11
    1
 1.10
    1
 1.30
    1
 0.78
 0.77
    1
 0.78
 0.65
 0.85
    1
 1.01
    1
 1.13
    1
 1.53
    1
 1.14
    1
 1.29
95% CI
   (Reference)
  (0.84; 1.25)
  (0.80; 1.20)
  (0.96; 1.42)
  (0.93; 1.38)
  (0.10; 1.68)
  (0.63; 2.13)
  (0.72; 2.00)
   (Reference)
  (0.74; 1.57)
  (0.91; 1.86)
  (0.89; 1.80)
  (1.31; 2.58)
  (1.90; 3.72)
  (2.53; 4.96)
  (3.63; 7.19)
   (Reference)
  (0.99; 1.23)
   (Reference)
  (1.11; 1.52)
   (Reference)
  (0.67; 0.92)
  (0.66; 0.90)
   (Reference)
  (0.68; 0.90)
  (0.54; 0.79)
  (0.57; 1.28)
   (Reference)
  (0.84; 1.21)
   (Reference)
  (0.99; 1.29)
   (Reference)
  (1.37; 1.71)
   (Reference)
  (1.01; 1.29)
   (Reference)
  (0.99; 1.68)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.19
    1
 1.22
    1
 1.24
 1.37
95% CI
  (0.89; 1.59)
   (Reference)
  (0.99; 1.50)
   (Reference)
  (1.08; 1.42)
  (1.10; 1.72)
Mixed−effects model for 'unstable angina' and 'ACE inhibitor'.  Drug
cessation
Number of clinical triggers 7860; Number of clinical actions 1443. ICC for
practice = 0.141. ICC for hospital = < 0.005. Missing values imputed using
MICE.
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        No CVA
           CVA
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     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.99
 1.10
 1.13
 1.15
 1.79
 1.91
 1.04
    1
 0.92
 1.27
 1.69
 2.20
 2.99
 4.26
 6.03
    1
 1.02
    1
 1.06
    1
 0.89
 0.85
    1
 0.96
 0.77
 0.73
    1
 1.04
    1
 1.17
    1
 1.69
    1
 1.20
    1
 1.07
95% CI
   (Reference)
  (0.84; 1.18)
  (0.93; 1.30)
  (0.96; 1.33)
  (0.96; 1.36)
  (1.03; 3.09)
  (1.26; 2.87)
  (0.68; 1.60)
   (Reference)
  (0.65; 1.32)
  (0.92; 1.74)
  (1.25; 2.29)
  (1.64; 2.95)
  (2.23; 4.01)
  (3.18; 5.70)
  (4.49; 8.10)
   (Reference)
  (0.93; 1.13)
   (Reference)
  (0.93; 1.22)
   (Reference)
  (0.80; 1.00)
  (0.74; 0.98)
   (Reference)
  (0.85; 1.07)
  (0.65; 0.91)
  (0.53; 1.02)
   (Reference)
  (0.92; 1.16)
   (Reference)
  (1.04; 1.32)
   (Reference)
  (1.53; 1.86)
   (Reference)
  (1.08; 1.34)
   (Reference)
  (0.82; 1.40)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.00
    1
 1.13
    1
 1.10
 1.03
95% CI
  (0.75; 1.34)
   (Reference)
  (0.86; 1.48)
   (Reference)
  (0.98; 1.23)
  (0.83; 1.26)
Mixed−effects model for 'MI' and 'ACE inhibitor'.  Drug cessation
Number of clinical triggers 10772; Number of clinical actions 1916. ICC
for practice = 0.083. ICC for hospital = 0.02. Missing values imputed
using MICE.
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 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
HR
    1
 0.89
 1.05
 0.92
 0.87
21.19
 0.62
 1.13
    1
 1.34
 1.36
 0.93
 0.79
 1.23
 1.43
 1.25
    1
 1.51
    1
 1.10
    1
 1.40
 0.87
    1
 0.59
 0.84
 0.83
    1
 0.88
    1
 0.90
    1
 1.15
    1
 1.14
95% CI
   (Reference)
  (0.56; 1.41)
  (0.68; 1.63)
  (0.57; 1.50)
  (0.54; 1.41)
   (2.42; >99)
  (0.21; 1.83)
  (0.42; 3.09)
   (Reference)
  (0.70; 2.58)
  (0.69; 2.68)
  (0.46; 1.90)
  (0.40; 1.56)
  (0.60; 2.53)
  (0.68; 3.03)
  (0.55; 2.84)
   (Reference)
  (1.10; 2.08)
   (Reference)
  (0.69; 1.74)
   (Reference)
  (0.94; 2.09)
  (0.54; 1.41)
   (Reference)
  (0.40; 0.85)
  (0.54; 1.32)
  (0.33; 2.05)
   (Reference)
  (0.58; 1.35)
   (Reference)
  (0.57; 1.43)
   (Reference)
  (0.80; 1.67)
   (Reference)
  (0.77; 1.70)
Mixed−effects model for 'old ACS' and 'beta−blocker'.  Drug cessation
Number of clinical triggers 332; Number of clinical actions 190. ICC for
practice < 0.005. Missing values imputed using MICE.
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 Hyp. uncontr.
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  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.75
 0.71
 0.91
 0.82
 1.39
 1.49
 1.03
    1
 0.97
 1.09
 0.90
 1.44
 1.02
 1.71
 1.59
    1
 1.08
    1
 0.89
    1
 1.00
 0.91
    1
 1.01
 1.08
 1.12
    1
 0.76
    1
 0.91
    1
 1.30
    1
 1.36
    1
 1.08
95% CI
   (Reference)
  (0.54; 1.06)
  (0.52; 0.97)
  (0.67; 1.24)
  (0.61; 1.11)
  (0.39; 4.98)
  (0.72; 3.07)
  (0.57; 1.86)
   (Reference)
  (0.63; 1.52)
  (0.71; 1.69)
  (0.57; 1.40)
  (0.93; 2.23)
  (0.65; 1.62)
  (1.09; 2.66)
  (0.93; 2.74)
   (Reference)
  (0.89; 1.32)
   (Reference)
  (0.67; 1.19)
   (Reference)
  (0.75; 1.33)
  (0.68; 1.22)
   (Reference)
  (0.76; 1.34)
  (0.77; 1.51)
  (0.42; 2.98)
   (Reference)
  (0.53; 1.08)
   (Reference)
  (0.68; 1.22)
   (Reference)
  (1.05; 1.60)
   (Reference)
  (1.09; 1.69)
   (Reference)
  (0.72; 1.60)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.22
    1
 1.33
    1
 0.91
 0.70
95% CI
  (0.78; 1.91)
   (Reference)
  (1.03; 1.71)
   (Reference)
  (0.71; 1.18)
  (0.47; 1.04)
Mixed−effects model for 'unstable angina' and 'beta−blocker'.  Drug
cessation
Number of clinical triggers 968; Number of clinical actions 506. ICC for
practice = 0.133. ICC for hospital = < 0.005. Missing values imputed using
MICE.
582
Drug
management of
ACS
0.00
0.25
0.50
0.75
1.00
0 1 2 3 4 5 6 7
Time (years)
Pr
op
or
ti
on
 w
it
ho
ut
 a
ct
io
n
Quintile
1
2
3
4
5
Kaplan−Meier plot for 'MI' and
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   No diabetes
      Diabetes
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HR
    1
 1.06
 1.17
 0.94
 1.09
 0.46
 1.02
 0.72
    1
 1.02
 0.68
 1.59
 1.26
 1.53
 1.39
 1.79
    1
 0.98
    1
 1.03
    1
 1.05
 1.02
    1
 1.31
 1.16
 0.85
    1
 0.94
    1
 1.06
    1
 1.07
    1
 1.08
    1
 0.46
95% CI
   (Reference)
  (0.76; 1.48)
  (0.84; 1.63)
  (0.67; 1.32)
  (0.78; 1.51)
  (0.16; 1.34)
  (0.54; 1.92)
  (0.38; 1.33)
   (Reference)
  (0.62; 1.66)
  (0.42; 1.09)
  (1.03; 2.45)
  (0.80; 1.99)
  (0.98; 2.41)
  (0.87; 2.22)
  (1.08; 2.97)
   (Reference)
  (0.78; 1.22)
   (Reference)
  (0.78; 1.35)
   (Reference)
  (0.81; 1.36)
  (0.77; 1.35)
   (Reference)
  (0.99; 1.73)
  (0.83; 1.62)
  (0.32; 2.25)
   (Reference)
  (0.66; 1.32)
   (Reference)
  (0.76; 1.46)
   (Reference)
  (0.85; 1.37)
   (Reference)
  (0.85; 1.37)
   (Reference)
  (0.28; 0.76)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 0.41
    1
 1.05
    1
 0.92
 0.46
95% CI
  (0.24; 0.71)
   (Reference)
  (0.81; 1.35)
   (Reference)
  (0.71; 1.19)
  (0.27; 0.80)
Mixed−effects model for 'MI' and 'beta−blocker'.  Drug cessation
Number of clinical triggers 820; Number of clinical actions 458. ICC for
practice = 0.104. ICC for hospital = < 0.005. Missing values imputed using
MICE.
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Kaplan−Meier plot for 'unstable
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   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.95
 0.96
 0.97
 1.03
 0.55
 1.25
 1.01
    1
 1.13
 1.30
 1.19
 1.28
 1.37
 1.18
 1.57
    1
 1.05
    1
 1.00
    1
 1.08
 1.00
    1
 0.89
 0.93
 0.86
    1
 1.02
    1
 0.89
    1
 0.88
    1
 0.86
    1
 0.87
95% CI
   (Reference)
  (0.83; 1.09)
  (0.85; 1.09)
  (0.86; 1.11)
  (0.91; 1.17)
  (0.31; 0.97)
  (0.95; 1.64)
  (0.80; 1.27)
   (Reference)
  (0.95; 1.34)
  (1.10; 1.53)
  (1.01; 1.41)
  (1.09; 1.52)
  (1.15; 1.63)
  (0.98; 1.41)
  (1.30; 1.89)
   (Reference)
  (0.97; 1.13)
   (Reference)
  (0.91; 1.10)
   (Reference)
  (0.98; 1.19)
  (0.90; 1.11)
   (Reference)
  (0.82; 0.98)
  (0.82; 1.05)
  (0.66; 1.11)
   (Reference)
  (0.92; 1.12)
   (Reference)
  (0.81; 0.99)
   (Reference)
  (0.82; 0.95)
   (Reference)
  (0.79; 0.93)
   (Reference)
  (0.75; 1.01)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 0.88
    1
 0.97
    1
 1.04
 1.18
95% CI
  (0.75; 1.04)
   (Reference)
  (0.83; 1.14)
   (Reference)
  (0.95; 1.13)
  (1.00; 1.40)
Mixed−effects model for 'unstable angina' and 'clopidogrel'.  Drug
cessation
Number of clinical triggers 5783; Number of clinical actions 3419. ICC for
practice = 0.072. ICC for hospital = 0.005. Missing values imputed using
MICE.
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'clopidogrel'.  Drug cessation
(triggers = 10133; actions = 6536)
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Drug
management of
ACS
    Quintile 1
    Quintile 2
    Quintile 3
    Quintile 4
    Quintile 5
              
  Age 35 to 39
  Age 40 to 44
  Age 45 to 49
  Age 50 to 54
  Age 55 to 59
  Age 60 to 64
  Age 65 to 69
  Age 70 to 74
  Age 75 to 79
  Age 80 to 84
       Age 85+
          Male
        Female
    Non−smoker
        Smoker
 BMI low/norm.
    Overweight
         Obese
       No hyp.
   Hyp. contr.
 Hyp. uncontr.
 Untreat. hyp.
  Chol:HDL < 4
 Chol:HDL >= 4
        No CVA
           CVA
   No oth. co.
     Other co.
   No diabetes
      Diabetes
   Elect. adm.
    Emer. adm.
HR
    1
 0.99
 0.91
 0.98
 0.86
 1.04
 1.00
 0.96
    1
 0.94
 0.93
 1.05
 1.11
 1.22
 1.03
 1.12
    1
 0.99
    1
 0.98
    1
 1.05
 1.02
    1
 0.92
 0.95
 0.91
    1
 0.98
    1
 0.88
    1
 0.97
    1
 0.88
    1
 1.03
95% CI
   (Reference)
  (0.90; 1.09)
  (0.83; 1.00)
  (0.89; 1.07)
  (0.78; 0.95)
  (0.83; 1.31)
  (0.85; 1.18)
  (0.84; 1.10)
   (Reference)
  (0.83; 1.05)
  (0.83; 1.04)
  (0.94; 1.17)
  (1.00; 1.25)
  (1.09; 1.37)
  (0.91; 1.17)
  (0.98; 1.28)
   (Reference)
  (0.94; 1.05)
   (Reference)
  (0.92; 1.05)
   (Reference)
  (0.99; 1.12)
  (0.95; 1.09)
   (Reference)
  (0.87; 0.98)
  (0.87; 1.03)
  (0.79; 1.05)
   (Reference)
  (0.93; 1.04)
   (Reference)
  (0.81; 0.95)
   (Reference)
  (0.92; 1.02)
   (Reference)
  (0.82; 0.94)
   (Reference)
  (0.86; 1.23)
    Other adm.
  Cardiac cen.
    Other cen.
    Cardiology
    Med. spec.
   Other spec.
HR
 1.07
    1
 1.01
    1
 1.03
 1.08
95% CI
  (0.89; 1.30)
   (Reference)
  (0.85; 1.19)
   (Reference)
  (0.97; 1.10)
  (0.92; 1.26)
Mixed−effects model for 'MI' and 'clopidogrel'.  Drug cessation
Number of clinical triggers 10133; Number of clinical actions 6536. ICC
for practice = 0.068. ICC for hospital = 0.009. Missing values imputed
using MICE.
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EC L I N I C A L C O D E S
In this electronic appendix, I have shown in tabular format the nature
of the clinical codes that I used to define different clinical conditions.
In the following table, I show the condition or state that I am defining,
the code used in that definition, the coding system to which the code
pertains, the text description relating to that code. I have also included
a notes column, where, for example, I show which drugs have been
included in the antihypertensive category.
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Table E.1: Summary of clinical codes used for defining different conditions in this thesis
Defined System Code Description Notes
Diabetes ICD-10 E10 Insulin-dependent diabetes mellitus
Diabetes ICD-10 E100 Insulin-dependent diabetes mellitus: With coma
Diabetes ICD-10 E101 Insulin-dependent diabetes mellitus: With ketoacidosis
Diabetes ICD-10 E102 Insulin-dependent diabetes mellitus: With renal
complications
Diabetes ICD-10 E103 Insulin-dependent diabetes mellitus: With ophthalmic
complications
Diabetes ICD-10 E104 Insulin-dependent diabetes mellitus: With neurological
complications
Diabetes ICD-10 E105 Insulin-dependent diabetes mellitus: With peripheral
circulatory complications
Diabetes ICD-10 E106 Insulin-dependent diabetes mellitus: With other specified
complications
Diabetes ICD-10 E107 Insulin-dependent diabetes mellitus: With multiple
complications
Diabetes ICD-10 E108 Insulin-dependent diabetes mellitus: With unspecified
complications
Diabetes ICD-10 E109 Insulin-dependent diabetes mellitus: Without
complications
Diabetes ICD-10 E11 Non-insulin-dependent diabetes mellitus
Diabetes ICD-10 E110 Non-insulin-dependent diabetes mellitus: With coma
Diabetes ICD-10 E111 Non-insulin-dependent diabetes mellitus: With
ketoacidosis
Diabetes ICD-10 E112 Non-insulin-dependent diabetes mellitus: With renal
complications
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes ICD-10 E113 Non-insulin-dependent diabetes mellitus: With
ophthalmic complications
Diabetes ICD-10 E114 Non-insulin-dependent diabetes mellitus: With
neurological complications
Diabetes ICD-10 E115 Non-insulin-dependent diabetes mellitus: With peripheral
circulatory complications
Diabetes ICD-10 E116 Non-insulin-dependent diabetes mellitus: With other
specified complications
Diabetes ICD-10 E117 Non-insulin-dependent diabetes mellitus: With multiple
complications
Diabetes ICD-10 E118 Non-insulin-dependent diabetes mellitus: With
unspecified complications
Diabetes ICD-10 E119 Non-insulin-dependent diabetes mellitus: Without
complications
Diabetes ICD-10 E14 Unspecified diabetes mellitus
Diabetes ICD-10 E140 Unspecified diabetes mellitus: With coma
Diabetes ICD-10 E141 Unspecified diabetes mellitus: With ketoacidosis
Diabetes ICD-10 E142 Unspecified diabetes mellitus: With renal complications
Diabetes ICD-10 E143 Unspecified diabetes mellitus: With ophthalmic
complications
Diabetes ICD-10 E144 Unspecified diabetes mellitus: With neurological
complications
Diabetes ICD-10 E145 Unspecified diabetes mellitus: With peripheral circulatory
complications
Diabetes ICD-10 E146 Unspecified diabetes mellitus: With other specified
complications
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes ICD-10 E147 Unspecified diabetes mellitus: With multiple
complications
Diabetes ICD-10 E148 Unspecified diabetes mellitus: With unspecified
complications
Diabetes ICD-10 E149 Unspecified diabetes mellitus: Without complications
Diabetes Read v2 66A.. Diabetic monitoring
Diabetes Read v2 66AS. Diabetic annual review
Diabetes Read v2 68A7. Diabetic retinopathy screening
Diabetes Read v2 9OL.. Diabetes monitoring admin.
Diabetes Read v2 9OL4. Diabetes monitoring 1st letter
Diabetes Read v2 C10F. Type 2 diabetes mellitus
Diabetes Read v2 66AP. Diabetes: practice programme
Diabetes Read v2 66A4. Diabetic on oral treatment
Diabetes Read v2 66A2. Follow-up diabetic assessment
Diabetes Read v2 C10.. [X]Diabetes mellitus
Diabetes Read v2 Cyu2. [X]Diabetes mellitus
Diabetes Read v2 66A3. Diabetic on diet only
Diabetes Read v2 66Ac. Diabetic periph neurop screen
Diabetes Read v2 9NND. Under care of diab foot screen
Diabetes Read v2 2G5E. O/E - R diab foot at low risk
Diabetes Read v2 2G5I. O/E - L diab foot at low risk
Diabetes Read v2 66A5. Diabetic on insulin
Continued on next page
c
lin
ic
a
l
c
o
d
es
593
Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 8B3l. Diabetes medication review
Diabetes Read v2 13AB. Diabetic lipid lowering diet
Diabetes Read v2 C109. Non-insulin depd diabetes mell
Diabetes Read v2 9OLA. Diabetes monitor. check done
Diabetes Read v2 9OL5. Diabetes monitoring 2nd letter
Diabetes Read v2 66AD. Fundoscopy - diabetic check
Diabetes Read v2 F4200 Background diabetic retinopath
Diabetes Read v2 66Aq. Diabetic foot screen
Diabetes Read v2 66AZ. Diabetic monitoring NOS
Diabetes Read v2 66A8. Has seen dietician - diabetes
Diabetes Read v2 8BL2. Pt on max tol ther for diabet
Diabetes Read v2 F420. Diabetic retinopathy
Diabetes Read v2 C10E. Type 1 diabetes mellitus
Diabetes Read v2 66Ab. Diabetic foot examination
Diabetes Read v2 66AI. Diabetic - good control
Diabetes Read v2 66AY. Diabetic diet-good compliance
Diabetes Read v2 679L. Health education - diabetes
Diabetes Read v2 66AU. Diabetes care by hospital only
Diabetes Read v2 9OL6. Diabetes monitoring 3rd letter
Diabetes Read v2 66AR. Diabetes management plan given
Diabetes Read v2 13AC. Diabetic weight reducing diet
Diabetes Read v2 66AJ. Diabetic - poor control
Continued on next page
594
c
lin
ic
a
l
c
o
d
es
Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 C1001 Diab.mell.no comp. - adult
Diabetes Read v2 2BBF. Retina abnormal - diabet relat
Diabetes Read v2 C109J Insul treated Type 2 diab mell
Diabetes Read v2 C10FJ Insul treated Type 2 diab mell
Diabetes Read v2 8Hl1. Ref diabetc retinopathy screen
Diabetes Read v2 2G5F. O/E - R diab foot at mod risk
Diabetes Read v2 2G5J. O/E - L diab foot at mod risk
Diabetes Read v2 66A9. Understands diet - diabetes
Diabetes Read v2 9OL7. Diabetes monitor.verbal invite
Diabetes Read v2 66AW. Diabetic foot risk assessment
Diabetes Read v2 9OL8. Diabetes monitor.phone invite
Diabetes Read v2 C108. Insulin depnd diabetes melitus
Diabetes Read v2 F4204 Diabetic maculopathy
Diabetes Read v2 66AT. Annual diabetic blood test
Diabetes Read v2 1434. H/O: diabetes mellitus
Diabetes Read v2 66Aa. Diabetic diet-poor compliance
Diabetes Read v2 8I3W. Diabetic foot exam declined
Diabetes Read v2 8HBG. Diab retinopathy 12 mth review
Diabetes Read v2 2G5G. O/E - R diab foot at high risk
Diabetes Read v2 F372. Polyneuropathy in diabetes
Diabetes Read v2 2G5K. O/E - L diab foot at high risk
Diabetes Read v2 9OLZ. Diabetes monitoring admin.NOS
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 68A9. Diabetic retinopathy scr offer
Diabetes Read v2 C1000 Diab.mell.no comp. - juvenile
Diabetes Read v2 F4201 Proliferative diabetic retinop
Diabetes Read v2 66AV. Diabetic on insulin+oral treat
Diabetes Read v2 9h4.. Except report: diabet qual ind
Diabetes Read v2 8I3X. Diab retinopath screen refused
Diabetes Read v2 9OLD. Diabet pt unsuit dig ret photo
Diabetes Read v2 9OL3. Diabetes monitoring default
Diabetes Read v2 C101. Diab.mell.with ketoacidosis
Diabetes Read v2 9360. Pt held diabetic record issued
Diabetes Read v2 F4202 Preproliferative diabetic ret
Diabetes Read v2 C104. Diab.mell. with nephropathy
Diabetes Read v2 66AH. Diabetic treatment changed
Diabetes Read v2 2G5B. O/E-Left diabet foot at risk
Diabetes Read v2 66AK. Diabetic - cooperative patient
Diabetes Read v2 2G5A. O/E-Right diabet foot at risk
Diabetes Read v2 2BBL. O/E - diabet maculop both eyes
Diabetes Read v2 7276. Pan retinal photocoag diabetes
Diabetes Read v2 C106. Diab.mell. with neuropathy
Diabetes Read v2 F4206 Non prolif diab retinop
Diabetes Read v2 F4640 Diabetic cataract
Diabetes Read v2 9N0n. Seen community diab spec clin
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 66Ao. Diabetes type 2 review
Diabetes Read v2 9NM0. Attending diabetes clinic
Diabetes Read v2 8Hj4. Refer to DESMOND diab st ed pr
Diabetes Read v2 66AJz Diabetic - poor control NOS
Diabetes Read v2 C100. Diab.mell. - no complication
Diabetes Read v2 679L0 Educa self management diabetes
Diabetes Read v2 8HHy. Referral to diabetic register
Diabetes Read v2 66Af. Pt diabetes education review
Diabetes Read v2 C1097 Type 2 diab mell+poor control
Diabetes Read v2 C10F7 Type 2 diab mell+poor control
Diabetes Read v2 F420z Diabetic retinopathy NOS
Diabetes Read v2 9OL2. Refuses diabetes monitoring
Diabetes Read v2 8H2J. Admit diabetic emergency
Diabetes Read v2 F3722 Asymptomatic diab neuropathy
Diabetes Read v2 679R. Pt offered diab struct ed prog
Diabetes Read v2 66AN. Date diabetic treatment start
Diabetes Read v2 M2711 Neuropathic diab ulcer - foot
Diabetes Read v2 9m0A. Declined diabetic retinop scrn
Diabetes Read v2 F1711 Autonomic neuropathy-diabetes
Diabetes Read v2 M2712 Mixed diabetic ulcer - foot
Diabetes Read v2 8A13. Diabetic stabilisation
Diabetes Read v2 F3721 Chron painful diab neuropathy
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 M2710 Ischaemic ulcer diabetic foot
Diabetes Read v2 2G5H. O/E - R diab foot - ulcerated
Diabetes Read v2 F4203 Advanced diabetic maculopathy
Diabetes Read v2 2G5L. O/E - L diab foot - ulcerated
Diabetes Read v2 2G510 Foot abnormal-diabetes related
Diabetes Read v2 2G5C. Foot abnormal-diabetes related
Diabetes Read v2 C1096 Type 2 diab mell + retinopathy
Diabetes Read v2 C10F6 Type 2 diab mell + retinopathy
Diabetes Read v2 C10FC Type 2 diab mell + nephropathy
Diabetes Read v2 9OLM. Diabetes struc edu prog declin
Diabetes Read v2 66AL. Diabetic-uncooperative patient
Diabetes Read v2 M0372 Cellulitis in diabetic foot
Diabetes Read v2 C105. Diab.mell.+ eye manifestation
Diabetes Read v2 C1099 Non-insul-dep diab mel no comp
Diabetes Read v2 N0301 Diabetic Charcot arthropathy
Diabetes Read v2 8HBH. Diab retinopathy 6 mth review
Diabetes Read v2 C107. Diab.mell.+periph.circul.dis
Diabetes Read v2 C1087 Type 1 diab mell + retinopathy
Diabetes Read v2 C10E7 Type 1 diab mell + retinopathy
Diabetes Read v2 8CR2. Diabetes clin management plan
Diabetes Read v2 C1088 Type 1 diab mell poor control
Diabetes Read v2 C10E8 Type 1 diab mell poor control
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 C1090 Type 2 diab mell + renal compl
Diabetes Read v2 C10F0 Type 2 diab mell + renal compl
Diabetes Read v2 C10F9 Type 2 diab mell without comp
Diabetes Read v2 N0300 Diabetic cheiroarthropathy
Diabetes Read v2 C1089 Type 1 diab mell matur onset
Diabetes Read v2 C10E9 Type 1 diab mell matur onset
Diabetes Read v2 66AJ1 Brittle diabetes
Diabetes Read v2 68AB. Diabtic dig retnpthy scrn offd
Diabetes Read v2 F3720 Acute painful diab neuropathy
Diabetes Read v2 66At1 Type II diabetic dietary revie
Diabetes Read v2 F3y0. Diabetic mononeuropathy
Diabetes Read v2 8CS0. Diabetes care plan agreed
Diabetes Read v2 C101z Diab.mell.+ketoacid -onset NOS
Diabetes Read v2 C106z Diab.mell.+neuropathy NOS
Diabetes Read v2 C10ED Type 1 diab mell + nephropathy
Diabetes Read v2 F3813 Myasthenic syndrome+diabetes
Diabetes Read v2 8A12. Diabetic crisis monitoring
Diabetes Read v2 C104z Diab.mell.+nephropathy NOS
Diabetes Read v2 C1094 Type 2 diab mell with ulcer
Diabetes Read v2 C10F4 Type 2 diab mell with ulcer
Diabetes Read v2 C1061 Diab.mell.+neuropathy - adult
Diabetes Read v2 K01x1 Nephrotic syndrome+diabetes M.
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 C1011 Diab.mell.+ketoacid - adult
Diabetes Read v2 F35z0 Diabetic mononeuritis NOS
Diabetes Read v2 F4205 Advanced diabetic retinal dis
Diabetes Read v2 R0542 [D]Gangrene of toe in diabetic
Diabetes Read v2 C1092 Type 2 diab mell + neurol comp
Diabetes Read v2 C10F2 Type 2 diab mell + neurol comp
Diabetes Read v2 C10ER Latent autoimm diab mell adult
Diabetes Read v2 C103. Diab.mell. + ketoacidotic coma
Diabetes Read v2 C10EE Type 1 diab mell + hypo coma
Diabetes Read v2 C1085 Type 1 diab mell with ulcer
Diabetes Read v2 C10E5 Type 1 diab mell with ulcer
Diabetes Read v2 C109E NIDDM with diabetic cataract
Diabetes Read v2 9OLF. Diabetes struc ed prog complet
Diabetes Read v2 C100z Diab.mell.no comp. - onset NOS
Diabetes Read v2 F4407 Diabetic iritis
Diabetes Read v2 8H3O. Non-urgent diabetic admission
Diabetes Read v2 C10C. Diab mell aut dom
Diabetes Read v2 C10z. Diab.mell. + unspec comp
Diabetes Read v2 C1095 Type 2 diab mell + gangrene
Diabetes Read v2 C10F5 Type 2 diab mell + gangrene
Diabetes Read v2 C10FH Type 2 diab mell neurop+arthr
Diabetes Read v2 C10E4 Unstab type 1 diabet mellitus
Continued on next page
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Table E.1 – Continued from previous page
Defined System Code Description Notes
Diabetes Read v2 G73y0 Diabetic peripheral angiopathy
Diabetes Read v2 C1081 Type 1 diab mell + ophth comps
Diabetes Read v2 C10E1 Type 1 diab mell + ophth comps
Diabetes Read v2 C1091 Type 2 diab mell+ophthal comp
Diabetes Read v2 C10F1 Type 2 diab mell+ophthal comp
Diabetes Read v2 L1806 Pre-ex diab mel non insuln-dep
Diabetes Read v2 C10FG Type 2 diab mell + arthropathy
Diabetes Read v2 2G5V. O/E - R chron diab foot ulcer
Diabetes Read v2 C10FE Type 2 diab mell+diab catarct
Diabetes Read v2 2G5W. O/E - L chron diab foot ulcer
Diabetes Read v2 C10FB Type 2 diab mell + polyneurop
Diabetes Read v2 C10FD Type 2 diab mell+hypogly coma
Diabetes Read v2 8HLE. Diabetology D.V. done
Diabetes Read v2 C1084 Unstab insul depend diab mell
Diabetes Read v2 C1041 Diab.mell.+nephropathy - adult
Diabetes Read v2 C10D. Diab mell aut dom type 2
Diabetes Read v2 C1051 Diab.mell.+eye manif - adult
Diabetes Read v2 C10N1 Cyst fibro relat diab mellitus
Diabetes Read v2 C1086 Type 1 diab mell with gangrene
Diabetes Read v2 C10E6 Type 1 diab mell with gangrene
Diabetes Read v2 C10FA Type 2 diab mell mononeurop
Diabetes Read v2 C10EJ Type 1 diab mell+neuro arthrop
Continued on next page
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Defined System Code Description Notes
Diabetes Read v2 C10N. Secondary diabetes mellitus
Diabetes Read v2 C102. Diab.mell. + hyperosmolar coma
Diabetes Read v2 C10EC Type 1 diab mell + polyneurop
Diabetes Read v2 C10y. Diab.mell.+other manifestation
Diabetes Read v2 C1080 Insuln-dep diab mel+renal comp
Diabetes Read v2 C101y Oth specfd diab mel+ketoacidos
Diabetes Read v2 C1083 Type 1 diab mell + mult comps
Diabetes Read v2 C10E3 Type 1 diab mell + mult comps
Diabetes Read v2 F3450 Diabet mononeuritis multiplex
Diabetes Read v2 C103z Diab.mell.+ketoac coma NOS
Diabetes Read v2 C10z1 Diab.mell.+comp NOS - adult
Diabetes Read v2 C10EA Type 1 diab mell without comp
Diabetes Read v2 C10F3 Type 2 diab mell + multip comp
Diabetes Read v2 C1072 Diabetic gangrene - adult
Diabetes Read v2 C10y1 Diab.mell.+other manif. -adult
Diabetes Read v2 C108F IDDM with diabetic cataract
Diabetes Read v2 C103y Oth specif diab mell with coma
Diabetes Read v2 C1021 Diab.mell.+hyperosm.coma-adult
Diabetes Read v2 C10A. Malnutritn-relat diab mellitus
Diabetes Read v2 C1082 Type 1 diab mell + neuro comps
Diabetes Read v2 C10E2 Type 1 diab mell + neuro comps
Diabetes Read v2 C1050 Diab.mell.+eye manif -juvenile
Continued on next page
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Defined System Code Description Notes
Diabetes Read v2 Cyu20 [X]Oth specf diabetes mellitus
Diabetes Read v2 C102z Diabetes+hyperosmolar coma NOS
Diabetes Read v2 C109F NIDDM with periph angiopath
Diabetes Read v2 TJ23z AR - insulins/antidiabetic NOS
Diabetes Read v2 6761. Diabetic pre-pregnancy counsel
Diabetes Read v2 C10yy Oth spec diab mel+oth spec cmp
Diabetes Read v2 C108G IDDM with peripheral angiopath
Diabetes Read v2 C10EH Type 1 diab mell + arthropathy
Diabetes Read v2 R0543 [D]Widespread diab foot gangr
Diabetes Read v2 C10zz Diab.mell. + unspec comp NOS
Diabetes Read v2 C10EB Type 1 diab mell + mononeurop
Diabetes Read v2 3883. Diabetes treatmt satisf quest
Diabetes Read v2 9M00. Informd consent diab nat audit
Diabetes Read v2 L1800 Preg.+diabetes mellitus unspec
Diabetes Read v2 C10z0 Diab.mell.+comp NOS - juvenile
Diabetes Read v2 2BBr. Impair vision due diab retinop
Diabetes Read v2 C105y Oth specfd diab mel+ophth comp
Smoking
ascertainment
Read v2 1371. Never smoked tobacco
Smoking
ascertainment
Read v2 137S. Ex smoker
Smoking
ascertainment
Read v2 137P. Cigarette smoker
Continued on next page
c
lin
ic
a
l
c
o
d
es
603
Table E.1 – Continued from previous page
Defined System Code Description Notes
Smoking
ascertainment
Read v2 137L. Current non-smoker
Smoking
ascertainment
Read v2 137R. Current smoker
Smoking
ascertainment
Read v2 1374. Moderate smoker - 10-19 cigs/d
Smoking
ascertainment
Read v2 1373. Light smoker - 1-9 cigs/day
Smoking
ascertainment
Read v2 1379. Ex-moderate smoker (10-19/day)
Smoking
ascertainment
Read v2 1375. Heavy smoker - 20-39 cigs/day
Smoking
ascertainment
Read v2 137K. Stopped smoking
Smoking
ascertainment
Read v2 1378. Ex-light smoker (1-9/day)
Smoking
ascertainment
Read v2 137G. Trying to give up smoking
Smoking
ascertainment
Read v2 137A. Ex-heavy smoker (20-39/day)
Smoking
ascertainment
Read v2 137F. Ex-smoker - amount unknown
Smoking
ascertainment
Read v2 1372. Trivial smoker - < 1 cig/day
Smoking
ascertainment
Read v2 137M. Rolls own cigarettes
Continued on next page
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Defined System Code Description Notes
Smoking
ascertainment
Read v2 137Z. Tobacco consumption NOS
Smoking
ascertainment
Read v2 1377. Ex-trivial smoker (<1/day)
Smoking
ascertainment
Read v2 137T. Date ceased smoking
Smoking
ascertainment
Read v2 137H. Pipe smoker
Smoking
ascertainment
Read v2 137J. Cigar smoker
Smoking
ascertainment
Read v2 137B. Ex-very heavy smoker (40+/day)
Smoking
ascertainment
Read v2 1376. Very heavy smoker - 40+cigs/d
Smoking
ascertainment
Read v2 137X. Cigarette consumption
Smoking
ascertainment
Read v2 137N. Ex pipe smoker
Smoking
ascertainment
Read v2 137Q. Smoking started
Smoking
ascertainment
Read v2 137O. Ex cigar smoker
Smoking
ascertainment
Read v2 137Y. Cigar consumption
Smoking
ascertainment
Read v2 137V. Smoking reduced
Continued on next page
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Defined System Code Description Notes
Smoking
ascertainment
Read v2 137K0 Recently stopped smoking
Smoking
ascertainment
Read v2 9kn.. Non-smoker annual review - enhanced services
administration
Smoking
ascertainment
Read v2 9ko.. Current smoker annual review - enhanced services
administration
Smoking advice Read v2 8CAL. Smoking cessation advice
Smoking advice Read v2 6791. Health ed. - smoking
Smoking advice Read v2 67H1. Lifestyle adv re smoking
Smoking advice Read v2 67H6. Brf intervention smoking cessn
Smoking
cessation
referral
Read v2 8H7i. Referral: smok cessatn advisor
Smoking
cessation
referral
Read v2 8HTK. Referl to stop-smoking clinic
Smoking
cessation
referral
Read v2 9N2k. Seen by smoking cesstn advisor
Smoking
cessation
referral
Read v2 9N4M. DNA - Smoking cessation clinic
Smoking
cessation
referral
Read v2 13p5. Smoking cessn progm start date
Continued on next page
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Defined System Code Description Notes
Smoking
cessation
referral
Read v2 8HkQ. Refer to NHS stop smoking srvc
Chronic renal
disease
Read v2 66i.. CKD monitoring
Chronic renal
disease
Read v2 9Ot0. CKD monitoring first letter
Chronic renal
disease
Read v2 K05.. Chronic renal failure
Chronic renal
disease
Read v2 1Z1.. Chronic renal impairment
Chronic renal
disease
Read v2 K060. Renal impairment
Chronic renal
disease
Read v2 1Z1B. CKD stage 3 with proteinuria
Chronic renal
disease
Read v2 9Ot1. CKD monitoring second letter
Chronic renal
disease
Read v2 9Ot.. CKD monitoring administration
Chronic renal
disease
Read v2 9Ot4. CKD monitoring telephone invte
Chronic renal
disease
Read v2 9Ot2. CKD monitoring third letter
Chronic renal
disease
Read v2 K08.. Impaired renal function disord
Chronic renal
disease
Read v2 K050. End stage renal failure
Continued on next page
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Chronic renal
disease
Read v2 9Ot3. CKD monitoring verbal invite
Chronic renal
disease
Read v2 1Z1H. CKD stage 4 with proteinuria
Chronic renal
disease
Read v2 1Z1D. CKD stage 3A with proteinuria
Chronic renal
disease
Read v2 1Z1F. CKD stage 3B with proteinuria
Chronic renal
disease
Read v2 1Z19. CKD stage 2 with proteinuria
Chronic renal
disease
Read v2 Kyu2. [X]Renal failure
Chronic renal
disease
Read v2 K08z. Impaired renal funct.dis.NOS
Chronic renal
disease
Read v2 D2150 Anaemia secondary to CRF
Chronic renal
disease
Read v2 D215. Anaemia second renal failure
Chronic renal
disease
Read v2 1Z1K. CKD stage 5 with proteinuria
Chronic renal
disease
Read v2 K0E.. Acute-on-chronic renal failure
Chronic renal
disease
Read v2 Kyu21 [X]Other chronic renal failure
Chronic renal
disease
Read v2 G222. Hypertens renal dis+renal fail
Continued on next page
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Chronic renal
disease
Read v2 G233. Hypertn hrt+ren dis+renal fail
Lipid disorders Read v2 C3200 LDL hyperlipoproteinaemia
Peripheral
vascular disease
ICD-10 I702 Atherosclerosis of arteries of extremities
Peripheral
vascular disease
ICD-10 I708 Atherosclerosis of other arteries
Peripheral
vascular disease
ICD-10 I709 Generalized and unspecified atherosclerosis
Peripheral
vascular disease
ICD-10 I739 Peripheral vascular disease, unspecified
Peripheral
vascular disease
ICD-10 I792 Peripheral angiopathy in diseases classified elsewhere
Old MI ICD-10 I252 Old myocardial infarction
Old MI Read v2 G30.. Acute myocardial infarction
Old MI Read v2 G3115 Acute coronary syndrome
Old MI Read v2 G3111 Unstable angina
Old MI Read v2 G32.. Old myocardial infarction
Old MI Read v2 G308. Inferior myocard. infarct NOS
Old MI Read v2 14A3. H/O: myocardial infarct <60
Old MI Read v2 G30z. Acute myocardial infarct. NOS
Old MI Read v2 G301z Anterior myocard.infarct NOS
Old MI Read v2 G301. Anterior myocard. infarct OS
Old MI Read v2 323.. ECG: myocardial infarction
Continued on next page
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Old MI Read v2 G31y0 Acute coronary insufficiency
Old MI Read v2 G3112 Angina at rest
Old MI Read v2 14A4. H/O: myocardial infarct >60
Old MI Read v2 3232. ECG: old myocardial infarction
Old MI Read v2 G304. Posterior myocard.infarct NOS
Old MI Read v2 G305. Lateral myocardial infarct NOS
Old MI Read v2 G35.. Subseqnt myocardial infarction
Old MI Read v2 G30y. Other acute myocardial infarct
Old MI Read v2 323Z. ECG: myocardial infarct NOS
Old MI Read v2 14AT. H/O: myocardial infarction
Old MI Read v2 G30yz Other acute myocardial inf.NOS
Old MI Read v2 14AH. H/O: Myoc infarct in last year
Old MI Read v2 G351. Subsqnt myocrd infarc/inf wall
Old MI Read v2 ZV719 [V]Obs/suspct myocard infarctn
Old MI Read v2 G306. True posterior myocard.infarct
Old MI Read v2 G350. Subsqnt myocrd infarc/ant wall
Old MI Read v2 G30B. Acute posterol myocard infarct
Old MI Read v2 G33z0 Status anginosus
MI ICD-10 I21 Acute myocardial infarction
MI ICD-10 I210 Acute transmural myocardial infarction of anterior wall
MI ICD-10 I211 Acute transmural myocardial infarction of inferior wall
MI ICD-10 I212 Acute transmural myocardial infarction of other sites
Continued on next page
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MI ICD-10 I213 Acute transmural myocardial infarction of unspecified site
MI ICD-10 I214 Acute subendocardial myocardial infarction
MI ICD-10 I219 Acute myocardial infarction, unspecified
MI ICD-10 I22 Subsequent myocardial infarction
MI ICD-10 I220 Subsequent myocardial infarction of anterior wall
MI ICD-10 I221 Subsequent myocardial infarction of inferior wall
MI ICD-10 I228 Subsequent myocardial infarction of other sites
MI ICD-10 I229 Subsequent myocardial infarction of unspecified site
Unstable angina ICD-10 I200 Unstable angina
Hypertension
diagnosis
ICD-10 I110 Hypertensive heart disease with (congestive) heart failure
Hypertension
diagnosis
ICD-10 I119 Hypertensive heart disease without (congestive) heart
failure
Hypertension
diagnosis
ICD-10 I120 Hypertensive renal disease with renal failure
Hypertension
diagnosis
ICD-10 I129 Hypertensive renal disease without renal failure
Hypertension
diagnosis
ICD-10 I130 Hypertensive heart and renal disease with (congestive)
heart failure
Hypertension
diagnosis
ICD-10 I131 Hypertensive heart and renal disease with renal failure
Hypertension
diagnosis
ICD-10 I132 Hypertensive heart and renal disease with both
(congestive) heart failure and renal failure
Hypertension
diagnosis
ICD-10 I139 Hypertensive heart and renal disease, unspecified
Continued on next page
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Hypertension
diagnosis
ICD-10 I150 Renovascular hypertension
Hypertension
diagnosis
ICD-10 I151 Hypertension secondary to other renal disorders
Hypertension
diagnosis
ICD-10 I152 Hypertension secondary to endocrine disorders
Hypertension
diagnosis
ICD-10 I158 Other secondary hypertension
Hypertension
diagnosis
ICD-10 I159 Secondary hypertension, unspecified
Hypertension
diagnosis
Read v2 G20.. Essential hypertension
Hypertension
diagnosis
Read v2 G2... Hypertensive disease
Hypertension
diagnosis
Read v2 14A2. H/O: hypertension
Hypertension
diagnosis
Read v2 G20z. Essential hypertension NOS
Hypertension
diagnosis
Read v2 G201. Benign essential hypertension
Hypertension
diagnosis
Read v2 G2z.. Hypertensive disease NOS
Hypertension
diagnosis
Read v2 G202. Systolic hypertension
Hypertension
diagnosis
Read v2 G2y.. Hypertensive disease OS
Continued on next page
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Hypertension
diagnosis
Read v2 G200. Malignant essential hypertension
Hypertension
diagnosis
Read v2 G203. Diastolic hypertension
Hypertension
diagnosis
Read v2 Gyu2. [X]Hypertensive diseases
CVA ICD-10 I110 Hypertensive heart disease with (congestive) heart failure
CVA ICD-10 I119 Hypertensive heart disease without (congestive) heart
failure
CVA ICD-10 I120 Hypertensive renal disease with renal failure
CVA ICD-10 I129 Hypertensive renal disease without renal failure
CVA ICD-10 I130 Hypertensive heart and renal disease with (congestive)
heart failure
CVA ICD-10 I131 Hypertensive heart and renal disease with renal failure
CVA ICD-10 I132 Hypertensive heart and renal disease with both
(congestive) heart failure and renal failure
CVA ICD-10 I139 Hypertensive heart and renal disease, unspecified
CVA ICD-10 I150 Renovascular hypertension
CVA ICD-10 I151 Hypertension secondary to other renal disorders
CVA ICD-10 I152 Hypertension secondary to endocrine disorders
CVA ICD-10 I158 Other secondary hypertension
CVA ICD-10 I159 Secondary hypertension, unspecified
CVA Read v2 G65.. Transient cerebral ischaemia
CVA Read v2 G66.. Stroke/CVA unspecified
Continued on next page
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CVA Read v2 662M. Stroke monitoring
CVA Read v2 9Om0. Stroke/TIA monitor 1st letter
CVA Read v2 662e. Stroke/CVA annual review
CVA Read v2 G6... [X]Cerebrovascular diseases
CVA Read v2 Gyu6. [X]Cerebrovascular diseases
CVA Read v2 9h21. Except stroke qual ind: Pt uns
CVA Read v2 G64.. Cerebral arterial occlusion
CVA Read v2 14A7. H/O: CVA/stroke
CVA Read v2 9h22. Exc stroke qual ind: Infor dis
CVA Read v2 8HBJ. Stroke / TIA referral
CVA Read v2 9Om1. Stroke/TIA monitor 2nd letter
CVA Read v2 8HTQ. Referral to stroke clinic
CVA Read v2 G64z. Cerebral infarction NOS
CVA Read v2 9N0p. Seen in stroke clinic
CVA Read v2 14AB. H/O: TIA
CVA Read v2 9N4X. Did not attend stroke clinic
CVA Read v2 9Om2. Stroke/TIA monitor 3rd letter
CVA Read v2 G667. Left sided CVA
CVA Read v2 388I. Stroke risk
CVA Read v2 9h2.. Except report: stroke qual ind
CVA Read v2 G668. Right sided CVA
CVA Read v2 G65z. Transient cerebral ischaem.NOS
Continued on next page
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CVA Read v2 G65zz Transient cerebral ischaem.NOS
CVA Read v2 9Om.. Stroke/TIA monitoring admin
CVA Read v2 1JA1. Suspect cerebrovasculr disease
CVA Read v2 9Om4. Stroke/TIA monitr phone invite
CVA Read v2 9Om3. Stroke/TIA monitor verb invit
CVA Read v2 G6z.. Cerebrovascular disease NOS
CVA Read v2 G64z2 Left sided cerebral infarction
CVA Read v2 G640. Cerebral thrombosis
CVA Read v2 6F... Stroke prevention
CVA Read v2 G64z3 Right sided cerebral infarct
CVA Read v2 G63y0 Cerebr infct/throm/precere art
CVA Read v2 G6711 Chronic cerebral ischaemia
CVA Read v2 G663. Brain stem stroke syndrome
CVA Read v2 G641. Cerebral embolism
CVA Read v2 G664. Cerebellar stroke syndrome
CVA Read v2 G67.. Other cerebrovascular disease
CVA Read v2 7A252 Embolisation cerebral art NEC
CVA Read v2 Gyu64 [X]Other cerebral infarction
CVA Read v2 G670. Cerebral atherosclerosis
CVA Read v2 1JK.. Suspected TIA
CVA Read v2 G660. Middle cerebral artery syndrm
CVA Read v2 7A250 PC TL embolisation cerebr art
Continued on next page
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CVA Read v2 1477. H/O: cerebrovascular disease
CVA Read v2 G6400 Cerebr infct/throm/cerebrl art
CVA Read v2 G65y. Other transient cerebral isch.
CVA Read v2 1JA10 Suspct cerebrovasclar accident
CVA Read v2 G6y.. Cerebrovascular disease OS
CVA Read v2 Fyu55 [X]Oth cerebral TIA’s+rel synd
CVA Read v2 G63y1 Cerebr infct/embol/precere art
CVA Read v2 G63.. Precerebral arterial occlusion
CVA Read v2 G68X. Seql/strok,n spc/h’m,infarc
CVA Read v2 G65z1 Intermittent CVA
CVA Read v2 38DM. ABCD2 stroke risk score
CVA Read v2 G68.. Cerebrovasc.dis.-late effects
CVA Read v2 G6410 Cerebr infct/embol/cerebrl art
CVA Read v2 G661. Anterior cerebral artery syn
CVA Read v2 G67z. Other cerebrovasc.disease NOS
CVA Read v2 14AK. H/O: Stroke in last year
CVA Read v2 7A246 Open embolisation cerebral art
CVA Read v2 G63z. Precerebral artery occlus. NOS
CVA Read v2 G683. Sequelae/cerebral infarction
CVA Read v2 G63y. Other precerebral artery occl.
CVA Read v2 8HHM. Ref to stroke func improv serv
CVA Read v2 1M4.. Central post-stroke pain
Continued on next page
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CVA Read v2 Gyu66 [X]Oc+sten/o cerebral arteries
CVA Read v2 7A244 Open embolectomy cerebral art
CVA Read v2 G65z0 Impending CVA
CVA Read v2 Gyu65 [X]Oc+steno/o precerebral artr
CVA Read v2 G654. Multi+bilat precerebrl art syn
CVA Read v2 Gyu67 [X]Other spcfd cerebrovasc dis
CVA Read v2 Gyu6A [X]Oth cerebrovasc diso/dis CE
Beta-blocker Read v2 G65.. Transient cerebral ischaemia Antihypertensive
Beta-blocker Read v2 G66.. Stroke/CVA unspecified Antihypertensive
Beta-blocker Read v2 662M. Stroke monitoring Antihypertensive
Beta-blocker Read v2 9Om0. Stroke/TIA monitor 1st letter Antihypertensive
Beta-blocker Read v2 662e. Stroke/CVA annual review Antihypertensive
Beta-blocker Read v2 G6... [X]Cerebrovascular diseases Antihypertensive
Beta-blocker Read v2 Gyu6. [X]Cerebrovascular diseases Antihypertensive
Beta-blocker Read v2 9h21. Except stroke qual ind: Pt uns Antihypertensive
Beta-blocker Read v2 G64.. Cerebral arterial occlusion Antihypertensive
Beta-blocker Read v2 14A7. H/O: CVA/stroke Antihypertensive
Beta-blocker Read v2 9h22. Exc stroke qual ind: Infor dis Antihypertensive
Beta-blocker Read v2 8HBJ. Stroke / TIA referral Antihypertensive
Beta-blocker Read v2 9Om1. Stroke/TIA monitor 2nd letter Antihypertensive
Beta-blocker Read v2 8HTQ. Referral to stroke clinic Antihypertensive
Beta-blocker Read v2 G64z. Cerebral infarction NOS Antihypertensive
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Beta-blocker Read v2 9N0p. Seen in stroke clinic Antihypertensive
Beta-blocker Read v2 14AB. H/O: TIA Antihypertensive
Beta-blocker Read v2 9N4X. Did not attend stroke clinic Antihypertensive
Beta-blocker Read v2 9Om2. Stroke/TIA monitor 3rd letter Antihypertensive
Beta-blocker Read v2 G667. Left sided CVA Antihypertensive
Beta-blocker Read v2 388I. Stroke risk Antihypertensive
Beta-blocker Read v2 9h2.. Except report: stroke qual ind Antihypertensive
Beta-blocker Read v2 G668. Right sided CVA Antihypertensive
Beta-blocker Read v2 G65z. Transient cerebral ischaem.NOS Antihypertensive
Beta-blocker Read v2 G65zz Transient cerebral ischaem.NOS Antihypertensive
Beta-blocker Read v2 9Om.. Stroke/TIA monitoring admin Antihypertensive
Beta-blocker Read v2 1JA1. Suspect cerebrovasculr disease Antihypertensive
Beta-blocker Read v2 9Om4. Stroke/TIA monitr phone invite Antihypertensive
Beta-blocker Read v2 9Om3. Stroke/TIA monitor verb invit Antihypertensive
Beta-blocker Read v2 G6z.. Cerebrovascular disease NOS Antihypertensive
Beta-blocker Read v2 G64z2 Left sided cerebral infarction Antihypertensive
Beta-blocker Read v2 G640. Cerebral thrombosis Antihypertensive
Beta-blocker Read v2 6F... Stroke prevention Antihypertensive
Beta-blocker Read v2 G64z3 Right sided cerebral infarct Antihypertensive
Beta-blocker Read v2 G63y0 Cerebr infct/throm/precere art Antihypertensive
Beta-blocker Read v2 G6711 Chronic cerebral ischaemia Antihypertensive
Beta-blocker Read v2 G663. Brain stem stroke syndrome Antihypertensive
Continued on next page
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Beta-blocker Read v2 G641. Cerebral embolism Antihypertensive
Beta-blocker Read v2 G664. Cerebellar stroke syndrome Antihypertensive
Beta-blocker Read v2 G67.. Other cerebrovascular disease Antihypertensive
Beta-blocker Read v2 7A252 Embolisation cerebral art NEC Antihypertensive
Beta-blocker Read v2 Gyu64 [X]Other cerebral infarction Antihypertensive
Beta-blocker Read v2 G670. Cerebral atherosclerosis Antihypertensive
Beta-blocker Read v2 1JK.. Suspected TIA Antihypertensive
Beta-blocker Read v2 G660. Middle cerebral artery syndrm Antihypertensive
Beta-blocker Read v2 7A250 PC TL embolisation cerebr art Antihypertensive
Beta-blocker Read v2 1477. H/O: cerebrovascular disease Antihypertensive
Beta-blocker Read v2 G6400 Cerebr infct/throm/cerebrl art Antihypertensive
Beta-blocker Read v2 G65y. Other transient cerebral isch. Antihypertensive
Beta-blocker Read v2 1JA10 Suspct cerebrovasclar accident Antihypertensive
Beta-blocker Read v2 G6y.. Cerebrovascular disease OS Antihypertensive
Beta-blocker Read v2 Fyu55 [X]Oth cerebral TIA’s+rel synd Antihypertensive
Beta-blocker Read v2 G63y1 Cerebr infct/embol/precere art Antihypertensive
Beta-blocker Read v2 G63.. Precerebral arterial occlusion Antihypertensive
Beta-blocker Read v2 G68X. Seql/strok,n spc/h’m,infarc Antihypertensive
Beta-blocker Read v2 G65z1 Intermittent CVA Antihypertensive
Beta-blocker Read v2 38DM. ABCD2 stroke risk score Antihypertensive
Beta-blocker Read v2 G68.. Cerebrovasc.dis.-late effects Antihypertensive
Beta-blocker Read v2 G6410 Cerebr infct/embol/cerebrl art Antihypertensive
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Beta-blocker Read v2 G661. Anterior cerebral artery syn Antihypertensive
Beta-blocker Read v2 G67z. Other cerebrovasc.disease NOS Antihypertensive
Beta-blocker Read v2 14AK. H/O: Stroke in last year Antihypertensive
Beta-blocker Read v2 7A246 Open embolisation cerebral art Antihypertensive
Beta-blocker Read v2 G63z. Precerebral artery occlus. NOS Antihypertensive
Beta-blocker Read v2 G683. Sequelae/cerebral infarction Antihypertensive
Beta-blocker Read v2 G63y. Other precerebral artery occl. Antihypertensive
Beta-blocker Read v2 8HHM. Ref to stroke func improv serv Antihypertensive
Beta-blocker Read v2 1M4.. Central post-stroke pain Antihypertensive
Beta-blocker Read v2 Gyu66 [X]Oc+sten/o cerebral arteries Antihypertensive
Beta-blocker Read v2 7A244 Open embolectomy cerebral art Antihypertensive
Beta-blocker Read v2 G65z0 Impending CVA Antihypertensive
Beta-blocker Read v2 Gyu65 [X]Oc+steno/o precerebral artr Antihypertensive
Beta-blocker Read v2 G654. Multi+bilat precerebrl art syn Antihypertensive
Beta-blocker Read v2 Gyu67 [X]Other spcfd cerebrovasc dis Antihypertensive
Beta-blocker Read v2 Gyu6A [X]Oth cerebrovasc diso/dis CE Antihypertensive
Clopidogrel Read v2 bu51. CLOPIDOGREL 75mg tablets
Clopidogrel Read v2 bu52. PLAVIX 75mg tablets
Clopidogrel Read v2 bu54. CLOPIDOGREL 300mg tablets
Cholesterol Read v2 44P.. Serum cholesterol
Cholesterol Read v2 44P3. Serum cholesterol raised
Cholesterol Read v2 44PJ. Serum total cholesterol level
Continued on next page
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Cholesterol Read v2 44P1. Serum cholesterol normal
Cholesterol Read v2 44OE. Plasma total cholesterol level
Cholesterol Read v2 44P2. Serum cholesterol borderline
Cholesterol Read v2 44PZ. Serum cholesterol NOS
Cholesterol Read v2 44PH. Total cholesterol measurement
Cholesterol Read v2 44P4. Serum cholesterol very high
Cholesterol Read v2 44P9. Serum cholesterol studies
Cholesterol Read v2 44PK. Serum fastng total cholesterol
Cholesterol Read v2 662a. Pre-treatmnt serum cholest lev
BMI Read v2 22K.. Body Mass Index
BMI Read v2 22K5. Body mass index 30+ - obesity
BMI Read v2 22K1. Body Mass Index normal K/M2
BMI Read v2 22K2. Body Mass Index high K/M2
BMI Read v2 22K4. BMI 25-29 - overweight
BMI Read v2 22K8. Body mass index 20-24 - normal
BMI Read v2 22K7. BMI 40+ - severely obese
BMI Read v2 22K3. Body Mass Index low K/M2
BMI Read v2 22K6. Body mass index less than 20
Blood pressure
measurement
Read v2 246.. O/E - blood pressure
Blood pressure
measurement
Read v2 2464. O/E - BP reading normal
Continued on next page
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Blood pressure
measurement
Read v2 2466. O/E - BP reading raised
Blood pressure
measurement
Read v2 2469. O/E - Systolic BP reading
Blood pressure
measurement
Read v2 662L. 24 hr blood pressure monitor.
Blood pressure
measurement
Read v2 2465. O/E - BP borderline raised
Blood pressure
measurement
Read v2 246E. Sitting blood pressure reading
Blood pressure
measurement
Read v2 246Z. O/E-blood pressure reading NOS
Blood pressure
measurement
Read v2 246M. White coat hypertension
Blood pressure
measurement
Read v2 246D. Standing blood pressure reading
Blood pressure
measurement
Read v2 246W. Ave 24h systol blood pressure
Blood pressure
measurement
Read v2 246Y. Average day interval systolic blood pressure
Blood pressure
measurement
Read v2 246b. Average night interval systolic blood pressure
Blood pressure
measurement
Read v2 2467. O/E - BP reading very high
Blood pressure
measurement
Read v2 2462. O/E - BP reading low
Continued on next page
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Blood pressure
measurement
Read v2 246N. Standing systolic blood pressure
Blood pressure
measurement
Read v2 246C. Lying blood pressure reading
Blood pressure
measurement
Read v2 246F. O/E - blood pressure decreased
Blood pressure
measurement
Read v2 246V. Ave 24h diastol blood pressure
Blood pressure
measurement
Read v2 2463. O/E - BP borderline low
Blood pressure
measurement
Read v2 246Q. Sitting systolic blood pressure
Blood pressure
measurement
Read v2 246X. Ave day diastol blood pressure
Blood pressure
measurement
Read v2 246a. Ave night diast blood pressure
Blood pressure
measurement
Read v2 246S. Lying systolic blood pressure
Blood pressure
measurement
Read v2 246T. Lying diastolic blood pressure
HDL reading Read v2 44P5. Serum HDL cholesterol level
HDL reading Read v2 44PB. Serum fast HDL cholesterol lev
HDL reading Read v2 44PC. Ser random HDL cholesterol lev
HDL reading Read v2 44d3. Plasma fast HDL cholest level
HDL reading Read v2 44R3. Lipoprotein electroph. - HDL
Continued on next page
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HDL reading Read v2 44dA. Plasma HDL cholesterol level
HDL reading Read v2 44d2. Plasma rndm HDL cholest level
Cholesterol
HDL ratio
reading
Read v2 44lF. Serum cholesterol/HDL ratio
Cholesterol
HDL ratio
reading
Read v2 44PF. Total cholesterol:HDL ratio
Cholesterol
HDL ratio
reading
Read v2 44l2. Cholesterol/HDL ratio
Cholesterol
HDL ratio
reading
Read v2 44lG. Plasma cholesterol/HDL ratio
Calcium
channel blocker
Read v2 blb1. AMLODIPINE 5mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 blb2. AMLODIPINE 10mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8i. ADALAT LA 30mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8j. ADALAT LA 60mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 blh1. LERCANIDIPINE HCL 10mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8M. ADALAT LA 20mg m/r tablets Antihypertensive only
Continued on next page
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Calcium
channel blocker
Read v2 bl5Z. TILDIEM LA 200mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl83. ADALAT RETARD 20mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 ble2. LACIDIPINE 4mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl84. ADALAT RETARD 10mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3k. SECURON SR 240mg m/r tabs 28CP Antihypertensive only
Calcium
channel blocker
Read v2 ble1. LACIDIPINE 2mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5I. ADIZEM-XL 240mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5A. TILDIEM LA 300mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8A. ADIPINE MR 20 m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl58. TILDIEM RETARD 90mg m/r tabs Antihypertensive only
Calcium
channel blocker
Read v2 blb3. ISTIN 5mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5K. ADIZEM-XL 120mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3j. SECURON SR 240mg m/r tablets Antihypertensive only
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Calcium
channel blocker
Read v2 bl8z. NIFEDIPINE 20mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb31. VERAPAMIL 40mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5E. ADIZEM-XL 300mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8B. ADIPINE MR 10 m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5J. ADIZEM-XL 180mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5B. ADIZEM-SR 90mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl59. TILDIEM RETARD 120mg m/r tabs Antihypertensive only
Calcium
channel blocker
Read v2 bl86. NIFEDIPINE 10mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl51. TILDIEM 60mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5R. ANGITIL SR 90 m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8e. CORACTEN SR 20mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3A. VERAPAMIL 240mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8X. CORACTEN XL 30mg m/r capsules Antihypertensive only
Continued on next page
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Calcium
channel blocker
Read v2 bl85. NIFEDIPINE 5mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 blb4. ISTIN 10mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8w. NIFEDIPINE 10mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5Q. SLOZEM 240mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8k. CORACTEN SR 10mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb32. VERAPAMIL 80mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5C. ADIZEM-SR 120mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb33. VERAPAMIL 120mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5F. DILZEM SR 60mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5S. ANGITIL SR 120 m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3F. HALF-SECURON SR 120mg 28CP Antihypertensive only
Calcium
channel blocker
Read v2 blh3. LERCANIDIPINE HCl 20mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3y. VERAPAMIL 240mg m/r capsules Antihypertensive only
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Calcium
channel blocker
Read v2 bl8Y. CORACTEN XL 60mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5D. ADIZEM-SR 180mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5G. DILZEM SR 90mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl82. ADALAT 10mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3s. VERTAB SR 240 m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5O. SLOZEM 120mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 ble3. MOTENS 2mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5P. SLOZEM 180mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8u. NIFEDIPINE 10mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8v. NIFEDIPINE 20mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 ble4. MOTENS 4mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3n. UNIVER 240mg m/r capsules x28 Antihypertensive only
Calcium
channel blocker
Read v2 bl5M. DILZEM-XL 180mg m/r capsules Antihypertensive only
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Calcium
channel blocker
Read v2 bl5U. ANGITIL SR 180 m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5L. DILZEM-XL 120mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl81. ADALAT 5mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3C. VERAPAMIL 120mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl7y. NICARDIPINE 20mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3l. UNIVER 120mg m/r capsules x28 Antihypertensive only
Calcium
channel blocker
Read v2 bl54. ADIZEM-SR 120mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl7z. NICARDIPINE 30mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5x. ANGITIL XL 240 m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 blh2. ZANIDIP 10mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5N. DILZEM-XL 240mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3v. VERAPAMIL 120mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5h. DILTIAZEM HCL 200mg m/r caps Antihypertensive only
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Calcium
channel blocker
Read v2 bb3B. HALF SECURON SR 120mg m/r tabs Antihypertensive only
Calcium
channel blocker
Read v2 bl5y. ANGITIL XL 300 m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl55. DILTIAZEM HCL 120mg m/r tabs Antihypertensive only
Calcium
channel blocker
Read v2 bl71. CARDENE 20mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl7x. NICARDIPINE 30mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8L. FORTIPINE LA40 m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3w. VERAPAMIL 160mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl5t. VIAZEM XL 360mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bb3m. UNIVER 180mg m/r capsules x56 Antihypertensive only
Calcium
channel blocker
Read v2 bl5V. CALCICARD CR 90mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3g. *SECURON 120mg tablets 56CP Antihypertensive only
Calcium
channel blocker
Read v2 bl73. CARDENE SR 30mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl7w. NICARDIPINE 45mg m/r capsules Antihypertensive only
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Calcium
channel blocker
Read v2 bl72. CARDENE 30mg capsules Antihypertensive only
Calcium
channel blocker
Read v2 bla1. ISRADIPINE 2.5mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3z. VERAPAMIL 180mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl8h. *NIFENSAR XL 20mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bla2. PRESCAL 2.5mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl74. CARDENE SR 45mg m/r capsules Antihypertensive only
Calcium
channel blocker
Read v2 bl5W. CALCICARD CR 120mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8S. NIFEDIPRESS MR 10 m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8F. NIFEDIPINE 40mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb39. *CORDILOX 80mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb38. *CORDILOX 40mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3D. VERAPAMIL 40mg/5mL s/f soln Antihypertensive only
Calcium
channel blocker
Read v2 bl57. *ADIZEM 60mg tablets Antihypertensive only
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Calcium
channel blocker
Read v2 bb3e. *SECURON 80mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 blh4. ZANIDIP 20mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8P. *ANGIOPINE MR 10mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8t. *NIFOPRESS RETRD 20mg m/r tabs Antihypertensive only
Calcium
channel blocker
Read v2 bl8D. *NIMODREL MR 10 m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8q. HYPOLAR RETARD 20 m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl53. *BRITIAZIM 60mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3Q. VERA-TIL SR 120mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3P. VERA-TIL SR 240mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 dt13. NIMODIPINE 30mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 blb5. AMLOSTIN 5mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3i. *SECURON 160mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3x. *VERPAMIL HCL 120mg tabs x56 Antihypertensive only
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Calcium
channel blocker
Read v2 blb6. AMLOSTIN 10mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8C. *UNIPINE XL 30mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl56. *ANGIOZEM 60mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 dt14. NIMOTOP 30mg tablets Antihypertensive only
Calcium
channel blocker
Read v2 bl8R. *GENALAT RETARD 20mg m/r tabs Antihypertensive only
Calcium
channel blocker
Read v2 bl8G. *ANGIOPINE 40 LA m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3o. SECURON IV 5mg/2mL injection Antihypertensive only
Calcium
channel blocker
Read v2 bl8O. *SLOFEDIPINE 20mg m/r tablets Antihypertensive only
Calcium
channel blocker
Read v2 bb3h. *SECURON 160mg tablets 56CP Antihypertensive only
Calcium
channel blocker
Read v2 bl52. *CALCICARD 60mg tablets Antihypertensive only
ACE inhibitor Read v2 bi67. RAMIPRIL 10mg capsules Antihypertensive
ACE inhibitor Read v2 bi63. RAMIPRIL 5mg capsules Antihypertensive
ACE inhibitor Read v2 bi62. RAMIPRIL 2.5mg capsules Antihypertensive
ACE inhibitor Read v2 bi34. LISINOPRIL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi33. LISINOPRIL 10mg tablets Antihypertensive
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ACE inhibitor Read v2 bi52. PERINDOPRIL ERBUMINE 4mg tabs Antihypertensive
ACE inhibitor Read v2 bi32. LISINOPRIL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bi51. PERINDOPRIL ERBUMINE 2mg tabs Antihypertensive
ACE inhibitor Read v2 bk42. VALSARTAN 80mg capsules Antihypertensive
ACE inhibitor Read v2 bi61. RAMIPRIL 1.25mg capsules Antihypertensive
ACE inhibitor Read v2 bk32. LOSARTAN POTASSIUM 50mg tabs Antihypertensive
ACE inhibitor Read v2 bi57. PERINDOPRIL ERBUMINE 8mg tabs Antihypertensive
ACE inhibitor Read v2 bi31. LISINOPRIL 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk43. VALSARTAN 160mg capsules Antihypertensive
ACE inhibitor Read v2 bk52. IRBESARTAN 150mg tablets Antihypertensive
ACE inhibitor Read v2 bk37. LOSARTAN POTASSIUM 100mg tabs Antihypertensive
ACE inhibitor Read v2 bi2z. ENALAPRIL MAL 20mg tabs x28 Antihypertensive
ACE inhibitor Read v2 bk53. IRBESARTAN 300mg tablets Antihypertensive
ACE inhibitor Read v2 bk73. CANDESARTAN CILEXETIL 8mg tabs Antihypertensive
ACE inhibitor Read v2 bi2x. ENALAPRIL MAL 10mg tabs x28 Antihypertensive
ACE inhibitor Read v2 bk41. VALSARTAN 40mg capsules Antihypertensive
ACE inhibitor Read v2 bi2y. ENALAPRIL MALEATE 20mg tablets Antihypertensive
ACE inhibitor Read v2 bk31. LOSARTAN POTASSIUM 25mg tabs Antihypertensive
ACE inhibitor Read v2 bi2v. ENALAPRIL MALEATE 5mg tabs x28 Antihypertensive
ACE inhibitor Read v2 bk72. CANDESARTAN CILEXETIL 4mg tabs Antihypertensive
ACE inhibitor Read v2 bi2w. ENALAPRIL MALEATE 10mg tablets Antihypertensive
ACE inhibitor Read v2 bk74. CANDESARTAN CILEXET 16mg tabs Antihypertensive
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ACE inhibitor Read v2 bk51. IRBESARTAN 75mg tablets Antihypertensive
ACE inhibitor Read v2 bi93. TRANDOLAPRIL 2mg capsules Antihypertensive
ACE inhibitor Read v2 bi2u. ENALAPRIL MALEATE 5mg tablets Antihypertensive
ACE inhibitor Read v2 bi72. FOSINOPRIL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi1v. CAPTOPRIL 12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi6D. RAMIPRIL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bi2t. ENALAPRIL MALEATE 2.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi6E. RAMIPRIL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bk81. TELMISARTAN 40mg tablets Antihypertensive
ACE inhibitor Read v2 bi1x. CAPTOPRIL 25mg tablets x56 Antihypertensive
ACE inhibitor Read v2 bi6C. RAMIPRIL 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi1z. CAPTOPRIL 50mg tablets Antihypertensive
ACE inhibitor Read v2 bi1w. CAPTOPRIL 25mg tablets Antihypertensive
ACE inhibitor Read v2 bk82. TELMISARTAN 80mg tablets Antihypertensive
ACE inhibitor Read v2 bi43. QUINAPRIL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi54. *COVERSYL 4mg tablets Antihypertensive
ACE inhibitor Read v2 bi71. FOSINOPRIL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bkB2. OLMESARTAN MEDOXOMIL 20mg tabs Antihypertensive
ACE inhibitor Read v2 bkB1. OLMESARTAN MEDOXOMIL 10mg tabs Antihypertensive
ACE inhibitor Read v2 bi3p. LISINO+HYDROCHL 20/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi42. QUINAPRIL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bi4A. QUINAPRIL 40mg tablets Antihypertensive
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ACE inhibitor Read v2 bk71. CANDESARTAN CILEXETIL 2mg tabs Antihypertensive
ACE inhibitor Read v2 bi92. TRANDOLAPRIL 1mg capsules Antihypertensive
ACE inhibitor Read v2 bk45. DIOVAN 80mg capsules Antihypertensive
ACE inhibitor Read v2 bi3h. ZESTRIL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bk9z. EPROSARTAN 600mg tablets Antihypertensive
ACE inhibitor Read v2 bk8z. TELMISARTAN 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi1y. CAPTOPRIL 50mg tablets x56 Antihypertensive
ACE inhibitor Read v2 bi53. *COVERSYL 2mg tablets Antihypertensive
ACE inhibitor Read v2 bi3f. ZESTRIL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bi3j. ZESTRIL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi3t. LISINO+HYDROCHL 10/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bk34. COZAAR 50mg tablets Antihypertensive
ACE inhibitor Read v2 bk7z. CANDESARTAN CILEXETL 32mg tabs Antihypertensive
ACE inhibitor Read v2 bi55. *PERIND ERB+INDAP 4/1.25mg tab Antihypertensive
ACE inhibitor Read v2 bi6B. RAMIPRIL 1.25mg tablets Antihypertensive
ACE inhibitor Read v2 bi41. QUINAPRIL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bkB3. OLMESARTAN MEDOXOMIL 40mg tabs Antihypertensive
ACE inhibitor Read v2 bi25. INNOVACE 10mg tablets x28 Antihypertensive
ACE inhibitor Read v2 bi3n. ZESTORETIC 20/12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk9y. EPROSARTAN 400mg tablets Antihypertensive
ACE inhibitor Read v2 bk35. LOSART+HYDROCHLTHZ 50/12.5 tab Antihypertensive
ACE inhibitor Read v2 bi27. INNOVACE 20mg tablets x28 Antihypertensive
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ACE inhibitor Read v2 bk5y. IRBES+HYDROCHL 300/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bk46. DIOVAN 160mg capsules Antihypertensive
ACE inhibitor Read v2 bi9z. TRANDOLAPRIL 4mg capsules Antihypertensive
ACE inhibitor Read v2 bk36. COZAAR-COMP 50mg/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bk9x. EPROSARTAN 300mg tablets Antihypertensive
ACE inhibitor Read v2 bi1c. *CAPOZIDE 50mg tablets x28 Antihypertensive
ACE inhibitor Read v2 bk5z. IRBES+HYDROCHL 150/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bk55. APROVEL 150mg tablets Antihypertensive
ACE inhibitor Read v2 bi91. TRANDOLAPRIL 500mcg capsules Antihypertensive
ACE inhibitor Read v2 bi3g. ZESTRIL 10mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bi23. INNOVACE 5mg tablets x28 Antihypertensive
ACE inhibitor Read v2 bi3e. ZESTRIL 5mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bi3d. ZESTRIL 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi74. *STARIL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bk4w. VALSARTAN 40mg tablets Antihypertensive
ACE inhibitor Read v2 bi73. *STARIL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bi24. INNOVACE 10mg tablets Antihypertensive
ACE inhibitor Read v2 bi56. *COVERSYL PLUS 4mg/1.25mg tabs Antihypertensive
ACE inhibitor Read v2 bk58. COAPROVEL 300mg/12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi96. GOPTEN 2mg capsules Antihypertensive
ACE inhibitor Read v2 bi26. INNOVACE 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi22. INNOVACE 5mg tablets Antihypertensive
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ACE inhibitor Read v2 bi18. CAPOTEN 25mg tablets x56 Antihypertensive
ACE inhibitor Read v2 bi16. *CAPOTEN 12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi28. INNOZIDE 20/12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk44. DIOVAN 40mg capsules Antihypertensive
ACE inhibitor Read v2 bi17. CAPOTEN 25mg tablets Antihypertensive
ACE inhibitor Read v2 bi45. ACCUPRO 10mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bk4z. VALSRT+HYDROCHL 160/12.5mg tab Antihypertensive
ACE inhibitor Read v2 bi3i. ZESTRIL 20mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bk8y. TELMIS+HYDROCHL 80/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi69. *RAMIPRIL 2.5mg+5mg+10mg caps Antihypertensive
ACE inhibitor Read v2 bi66. *TRITACE 5mg capsules Antihypertensive
ACE inhibitor Read v2 bk3z. LOSART+HYDROCHLTHZ 100/25 tabs Antihypertensive
ACE inhibitor Read v2 bi1G. *CO-ZIDOCAPT 50mg/25mg tablets Antihypertensive
ACE inhibitor Read v2 bk56. APROVEL 300mg tablets Antihypertensive
ACE inhibitor Read v2 bk4x. VALSART+HYDROCHL 80/12.5mg tab Antihypertensive
ACE inhibitor Read v2 bk77. AMIAS 8mg tablets Antihypertensive
ACE inhibitor Read v2 bi1a. CAPOTEN 50mg tablets x56 Antihypertensive
ACE inhibitor Read v2 bi44. ACCUPRO 5mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bk57. COAPROVEL 150mg/12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi46. ACCUPRO 20mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bi1s. CAPOZIDE 50mg/25mg tablets Antihypertensive
ACE inhibitor Read v2 bk54. APROVEL 75mg tablets Antihypertensive
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ACE inhibitor Read v2 bk76. AMIAS 4mg tablets Antihypertensive
ACE inhibitor Read v2 bi2b. ENALAP+HYDROCHL 20/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi65. *TRITACE 2.5mg capsules Antihypertensive
ACE inhibitor Read v2 biC8. PERIND ARG+INDAP 5/1.25mg tabs Antihypertensive
ACE inhibitor Read v2 biBz. IMIDAPRIL HCL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bi3s. ZESTORETIC 10/12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk4y. VALSART+HYDROCHL 160/25mg tabs Antihypertensive
ACE inhibitor Read v2 bk33. COZAAR HALF-STRENGTH 25mg tabs Antihypertensive
ACE inhibitor Read v2 bkB4. OLMETEC 10mg tablets Antihypertensive
ACE inhibitor Read v2 bi3m. *ZESTORETIC tablets 28CP Antihypertensive
ACE inhibitor Read v2 bk8x. TELMIS+HYDROCHL 40/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi21. INNOVACE 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi39. *CARACE 10mg tablets Antihypertensive
ACE inhibitor Read v2 bi95. GOPTEN 1mg capsules Antihypertensive
ACE inhibitor Read v2 bi3k. CARACE 20 PLUS tablets Antihypertensive
ACE inhibitor Read v2 bk83. MICARDIS 40mg tablets Antihypertensive
ACE inhibitor Read v2 bk78. AMIAS 16mg tablets Antihypertensive
ACE inhibitor Read v2 bk87. MICARDISPLUS 80mg/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi47. ACCURETIC tablets Antihypertensive
ACE inhibitor Read v2 bi3b. *CARACE 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi3q. *ZESTRIL 2.5mg starter pack Antihypertensive
ACE inhibitor Read v2 bi64. *TRITACE 1.25mg capsules Antihypertensive
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ACE inhibitor Read v2 bk38. COZAAR 100mg tablets Antihypertensive
ACE inhibitor Read v2 bi49. ACCUPRO 40mg tablets Antihypertensive
ACE inhibitor Read v2 bi35. *CARACE 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi8a. CILAZAPRIL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bi38. *CARACE 10mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bk4v. VALSARTAN 320mg tablets Antihypertensive
ACE inhibitor Read v2 bi19. CAPOTEN 50mg tablets Antihypertensive
ACE inhibitor Read v2 bi3c. ZESTRIL 2.5mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bi36. *CARACE 5mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bkD1. AMLODIPNE+VALSARTN 5/80mg tabs Antihypertensive
ACE inhibitor Read v2 bi68. *TRITACE 10mg capsules Antihypertensive
ACE inhibitor Read v2 bi37. *CARACE 5mg tablets Antihypertensive
ACE inhibitor Read v2 bkFy. ALISKIREN 300mg tablets Antihypertensive
ACE inhibitor Read v2 bi58. *COVERSYL 8mg tablets Antihypertensive
ACE inhibitor Read v2 biBy. IMIDAPRIL HCL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bk62. TARKA 2mg/180mg m/r capsules Antihypertensive
ACE inhibitor Read v2 bi3a. *CARACE 20mg tablets 28CP Antihypertensive
ACE inhibitor Read v2 bk84. MICARDIS 80mg tablets Antihypertensive
ACE inhibitor Read v2 bk93. TEVETEN 600mg tablets Antihypertensive
ACE inhibitor Read v2 bi3l. CARACE 10 PLUS tablets Antihypertensive
ACE inhibitor Read v2 bk47. CO-DIOVAN 160mg/12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk49. CO-DIOVAN 80mg/12.5mg tablets Antihypertensive
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ACE inhibitor Read v2 bA1z. FELODIPINE+RAMIPRIL 5/5mg tabs Antihypertensive
ACE inhibitor Read v2 bkD2. AMLODPNE+VALSARTN 5/160mg tabs Antihypertensive
ACE inhibitor Read v2 bi13. ACEPRIL 25mg tablets x56 Antihypertensive
ACE inhibitor Read v2 bkB5. OLMETEC 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi2a. *ENALAPRIL MAL tabs titre pack Antihypertensive
ACE inhibitor Read v2 bi15. ACEPRIL 50mg tablets x56 Antihypertensive
ACE inhibitor Read v2 bi6x. TRITACE 5mg tablets Antihypertensive
ACE inhibitor Read v2 bA12. TRIAPIN 5mg/5mg tablets Antihypertensive
ACE inhibitor Read v2 bk86. MICARDISPLUS 40mg/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bkCz. OLMESAR+HYDROCH 20/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi6w. TRITACE 10mg tablets Antihypertensive
ACE inhibitor Read v2 bkD3. AMLODPNE+VALSRTN 10/160mg tabs Antihypertensive
ACE inhibitor Read v2 bi6y. TRITACE 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 biBx. IMIDAPRIL HCL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi3r. *LISINOPRIL 2.5mg tabs starter Antihypertensive
ACE inhibitor Read v2 bk75. AMIAS 2mg tablets Antihypertensive
ACE inhibitor Read v2 bk3C. LOSARTAN POTASSIUM 12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi11. ACEPRIL 12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi82. CILAZAPRIL 500mcg tablets Antihypertensive
ACE inhibitor Read v2 bi94. GOPTEN 500micrograms capsules Antihypertensive
ACE inhibitor Read v2 bk39. COZAAR-COMP 100mg/25mg tablets Antihypertensive
ACE inhibitor Read v2 bi89. VASCACE 5mg tablets Antihypertensive
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ACE inhibitor Read v2 bk48. CO-DIOVAN 160mg/25mg tablets Antihypertensive
ACE inhibitor Read v2 bk85. MICARDIS 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi88. VASCACE 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 biC7. COVRSYL ARGIN PLS 5/1.25mg tab Antihypertensive
ACE inhibitor Read v2 bi48. QUINAPRIL+HYDROCHLOROTHIAZIDE Antihypertensive
ACE inhibitor Read v2 bi1d. CAPOZIDE LS 25mg tablets x28CP Antihypertensive
ACE inhibitor Read v2 biC2. PERINDOPRIL ARGININE 2.5mg tab Antihypertensive
ACE inhibitor Read v2 biC4. PERINDOPRIL ARGININE 5mg tabs Antihypertensive
ACE inhibitor Read v2 biC6. PERINDOPRIL ARGININE 10mg tabs Antihypertensive
ACE inhibitor Read v2 bi1b. ACEZIDE 50mg tablets x56 Antihypertensive
ACE inhibitor Read v2 bi87. VASCACE 1mg tablets Antihypertensive
ACE inhibitor Read v2 bkDx. EXFORGE 10mg/160mg tablets Antihypertensive
ACE inhibitor Read v2 bi84. CILAZAPRIL 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk3y. LOSART+HYDRCHL 100/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi6A. *TRITACE Titration Pack caps Antihypertensive
ACE inhibitor Read v2 bA1y. FELODIP+RAMIPRL 2.5/2.5mg tabs Antihypertensive
ACE inhibitor Read v2 biA1. MOEXIPRIL HCL 7.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk91. TEVETEN 300mg tablets Antihypertensive
ACE inhibitor Read v2 bi1f. CAPTOP+HYDROCHL 50/25mg tabs Antihypertensive
ACE inhibitor Read v2 bkDy. EXFORGE 5mg/160mg tablets Antihypertensive
ACE inhibitor Read v2 bi12. ACEPRIL 25mg tablets Antihypertensive
ACE inhibitor Read v2 bi6F. RAMIPRIL 2.5+5+10mg tabs pack Antihypertensive
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ACE inhibitor Read v2 bk5x. IRBES+HYDROCHL 300mg/25mg tabs Antihypertensive
ACE inhibitor Read v2 bk92. TEVETEN 400mg tablets Antihypertensive
ACE inhibitor Read v2 bkDz. EXFORGE 5mg/80mg tablets Antihypertensive
ACE inhibitor Read v2 bi6z. TRITACE 1.25mg tablets Antihypertensive
ACE inhibitor Read v2 biB1. TANATRIL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bkCy. OLMESART+HYDROCHL 20/25mg tabs Antihypertensive
ACE inhibitor Read v2 bi83. CILAZAPRIL 1mg tablets Antihypertensive
ACE inhibitor Read v2 biB2. TANATRIL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bk61. TRANDOL+VERAP 2/180mg m/r caps Antihypertensive
ACE inhibitor Read v2 bi86. VASCACE 500micrograms tablets Antihypertensive
ACE inhibitor Read v2 biA3. PERDIX 7.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi14. ACEPRIL 50mg tablets Antihypertensive
ACE inhibitor Read v2 bkB6. OLMETEC 40mg tablets Antihypertensive
ACE inhibitor Read v2 bkC1. OLMETEC PLUS 20mg/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bk8w. TELMIS+HYDROCHL 80mg/25mg tabs Antihypertensive
ACE inhibitor Read v2 biA2. MOEXIPRIL HCL 15mg tablets Antihypertensive
ACE inhibitor Read v2 biC3. COVERSYL ARGININE 5mg tablets Antihypertensive
ACE inhibitor Read v2 bk4A. DIOVAN 40mg tablets Antihypertensive
ACE inhibitor Read v2 bi9A. GOPTEN 4mg capsules Antihypertensive
ACE inhibitor Read v2 bkHz. OLMESART+AMLODIPNE 20/5mg tabs Antihypertensive
ACE inhibitor Read v2 bk59. COAPROVEL 300mg/25mg tablets Antihypertensive
ACE inhibitor Read v2 biC5. COVERSYL ARGININE 10mg tablets Antihypertensive
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ACE inhibitor Read v2 bkHy. OLMESART+AMLODIPNE 40/5mg tabs Antihypertensive
ACE inhibitor Read v2 bA11. TRIAPIN MITE 2.5mg/2.5mg tabs Antihypertensive
ACE inhibitor Read v2 biA4. PERDIX 15mg tablets Antihypertensive
ACE inhibitor Read v2 bi1p. *TENSOPRIL 12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bk3A. COZAAR-COMP 100mg/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi6o. TRITACE Titration Pack tablets Antihypertensive
ACE inhibitor Read v2 bkHx. OLMESART+AMLODIPN 40/10mg tabs Antihypertensive
ACE inhibitor Read v2 bk79. AMIAS 32mg tablets Antihypertensive
ACE inhibitor Read v2 bi6v. *LOPACE 10mg capsules Antihypertensive
ACE inhibitor Read v2 bkH3. SEVIKAR 40mg/10mg tablets Antihypertensive
ACE inhibitor Read v2 bk88. MICARDISPLUS 80mg/25mg tablets Antihypertensive
ACE inhibitor Read v2 bi2F. *INNOVACE MELT 5mg wafer Antihypertensive
ACE inhibitor Read v2 bi2G. *INNOVACE MELT 10mg wafer Antihypertensive
ACE inhibitor Read v2 bkH2. SEVIKAR 40mg/5mg tablets Antihypertensive
ACE inhibitor Read v2 bkH1. SEVIKAR 20mg/5mg tablets Antihypertensive
ACE inhibitor Read v2 bkC3. OLMETEC PLUS 40mg/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi2D. *ENALAPRIL MALEATE 20mg wafer Antihypertensive
ACE inhibitor Read v2 biC1. COVERSYL ARGININE 2.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi2L. *PRALENAL 10mg tablets Antihypertensive
ACE inhibitor Read v2 bi81. *CILAZAPRIL 250mcg tablets Antihypertensive
ACE inhibitor Read v2 bi2E. *INNOVACE MELT 2.5mg wafer Antihypertensive
ACE inhibitor Read v2 bi6u. *LOPACE 5mg capsules Antihypertensive
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ACE inhibitor Read v2 bi29. *INNOVACE tabs titration pack Antihypertensive
ACE inhibitor Read v2 bi2M. *PRALENAL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi2C. *ENALAPRIL MALEATE 10mg wafer Antihypertensive
ACE inhibitor Read v2 bi1q. *TENSOPRIL 25mg tablets Antihypertensive
ACE inhibitor Read v2 bkCx. OLMESAR+HYDROCH 40/12.5mg tabs Antihypertensive
ACE inhibitor Read v2 bi4D. QUINIL 20mg tablets Antihypertensive
ACE inhibitor Read v2 biB3. TANATRIL 20mg tablets Antihypertensive
ACE inhibitor Read v2 bi1k. *KAPLON 25mg tablets Antihypertensive
ACE inhibitor Read v2 bi1j. *KAPLON 12.5mg tablets Antihypertensive
ACE inhibitor Read v2 bi2K. *PRALENAL 5mg tablets Antihypertensive
ACE inhibitor Read v2 bi6t. *LOPACE 2.5mg capsules Antihypertensive
ACE inhibitor Read v2 bi2J. *PRALENAL 2.5mg tablets Antihypertensive
ACE inhibitor Read v2 bkGy. AMBRISENTAN 10mg tablets Antihypertensive
ACE inhibitor Read v2 bk3E. LOSARTAN POTASS 2.5mg/mL susp Antihypertensive
ACE inhibitor Read v2 bkGz. AMBRISENTAN 5mg tablets Antihypertensive
Thiazide
diuretic
Read v2 b211. BENDROFLUMETHIAZIDE 2.5mg tabs Antihypertensive only
Thiazide
diuretic
Read v2 b212. BENDROFLUMETHIAZIDE 5mg tablet Antihypertensive only
Thiazide
diuretic
Read v2 b28z. INDAPAMIDE 2.5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b285. INDAPAMIDE 1.5mg m/r tablets Antihypertensive only
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Thiazide
diuretic
Read v2 b281. NATRILIX 2.5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b286. NATRILIX SR 1.5mg m/r tablets Antihypertensive only
Thiazide
diuretic
Read v2 b2bz. METOLAZONE 5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b25z. CYCLOPENTHIAZIDE 500mcg tabs Antihypertensive only
Thiazide
diuretic
Read v2 b23y. CHLORTALIDONE 50mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b2d1. DIUREXAN 20mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b2dz. XIPAMIDE 20mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b214. APRINOX 5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b231. HYGROTON 50mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b251. NAVIDREX 500micrograms tablets Antihypertensive only
Thiazide
diuretic
Read v2 b26z. *HYDROCHLOROTHIAZIDE 25mg tabs Antihypertensive only
Thiazide
diuretic
Read v2 b213. APRINOX 2.5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b26y. *HYDROCHLOROTHIAZIDE 50mg tabs Antihypertensive only
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Thiazide
diuretic
Read v2 b219. NEO-NACLEX 5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b2b1. METENIX-5 5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b283. *NATRAMID 2.5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b2c1. *NEPHRIL 1mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b2b2. *XURET 500micrograms tablets Antihypertensive only
Thiazide
diuretic
Read v2 b263. *HYDROSALURIC 25mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b216. *BERKOZIDE 5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b232. *HYGROTON 100mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b22y. CHLOROTHIAZIDE 250mg/5mL susp Antihypertensive only
Thiazide
diuretic
Read v2 b291. *BAYCARON 25mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b22z. *CHLOROTHIAZIDE 500mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b215. *BERKOZIDE 2.5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b221. *SALURIC 500mg tablets Antihypertensive only
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Thiazide
diuretic
Read v2 b2cz. *POLYTHIAZIDE 1mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b264. *HYDROSALURIC 50mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b21A. *NEO-BENDROMAX 2.5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b23z. *CHLORTHALIDONE 100mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b2b3. *METOLAZONE 500mcg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b29z. *MEFRUSIDE 25mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b271. *HYDRENOX 50mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b21B. *NEO-BENDROMAX 5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b218. *CENTYL 5mg tablets Antihypertensive only
Thiazide
diuretic
Read v2 b217. *CENTYL 2.5mg tablets Antihypertensive only
Aspirin Read v2 bu23. ASPIRIN 75mg disp tabs
Aspirin Read v2 bu25. *ASPIRIN 75mg tablets
Aspirin Read v2 bu2B. ASPIRIN 75mg e/c tablets
Aspirin Read v2 di1f. ASPIRIN 300mg e/c tablets
Aspirin Read v2 di13. *ASPIRIN 75mg disp tabs
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Aspirin Read v2 j112. ASPIRIN 300mg disp tablets
Aspirin Read v2 j111. ASPIRIN 300mg tablets
Aspirin Read v2 bu2A. NU-SEALS ASPIRIN 75mg e/c tabs
Aspirin Read v2 di1m. ASPIRIN 300mg soluble tablets
Aspirin Read v2 bu27. *ASPIRIN 300mg eff tabs
Aspirin Read v2 bu2c. ASPIRIN 75mg soluble tablets
Aspirin Read v2 di1c. NU-SEALS ASPIRIN 300mg e/ctabs
Aspirin Read v2 di11. ASPIRIN [CNS] 300mg tablets
Aspirin Read v2 bu2F. CAPRIN 75mg e/c tablets
Aspirin Read v2 bu28. *DISPRIN CV 100mg m/r tablets
Aspirin Read v2 bu29. *ASPIRIN 100mg m/r tablets
Aspirin Read v2 di12. ASPIRIN [CNS] 300mg disp tabs
Aspirin Read v2 bu2E. *POSTMI 75mg e/c tablets
Aspirin Read v2 bu2K. MICROPIRIN 75mg e/c tablets
Aspirin Read v2 bu2G. *NU-SEALS CARDIO 75 e/c tabs
Aspirin Read v2 di1g. *ASPIRIN 600mg e/c tablets
Aspirin Read v2 bu21. *ASPIRIN 100mg eff tabs
Aspirin Read v2 di1h. *ASPIRIN 324mg e/c tablets
Aspirin Read v2 di1r. DISPRIN 300mg disp tabs
Aspirin Read v2 bu24. *ANGETTES 75mg tablets
Aspirin Read v2 di1k. CAPRIN 300mg e/c tablets
Aspirin Read v2 di1e. *PALAPRIN FORTE 600mg tablets
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Aspirin Read v2 di1d. *NU-SEALS ASPIRIN 600mg tabs
Aspirin Read v2 di1o. ASPIRIN 150mg suppositories
Aspirin Read v2 di1n. ASPIRIN 300mg suppositories
Aspirin Read v2 bu2H. *ENPRIN 75mg e/c tablets
Aspirin Read v2 bu2I. ASPIRIN 162.5mg m/r capsules
Aspirin Read v2 di14. *ASPERGUM 227mg chewing gum
Aspirin Read v2 di18. *SOLPRIN 300mg disp tabs
CABG OPCS K401 SAPHENOUS VEIN GRAFT REPLACEMENT OF
CORONARY ARTERY
CABG OPCS K402 SAPHENOUS VEIN GRAFT REPLACEMENT OF
CORONARY ARTERY
CABG OPCS K403 SAPHENOUS VEIN GRAFT REPLACEMENT OF
CORONARY ARTERY
CABG OPCS K404 SAPHENOUS VEIN GRAFT REPLACEMENT OF
CORONARY ARTERY
CABG OPCS K408 SAPHENOUS VEIN GRAFT REPLACEMENT OF
CORONARY ARTERY
CABG OPCS K409 SAPHENOUS VEIN GRAFT REPLACEMENT OF
CORONARY ARTERY
CABG OPCS K411 OTHER AUTOGRAFT REPLACEMENT OF CORONARY
ARTERY
CABG OPCS K412 OTHER AUTOGRAFT REPLACEMENT OF CORONARY
ARTERY
CABG OPCS K413 OTHER AUTOGRAFT REPLACEMENT OF CORONARY
ARTERY
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CABG OPCS K414 OTHER AUTOGRAFT REPLACEMENT OF CORONARY
ARTERY
CABG OPCS K419 OTHER AUTOGRAFT REPLACEMENT OF CORONARY
ARTERY
CABG OPCS K421 ALLOGRAFT REPLACEMENT OF CORONARY ARTERY
CABG OPCS K423 ALLOGRAFT REPLACEMENT OF CORONARY ARTERY
CABG OPCS K424 ALLOGRAFT REPLACEMENT OF CORONARY ARTERY
CABG OPCS K429 ALLOGRAFT REPLACEMENT OF CORONARY ARTERY
CABG OPCS K431 PROSTHETIC REPLACEMENT OF CORONARY ARTERY
CABG OPCS K433 PROSTHETIC REPLACEMENT OF CORONARY ARTERY
CABG OPCS K434 PROSTHETIC REPLACEMENT OF CORONARY ARTERY
CABG OPCS K441 OTHER REPLACEMENT OF CORONARY ARTERY
CABG OPCS K442 OTHER REPLACEMENT OF CORONARY ARTERY
CABG OPCS K448 OTHER REPLACEMENT OF CORONARY ARTERY
CABG OPCS K449 OTHER REPLACEMENT OF CORONARY ARTERY
CABG OPCS K451 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
CABG OPCS K452 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
CABG OPCS K453 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
CABG OPCS K454 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
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CABG OPCS K455 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
CABG OPCS K456 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
CABG OPCS K458 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
CABG OPCS K459 CONNECTION OF THORACIC ARTERY TO
CORONARY ARTERY
CABG OPCS K463 OTHER BYPASS OF CORONARY ARTERY
CABG OPCS K468 OTHER BYPASS OF CORONARY ARTERY
CABG OPCS K473 REPAIR OF CORONARY ARTERY
CABG OPCS K475 REPAIR OF CORONARY ARTERY
CABG OPCS K478 REPAIR OF CORONARY ARTERY
CABG OPCS K479 REPAIR OF CORONARY ARTERY
CABG OPCS K482 OTHER OPEN OPERATIONS ON CORONARY ARTERY
CABG OPCS K484 OTHER OPEN OPERATIONS ON CORONARY ARTERY
CABG OPCS K488 OTHER OPEN OPERATIONS ON CORONARY ARTERY
PCI OPCS K491 TRANSLUMINAL BALLOON ANGIOPLASTY OF
CORONARY ARTERY
PCI OPCS K492 TRANSLUMINAL BALLOON ANGIOPLASTY OF
CORONARY ARTERY
PCI OPCS K493 TRANSLUMINAL BALLOON ANGIOPLASTY OF
CORONARY ARTERY
PCI OPCS K494 TRANSLUMINAL BALLOON ANGIOPLASTY OF
CORONARY ARTERY
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PCI OPCS K498 TRANSLUMINAL BALLOON ANGIOPLASTY OF
CORONARY ARTERY
PCI OPCS K499 TRANSLUMINAL BALLOON ANGIOPLASTY OF
CORONARY ARTERY
PCI OPCS K501 OTHER THERAPEUTIC TRANSLUMINAL
OPERATIONS ON CORONARY
PCI OPCS K502 OTHER THERAPEUTIC TRANSLUMINAL
OPERATIONS ON CORONARY
PCI OPCS K503 OTHER THERAPEUTIC TRANSLUMINAL
OPERATIONS ON CORONARY
PCI OPCS K508 OTHER THERAPEUTIC TRANSLUMINAL
OPERATIONS ON CORONARY
PCI OPCS K509 OTHER THERAPEUTIC TRANSLUMINAL
OPERATIONS ON CORONARY
PCI OPCS K751 PERCUTANEOUS TRANSLUMINAL BALLOON
ANGIOPLASTY AND INSER
PCI OPCS K752 PERCUTANEOUS TRANSLUMINAL BALLOON
ANGIOPLASTY AND INSER
PCI OPCS K753 PERCUTANEOUS TRANSLUMINAL BALLOON
ANGIOPLASTY AND INSER
PCI OPCS K754 PERCUTANEOUS TRANSLUMINAL BALLOON
ANGIOPLASTY AND INSER
PCI OPCS K758 PERCUTANEOUS TRANSLUMINAL BALLOON
ANGIOPLASTY AND INSER
PCI OPCS K759 PERCUTANEOUS TRANSLUMINAL BALLOON
ANGIOPLASTY AND INSER
Charlson ICD-10 F00 Dementia in Alzheimer disease
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Charlson ICD-10 F01 Vascular dementia
Charlson ICD-10 F02 Dementia in other diseases classified elsewhere
Charlson ICD-10 F03 Unspecified dementia
Charlson ICD-10 F051 Delirium superimposed on dementia
Charlson ICD-10 G30 Alzheimer disease
Charlson ICD-10 G311 Senile degeneration of brain, not elsewhere classified
Charlson ICD-10 I278 Other specified pulmonary heart diseases
Charlson ICD-10 I279 Pulmonary heart disease, unspecified
Charlson ICD-10 J40 Bronchitis, not specified as acute or chronic
Charlson ICD-10 J41 Simple and mucopurulent chronic bronchitis
Charlson ICD-10 J42 Unspecified chronic bronchitis
Charlson ICD-10 J43 Emphysema
Charlson ICD-10 J44 Other chronic obstructive pulmonary disease
Charlson ICD-10 J45 Asthma
Charlson ICD-10 J46 Status asthmaticus
Charlson ICD-10 J47 Bronchiectasis
Charlson ICD-10 J60 Coalworker pneumoconiosis
Charlson ICD-10 J61 Pneumoconiosis due to asbestos and other mineral fibres
Charlson ICD-10 J62 Pneumoconiosis due to dust containing silica
Charlson ICD-10 J63 Pneumoconiosis due to other inorganic dusts
Charlson ICD-10 J64 Unspecified pneumoconiosis
Charlson ICD-10 J65 Pneumoconiosis associated with tuberculosis
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Charlson ICD-10 J66 Airway disease due to specific organic dust
Charlson ICD-10 J67 Hypersensitivity pneumonitis due to organic dust
Charlson ICD-10 J684 Chronic respiratory conditions due to chemicals, gases,
fumes and vapours
Charlson ICD-10 J701 Chronic and other pulmonary manifestations due to
radiation
Charlson ICD-10 J703 Chronic drug-induced interstitial lung disorders
Charlson ICD-10 M05 Seropositive rheumatoid arthritis
Charlson ICD-10 M06 Other rheumatoid arthritis
Charlson ICD-10 M315 Giant cell arteritis with polymyalgia rheumatica
Charlson ICD-10 M32 Systemic lupus erythematosus
Charlson ICD-10 M33 Dermatopolymyositis
Charlson ICD-10 M34 Systemic sclerosis
Charlson ICD-10 M351 Other overlap syndromes
Charlson ICD-10 M353 Polymyalgia rheumatica
Charlson ICD-10 M360 Dermato(poly)myositis in neoplastic disease
Charlson ICD-10 K25 Gastric ulcer
Charlson ICD-10 K26 Duodenal ulcer
Charlson ICD-10 K27 Peptic ulcer, site unspecified
Charlson ICD-10 K28 Gastrojejunal ulcer
Charlson ICD-10 B18 Chronic viral hepatitis
Charlson ICD-10 K700 Alcoholic fatty liver
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Charlson ICD-10 K701 Alcoholic hepatitis
Charlson ICD-10 K702 Alcoholic fibrosis and sclerosis of liver
Charlson ICD-10 K703 Alcoholic cirrhosis of liver
Charlson ICD-10 K709 Alcoholic liver disease, unspecified
Charlson ICD-10 K713 Toxic liver disease with chronic persistent hepatitis
Charlson ICD-10 K714 Toxic liver disease with chronic lobular hepatitis
Charlson ICD-10 K715 Toxic liver disease with chronic active hepatitis
Charlson ICD-10 K717 Toxic liver disease with fibrosis and cirrhosis of liver
Charlson ICD-10 K73 Chronic hepatitis, not elsewhere classified
Charlson ICD-10 K74 Fibrosis and cirrhosis of liver
Charlson ICD-10 K760 Fatty (change of) liver, not elsewhere classified
Charlson ICD-10 K762 Central haemorrhagic necrosis of liver
Charlson ICD-10 K763 Infarction of liver
Charlson ICD-10 K744 Secondary biliary cirrhosis
Charlson ICD-10 K768 Other specified diseases of liver
Charlson ICD-10 K769 Liver disease, unspecified
Charlson ICD-10 Z944 Liver transplant status
Charlson ICD-10 G041 Tropical spastic paraplegia
Charlson ICD-10 G114 Hereditary spastic paraplegia
Charlson ICD-10 G801 Spastic diplegic cerebral palsy
Charlson ICD-10 G802 Spastic hemiplegic cerebral palsy
Charlson ICD-10 G81 Hemiplegia
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Charlson ICD-10 G82 Paraplegia and tetraplegia
Charlson ICD-10 G830 Diplegia of upper limbs
Charlson ICD-10 G831 Monoplegia of lower limb
Charlson ICD-10 G832 Monoplegia of upper limb
Charlson ICD-10 G833 Monoplegia, unspecified
Charlson ICD-10 G834 Cauda equina syndrome
Charlson ICD-10 G839 Paralytic syndrome, unspecified
Charlson ICD-10 I120 Hypertensive renal disease with renal failure
Charlson ICD-10 I131 Hypertensive heart and renal disease with renal failure
Charlson ICD-10 N032 Chronic nephritic syndrome: Diffuse membranous
glomerulonephritis
Charlson ICD-10 N033 Chronic nephritic syndrome: Diffuse mesangial
proliferative glomerulonephritis
Charlson ICD-10 N034 Chronic nephritic syndrome: Diffuse endocapillary
proliferative glomerulonephritis
Charlson ICD-10 N035 Chronic nephritic syndrome: Diffuse mesangiocapillary
glomerulonephritis
Charlson ICD-10 N036 Chronic nephritic syndrome: Dense deposit disease
Charlson ICD-10 N037 Chronic nephritic syndrome: Diffuse crescentic
glomerulonephritis
Charlson ICD-10 N052 Unspecified nephritic syndrome: Diffuse membranous
glomerulonephritis
Charlson ICD-10 N053 Unspecified nephritic syndrome: Diffuse mesangial
proliferative glomerulonephritis
Continued on next page
c
lin
ic
a
l
c
o
d
es
657
Table E.1 – Continued from previous page
Defined System Code Description Notes
Charlson ICD-10 N054 Unspecified nephritic syndrome: Diffuse endocapillary
proliferative glomerulonephritis
Charlson ICD-10 N055 Unspecified nephritic syndrome: Diffuse
mesangiocapillary glomerulonephritis
Charlson ICD-10 N056 Unspecified nephritic syndrome: Dense deposit disease
Charlson ICD-10 N057 Unspecified nephritic syndrome: Diffuse crescentic
glomerulonephritis
Charlson ICD-10 N18 Chronic kidney disease
Charlson ICD-10 N19 Unspecified kidney failure
Charlson ICD-10 N250 Renal osteodystrophy
Charlson ICD-10 Z490 Preparatory care for dialysis
Charlson ICD-10 Z491 Extracorporeal dialysis
Charlson ICD-10 Z492 Other dialysis
Charlson ICD-10 Z940 Kidney transplant status
Charlson ICD-10 Z992 Dependence on renal dialysis
Charlson ICD-10 C00 Malignant neoplasm of lip
Charlson ICD-10 C01 Malignant neoplasm of base of tongue
Charlson ICD-10 C02 Malignant neoplasm of other and unspecified parts of
tongue
Charlson ICD-10 C03 Malignant neoplasm of gum
Charlson ICD-10 C04 Malignant neoplasm of floor of mouth
Charlson ICD-10 C05 Malignant neoplasm of palate
Charlson ICD-10 C06 Malignant neoplasm of other and unspecified parts of
mouth
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Charlson ICD-10 C07 Malignant neoplasm of parotid gland
Charlson ICD-10 C08 Malignant neoplasm of other and unspecified major
salivary glands
Charlson ICD-10 C09 Malignant neoplasm of tonsil
Charlson ICD-10 C10 Malignant neoplasm of oropharynx
Charlson ICD-10 C11 Malignant neoplasm of nasopharynx
Charlson ICD-10 C12 Malignant neoplasm of piriform sinus
Charlson ICD-10 C13 Malignant neoplasm of hypopharynx
Charlson ICD-10 C14 Malignant neoplasm of other and ill-defined sites in the
lip, oral cavity and pharynx
Charlson ICD-10 C15 Malignant neoplasm of oesophagus
Charlson ICD-10 C16 Malignant neoplasm of stomach
Charlson ICD-10 C17 Malignant neoplasm of small intestine
Charlson ICD-10 C18 Malignant neoplasm of colon
Charlson ICD-10 C19 Malignant neoplasm of rectosigmoid junction
Charlson ICD-10 C20 Malignant neoplasm of rectum
Charlson ICD-10 C21 Malignant neoplasm of anus and anal canal
Charlson ICD-10 C22 Malignant neoplasm of liver and intrahepatic bile ducts
Charlson ICD-10 C23 Malignant neoplasm of gallbladder
Charlson ICD-10 C24 Malignant neoplasm of other and unspecified parts of
biliary tract
Charlson ICD-10 C25 Malignant neoplasm of pancreas
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Charlson ICD-10 C26 Malignant neoplasm of other and ill-defined digestive
organs
Charlson ICD-10 C30 Malignant neoplasm of nasal cavity and middle ear
Charlson ICD-10 C31 Malignant neoplasm of accessory sinuses
Charlson ICD-10 C32 Malignant neoplasm of larynx
Charlson ICD-10 C33 Malignant neoplasm of trachea
Charlson ICD-10 C34 Malignant neoplasm of bronchus and lung
Charlson ICD-10 C37 Malignant neoplasm of thymus
Charlson ICD-10 C38 Malignant neoplasm of heart, mediastinum and pleura
Charlson ICD-10 C39 Malignant neoplasm of other and ill-defined sites in the
respiratory system and intrathoracic organs
Charlson ICD-10 C40 Malignant neoplasm of bone and articular cartilage of
limbs
Charlson ICD-10 C41 Malignant neoplasm of bone and articular cartilage of
other and unspecified sites
Charlson ICD-10 C43 Malignant melanoma of skin
Charlson ICD-10 C45 Mesothelioma
Charlson ICD-10 C46 Kaposi sarcoma
Charlson ICD-10 C47 Malignant neoplasm of peripheral nerves and autonomic
nervous system
Charlson ICD-10 C48 Malignant neoplasm of retroperitoneum and peritoneum
Charlson ICD-10 C49 Malignant neoplasm of other connective and soft tissue
Charlson ICD-10 C50 Malignant neoplasm of breast
Charlson ICD-10 C51 Malignant neoplasm of vulva
Continued on next page
660
c
lin
ic
a
l
c
o
d
es
Table E.1 – Continued from previous page
Defined System Code Description Notes
Charlson ICD-10 C52 Malignant neoplasm of vagina
Charlson ICD-10 C53 Malignant neoplasm of cervix uteri
Charlson ICD-10 C54 Malignant neoplasm of corpus uteri
Charlson ICD-10 C55 Malignant neoplasm of uterus, part unspecified
Charlson ICD-10 C56 Malignant neoplasm of ovary
Charlson ICD-10 C57 Malignant neoplasm of other and unspecified female
genital organs
Charlson ICD-10 C58 Malignant neoplasm of placenta
Charlson ICD-10 C60 Malignant neoplasm of penis
Charlson ICD-10 C61 Malignant neoplasm of prostate
Charlson ICD-10 C62 Malignant neoplasm of testis
Charlson ICD-10 C63 Malignant neoplasm of other and unspecified male genital
organs
Charlson ICD-10 C64 Malignant neoplasm of kidney, except renal pelvis
Charlson ICD-10 C65 Malignant neoplasm of renal pelvis
Charlson ICD-10 C66 Malignant neoplasm of ureter
Charlson ICD-10 C67 Malignant neoplasm of bladder
Charlson ICD-10 C68 Malignant neoplasm of other and unspecified urinary
organs
Charlson ICD-10 C69 Malignant neoplasm of eye and adnexa
Charlson ICD-10 C70 Malignant neoplasm of meninges
Charlson ICD-10 C71 Malignant neoplasm of brain
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Charlson ICD-10 C72 Malignant neoplasm of spinal cord, cranial nerves and
other parts of central nervous system
Charlson ICD-10 C73 Malignant neoplasm of thyroid gland
Charlson ICD-10 C74 Malignant neoplasm of adrenal gland
Charlson ICD-10 C75 Malignant neoplasm of other endocrine glands and
related structures
Charlson ICD-10 C76 Malignant neoplasm of other and ill-defined sites
Charlson ICD-10 C81 Hodgkin lymphoma
Charlson ICD-10 C82 Follicular lymphoma
Charlson ICD-10 C83 Non-follicular lymphoma
Charlson ICD-10 C84 Mature T/NK-cell lymphomas
Charlson ICD-10 C85 Other and unspecified types of non-Hodgkin lymphoma
Charlson ICD-10 C88 Malignant immunoproliferative diseases
Charlson ICD-10 C90 Multiple myeloma and malignant plasma cell neoplasms
Charlson ICD-10 C91 Lymphoid leukaemia
Charlson ICD-10 C92 Myeloid leukaemia
Charlson ICD-10 C93 Monocytic leukaemia
Charlson ICD-10 C94 Other leukaemias of specified cell type
Charlson ICD-10 C95 Leukaemia of unspecified cell type
Charlson ICD-10 C96 Other and unspecified malignant neoplasms of lymphoid,
haematopoietic and related tissue
Charlson ICD-10 C97 Malignant neoplasms of independent (primary) multiple
sites
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Charlson ICD-10 I850 Oesophageal varices with bleeding
Charlson ICD-10 I859 Oesophageal varices without bleeding
Charlson ICD-10 I864 Gastric varices
Charlson ICD-10 I982 Oesophageal varices without bleeding in diseases
classified elsewhere
Charlson ICD-10 K704 Alcoholic hepatic failure
Charlson ICD-10 K711 Toxic liver disease with hepatic necrosis
Charlson ICD-10 K721 Chronic hepatic failure
Charlson ICD-10 K729 Hepatic failure, unspecified
Charlson ICD-10 K765 Hepatic veno-occlusive disease
Charlson ICD-10 K766 Portal hypertension
Charlson ICD-10 K767 Hepatorenal syndrome
Charlson ICD-10 C77 Secondary and unspecified malignant neoplasm of lymph
nodes
Charlson ICD-10 C78 Secondary malignant neoplasm of respiratory and
digestive organs
Charlson ICD-10 C79 Secondary malignant neoplasm of other and unspecified
sites
Charlson ICD-10 C80 Malignant neoplasm, without specification of site
Charlson ICD-10 B20 Human immunodeficiency virus [HIV] disease resulting
in infectious and parasitic diseases
Charlson ICD-10 B21 Human immunodeficiency virus [HIV] disease resulting
in malignant neoplasms
Continued on next page
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Charlson ICD-10 B22 Human immunodeficiency virus [HIV] disease resulting
in other specified diseases
Charlson ICD-10 B24 Unspecified human immunodeficiency virus [HIV] disease

FC A L C U L AT I O N O F I L L U S T R AT I V E E X A M P L E I N
D I S C U S S I O N C H A P T E R
In order to calculate the necessary information for the initiative ex-
ample shown in chapter 10, I use the following definitions and method
of calculation for each quintile Qi where i is quintile numbers 1 to 5: I acknowledge the
help and advice that
I have had from
statisticians with the
methods outlined in
this section
ni = number at risk in Qi
pi = number with PCI in Qi
hi = fully adjusted hazard ratio for Qi
qi = number who would have had a PCI rate were as for Q1
= pi//hi
mi = mortality rate in those at risk, no PCI in Qi
ri = mortality rate in those at risk, PCI in Qi
number of deaths in Qi = (ni − pi)mi + piri = D1i
number of deaths if quintile 1 rate used for Qi = (ni−qi)mi+qiri = D2i
number of deaths prevented or postponed in Qi = D1i −D2i
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